

disorders related to the secreted proteins. The proteins, and polynucleotide sequences may be useful for treating disorders of the immune system, hyperproliferative disorders, infectious disease, regeneration of tissues, for chemotaxis and for screening molecules that bind to the proteins. The proteins or polynucleotide sequences may be used as food additives or preservatives, to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, co-factors or other nutritional components. Agonists or antagonists of the proteins may be used to prevent scar tissue growth during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051 and AAB08890 are sequences used in the exemplification of the present invention

Sequence 327 AA;
Query Match 99.6%; Score 1692; DB 3; Length 327;
Best Local Similarity 99.7%; Pred. No. 7.4e-114; Indels 0; Gaps 0;
Matches 326; Conservative 0; Mismatches 1;
Y 1 MAELPGPFLCGALGFLCLSLGLAVEVKTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
b 1 MAELPGPFLCGALGFLCLSLGLAVEVKTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Y 61 FVQPGKPISESHPTLYFTNGHLVPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
b 61 FVQPGKPISESHPTLYFTNGHLVPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
Y 121 CQVNNPPDFYTNGLINLTVLVPPSNPLCSQSGTSTALRCSSSGAPKPVYNNV 180
b 121 CQVNNPPDFYTNGLINLTVLVPPSNPLCSQSGTSTALRCSSSGAPKPVYNNV 180
Y 181 RLGTPTPSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNQMSASCELTLVTEPPQG 240
b 181 RLGTPTPSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNQMSASCELTLVTEPPQG 240
Y 241 RVAGALIGVLLGLVLLSVAAFLVRFQKRGKPKETTYGGSDLRDAIAPGISEHTCMRA 300
b 241 RVAGALIGVLLGLVLLSVAAFLVRFQKRGKPKETTYGGSDLRDAIAPGISEHTCMRA 300
Y 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327
b 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327

RESULT 2
AA87251
ID AAY87251 standard; protein; 327 AA.
XX AAY87251;
XX AC
XX DT
XX 11-MAY-2000 (first entry)
XX Human signal peptide containing protein HSPP-28 SEQ ID NO:28.
DE Human; signal peptide-containing protein; HSPP; diagnosis; cancer;
XX Human; inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW inflammation; nontropic; neuroprotective; cardiovascular; hepatotropic;
KW antimicrobial; nontropic; neuroprotective; cardiovascular; hepatotropic;
KW antiasthmatic; gene therapy; cell proliferation; neurological disorder;
KW reproductive disorder; developmental disorder; arteriosclerosis;
KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
KW Parkinson's disease; Huntington's diseases; ovulatory defect;
KW muscular dystrophy.
XX Homo sapiens.
OS
XX WO200000610-A2.
XX PN
XX 06-JAN-2000.
PD
XX 25-JUN-1999; 99WO-US014484.
XX PF
XX 26-JUN-1998; 98US-0090762P.
XX

31-JUL-1998; 98US-0094983P.
PR 01-OCT-1998; 98US-0102686P.
PR 11-DEC-1998; 98US-0112129P.
XX (INCY-) INCYTE PHARM INC.
XX Lal P, Tang YT, Gorgone GA, Corley MC, Guegler KJ, Baughn MR;
PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
PI Bandman O;
XX WPI; 2000-160673/14.
DR N-PSDB; AAZ98136.
XX New human signal peptide-containing proteins useful in treatment,
PT prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
PT disease.
XX Claim 1; Page 177-178; 327pp; English.

AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the human signal peptide-containing proteins HSPP-1 to HSPP-134. HSPPs have anticancer, anti-inflammatory, antimicrobial, nontropic, hepatotropic, neuroprotective, cardiovascular and antiasthmatic activities, and can be used in gene therapy. HSPPs can be used to treat or prevent disorders associated with decreased activity or function of HSPP. Antagonists of HSPP are used to treat or prevent disorders associated with increased activity or function of HSPP. Such diseases include cell proliferation (including cancer), inflammation, cardiovascular, neurological, reproductive or developmental disorders, (e.g. arteriosclerosis, cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia, asthma, Crohn's disease, microbial or other infections, congestive or ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSPP nucleic acids can be used for the recombinant production of HSPP, for detecting HSPP in standard hybridisation and amplification assays (for or ribozyme therapeutics, for detecting related sequences or genetic variations, and for chromosomal mapping. HSPP are also used to raise specific antibodies (Ab) and to screen for agonists and antagonists (potential therapeutic agents). Ab are used to diagnose, or monitor, HSPP-related diseases (in usual immunoassays), as therapeutic antagonists, in competitive drug screens, and for purification of HSPP from natural sources

Sequence 327 AA;
Query Match 99.5%; Score 1691; DB 3; Length 327;
Best Local Similarity 99.7%; Pred. No. 8.8e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALGFLCLSLGLAVEVKTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGPFLCGALGFLCLSLGLAVEVKTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
QY 61 FVQPGKPISESHPTLYFTNGHLVPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISESHPTLYFTNGHLVPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDFYTNGLINLTVLVPPSNPLCSQSGTSTALRCSSSGAPKPVYNNV 180
Db 121 CQVNNPPDFYTNGLINLTVLVPPSNPLCSQSGTSTALRCSSSGAPKPVYNNV 180
QY 181 RLGTPTPSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNQMSASCELTLVTEPPQG 240
Db 181 RLGTPTPSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNQMSASCELTLVTEPPQG 240
QY 241 RVAGALIGVLLGLVLLSVAAFLVRFQKRGKPKETTYGGSDLRDAIAPGISEHTCMRA 300
Db 241 RVAGALIGVLLGLVLLSVAAFLVRFQKRGKPKETTYGGSDLRDAIAPGISEHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327
Db 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327

This Page Blank (uspto)

DT	25-OCT-2004 (TReMBLrel. 28, Last annotation update)	
DE	V-set and immunoglobulin domain containing 2 (CTH Variant).	
GN	Name=VSG2; ORFNames=UNQ2770;	
OS	Homo sapiens (Human).	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
OX	NCBI_TaxID=9606;	
RN	[1]	
RP	SEQUENCE FROM N.A.	
RC	TISSUE=Colon;	
EX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;	
RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,	
RA	Klausner R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,	
RA	Altshuler S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,	
RA	Hopkins R.P., Jordan H., Moore T.J., Wang J., Hsieh P.,	
RA	Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,	
RA	Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,	
RA	Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,	
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,	
RA	Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,	
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,	
RA	Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,	
RA	Fahy J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,	
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,	
RA	Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,	
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,	
RA	Krzywinski M.I., Skaleka J., Smalusz D.E., Schnerch A., Schein J.E.,	
RA	Jones S.J., Marra M.A.;	
RT	"Generation and initial analysis of more than 15,000 full-length human	
RT	and mouse cDNA sequences."	
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).	
RN	[2]	
RP	SEQUENCE FROM N.A.	
RC	TISSUE=Colon;	
RA	Director MGC Project;	
RL	Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.	
RN	[3]	
RP	SEQUENCE FROM N.A.	
EX	MEDLINE=22987296; PubMed=12975309; DOI=10.1101/gr.1293003;	
RA	Clark H.P., Gurney A.L., Abaya E., Baker K., Baldwin D., Brush J.,	
RA	Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,	
RA	Eaton D., Foster J., Grimaldi C., Gu Q., Hass P.E., Heldeng S.,	
RA	Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,	
RA	Lewis L., Liao D., Mark M., Robbie B., Sanchez C., Schoenfeld J.,	
RA	Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,	
RA	Vandlen R., Watanabe C., Wiedand D., Woods K., Xie M.H., Yansura D.,	
RA	Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,	
RA	Godowski P.;	
RT	"The secreted protein discovery initiative (SPDI), a large-scale	
RT	effort to identify novel human secreted and transmembrane proteins: a	
RT	bioinformatics assessment."	
RL	Genome Res. 13:2265-2270 (2003).	
DR	EMBL; BC007313; AA070131.1; -	
DR	EMBL; AY358897; AA089256.1; -	
DR	HSSP; 088792; 1P97.	
DR	GO; GO:0004872; F:receptor activity; IRA.	
DR	InterPro; IPR007110; Ig-like.	
DR	Pfam; PF00047; Ig; 1.	
DR	PROSITE; PS00835; IG-LIKE; 2.	
SQ	SEQUENCE 327 AA; 34348 MW; CP395ACTFEF951AC1 CRC64;	
Query Match	99.2%; Score 1155; DB 2; Length 327;	
Best Local Similarity	100.0%; Pred. No. 2.1e-83;	
Matches	220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 VEVKVTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60	
Db	24 VEVKVTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83	
Qy	61 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYTLCOVNNPPDFYTNGLGLNLTVLV 120	
Db	84 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYTLCOVNNPPDFYTNGLGLNLTVLV 143	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	144 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 203	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRVA 220	
Db	204 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRVA 243	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASGASCELTLSTVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180	

This Page Blank (uspto)

Db 1 MAELPGPLCCAGLGLCLSLAVENKVTPEPLSTPLGKTAELICTTSTVSDSFALEWS 60
QY 61 FVQPKPTISRHPIILYFTNGHLYPTGSKSRVSLLONPPTVGVATLKLTDVHPDSTGYL 120
Db 61 FVQPKPTISRHPIILYFTNGHLYPTGSKSRVSLLONPPTVGVATLKLTDVHPDSTGYL 120
QY 121 CQVNNPDPFYNGGLNLTLVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVNVW 180
Db 121 CQVNNPDPFYNGGLNLTLVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVNVW 180
QY 181 RLGTFTPTSPGSMVDVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSTVTSRQ 240
Db 181 RLGTFTPTSPGSMVDVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSTVTSRQ 240
QY 241 RVREL 245
Db 241 RVREL 245

RESULT 5

US-10-227-884-236
; Sequence 236, Application US/10227884
; Publication No. US20030027988A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Deenoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C79
; CURRENT APPLICATION NUMBER: US/10/227,884
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15

; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464

This Page Blank (uspto)

;; PRIOR FILING DATE: 1998-10-30
;; PRIOR APPLICATION NUMBER: 60/106905
;; PRIOR FILING DATE: 1998-11-03
;; PRIOR APPLICATION NUMBER: 60/108787
;; PRIOR FILING DATE: 1998-11-17
;; PRIOR APPLICATION NUMBER: 60/108801
;; PRIOR FILING DATE: 1998-11-17
;; PRIOR APPLICATION NUMBER: 60/108849
;; PRIOR FILING DATE: 1998-11-18
;; PRIOR APPLICATION NUMBER: 60/112422
;; PRIOR FILING DATE: 1998-12-15
;; PRIOR APPLICATION NUMBER: 60/113296
;; PRIOR FILING DATE: 1998-12-22
;; PRIOR APPLICATION NUMBER: 60/113605
;; PRIOR FILING DATE: 1998-12-23
;; PRIOR APPLICATION NUMBER: 60/113621
;; PRIOR FILING DATE: 1998-12-23
;; PRIOR APPLICATION NUMBER: 60/115558
;; PRIOR FILING DATE: 1999-01-12
;; PRIOR APPLICATION NUMBER: 60/115565
;; PRIOR FILING DATE: 1999-01-12
;; PRIOR APPLICATION NUMBER: 60/115733
;; PRIOR FILING DATE: 1999-01-12
;; PRIOR APPLICATION NUMBER: 60/119549
;; PRIOR FILING DATE: 1999-02-10
;; PRIOR APPLICATION NUMBER: 60/123618
;; PRIOR FILING DATE: 1999-03-10
;; PRIOR APPLICATION NUMBER: 60/125259
;; PRIOR FILING DATE: 1999-03-19
;; PRIOR APPLICATION NUMBER: 60/125775
;; PRIOR FILING DATE: 1999-03-23
;; PRIOR APPLICATION NUMBER: 60/126773
;; PRIOR FILING DATE: 1999-03-29
;; PRIOR APPLICATION NUMBER: 60/127887
;; PRIOR FILING DATE: 1999-04-05
;; PRIOR APPLICATION NUMBER: 60/130232
;; PRIOR FILING DATE: 1999-04-21
;; PRIOR APPLICATION NUMBER: 60/131022
;; PRIOR FILING DATE: 1999-04-26
;; PRIOR APPLICATION NUMBER: 60/131270
;; PRIOR FILING DATE: 1999-04-27
;; PRIOR APPLICATION NUMBER: 60/131291
;; PRIOR FILING DATE: 1999-04-27
;; PRIOR APPLICATION NUMBER: 60/131445
;; PRIOR FILING DATE: 1999-04-28
;; PRIOR APPLICATION NUMBER: 60/134287
;; PRIOR FILING DATE: 1999-05-14
;; PRIOR APPLICATION NUMBER: 60/140650
;; PRIOR FILING DATE: 1999-06-22
;; PRIOR APPLICATION NUMBER: 60/140723
;; PRIOR FILING DATE: 1999-06-22
;; PRIOR APPLICATION NUMBER: 60/141037
;; PRIOR FILING DATE: 1999-06-23
;; PRIOR APPLICATION NUMBER: 60/144758
;; PRIOR FILING DATE: 1999-07-20
;; PRIOR APPLICATION NUMBER: 60/145698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: 60/146222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: 60/146963
;; PRIOR FILING DATE: 1999-08-03
;; PRIOR APPLICATION NUMBER: 60/149320
;; PRIOR FILING DATE: 1999-08-17
;; PRIOR APPLICATION NUMBER: 60/149638
;; PRIOR FILING DATE: 1999-08-17
;; PRIOR APPLICATION NUMBER: 60/151733
;; PRIOR FILING DATE: 1999-08-31
;; PRIOR APPLICATION NUMBER: 60/164418
;; PRIOR FILING DATE: 1999-11-09
;; PRIOR APPLICATION NUMBER: 60/166361
;; PRIOR FILING DATE: 1999-11-16
;; PRIOR APPLICATION NUMBER: 60/169445
;; PRIOR FILING DATE: 1999-12-07

;; PRIOR APPLICATION NUMBER: 60/169495
;; PRIOR FILING DATE: 1999-12-07
;; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCAGLIGFLCGLAVEVVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
DB 1 MAELPGPFLCAGLIGFLCGLAVEVVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60

QY 61 FVQPKDISSHPILYFTNGHLVPTGSKSRVSLLOQNPPTVGATLKLTDVHPSDTGYL 120
DB 61 FVQPKDISSHPILYFTNGHLVPTGSKSRVSLLOQNPPTVGATLKLTDVHPSDTGYL 120

QY 121 CQVNNPDPFTYNGLGLINLTVLPPSPNPLCSQSGTSSGSTRYRCVATNMGASCELTLSTVTEPSQG 240
DB 121 CQVNNPDPFTYNGLGLINLTVLPPSPNPLCSQSGTSSGSTRYRCVATNMGASCELTLSTVTEPSQG 240

QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLSTVTEPSQG 240
DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLSTVTEPSQG 240

QY 241 RVA 243
DB 241 RVA 243

RESULT 6

US-10-230-163-236
;; Sequence 236, Application US/10230163
;; Publication No. US20030036635A1
;; GENERAL INFORMATION:
;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Gerritsen, Mary
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, J. Christopher
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Smith, Victoria
;; APPLICANT: Stephan, Jean-Philippe F.
;; APPLICANT: Watanabe, Colin L.
;; APPLICANT: Wood, William I.
;; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;; TITLE OF INVENTION: ACIDS ENCODING THE SAME
;; FILE REFERENCE: P3530PIC96
;; CURRENT APPLICATION NUMBER: US/10/230,163
;; CURRENT FILING DATE: 2002-08-28
;; PRIOR APPLICATION NUMBER: 10/119,480
;; PRIOR FILING DATE: 2002-04-09
;; PRIOR APPLICATION NUMBER: 60/059113
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/062287
;; PRIOR FILING DATE: 1997-10-17
;; PRIOR APPLICATION NUMBER: 60/063549
;; PRIOR FILING DATE: 1997-10-28
;; PRIOR APPLICATION NUMBER: 60/064103
;; PRIOR FILING DATE: 1997-10-31
;; PRIOR APPLICATION NUMBER: 60/069873
;; PRIOR FILING DATE: 1997-12-17
;; PRIOR APPLICATION NUMBER: 60/078910
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/079294
;; PRIOR FILING DATE: 1998-03-25
;; PRIOR APPLICATION NUMBER: 60/079656
;; PRIOR FILING DATE: 1998-03-26
;; PRIOR APPLICATION NUMBER: 60/079728
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/081819
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081955

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 06:13:42 ; Search time 66.0997 Seconds
(without alignments)
1447.018 Million cell updates/sec

Title: US-10-607-565-83_COPY_1_245

Perfect score: 1286
Sequence: 1 MAELPGFLCGALLGFLCLS.....ASCELTLSTVPSQGRVABL 245

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1752860 seqs, 390397842 residues

Total number of hits satisfying chosen parameters: 1752860

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA:*

- 1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW PUB.pep.*
- 3: /cgn2_6/ptodata/1/pubpaa/US06_NEW PUB.pep.*
- 4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
- 5: /cgn2_6/ptodata/1/pubpaa/US07_NEW PUB.pep.*
- 6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
- 7: /cgn2_6/ptodata/1/pubpaa/US08_NEW PUB.pep.*
- 8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
- 9: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
- 10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
- 11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
- 12: /cgn2_6/ptodata/1/pubpaa/US09_NEW PUB.pep.*
- 13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
- 14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
- 15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
- 16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
- 17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
- 18: /cgn2_6/ptodata/1/pubpaa/US10_NEW PUB.pep.*
- 19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
- 20: /cgn2_6/ptodata/1/pubpaa/US11_NEW PUB.pep.*
- 21: /cgn2_6/ptodata/1/pubpaa/US60_NEW PUB.pep.*
- 22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1286	100.0	245	9	US-09-820-893-98
2	1286	100.0	245	15	US-10-607-565-98
3	1286	100.0	246	9	US-09-820-893-83
4	1286	100.0	246	15	US-10-607-565-83
5	1277	99.3	327	14	US-10-227-884-236
6	1277	99.3	327	14	US-10-230-163-236
7	1277	99.3	327	14	US-10-230-338-236
8	1277	99.3	327	14	US-10-218-631-236
9	1277	99.3	327	14	US-10-230-414-236
10	1277	99.3	327	14	US-10-232-224-236
11	1277	99.3	327	14	US-10-216-159A-236

12	1277	99.3	327	14	US-10-218-849-236	Sequence 236, App
13	1277	99.3	327	14	US-10-227-873-236	Sequence 236, App
14	1277	99.3	327	14	US-10-227-883-236	Sequence 236, App
15	1277	99.3	327	14	US-10-219-076-236	Sequence 236, App
16	1277	99.3	327	14	US-10-230-434-236	Sequence 236, App
17	1277	99.3	327	14	US-10-219-003-236	Sequence 236, App
18	1277	99.3	327	14	US-10-219-075-236	Sequence 236, App
19	1277	99.3	327	14	US-10-219-464-236	Sequence 236, App
20	1277	99.3	327	14	US-10-219-466-236	Sequence 236, App
21	1277	99.3	327	14	US-10-219-479-236	Sequence 236, App
22	1277	99.3	327	14	US-10-219-481-236	Sequence 236, App
23	1277	99.3	327	14	US-10-230-260-236	Sequence 236, App
24	1277	99.3	327	14	US-10-232-231-236	Sequence 236, App
25	1277	99.3	327	14	US-10-232-233-236	Sequence 236, App
26	1277	99.3	327	14	US-10-216-165-236	Sequence 236, App
27	1277	99.3	327	14	US-10-218-956-236	Sequence 236, App
28	1277	99.3	327	14	US-10-219-488-236	Sequence 236, App
29	1277	99.3	327	14	US-10-219-478-236	Sequence 236, App
30	1277	99.3	327	14	US-10-219-536-236	Sequence 236, App
31	1277	99.3	327	14	US-10-233-205-236	Sequence 236, App
32	1277	99.3	327	14	US-10-219-072-236	Sequence 236, App
33	1277	99.3	327	14	US-10-219-470-236	Sequence 236, App
34	1277	99.3	327	14	US-10-219-474-236	Sequence 236, App
35	1277	99.3	327	14	US-10-219-524-236	Sequence 236, App
36	1277	99.3	327	14	US-10-219-528-236	Sequence 236, App
37	1277	99.3	327	14	US-10-227-881-236	Sequence 236, App
38	1277	99.3	327	14	US-10-227-882-236	Sequence 236, App
39	1277	99.3	327	14	US-10-232-223-236	Sequence 236, App
40	1277	99.3	327	14	US-10-232-225-236	Sequence 236, App
41	1277	99.3	327	14	US-10-232-227-236	Sequence 236, App
42	1277	99.3	327	14	US-10-232-229-236	Sequence 236, App
43	1277	99.3	327	14	US-10-232-234-236	Sequence 236, App
44	1277	99.3	327	14	US-10-232-236	Sequence 236, App
45	1277	99.3	327	14	US-10-232-236	Sequence 236, App

ALIGNMENTS

RESULT 1
US-09-820-893-98
; Sequence 98, Application US/09820893
; Patent No. US20020076705A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033P1
; CURRENT APPLICATION NUMBER: US/09/820,893
; CURRENT FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 98
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-820-893-98

Query Match	100.0%	Score 1286;	DB 9;	Length 245;
Best Local Similarity	100.0%	Pred. No. 1.1e-96;		
Matches 245;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	MAELPGFLCGALLGFLCLSGLAVEVKVPTPELSTPLGKTABLTCTYSTVSGDSFALEWS	60	
Db	1	MAELPGFLCGALLGFLCLSGLAVEVKVPTPELSTPLGKTABLTCTYSTVSGDSFALEWS	60	
QY	61	FVOPGKPISESHPIYFTNGHLYPTGSKSKRVSLQNPPTVGATVATLKLTDVHPSDGTYL	120	
Db	61	FVOPGKPISESHPIYFTNGHLYPTGSKSKRVSLQNPPTVGATVATLKLTDVHPSDGTYL	120	

Qy	121	CQVNNPPDPYTNGLGLINLTVLVPPSNPLCSQSQTSGGSTALRCSSSGAPKPYNVW	180
Dδ	121	CQVNNPPDPYTNGLGLINLTVLVPPSNPLCSQSQTSGGSTALRCSSSGAPKPYNVW	180
Qy	181	RIGTFPTPSPGSMVDVSGQLITNLISLTSSGTTCVATNQMGASCELLTSVTSPSQG	240
Dδ	181	RIGTFPTPSPGSMVDVSGQLITNLISLTSSGTTCVATNQMGASCELLTSVTSPSQG	240
Qy	241	RVABL 245	
Dδ	241	RVABL 245	

RESULT 2

```

US-10-607-565-98
; Sequence 98, Application US/10607565
; Publication No. US20040048294A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033P1
; CURRENT APPLICATION NUMBER: US/10/607,565
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: US/09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/101,546
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 98
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-607-565-98

```

Query Match	100.0%;	Score 1286;	DB 15;	Length 245;
Best Local Similarity	100.0%;	Pred. No. 1.1e-96;		
Matches 245;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	MAELPGPFLCGALIGFLCSGLAIVGVKVPTEPLSTPLGKTABLTCTYTSTSVGDSFALEWS	60	
Db	1	MAELPGPFLCGALIGFLCSGLAIVGVKVPTEPLSTPLGKTABLTCTYTSTSVGDSFALEWS	60	
Qy	61	FVQPKPISESHPILYFTNGHLYPTGSKSRVSLIQNPPTVGVATLKLTDVHRPSDGTGYL	120	
Db	61	FVQPKPISESHPILYFTNGHLYPTGSKSRVSLIQNPPTVGVATLKLTDVHRPSDGTGYL	120	
Qy	121	CQVNNPDPFYNTGGLINLTLVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVNVV	180	
Db	121	CQVNNPDPFYNTGGLINLTLVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVNVV	180	
Qy	181	RLGFTFPSPGSMVQDEVSGQLITNLISLTSSGTYRCVATNQMGSAACELTSLVTPESQ	240	
Db	181	RLGFTFPSPGSMVQDEVSGQLITNLISLTSSGTYRCVATNQMGSAACELTSLVTPESQ	240	
Qy	241	RVAEI 245		
Db	241	RVAEI 245		

RESULT 3

```

US-09-820-893-83
; Sequence 83, Application US/09820893
; Patent No. US20020076705A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033F1
; CURRENT APPLICATION NUMBER: US/09/820,893
; CURRENT FILING DATE: 2001-03-30
; PRIORITY APPLICATION NUMBER: 09/531,119

```

```

; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 83
; LENGTH: 246
; TYPE: PR1
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (246)
; OTHER INFORMATION: Xaa equals stop translation
; OS=820-893-83

```

RESULT 4

```

US-10-607-565-83
; Sequence 83, Application US/10607565
; Publication No. US20040048294A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033p1
; CURRENT APPLICATION NUMBER: US/10/607,565
; CURRENT FILING DATE: 2003-06-27/531,119
; PRIOR APPLICATION NUMBER: US/09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/101,546
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 83
; LENGTH: 246
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (246)
; OTHER INFORMATION: Xaa equals stop translation
US-10-607-565-83

```

Query Match 100.0%; Score 1286; DB 15; Length 246;
Best Local Similarity 100.0%; Pred. No. 1.1e-96;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 MASELPGLCGALLGFLCSGLAVEKVPTEPLSTPLGKTAELTCTVSTVGDSFALEWS 60
Qy 61 FVOPGKPISSHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTGYL 120
Db 61 FVOPGKPISSHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTGYL 120
Qy 121 CQVNNPPDFYTNGLGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSSGAPKPVYVNW 180
Db 121 CQVNNPPDFYTNGLGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSSGAPKPVYVNW 180
Qy 181 RLGTFTPPSGSMQVDEVSQQLILTNLSLTSSGTTCYRCVATNMGSAACELTSLVTPBSQ 240
Db 181 RLGTFTPPSGSMQVDEVSQQLILTNLSLTSSGTTCYRCVATNMGSAACELTSLVTPBSQ 240
Qy 241 RVAEL 245
Db 241 RVAEL 245

RESULT 5

US-10-227-884-236

; Sequence 236, Application US/10227884

; Publication No. US20030027988A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Deenover, Luc

; APPLICANT: Gerritsen, Mary

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Smith, Victoria

; APPLICANT: Stephan, Jean-Philippe F.

; APPLICANT: Watanabe, Colin L.

; APPLICANT: Wood, William I.

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3530P1C79

; CURRENT APPLICATION NUMBER: US/10/227,884

; CURRENT FILING DATE: 2002-08-26

; PRIOR APPLICATION NUMBER: 10/119,480

; PRIOR FILING DATE: 2002-04-09

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/062287

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/063549

; PRIOR FILING DATE: 1997-10-28

; PRIOR APPLICATION NUMBER: 60/064103

; PRIOR FILING DATE: 1997-10-31

; PRIOR APPLICATION NUMBER: 60/069873

; PRIOR FILING DATE: 1997-12-17

; PRIOR APPLICATION NUMBER: 60/078910

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/079294

; PRIOR FILING DATE: 1998-03-25

; PRIOR APPLICATION NUMBER: 60/079656

; PRIOR FILING DATE: 1998-03-26

; PRIOR APPLICATION NUMBER: 60/079728

; PRIOR FILING DATE: 1998-03-27

; PRIOR APPLICATION NUMBER: 60/081819

; PRIOR FILING DATE: 1998-04-15

; PRIOR APPLICATION NUMBER: 60/081955

; PRIOR FILING DATE: 1998-04-15

; PRIOR APPLICATION NUMBER: 60/082804

; PRIOR FILING DATE: 1998-04-22

; PRIOR APPLICATION NUMBER: 60/084441

; PRIOR FILING DATE: 1998-05-06

; PRIOR APPLICATION NUMBER: 60/085323

; PRIOR FILING DATE: 1998-05-13

; PRIOR APPLICATION NUMBER: 60/085579

; PRIOR FILING DATE: 1998-05-15

; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464

```
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07

; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match          99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAELPGPFLCGALIGFLCGLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
   |||||
Db 1 MAELPGPFLCGALIGFLCGLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
   |||||

Qy 61 FVQPKPISESHPILYFTNGHLYPTGSKSKVSVLLQNPPTVGVATLKLTDVHPSDTGYL 120
   |||||
Db 61 FVQPKPISESHPILYFTNGHLYPTGSKSKVSVLLQNPPTVGVATLKLTDVHPSDTGYL 120
   |||||

Qy 121 QVANNPPDFYTNGLGLINLTVLVPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
   |||||
Db 121 QVANNPPDFYTNGLGLINLTVLVPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
   |||||

Qy 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSASCELTLVTEPSQG 240
   |||||
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSASCELTLVTEPSQG 240
   |||||

Qy 241 RVA 243
   |||
Db 241 RVA 243
   |||

RESULT 6
US-10-230-163-236
; Sequence 236, Application US/10230163
; Publication No. US20030036635A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PlC96
; CURRENT APPLICATION NUMBER: US/10/230,163
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
```


/ PRIOR FILING DATE: 1998-04-15
/ PRIOR APPLICATION NUMBER: 60/082804
/ PRIOR FILING DATE: 1998-04-22
/ PRIOR APPLICATION NUMBER: 60/084441
/ PRIOR FILING DATE: 1998-05-06
/ PRIOR APPLICATION NUMBER: 60/085323
/ PRIOR FILING DATE: 1998-05-13
/ PRIOR APPLICATION NUMBER: 60/085579
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/086392
/ PRIOR FILING DATE: 1998-05-22
/ PRIOR APPLICATION NUMBER: 60/089532
/ PRIOR FILING DATE: 1998-06-17
/ PRIOR APPLICATION NUMBER: 60/089538
/ PRIOR FILING DATE: 1998-06-17
/ PRIOR APPLICATION NUMBER: 60/089905
/ PRIOR FILING DATE: 1998-06-18
/ PRIOR APPLICATION NUMBER: 60/090472
/ PRIOR FILING DATE: 1998-06-24
/ PRIOR APPLICATION NUMBER: 60/090557
/ PRIOR FILING DATE: 1998-06-24
/ PRIOR APPLICATION NUMBER: 60/090691
/ PRIOR FILING DATE: 1998-06-25
/ PRIOR APPLICATION NUMBER: 60/090695
/ PRIOR FILING DATE: 1998-06-25
/ PRIOR APPLICATION NUMBER: 60/091982
/ PRIOR FILING DATE: 1998-07-07
/ PRIOR APPLICATION NUMBER: 60/095302
/ PRIOR FILING DATE: 1998-08-04
/ PRIOR APPLICATION NUMBER: 60/095318
/ PRIOR FILING DATE: 1998-08-04
/ PRIOR APPLICATION NUMBER: 60/095916
/ PRIOR FILING DATE: 1998-08-10
/ PRIOR APPLICATION NUMBER: 60/096146
/ PRIOR FILING DATE: 1998-08-11
/ PRIOR APPLICATION NUMBER: 60/096791
/ PRIOR FILING DATE: 1998-08-17
/ PRIOR APPLICATION NUMBER: 60/097986
/ PRIOR FILING DATE: 1998-08-26
/ PRIOR APPLICATION NUMBER: 60/098544
/ PRIOR FILING DATE: 1998-08-31
/ PRIOR APPLICATION NUMBER: 60/099596
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099598
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099803
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099811
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099812
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099816
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/100038
/ PRIOR FILING DATE: 1998-09-11
/ PRIOR APPLICATION NUMBER: 60/100385
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100390
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100627
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100848
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/100919
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/101477
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101738
/ PRIOR FILING DATE: 1998-09-24
/ PRIOR APPLICATION NUMBER: 60/101741
/ PRIOR FILING DATE: 1998-09-24
/ PRIOR APPLICATION NUMBER: 60/101786
/ PRIOR FILING DATE: 1998-09-25

/ PRIOR APPLICATION NUMBER: 60/101916
/ PRIOR FILING DATE: 1998-09-24
/ PRIOR APPLICATION NUMBER: 60/101922
/ PRIOR FILING DATE: 1998-09-24
/ PRIOR APPLICATION NUMBER: 60/106178
/ PRIOR FILING DATE: 1998-10-28
/ PRIOR APPLICATION NUMBER: 60/106248
/ PRIOR FILING DATE: 1998-10-29
/ PRIOR APPLICATION NUMBER: 60/106464
/ PRIOR FILING DATE: 1998-10-30
/ PRIOR APPLICATION NUMBER: 60/106905
/ PRIOR FILING DATE: 1998-11-03
/ PRIOR APPLICATION NUMBER: 60/108787
/ PRIOR FILING DATE: 1998-11-17
/ PRIOR APPLICATION NUMBER: 60/108801
/ PRIOR FILING DATE: 1998-11-17
/ PRIOR APPLICATION NUMBER: 60/108849
/ PRIOR FILING DATE: 1998-11-18
/ PRIOR APPLICATION NUMBER: 60/112422
/ PRIOR FILING DATE: 1998-12-15
/ PRIOR APPLICATION NUMBER: 60/113296
/ PRIOR FILING DATE: 1998-12-22
/ PRIOR APPLICATION NUMBER: 60/113605
/ PRIOR FILING DATE: 1998-12-23
/ PRIOR APPLICATION NUMBER: 60/113621
/ PRIOR FILING DATE: 1998-12-23
/ PRIOR APPLICATION NUMBER: 60/115558
/ PRIOR FILING DATE: 1999-01-12
/ PRIOR APPLICATION NUMBER: 60/115565
/ PRIOR FILING DATE: 1999-01-12
/ PRIOR APPLICATION NUMBER: 60/115733
/ PRIOR FILING DATE: 1999-01-12
/ PRIOR APPLICATION NUMBER: 60/119549
/ PRIOR FILING DATE: 1999-02-10
/ PRIOR APPLICATION NUMBER: 60/123618
/ PRIOR FILING DATE: 1999-03-10
/ PRIOR APPLICATION NUMBER: 60/125259
/ PRIOR FILING DATE: 1999-03-19
/ PRIOR APPLICATION NUMBER: 60/125775
/ PRIOR FILING DATE: 1999-03-23
/ PRIOR APPLICATION NUMBER: 60/126773
/ PRIOR FILING DATE: 1999-03-29
/ PRIOR APPLICATION NUMBER: 60/127887
/ PRIOR FILING DATE: 1999-04-05
/ PRIOR APPLICATION NUMBER: 60/130232
/ PRIOR FILING DATE: 1999-04-21
/ PRIOR APPLICATION NUMBER: 60/131022
/ PRIOR FILING DATE: 1999-04-26
/ PRIOR APPLICATION NUMBER: 60/131270
/ PRIOR FILING DATE: 1999-04-27
/ PRIOR APPLICATION NUMBER: 60/131291
/ PRIOR FILING DATE: 1999-04-27
/ PRIOR APPLICATION NUMBER: 60/131445
/ PRIOR FILING DATE: 1999-04-28
/ PRIOR APPLICATION NUMBER: 60/134287
/ PRIOR FILING DATE: 1999-05-14
/ PRIOR APPLICATION NUMBER: 60/140650
/ PRIOR FILING DATE: 1999-06-22
/ PRIOR APPLICATION NUMBER: 60/140723
/ PRIOR FILING DATE: 1999-06-22
/ PRIOR APPLICATION NUMBER: 60/141037
/ PRIOR FILING DATE: 1999-06-23
/ PRIOR APPLICATION NUMBER: 60/144758
/ PRIOR FILING DATE: 1999-07-20
/ PRIOR APPLICATION NUMBER: 60/145698
/ PRIOR FILING DATE: 1999-07-26
/ PRIOR APPLICATION NUMBER: 60/146222
/ PRIOR FILING DATE: 1999-07-28
/ PRIOR APPLICATION NUMBER: 60/146963
/ PRIOR FILING DATE: 1999-08-03
/ PRIOR APPLICATION NUMBER: 60/149320
/ PRIOR FILING DATE: 1999-08-17
/ PRIOR APPLICATION NUMBER: 60/149638

; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
Db 121 CQVNNPPDFYTNGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
QY 181 RLGTPTPSGSMQDEVSGQLILTNLSSTGYRCVATNQMGASCELTLVSVPESQ 240
Db 181 RLGTPTPSGSMQDEVSGQLILTNLSSTGYRCVATNQMGASCELTLVSVPESQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 7

US-10-230-338-236
; Sequence 236, Application US/10230338
; Publication No. US2003004934A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C92
; CURRENT APPLICATION NUMBER: US/10/230,338
; PRIOR FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-338-236

Query Match 99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
Db 121 CQVNNPPDFYTNGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
QY 181 RLGTPTPSGSMQDEVSGQLILTNLSSTGYRCVATNQMGASCELTLVSVPESQ 240
Db 181 RLGTPTPSGSMQDEVSGQLILTNLSSTGYRCVATNQMGASCELTLVSVPESQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 8

US-10-218-631-236
; Sequence 236, Application US/10218631
; Publication No. US20030045687A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C14
; CURRENT APPLICATION NUMBER: US/10/218,631
; PRIOR FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910

; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-631-236

Query Match 99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGILNLTVPBPNPLCSQSGQTSVGGSTALRCSSEGAKPKPVNW 180
Db 121 CQVNNPPDFYTNGLGILNLTVPBPNPLCSQSGQTSVGGSTALRCSSEGAKPKPVNW 180
QY 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLSTVTPSQ 240
Db 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLSTVTPSQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 9
US-10-230-414-236
; Sequence 236, Application US/10230414
; Publication No. US20030050448A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C98
; CURRENT APPLICATION NUMBER: US/10/230,414
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17

; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-414-236

Query Match 99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGILNLTVPBPNPLCSQSGQTSVGGSTALRCSSEGAKPKPVNW 180
Db 121 CQVNNPPDFYTNGLGILNLTVPBPNPLCSQSGQTSVGGSTALRCSSEGAKPKPVNW 180
QY 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLSTVTPSQ 240
Db 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLSTVTPSQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 10
US-10-232-224-236
; Sequence 236, Application US/10232224
; Publication No. US20030065147A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C111
; CURRENT APPLICATION NUMBER: US/10/232,224
; CURRENT FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873

Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MAELPGPFLCAGLGLCLSGLAVERVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS	60
Db	1	MAELPGPFLCAGLGLCLSGLAVERVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS	60
QY	61	FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYTL	120
Db	61	FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYTL	120
QY	121	QVNNPPDFYFTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAKPKVYNNV	180
Db	121	QVNNPPDFYFTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAKPKVYNNV	180
QY	181	RLGTFTPPSPGSMQDEVSQGLITLNLSTSSGTYRCVATNMGASCELTLSTVTPSQ	240
Db	181	RLGTFTPPSPGSMQDEVSQGLITLNLSTSSGTYRCVATNMGASCELTLSTVTPSQ	240
QY	241	RVA 243	
Db	241	RVA 243	

RESULT 13

US-10-227-873-236
; Sequence 236, Application US/10227873
; Publication No. US20030073816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P35301C72
; CURRENT APPLICATION NUMBER: US/10/227,873
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06

; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178

; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09

; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835
; PRIOR APPLICATION NUMBER: 60/169835
Query Match 99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTVGDSPALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTVGDSPALEWS 60
QY 61 FVQFGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVQFGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
QY 121 QVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
Db 121 QVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNMGMSASCELTLVTEPSQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNMGMSASCELTLVTEPSQG 240
QY 241 RVA 243
Db 241 RVA 243
RESULT 14
US-10-227-883-236
; Sequence 236, Application US/10227883
; Publication No. US20030073817A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C78
; CURRENT APPLICATION NUMBER: US/10/227,883
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728

; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96; Mismatches 0; Indels 0; Gaps 0;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
Db 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGINLTVLVPPSNPLCSOGQTSVGGSTALRCSSEGAPKPVYNNV 180
Db 121 CQVNNPPDFYTNGLGINLTVLVPPSNPLCSOGQTSVGGSTALRCSSEGAPKPVYNNV 180
QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLVTEPSQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLVTEPSQG 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 15

US-10-219-076-236
; Sequence 236, Application US/10219076
; Publication No. US20030078379A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530PIC62
; CURRENT APPLICATION NUMBER: US/10/219,076
; CURRENT FILING DATE: 2002-08-14
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31

; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 245
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-219-076-236

Query Match 99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96; Mismatches 0; Indels 0; Gaps 0;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
Db 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGINLTVLVPPSNPLCSOGQTSVGGSTALRCSSEGAPKPVYNNV 180
Db 121 CQVNNPPDFYTNGLGINLTVLVPPSNPLCSOGQTSVGGSTALRCSSEGAPKPVYNNV 180
QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLVTEPSQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLVTEPSQG 240
QY 241 RVA 243
Db 241 RVA 243

Search completed: August 4, 2005, 06:47:29
Job time : 67.0997 secs

GenCore version 5.1.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 05:56:06 ; Search time 61.3592 Seconds
(without alignments)
1852.722 Million cell updates/sec

Title: US-10-607-565-83_COPY_24_245

Perfect score: 1164

Sequence: 1 VEVKVTPLSTPLGKTAEL.....ASCELTSLVTEPSQGRVAEL 222

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt_03:*

1: uniprot_eprot:**

2: uniprot_trembl:**

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1155	99.2	284	Q9NX42	Q9NX42 homo sapien
2	1155	99.2	327	Q96IQ7	Q96IQ7 homo sapien
3	1145	98.4	325	Q95791	Q95791 homo sapien
4	982	84.4	304	Q9CVA4	Q9CVA4 mus musculus
5	960	82.5	328	Q9Z109	Q9Z109 mus musculus
6	656	56.4	248	Q9D0T4	Q9D0T4 mus musculus
7	352	30.2	259	Q7Z2Q1	Q7Z2Q1 homo sapien
8	352	30.2	387	Q86XK7	Q86XK7 homo sapien
9	352	30.2	412	Q6WZS4	Q6WZS4 homo sapien
10	332.5	28.6	407	Q9D2J4	Q9D2J4 mus musculus
11	329.5	28.3	430	Q8N4F1	Q8N4F1 homo sapien
12	316	27.1	318	Q91664	Q91664 xenopus lae
13	311.5	26.8	335	Q9PWR4	Q9PWR4 gallus gall
14	311.5	26.8	335	Q9YGH1	Q9YGH1 gallus gall
15	303.5	26.1	335	Q9YGV5	Q9YGV5 gallus gall
16	299	25.7	432	Q6DDE7	Q6DDE7 xenopus lae
17	289.5	24.9	323	Q8NDD2	Q8NDD2 homo sapien
18	286.5	24.6	181	Q91665	Q91665 xenopus lae
19	281	24.1	319	A33 HUMAN	Q99795 homo sapien
20	269.5	23.2	300	Q9D5J0	Q9D5J0 mus musculus
21	267.5	23.0	372	Q90Y50	Q90Y50 brachydanio
22	266.5	22.9	300	Q9DA22	Q9DA22 mus musculus
23	264.5	22.7	332	Q6F359	Q6F359 xenopus tro
24	264	22.7	319	A33 MOUSE	Q9JKA5 mus musculus
25	261.5	22.5	406	Q8N7T8	Q8N7T8 homo sapien
26	260.5	22.4	442	Q6NW88	Q6NW88 brachydanio
27	254.5	21.9	319	Q9TU80	Q9TU80 canis famill
28	249.5	21.4	394	Q925F2	Q925F2 mus musculus
29	248.5	21.3	352	Q91W66	Q91W66 mus musculus
30	248.5	21.3	365	1 CXAR MOUSE	P97792 mus musculus
31	248.5	21.3	365	2 Q9DBJ8	Q9DBJ8 mus musculus

```

32 243.5 20.9 394 2 Q6AYD4
33 240.5 20.7 344 2 Q9R067
34 240.5 20.7 358 2 Q9R066
35 237 20.4 298 2 Q804R4
36 236.5 20.3 344 2 Q9UKV4
37 236.5 20.3 365 1 CXAR HUMAN
38 233.5 20.1 319 2 Q9TU79
39 233.5 20.1 365 2 Q8MMV3
40 229.5 19.7 390 2 Q95K13
41 225.5 19.4 373 2 Q8R373
42 224.5 19.3 372 2 Q8KI60
43 224.5 19.3 373 2 Q9H6B4
44 221.5 19.0 373 2 Q920S5
45 221 19.0 332 2 Q640U3

```

```

Q6ayd4 rattus norv
Q9r067 rattus norv
Q9r066 rattus norv
Q804r4 brachydanio
Q9ukv4 homo sapien
P78310 homo sapien
Q9tu79 sus scrofa
Q8mmv3 bos taurus
Q95k13 macaca fasc
Q8r373 mus musculu
Q8ki60 rattus norv
Q9h6b4 mus sapien
Q920s5 mus musculu
Q640u3 xenopus tro

```

ALIGNMENTS

RESULT 1

```

Q9NX42
ID Q9NX42 PRELIMINARY; PRT; 284 AA.
AC Q9NX42;
DT 01-OCT-2000 (Tremblrel. 15, Created)
DT 01-OCT-2000 (Tremblrel. 15, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE Hypothetical protein FLJ20453.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Watanabe K., Kumagai A., Itakura S., Yamazaki M., Tashiro H., Ota T.,
RA Suzuki Y., Ohtsuka M., Nishi T., Shibahara T., Tanaka T.,
RA Nakamura Y., Isegai T., Sugano S.;
RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK000460; BAA91179.1; -
DR HSP; O88792; 1F97.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003598; IG_C2.
DR Pfam; PF00047; Ig_1.
DR SMART; SM00408; IGC2; 1.
DR PROSITE; PS00835; IG LIKE; 2.
SQ SEQUENCE 284 AA; 29829 MW; 1F9E09C60856B9A9 CRC64;

```

```

Query Match 99.2%; Score 1155; DB 2; Length 284;
Best Local Similarity 100.0%; Pred. No. 1.8e-83;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1 VEVKVTPLSTPLGKTAELCTYSTSYGDSFALEWSFVQPKPISESPILYFTNGHLY 60
Db 24 VEVKVTPLSTPLGKTAELCTYSTSYGDSFALEWSFVQPKPISESPILYFTNGHLY 83
QY 61 PTGSKSKRVSLQNPPPTGVATLKLTDVHPSDTGYLCQVNNPPDYFTNGGLINLTVLV 120
Db 84 PTGSKSKRVSLQNPPPTGVATLKLTDVHPSDTGYLCQVNNPPDYFTNGGLINLTVLV 143
QY 121 PPSNPLCSQSGTSGVGGSTALRCSSEGAPKPVYNNVRLGTPTPTSPGSMQDEVSGQLI 180
Db 144 PPSNPLCSQSGTSGVGGSTALRCSSEGAPKPVYNNVRLGTPTPTSPGSMQDEVSGQLI 203
QY 181 LTNLSTLSSGTVCVATNMQSGASCELTLSVTEPSQGRVA 220
Db 204 LTNLSTLSSGTVCVATNMQSGASCELTLSVTEPSQGRVA 243

```

RESULT 2

```

Q96IQ7 PRELIMINARY; PRT; 327 AA.
ID Q96IQ7
AC Q96IQ7;
DT 01-DEC-2001 (Tremblrel. 19, Created)
DT 01-DEC-2001 (Tremblrel. 19, Last sequence update)

```

```

DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE V-set and immunoglobulin domain containing 2 (CTH Variant).
GN Name=VSI2; ORFName=UNQ2770;
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RA Director MGC Project;
RN Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
[3]
RP SEQUENCE FROM N.A.
RX MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D., Brush J.,
RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA Eaton D., Foster J., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA Huang A., Kim H.S., Klinowski L., Jin Y., Johnson S., Lee J.,
RA Lewis L., Liao D., Mark M., Robbie E., Sanchez C., Schoenfeld J.,
RA Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA Vandlen R., Watanabe C., Wleand D., Woods K., Xie M.H., Yansura D.,
RA Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,
RA Godowski P.;
RT "The secreted protein discovery initiative (SPDI), a large-scale
effort to identify novel human secreted and transmembrane proteins: a
bioinformatics assessment.";
RL Genome Res. 13:2265-2270(2003).
DR EMBL; BC007313; AAH07313.1; -.
DR EMBL; AV358897; AAO89256.1; -.
DR HSSP; O88792; 1F97.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR007110; IG-like.
DR Pfam; PF00047; ig; 1.
DR PROSITE; PS50835; IG LIKE; 2.
SQ SEQUENCE 327 AA; 34348 MW; CF395AC7EF951AC1 CRC64;

Query Match 99.2%; Score 1155; DB 2; Length 327;
Best Local Similarity 100.0%; Pred. No. 2.1e-83;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB |||||
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DE Mus musculus adult male stomach cDNA, RIKEN full-length enriched
DE library, clone:2210413P10 product:CTM homolog (Fragment).
GN Name=2210413P10rik;
OS Mus musculus (Mouse).

QY 61 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGTLYCQVNNPPDFYTNGLINLTLV 120
DB |||||
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DE Mus musculus adult male stomach cDNA, RIKEN full-length enriched
DE library, clone:2210413P10rik;
GN Name=2210413P10rik;
OS Mus musculus (Mouse).

QY 84 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGTLYCQVNNPPDFYTNGLINLTLV 143
DB |||||

QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVNWRVRLGTFTPTSPGSMVQDEVSGQLI 180
DB |||||
QY 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVNWRVRLGTFTPTSPGSMVQDEVSGQLI 203
DB |||||
QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSVTEPSQGRVA 220
DB |||||
QY 204 LTNLSLTSSGTYRCVATNQMSASCELTLSVTEPSQGRVA 243
DB |||||

RESULT 3
Q95791 PRELIMINARY; PRT; 325 AA.
AC O95791;
DT 01-MAY-1999 (TrEMBLrel. 10, Created)
DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE CTH.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95077161; PubMed=9862345;
RX DOI=10.1002/(SICI)1521-4141(199812)28:12<4094::AID-IMMU4094>3.3.CO;2-U;
RA Chretien I., Marcuz A., Courtet M., Vainio O., Heath J.K.,
RA White S.J., Du Pasquier L.;
RT "CTX, a Xenopus thymocyte receptor, defines a molecular family
RT conserved throughout vertebrates.";
RL Eur. J. Immunol. 28:4094-4104(1998).
DR EMBL; AF061022; AAD17522.1; -.
DR HSSP; O88792; 1F97.
DR GO; GO:0005887; C:integral to plasma membrane; TAS.
DR GO; GO:0005624; C:membrane fraction; TAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003598; IG_c2.
DR Pfam; PF00047; ig; 1.
DR SMART; SM00408; IGC2; 1.
DR PROSITE; PS50835; IG LIKE; 2.
SQ SEQUENCE 325 AA; 34329 MW; B7B5B664CBCFF4BE CRC64;

Query Match 98.4%; Score 1145; DB 2; Length 325;
Best Local Similarity 99.1%; Pred. No. 1.3e-82;
Matches 217; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB |||||
QY 23 VEVKVTPEPLSTPLGKTAELTCTYSTVSGDTFALEWSFVQPKPISESHPILYFTNGHLY 82
DB |||||
QY 61 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGTLYCQVNNPPDFYTNGLINLTLV 120
DB |||||
QY 83 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGTLYCQVNNPPDFYTNGLINLTLV 142
DB |||||
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVNWRVRLGTFTPTSPGSMVQDEVSGQLI 180
DB |||||
QY 143 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVNWRVRLGTFTPTSPGSMVQDEVSGQLI 202
DB |||||
QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSVTEPSQGRV 219
DB |||||
QY 203 LTNLSLTSSGTYRCVATNQMSASCELTLSVTEPSQGRV 241
DB |||||

RESULT 4
Q9CVA4 PRELIMINARY; PRT; 304 AA.
AC Q9CVA4;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DE Mus musculus adult male stomach cDNA, RIKEN full-length enriched
DE library, clone:2210413P10 product:CTM homolog (Fragment).
GN Name=2210413P10rik;
OS Mus musculus (Mouse).

QY 1 VEVKVTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB |||||
QY 24 VEVKVTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
DB |||||
QY 61 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGTLYCQVNNPPDFYTNGLINLTLV 120
DB |||||
QY 84 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGTLYCQVNNPPDFYTNGLINLTLV 143
DB |||||
```


Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S., Krzywinaki M.I., Skalska U., Smallos D.E., Schnerch A., Schein J.E., Jones S.J., Maria M.A.;
 "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences";
 Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 [2]
 SEQUENCE FROM N.A.
 RA TISSUE=Brain;
 RC STRAUSBERG R.;
 RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC034411; AAH34411.1; -;
 DR HSSP; P78310; LEAF.
 DR Genew; HGNC:16669; IGSF11.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003598; IG_c2.
 DR Pfam; PF00047; ig; 1.
 DR SMART; SM00408; IGC2; 1.
 DR PROSITE; PS50835; IG_LIKE; 2.
 SQ SEQUENCE 430 AA; 46245 MW; E53FC718C10D049D CRC64;
 Query Match 28.3%; Score 329.5; DB 2; Length 430;
 Best Local Similarity 34.7%; Pred. No. 6.5e-18;
 Matches 75; Conservative 35; Mismatches 101; Indels 5; Gaps 5;
 QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTSVG-DGFALEWSEFVQPKPISESHPILYFTNGHL 59
 DB 22 LEVSESPGSIQVARGQTAVLPCTFTTSAALINLVIV-NVTPLSNANQPEQVILYGGQM 80
 QY 60 YPTGSK-SKRVSLQNPPPTGVATLKLTDVHPSDGTGTYLCQVNNPPDFYTNGLGLINLTV 118
 DB 81 FDGAPRFHGRVFTGTPATNV-SIFINNTQLSDTGTQCLVNNLPDIGNRIGVTLTV 139
 QY 119 LVPPSNPLCSQSGQTSVGSSTALRCSSSEGAPKPVYNNVRLTFTPTSPGSMVQDEVSQ 178
 DB 140 LVPPGAPHQIQSGDQSGSVLLCSSEGIPTTYLWEKLN-TLKLPTATQDQVQST 198
 QY 179 LILTNLSLTSSGTYRCVATNMGSASCELTLSVTEP 214
 DB 199 VTRINISALSSGLYQCVASNAIGTSTCLDLQVISP 234
 RESULT 12
 Q91664
 ID Q91664 PRELIMINARY; PRT; 318 AA.
 AC Q91664;
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE CTX.
 OS Xenopus laevis (African clawed frog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae;
 OC Xenopodinae; Xenopus.
 OX NCBI_TaxID=8355;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=ff; TISSUE=Thymus;
 RX MEDLINE=96210130; PubMed=8625968;
 RA Chretien I., Robert J., Marcuz A., Garcia-Sanz J.A., Courtet M., Du Pasquier L.;
 RT "CTX, a novel molecule specifically expressed on the surface of cortical thymocytes in Xenopus";
 RL Eur. J. Immunol. 26:780-791(1996).
 DR EMBL; U43330; AAC59899.1; -;
 DR HSSP; P78310; 1KAC.
 DR Pfam; PF00047; ig; 1.
 DR SMART; SM00409; IG; 2.
 DR PROSITE; PS50835; IG_LIKE; 2.
 SQ SEQUENCE 318 AA; 34429 MW; 6231D24B08806C09 CRC64;
 Query Match 27.1%; Score 316; DB 2; Length 318;
 Best Local Similarity 35.2%; Pred. No. 5.3e-17;

Matches 75; Conservative 40; Mismatches 84; Indels 14; Gaps 7;
 QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTSVGSPFALEWSEFVQPKPISESHPILYFTNGH 58
 DB 20 VQVTQNPIINTSGONATLYCTYILNNKNKLVQWNIQFQKSNQST--VFFYQNGQ 77
 QY 59 LYPTGSKSKRVSLQNPPPTGVATLKLTDVHPSDGTGTYLCQVNNPPDFYTNGLGLINLTV 118
 DB 78 SLSGPSYKRVTAAMSP---GNATITISNMQSDGTGYTCEVLNLP--SSGQKILLTV 132
 QY 119 LVPPSNPLCSQSGQTSVGSSTALRCSSSEGAPKPVYNNVRL--GTPTSPSGSMVQDEVS 176
 DB 133 LVPPSPVPHCSIRGAVETGHFISLLCYSEGMERPIYSWNRVENGLLKS-TPSQMNOOK-- 189
 QY 177 GOLILTNLSLTSSGTYRCVATNMGSASCELT 209
 DB 190 GSLIIGNLTFEEGYRCTASNNLGNATCELNL 222
 RESULT 13
 Q9PWR4
 ID Q9PWR4 PRELIMINARY; PRT; 335 AA.
 AC Q9PWR4;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Cht1 thymocyte antigen precursor.
 GN Name=Cht1;
 OS Gallus gallus (Chicken).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
 OC Gallus.
 OX NCBI_TaxID=9031;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=H.B19; TISSUE=Thymus;
 RA Katsuvu K.H., Boyd R., Gobel T.T., Bean A., Dunon D., Imhof B.A., Vainio O.;
 RL Submitted (JUN-1997) to the EMBL/GenBank/DBJ databases.
 DR EMBL; Y14064; CAA74391.1; -;
 DR HSSP; P78310; 1KAC.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003596; IG_v.
 DR Pfam; PF00047; ig; 1.
 DR SMART; SM00406; IGv; 1.
 DR PROSITE; PS50835; IG_LIKE; 2.
 KW Signal.
 FT SIGNAL 1 21 Potential.
 FT CHAIN 22 335 Cht1 thymocyte antigen.
 SQ SEQUENCE 335 AA; 36509 MW; AA6159598079B438 CRC64;
 Query Match 26.8%; Score 311.5; DB 2; Length 335;
 Best Local Similarity 33.5%; Pred. No. 1.3e-16;
 Matches 71; Conservative 43; Mismatches 89; Indels 9; Gaps 5;
 QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTSVGSPFALEWSEFVQPKPISESHPILYFTNGH 58
 DB 22 VVVTVPEKTVNVKTCGNATLCTYTSSQPLG-NFFIQWSEFYSAKE--SQHTIYYSEQ 78
 QY 59 LYPTGSKSKRVSLQNPPPTGVATLKLTDVHPSDGTGTYLCQVNNPPDFYTNGLGLINLTV 118
 DB 79 SYSGEPKDRITAATSP---GNATITISNMQSDGTGYTCEVFPQDDAGQSQSVIVNV 135
 QY 119 LVPPSNPLCSQSGQTSVGSSTALRCSSSEGAPKPVYNNVRLTFTPTSPSGSMVQDEVSQ 178
 DB 136 LVKPSKPFCKIEGTPEKGLIYLLCKDQGLPHPTRYWKVDE-NLTPVTEYFNPDTGI 194
 QY 179 LILTNLSLTSSGTYRCVATNMGSASCELTLS 210
 DB 195 LYIGNLTTFTGTHYRCIASNMGNSLCELDLT 226
 RESULT 14


```

Q9VGH1
ID Q9VGH1 PRELIMINARY; PRT; 335 AA.
AC Q9VGH1;
DT 01-MAY-1999 (Tremblrel. 10, Created)
DT 01-MAY-1999 (Tremblrel. 10, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE Cht1 thymocyte antigen precursor.
GN Name=Cht1;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]_TaxID=9031;
RP SEQUENCE FROM N.A.
RC STRAIN=RPRL line 0; TISSUE=Thymus;
RA Katelyuo K.H., Boyd R., Gobel T.T., Bean A., Dunon D., Imhof B.A.,
RA Vainio O.;
RL Submitted (JUN-1997) to the EMBL/GenBank/DBJ databases.
DR EMBL; Y14063; CAA74390.1; -.
DR HSSP; P78310; IKAC.
DR InterPro; IPR007110; Ig-like.
DR Pfam; PF00047; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IGV_LIKE; 2.
KW Signal.
FT SIGNAL.
FT CHAIN.
FT CHAIN.
SQ SEQUENCE 335 AA; 36553 MW; AA640C5CD02CB16D CRC64;

Query Match 26.8%; Score 311.5; DB 2; Length 335;
Best Local Similarity 33.5%; Pred. No. 1.3e-16;
Matches 71; Conservative 43; Mismatches 89; Indels 9; Gaps 5;

QY 1 VEVKVPTEPLSTPLGKTAEITCTYSTS--VGDSFALEWSFVQPKPISESHPILYFTNGH 58
DB 22 VVVTVPKTVNVKVTGNATLLCTYTSSQPLG-NFFIQWSFYSAKE--SQLHTIYYISGQ 78

QY 59 LYPTGSKKRVSLQNPPTVGATLKLTDVHPSTGTLYLCQVNNPPDFYTNGLGLINLTV 118
DB 79 SYSYGEFKDRITAATSP---GNASITISNMQPSDTGTYCEVFSQDDAGSQSKSVINV 135

QY 119 LVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSQ 178
DB 136 LVKPSKPFCKIEGTPEKGHLIYLLCKDQGLSHPTRYWKYDE-NLTLPVTEYFNPDTGI 194

QY 179 LILTNLSLTSSGTYRCVATNMGASCELTL 210
DB 195 LYIGNLTTFETGCHYRCIASNMGSTCELDLT 226

RESULT 15
Q9VGV5
ID Q9VGV5 PRELIMINARY; PRT; 335 AA.
AC Q9VGV5;
DT 01-MAY-1999 (Tremblrel. 10, Created)
DT 01-MAY-1999 (Tremblrel. 10, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE Cht1.
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]_TaxID=9031;
RP SEQUENCE FROM N.A.
RX MEDLINE=99077161; PubMed=9862345;
RX DOI=10.1002/(SICI)1521-4141(199812)28:12<4094::AID-IMMU4094>3.3.CO;2-U;
RA Chretien I., Marcuz A., Courtet M., Katelyuo K., Vainio O., Heath J.K.,
RA White S.J., Du Pasquier L.;
RT "CTX, a Xenopus thymocyte receptor, defines a molecular family
RT conserved throughout vertebrates.";

```

```

RL Eur. J. Immunol. 28:4094-4104 (1998).
DR EMBL; AF061023; AADI7523.1; -.
DR HSSP; P78310; IKAC.
DR InterPro; IPR007110; Ig-like.
DR Pfam; PF00047; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IGV_LIKE; 2.
SQ SEQUENCE 335 AA; 36561 MW; 071A3133CE6DCA0 CRC64;

Query Match 26.1%; Score 303.5; DB 2; Length 335;
Best Local Similarity 33.0%; Pred. No. 5.5e-16;
Matches 70; Conservative 43; Mismatches 90; Indels 9; Gaps 5;

QY 1 VEVKVPTEPLSTPLGKTAEITCTYSTS--VGDSFALEWSFVQPKPISESHPILYFTNGH 58
DB 22 VVVTVPKTVNVKVTGNATLLCTYTSSQPLG-NFFIQWSFYSAKE--SQLHTIYYISGQ 78

QY 59 LYPTGSKKRVSLQNPPTVGATLKLTDVHPSTGTLYLCQVNNPPDFYTNGLGLINLTV 118
DB 79 SYSYGEFKDRITAATSP---GNASITISNMQPSDTGTYCEVFSQDDAGSQSKSVINV 135

QY 119 LVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSQ 178
DB 136 LVKPSKPFCKIEGTPEKGHLIYLLCKDQGLSHPTRYWKYDE-NLTLPVTEYFNPDTGI 194

QY 179 LILTNLSLTSSGTYRCVATNMGASCELTL 210
DB 195 LYIGNLTTFETGCHYRCIASNMGSTCELDLT 226

```

Search completed: August 4, 2005, 06:13:31
Job time : 62.3592 secs

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.
 OM protein - protein search, using sw model
 Run on: August 4, 2005, 06:13:42 ; Search time 59.8944 Seconds
 (without alignments)
 1447.018 Million cell updates/sec

Title: US-10-607-565-83_COPY_24_245
 Perfect score: 1164
 Sequence: 1 VEVKVTEPLSTPLGKTAEI.....ASCELTSLVTPSQGRVABL 222

Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 1752860 seqs, 390397842 residues

Total number of hits satisfying chosen parameters: 1752860

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Published Applications AA:*

- 1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
- 3: /cgn2_6/ptodata/1/pubpaa/US05_NEW_PUB.pep.*
- 4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
- 5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
- 6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
- 7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
- 8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
- 9: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
- 10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
- 11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
- 12: /cgn2_6/ptodata/1/pubpaa/US09C_NEW_PUB.pep.*
- 13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
- 14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
- 15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
- 16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
- 17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
- 18: /cgn2_6/ptodata/1/pubpaa/US10E_NEW_PUB.pep.*
- 19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
- 20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
- 21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
- 22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1164	100.0	245	9	US-09-820-893-98
2	1164	100.0	245	15	US-10-607-565-98
3	1164	100.0	246	9	US-09-820-893-83
4	1164	100.0	246	15	US-10-607-565-83
5	1155	99.2	326	15	US-10-443-108-4
6	1155	99.2	327	14	US-10-227-884-236
7	1155	99.2	327	14	US-10-230-163-236
8	1155	99.2	327	14	US-10-230-338-236
9	1155	99.2	327	14	US-10-218-631-236
10	1155	99.2	327	14	US-10-230-414-236
11	1155	99.2	327	14	US-10-232-224-236

12	1155	99.2	327	14	US-10-216-159A-236	Sequence 236, App
13	1155	99.2	327	14	US-10-218-849-236	Sequence 236, App
14	1155	99.2	327	14	US-10-227-873-236	Sequence 236, App
15	1155	99.2	327	14	US-10-227-883-236	Sequence 236, App
16	1155	99.2	327	14	US-10-219-076-236	Sequence 236, App
17	1155	99.2	327	14	US-10-230-434-236	Sequence 236, App
18	1155	99.2	327	14	US-10-219-003-236	Sequence 236, App
19	1155	99.2	327	14	US-10-219-075-236	Sequence 236, App
20	1155	99.2	327	14	US-10-219-464-236	Sequence 236, App
21	1155	99.2	327	14	US-10-219-466-236	Sequence 236, App
22	1155	99.2	327	14	US-10-219-479-236	Sequence 236, App
23	1155	99.2	327	14	US-10-219-481-236	Sequence 236, App
24	1155	99.2	327	14	US-10-230-260-236	Sequence 236, App
25	1155	99.2	327	14	US-10-232-231-236	Sequence 236, App
26	1155	99.2	327	14	US-10-232-233-236	Sequence 236, App
27	1155	99.2	327	14	US-10-216-165-236	Sequence 236, App
28	1155	99.2	327	14	US-10-218-956-236	Sequence 236, App
29	1155	99.2	327	14	US-10-219-468-236	Sequence 236, App
30	1155	99.2	327	14	US-10-219-478-236	Sequence 236, App
31	1155	99.2	327	14	US-10-219-536-236	Sequence 236, App
32	1155	99.2	327	14	US-10-233-205-236	Sequence 236, App
33	1155	99.2	327	14	US-10-219-072-236	Sequence 236, App
34	1155	99.2	327	14	US-10-219-470-236	Sequence 236, App
35	1155	99.2	327	14	US-10-219-474-236	Sequence 236, App
36	1155	99.2	327	14	US-10-219-524-236	Sequence 236, App
37	1155	99.2	327	14	US-10-219-528-236	Sequence 236, App
38	1155	99.2	327	14	US-10-227-880-236	Sequence 236, App
39	1155	99.2	327	14	US-10-227-881-236	Sequence 236, App
40	1155	99.2	327	14	US-10-227-882-236	Sequence 236, App
41	1155	99.2	327	14	US-10-230-436-236	Sequence 236, App
42	1155	99.2	327	14	US-10-232-223-236	Sequence 236, App
43	1155	99.2	327	14	US-10-232-225-236	Sequence 236, App
44	1155	99.2	327	14	US-10-232-227-236	Sequence 236, App
45	1155	99.2	327	14	US-10-232-229-236	Sequence 236, App

ALIGNMENTS

RESULT 1
 US-09-820-893-98
 ; Sequence 98, Application US/09820893
 ; Patent No. US20020076705A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rosen et al.
 ; TITLE OF INVENTION: 31 Human Secreted Proteins
 ; FILE REFERENCE: P2033PI
 ; CURRENT APPLICATION NUMBER: US/09/820,893
 ; CURRENT FILING DATE: 2001-03-30
 ; PRIOR APPLICATION NUMBER: 09/531,119
 ; PRIOR FILING DATE: 2000-03-20
 ; PRIOR APPLICATION NUMBER: 60/102,895
 ; PRIOR FILING DATE: 1998-10-02
 ; NUMBER OF SEQ ID NOS: 140
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 98
 ; LENGTH: 245
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-09-820-893-98

Query Match 100.0%; Score 1164; DB 9; Length 245;
 Best Local Similarity 100.0%; Pred. No. 1.7e-88;
 Matches 222; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVTEPLSTPLGKTAEICTYSTSGVDSFALEWSFVQPKPISESHPILYFTNGHLY 60
 |||||
 DB 24 VEVKVTEPLSTPLGKTAEICTYSTSGVDSFALEWSFVQPKPISESHPILYFTNGHLY 83
 |||||

QY 61 PTGSKSKRVSLQNPPVTGVATLKLTDVHPSTGTLYLCQVNNPPDPFYTNGLGLINTVLV 120
 |||||
 DB 84 PTGSKSKRVSLQNPPVTGVATLKLTDVHPSTGTLYLCQVNNPPDPFYTNGLGLINTVLV 143
 |||||

QY 121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNWRLGTFPTSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNWRLGTFPTSPGSMVQDEVSGQLI 203
QY 181 LTNLSTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVAEL 222
Db 204 LTNLSTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVAEL 245

RESULT 2

US-10-607-565-98
; Sequence 98, Application US/10607565
; Publication No. US20040048294A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033P1
; CURRENT APPLICATION NUMBER: US/10/607,565
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: US/09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/101,546
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 98
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-607-565-98

Query Match 100.0%; Score 1164; DB 15; Length 245;
Best Local Similarity 100.0%; Pred. No. 1.7e-88;
Matches 222; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
Db 24 VEVKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
QY 61 PTGSKSRVSLQLQNPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTLVLV 120
Db 84 PTGSKSRVSLQLQNPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTLVLV 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNWRLGTFPTSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNWRLGTFPTSPGSMVQDEVSGQLI 203
QY 181 LTNLSTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVAEL 222
Db 204 LTNLSTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVAEL 245

RESULT 3

US-09-820-893-83
; Sequence 83, Application US/09820893
; Patent No. US20020076705A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033P1
; CURRENT APPLICATION NUMBER: US/09/820,893
; CURRENT FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 83
; LENGTH: 246
; TYPE: PRT

; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (246)
; OTHER INFORMATION: Xaa equals stop translation
US-09-820-893-83
Query Match 100.0%; Score 1164; DB 9; Length 246;
Best Local Similarity 100.0%; Pred. No. 1.8e-88;
Matches 222; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
Db 24 VEVKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
QY 61 PTGSKSRVSLQLQNPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTLVLV 120
Db 84 PTGSKSRVSLQLQNPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTLVLV 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNWRLGTFPTSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNWRLGTFPTSPGSMVQDEVSGQLI 203
QY 181 LTNLSTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVAEL 222
Db 204 LTNLSTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVAEL 245

RESULT 4

US-10-607-565-83
; Sequence 83, Application US/10607565
; Publication No. US20040048294A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033P1
; CURRENT APPLICATION NUMBER: US/10/607,565
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: US/09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/101,546
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 83
; LENGTH: 246
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (246)
; OTHER INFORMATION: Xaa equals stop translation
US-10-607-565-83

Query Match 100.0%; Score 1164; DB 15; Length 246;
Best Local Similarity 100.0%; Pred. No. 1.8e-88;
Matches 222; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
Db 24 VEVKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
QY 61 PTGSKSRVSLQLQNPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTLVLV 120
Db 84 PTGSKSRVSLQLQNPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTLVLV 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNWRLGTFPTSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNWRLGTFPTSPGSMVQDEVSGQLI 203
QY 181 LTNLSTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVAEL 222

```
Db 204 LTNLSTSSGTYRCVATNMGASASCELTLTSTVTEPSQGRVAEL 245
|||||
RESULT 5
US-10-443-108-4
; Sequence 4, Application US/10443108
; Publication No. US20040005615A1
; GENERAL INFORMATION:
; APPLICANT: LI, JING
; APPLICANT: MU, DAVID
; APPLICANT: YANG, JIANXIN
; TITLE OF INVENTION: AMPLIFICATION AND OVEREXPRESSION OF ONCOGENES
; FILE REFERENCE: 38002-0049
; CURRENT APPLICATION NUMBER: US/10/443,108
; CURRENT FILING DATE: 2003-05-22
; PRIOR APPLICATION NUMBER: 60/398,099
; PRIOR FILING DATE: 2002-07-25
; PRIOR APPLICATION NUMBER: 60/382,606
; PRIOR FILING DATE: 2002-05-24
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 326
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-443-108-4

Query Match 99.2%; Score 1155; DB 15; Length 326;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVTPELSTPLGKTAELTCTYSTVSGDSPALEWSFVQPGKPISESHPILYFTNGHLY 60
|||||
Db 23 VEVKVTPELSTPLGKTAELTCTYSTVSGDSPALEWSFVQPGKPISESHPILYFTNGHLY 82
|||||

QY 61 PTGSKSKRVSLQLQNPPTGVATLKLTDVHPSDTGYLCQVNNPPDFYTNGLGLINLTVLV 120
|||||
Db 83 PTGSKSKRVSLQLQNPPTGVATLKLTDVHPSDTGYLCQVNNPPDFYTNGLGLINLTVLV 142
|||||

QY 121 PPSNPLCSQSGQTSVCGSTALRCSSEGAPKPVYNNVRLGTPTTPSPGSMQDEVSGQLI 180
|||||
Db 143 PPSNPLCSQSGQTSVCGSTALRCSSEGAPKPVYNNVRLGTPTTPSPGSMQDEVSGQLI 202
|||||

QY 181 LTNLSTSSGTYRCVATNMGASASCELTLTSTVTEPSQGRVA 220
|||||
Db 203 LTNLSTSSGTYRCVATNMGASASCELTLTSTVTEPSQGRVA 242
|||||

RESULT 6
US-10-227-884-236
; Sequence 236, Application US/10227884
; Publication No. US20030027988A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C79
; CURRENT APPLICATION NUMBER: US/10/227,884
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
```

```
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
```

1	PRIOR APPLICATION NUMBER: 60/100318
2	PRIOR FILING DATE: 1998-09-11
3	PRIOR APPLICATION NUMBER: 60/100385
4	PRIOR FILING DATE: 1998-09-15
5	PRIOR APPLICATION NUMBER: 60/100390
6	PRIOR FILING DATE: 1998-09-15
7	PRIOR APPLICATION NUMBER: 60/100627
8	PRIOR FILING DATE: 1998-09-16
9	PRIOR APPLICATION NUMBER: 60/100848
10	PRIOR FILING DATE: 1998-09-18
11	PRIOR APPLICATION NUMBER: 60/100919
12	PRIOR FILING DATE: 1998-09-17
13	PRIOR APPLICATION NUMBER: 60/101477
14	PRIOR FILING DATE: 1998-09-23
15	PRIOR APPLICATION NUMBER: 60/101738
16	PRIOR FILING DATE: 1998-09-24
17	PRIOR APPLICATION NUMBER: 60/101741
18	PRIOR FILING DATE: 1998-09-24
19	PRIOR APPLICATION NUMBER: 60/101786
20	PRIOR FILING DATE: 1998-09-25
21	PRIOR APPLICATION NUMBER: 60/101916
22	PRIOR FILING DATE: 1998-09-24
23	PRIOR APPLICATION NUMBER: 60/101922
24	PRIOR FILING DATE: 1998-09-24
25	PRIOR APPLICATION NUMBER: 60/106178
26	PRIOR FILING DATE: 1998-10-28
27	PRIOR APPLICATION NUMBER: 60/106248
28	PRIOR FILING DATE: 1998-10-29
29	PRIOR APPLICATION NUMBER: 60/106464
30	PRIOR FILING DATE: 1998-10-30
31	PRIOR APPLICATION NUMBER: 60/106905
32	PRIOR FILING DATE: 1998-11-03
33	PRIOR APPLICATION NUMBER: 60/108787
34	PRIOR FILING DATE: 1998-11-17
35	PRIOR APPLICATION NUMBER: 60/108801
36	PRIOR FILING DATE: 1998-11-17
37	PRIOR APPLICATION NUMBER: 60/108849
38	PRIOR FILING DATE: 1998-11-18
39	PRIOR APPLICATION NUMBER: 60/112422
40	PRIOR FILING DATE: 1998-12-15
41	PRIOR APPLICATION NUMBER: 60/113296
42	PRIOR FILING DATE: 1998-12-22
43	PRIOR APPLICATION NUMBER: 60/113605
44	PRIOR FILING DATE: 1998-12-23
45	PRIOR APPLICATION NUMBER: 60/113621
46	PRIOR FILING DATE: 1998-12-23
47	PRIOR APPLICATION NUMBER: 60/115558
48	PRIOR FILING DATE: 1999-01-12
49	PRIOR APPLICATION NUMBER: 60/115565
50	PRIOR FILING DATE: 1999-01-12
51	PRIOR APPLICATION NUMBER: 60/115733
52	PRIOR FILING DATE: 1999-01-12
53	PRIOR APPLICATION NUMBER: 60/119549
54	PRIOR FILING DATE: 1999-02-10
55	PRIOR APPLICATION NUMBER: 60/123618
56	PRIOR FILING DATE: 1999-03-10
57	PRIOR APPLICATION NUMBER: 60/125259
58	PRIOR FILING DATE: 1999-03-19
59	PRIOR APPLICATION NUMBER: 60/125775
60	PRIOR FILING DATE: 1999-03-23
61	PRIOR APPLICATION NUMBER: 60/126773
62	PRIOR FILING DATE: 1999-03-29
63	PRIOR APPLICATION NUMBER: 60/127887
64	PRIOR FILING DATE: 1999-04-05
65	PRIOR APPLICATION NUMBER: 60/130232
66	PRIOR FILING DATE: 1999-04-21
67	PRIOR APPLICATION NUMBER: 60/131022
68	PRIOR FILING DATE: 1999-04-26
69	PRIOR APPLICATION NUMBER: 60/131270
70	PRIOR FILING DATE: 1999-04-27
71	PRIOR APPLICATION NUMBER: 60/131291
72	PRIOR FILING DATE: 1999-04-27
73	PRIOR APPLICATION NUMBER: 60/131445

/	PRIOR FILING DATE:	1999-04-28
/	PRIOR APPLICATION NUMBER:	60/134287
/	PRIOR FILING DATE:	1999-05-14
/	PRIOR APPLICATION NUMBER:	60/140650
/	PRIOR FILING DATE:	1999-06-22
/	PRIOR APPLICATION NUMBER:	60/140723
/	PRIOR FILING DATE:	1999-06-22
/	PRIOR APPLICATION NUMBER:	60/141037
/	PRIOR FILING DATE:	1999-06-23
/	PRIOR APPLICATION NUMBER:	60/144758
/	PRIOR FILING DATE:	1999-07-20
/	PRIOR APPLICATION NUMBER:	60/145698
/	PRIOR FILING DATE:	1999-07-26
/	PRIOR APPLICATION NUMBER:	60/146222
/	PRIOR FILING DATE:	1999-07-28
/	PRIOR APPLICATION NUMBER:	60/146963
/	PRIOR FILING DATE:	1999-08-03
/	PRIOR APPLICATION NUMBER:	60/149320
/	PRIOR FILING DATE:	1999-08-17
/	PRIOR APPLICATION NUMBER:	60/149638
/	PRIOR FILING DATE:	1999-08-17
/	PRIOR APPLICATION NUMBER:	60/151733
/	PRIOR FILING DATE:	1999-08-31
/	PRIOR APPLICATION NUMBER:	60/164418
/	PRIOR FILING DATE:	1999-11-09
/	PRIOR APPLICATION NUMBER:	60/166361
/	PRIOR FILING DATE:	1999-11-16
/	PRIOR APPLICATION NUMBER:	60/169445
/	PRIOR FILING DATE:	1999-12-07
/	PRIOR APPLICATION NUMBER:	60/169495
/	PRIOR FILING DATE:	1999-12-07
/	PRIOR APPLICATION NUMBER:	60/169835

Query Match
Best Local Similarity 99.2%; Score 1155; DB 14; Length 327;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	VEVKVTEPLSTPLGKTAELTCTYSTSVGDSPFALEWSFVPQGPPISESHDILYFTNGHLY	60
Dd	24	VEVKVTEPLSTPLGKTAELTCTYSTSVGDSPFALEWSFVPQGPPISESHDILYFTNGHLI	83
Qy	61	PTGSCKSRYSLLQNPPTVGVATLKLTDVHPSDTGTYLCQQNNPDPDFVTNGLGINLTVLV	120
Dd	84	PTGSCKSRYSLLQNPPTVGVATLKLTDVHPSDGTGYLCQQNNPDPFYTNGLGINLTVLV	143
Qy	121	PPSNPLCSGGQTSGVGSTALRCSSSEGAPKPYNWVRIGTFPTPSPGSMVDQEVSGQLI	180
Dd	144	PPSNPLCSGGQTSGVGSTALRCSSSEGAPKPYNWVRIGTFPTPSPGSMVDQEVSGOLI	203
Qy	181	LTLNSLTSGTRYCVATNQWGASCBELTISVTPESQGRVA	220
Dd	204	LTLNSLTSGTRYCVATNQWGASCBELTISVTPESQGRVA	243

•

1 CURRENT APPLICATION NUMBER: US/10/230,163
2 CURRENT FILING DATE: 2002-08-28
3 PRIOR APPLICATION NUMBER: 10/119,480
4 PRIOR FILING DATE: 2002-04-09
5 PRIOR APPLICATION NUMBER: 60/059113
6 PRIOR FILING DATE: 1997-09-17
7 PRIOR APPLICATION NUMBER: 60/062287
8 PRIOR FILING DATE: 1997-10-17
9 PRIOR APPLICATION NUMBER: 60/063549
10 PRIOR FILING DATE: 1997-10-28
11 PRIOR APPLICATION NUMBER: 60/064103
12 PRIOR FILING DATE: 1997-10-31
13 PRIOR APPLICATION NUMBER: 60/069873
14 PRIOR FILING DATE: 1997-12-17
15 PRIOR APPLICATION NUMBER: 60/078910
16 PRIOR FILING DATE: 1998-03-20
17 PRIOR APPLICATION NUMBER: 60/079294
18 PRIOR FILING DATE: 1998-03-25
19 PRIOR APPLICATION NUMBER: 60/079656
20 PRIOR FILING DATE: 1998-03-26
21 PRIOR APPLICATION NUMBER: 60/079728
22 PRIOR FILING DATE: 1998-03-27
23 PRIOR APPLICATION NUMBER: 60/081819
24 PRIOR FILING DATE: 1998-04-15
25 PRIOR APPLICATION NUMBER: 60/081955
26 PRIOR FILING DATE: 1998-04-15
27 PRIOR APPLICATION NUMBER: 60/082804
28 PRIOR FILING DATE: 1998-04-22
29 PRIOR APPLICATION NUMBER: 60/084441
30 PRIOR FILING DATE: 1998-05-06
31 PRIOR APPLICATION NUMBER: 60/085323
32 PRIOR FILING DATE: 1998-05-13
33 PRIOR APPLICATION NUMBER: 60/085579
34 PRIOR FILING DATE: 1998-05-15
35 PRIOR APPLICATION NUMBER: 60/086392
36 PRIOR FILING DATE: 1998-05-22
37 PRIOR APPLICATION NUMBER: 60/089532
38 PRIOR FILING DATE: 1998-06-17
39 PRIOR APPLICATION NUMBER: 60/089538
40 PRIOR FILING DATE: 1998-06-17
41 PRIOR APPLICATION NUMBER: 60/089905
42 PRIOR FILING DATE: 1998-06-18
43 PRIOR APPLICATION NUMBER: 60/090472
44 PRIOR FILING DATE: 1998-06-24
45 PRIOR APPLICATION NUMBER: 60/090557
46 PRIOR FILING DATE: 1998-06-24
47 PRIOR APPLICATION NUMBER: 60/090691
48 PRIOR FILING DATE: 1998-06-25
49 PRIOR APPLICATION NUMBER: 60/090695
50 PRIOR FILING DATE: 1998-06-25
51 PRIOR APPLICATION NUMBER: 60/091982
52 PRIOR FILING DATE: 1998-07-07
53 PRIOR APPLICATION NUMBER: 60/095302
54 PRIOR FILING DATE: 1998-08-04
55 PRIOR APPLICATION NUMBER: 60/095318
56 PRIOR FILING DATE: 1998-08-04
57 PRIOR APPLICATION NUMBER: 60/095916
58 PRIOR FILING DATE: 1998-08-10
59 PRIOR APPLICATION NUMBER: 60/096146
60 PRIOR FILING DATE: 1998-08-11
61 PRIOR APPLICATION NUMBER: 60/096791
62 PRIOR FILING DATE: 1998-08-17
63 PRIOR APPLICATION NUMBER: 60/097986
64 PRIOR FILING DATE: 1998-08-26
65 PRIOR APPLICATION NUMBER: 60/098544
66 PRIOR FILING DATE: 1998-08-31
67 PRIOR APPLICATION NUMBER: 60/099596
68 PRIOR FILING DATE: 1998-09-09
69 PRIOR APPLICATION NUMBER: 60/099598
70 PRIOR FILING DATE: 1998-09-09
71 PRIOR APPLICATION NUMBER: 60/099803
72 PRIOR FILING DATE: 1998-09-10
73 PRIOR APPLICATION NUMBER: 60/099811
74 PRIOR FILING DATE: 1998-09-10
75 PRIOR APPLICATION NUMBER: 60/099812
76 PRIOR FILING DATE: 1998-09-10
77 PRIOR APPLICATION NUMBER: 60/099816
78 PRIOR FILING DATE: 1998-09-10
79 PRIOR APPLICATION NUMBER: 60/100038
80 PRIOR FILING DATE: 1998-09-11
81 PRIOR APPLICATION NUMBER: 60/100385
82 PRIOR FILING DATE: 1998-09-15
83 PRIOR APPLICATION NUMBER: 60/100390
84 PRIOR FILING DATE: 1998-09-15
85 PRIOR APPLICATION NUMBER: 60/100627
86 PRIOR FILING DATE: 1998-09-16
87 PRIOR APPLICATION NUMBER: 60/100848
88 PRIOR FILING DATE: 1998-09-18
89 PRIOR APPLICATION NUMBER: 60/100919
90 PRIOR FILING DATE: 1998-09-17
91 PRIOR APPLICATION NUMBER: 60/101477
92 PRIOR FILING DATE: 1998-09-23
93 PRIOR APPLICATION NUMBER: 60/101738
94 PRIOR FILING DATE: 1998-09-24
95 PRIOR APPLICATION NUMBER: 60/101741
96 PRIOR FILING DATE: 1998-09-24
97 PRIOR APPLICATION NUMBER: 60/101786
98 PRIOR FILING DATE: 1998-09-25
99 PRIOR APPLICATION NUMBER: 60/101916
100 PRIOR FILING DATE: 1998-09-24
101 PRIOR APPLICATION NUMBER: 60/101922
102 PRIOR FILING DATE: 1998-09-24
103 PRIOR APPLICATION NUMBER: 60/106178
104 PRIOR FILING DATE: 1998-10-28
105 PRIOR APPLICATION NUMBER: 60/106248
106 PRIOR FILING DATE: 1998-10-29
107 PRIOR APPLICATION NUMBER: 60/106464
108 PRIOR FILING DATE: 1998-10-30
109 PRIOR APPLICATION NUMBER: 60/106905
110 PRIOR FILING DATE: 1998-11-03
111 PRIOR APPLICATION NUMBER: 60/108787
112 PRIOR FILING DATE: 1998-11-17
113 PRIOR APPLICATION NUMBER: 60/108801
114 PRIOR FILING DATE: 1998-11-17
115 PRIOR APPLICATION NUMBER: 60/108849
116 PRIOR FILING DATE: 1998-11-18
117 PRIOR APPLICATION NUMBER: 60/112422
118 PRIOR FILING DATE: 1998-12-15
119 PRIOR APPLICATION NUMBER: 60/113296
120 PRIOR FILING DATE: 1998-12-22
121 PRIOR APPLICATION NUMBER: 60/113605
122 PRIOR FILING DATE: 1998-12-23
123 PRIOR APPLICATION NUMBER: 60/113621
124 PRIOR FILING DATE: 1998-12-23
125 PRIOR APPLICATION NUMBER: 60/115558
126 PRIOR FILING DATE: 1999-01-12
127 PRIOR APPLICATION NUMBER: 60/115565
128 PRIOR FILING DATE: 1999-01-12
129 PRIOR APPLICATION NUMBER: 60/115733
130 PRIOR FILING DATE: 1999-01-12
131 PRIOR APPLICATION NUMBER: 60/119549
132 PRIOR FILING DATE: 1999-02-10
133 PRIOR APPLICATION NUMBER: 60/123618
134 PRIOR FILING DATE: 1999-03-10
135 PRIOR APPLICATION NUMBER: 60/125259
136 PRIOR FILING DATE: 1999-03-19
137 PRIOR APPLICATION NUMBER: 60/125775
138 PRIOR FILING DATE: 1999-03-23
139 PRIOR APPLICATION NUMBER: 60/126773
140 PRIOR FILING DATE: 1999-03-29
141 PRIOR APPLICATION NUMBER: 60/127887
142 PRIOR FILING DATE: 1999-04-05
143 PRIOR APPLICATION NUMBER: 60/130232
144 PRIOR FILING DATE: 1999-04-21
145 PRIOR APPLICATION NUMBER: 60/131022
146 PRIOR FILING DATE: 1999-04-26

; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.2%; Score 1155; DB 14; Length 327;

Best Local Similarity 100.0%; Pred. No. 1.4e-87;

Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 VEKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
Db 24 VEKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
Qy 61 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYLCQVNNPDPFYTNGLGLNLTVLV 120
Db 84 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYLCQVNNPDPFYTNGLGLNLTVLV 143
Qy 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTFPTPSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTFPTPSPGSMVQDEVSGQLI 203
Qy 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
Db 204 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 243

RESULT 8

US-10-230-338-236
; Sequence 236, Application US/10230338
; Publication No. US200300493441
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.

; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C92
; CURRENT APPLICATION NUMBER: US/10/230,338
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-338-236

Query Match 99.2%; Score 1155; DB 14; Length 327;

Best Local Similarity 100.0%; Pred. No. 1.4e-87;

Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 VEKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
Db 24 VEKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
Qy 61 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYLCQVNNPDPFYTNGLGLNLTVLV 120
Db 84 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYLCQVNNPDPFYTNGLGLNLTVLV 143
Qy 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTFPTPSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTFPTPSPGSMVQDEVSGQLI 203
Qy 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
Db 204 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 243

RESULT 9

US-10-218-631-236
; Sequence 236, Application US/10218631
; Publication No. US20030045687A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

```
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C14
; CURRENT APPLICATION NUMBER: US/10/218,631
; CURRENT FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-631-236

Query Match          99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISEHPILYFTNGHLY 60
Db 24 VEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISEHPILYFTNGHLY 83

QY 61 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSTGTGYLCQVNNPPDPYTNGLGLINLTVLV 120
Db 84 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSTGTGYLCQVNNPPDPYTNGLGLINLTVLV 143

QY 121 PPSNPLCSGGTSGVSGSTALRCSSSEGAPKPVYNNVRLGTPTTPSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSGGTSGVSGSTALRCSSSEGAPKPVYNNVRLGTPTTPSPGSMVQDEVSGQLI 203

QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
Db 204 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 243

RESULT 10
US-10-230-414-236
; Sequence 236, Application US/10230414
; Publication No. US20030050448A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C98
; CURRENT APPLICATION NUMBER: US/10/230,414
```

```
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-414-236

Query Match          99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISEHPILYFTNGHLY 60
Db 24 VEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISEHPILYFTNGHLY 83

QY 61 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSTGTGYLCQVNNPPDPYTNGLGLINLTVLV 120
Db 84 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSTGTGYLCQVNNPPDPYTNGLGLINLTVLV 143

QY 121 PPSNPLCSGGTSGVSGSTALRCSSSEGAPKPVYNNVRLGTPTTPSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSGGTSGVSGSTALRCSSSEGAPKPVYNNVRLGTPTTPSPGSMVQDEVSGQLI 203

QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
Db 204 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 243

RESULT 11
US-10-232-224-236
; Sequence 236, Application US/10232224
; Publication No. US20030065147A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C11
; CURRENT APPLICATION NUMBER: US/10/232,224
; CURRENT FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
```

```
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-232-224-236

Query Match          99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
Db 24 VEVKPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83

QY 61 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCOVNNPPDFYTNGLGLNLTVLV 120
Db 84 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCOVNNPPDFYTNGLGLNLTVLV 143

QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWRLGTFTPTSPGSMVQDEVSGOLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWRLGTFTPTSPGSMVQDEVSGOLI 203

QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
Db 204 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 243
```

```
RESULT 12
US-10-216-159A-236
; Sequence 236, Application US/10216159A
; Publication No. US20030069397A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Goddard, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC6
; CURRENT APPLICATION NUMBER: US/10/216,159A
; CURRENT FILING DATE: 2002-08-09
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
```

```
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-216-159A-236

Query Match          99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
Db 24 VEVKPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83

QY 61 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCOVNNPPDFYTNGLGLNLTVLV 120
Db 84 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCOVNNPPDFYTNGLGLNLTVLV 143

QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWRLGTFTPTSPGSMVQDEVSGOLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWRLGTFTPTSPGSMVQDEVSGOLI 203

QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
Db 204 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 243
```

```
RESULT 13
US-10-218-849-236
; Sequence 236, Application US/10218849
; Publication No. US20030073814A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Goddard, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC11
; CURRENT APPLICATION NUMBER: US/10/218,849
; CURRENT FILING DATE: 2002-08-12
; Remaining Prior Application data removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-849-236
```



```
Query Match          99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEKVPTEPLSTPLGTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
Db 24 VEKVPTEPLSTPLGTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83

QY 61 PTGSKSKRVSLQNPPVTGVATIKLTDVHPSDTGTLYLCOVNPPDPFTYTNGLGLINLTVLV 120
Db 84 PTGSKSKRVSLQNPPVTGVATIKLTDVHPSDTGTLYLCOVNPPDPFTYTNGLGLINLTVLV 143

QY 121 PRSNPLCSGGTSGVSTALRCSSSEGAPKPVYNNVRLGTFPTPGSGMWQDEVSGQLI 180
Db 144 PRSNPLCSGGTSGVSTALRCSSSEGAPKPVYNNVRLGTFPTPGSGMWQDEVSGQLI 203

QY 181 LTNLSLTSSGTVRCVATNMGWSASCELTLTSLVTEPSQGRVA 220
Db 204 LTNLSLTSSGTVRCVATNMGWSASCELTLTSLVTEPSQGRVA 243

RESULT 14
US-10-227-873-236
; Sequence 236, Application US/10227873
; Publication No. US20030073816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C72
; CURRENT APPLICATION NUMBER: US/10/227,873
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
```

```
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
```

```
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
```

```
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match          99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87; Indels 0; Gaps 0;
Matches 220; Conservative 0; Mismatches 0;

QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTVSVDGSALEWSEFVQPKPISESHPILYFTNGHLY 60
   |||||
Db 24 VEVKVPTEPLSTPLGKTAELTCTYSTVSVDGSALEWSEFVQPKPISESHPILYFTNGHLY 83
   |||||

QY 61 PTGSKSRVSLLONPPTVGATLKLTDVHPSDTGTLYLCQVNNPDPFYTNGLINLTVLV 120
   |||||
Db 84 PTGSKSRVSLLONPPTVGATLKLTDVHPSDTGTLYLCQVNNPDPFYTNGLINLTVLV 143
   |||||

QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVNWRVLTGTFPTSPGSMVQDEVSGOLI 180
   |||||
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVNWRVLTGTFPTSPGSMVQDEVSGOLI 203
   |||||

QY 181 LTNLSTSSGTYRCVATNQMSASCELTLSVTEPSQGRVA 220
   |||||
Db 204 LTNLSTSSGTYRCVATNQMSASCELTLSVTEPSQGRVA 243
   |||||

RESULT 15
US-10-227-883-236
; Sequence 236, Application US/10227883
; Publication No. US20030073817A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C78
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
```

1	PRIOR APPLICATION NUMBER: 60/084441	2	PRIOR FILING DATE: 1998-09-24
2	PRIOR FILING DATE: 1998-05-06	3	PRIOR APPLICATION NUMBER: 60/106178
3	PRIOR APPLICATION NUMBER: 60/085323	4	PRIOR FILING DATE: 1998-10-28
4	PRIOR FILING DATE: 1998-05-13	5	PRIOR APPLICATION NUMBER: 60/106248
5	PRIOR APPLICATION NUMBER: 60/085579	6	PRIOR FILING DATE: 1998-10-29
6	PRIOR FILING DATE: 1998-05-15	7	PRIOR APPLICATION NUMBER: 60/106464
7	PRIOR APPLICATION NUMBER: 60/086392	8	PRIOR FILING DATE: 1998-10-30
8	PRIOR FILING DATE: 1998-05-22	9	PRIOR APPLICATION NUMBER: 60/106905
9	PRIOR APPLICATION NUMBER: 60/089532	10	PRIOR FILING DATE: 1998-11-03
10	PRIOR FILING DATE: 1998-06-17	11	PRIOR APPLICATION NUMBER: 60/108787
11	PRIOR APPLICATION NUMBER: 60/089538	12	PRIOR FILING DATE: 1998-11-17
12	PRIOR FILING DATE: 1998-06-17	13	PRIOR APPLICATION NUMBER: 60/108801
13	PRIOR APPLICATION NUMBER: 60/089905	14	PRIOR FILING DATE: 1998-11-17
14	PRIOR FILING DATE: 1998-06-18	15	PRIOR APPLICATION NUMBER: 60/108849
15	PRIOR APPLICATION NUMBER: 60/090472	16	PRIOR FILING DATE: 1998-11-18
16	PRIOR FILING DATE: 1998-06-24	17	PRIOR APPLICATION NUMBER: 60/112422
17	PRIOR APPLICATION NUMBER: 60/090557	18	PRIOR FILING DATE: 1998-12-15
18	PRIOR FILING DATE: 1998-06-24	19	PRIOR APPLICATION NUMBER: 60/113296
19	PRIOR APPLICATION NUMBER: 60/090691	20	PRIOR FILING DATE: 1998-12-22
20	PRIOR FILING DATE: 1998-06-25	21	PRIOR APPLICATION NUMBER: 60/113605
21	PRIOR APPLICATION NUMBER: 60/090695	22	PRIOR FILING DATE: 1998-12-23
22	PRIOR FILING DATE: 1998-06-25	23	PRIOR APPLICATION NUMBER: 60/113621
23	PRIOR APPLICATION NUMBER: 60/091982	24	PRIOR FILING DATE: 1998-12-23
24	PRIOR FILING DATE: 1998-07-07	25	PRIOR APPLICATION NUMBER: 60/115558
25	PRIOR APPLICATION NUMBER: 60/095302	26	PRIOR FILING DATE: 1999-01-12
26	PRIOR FILING DATE: 1998-08-04	27	PRIOR APPLICATION NUMBER: 60/115565
27	PRIOR APPLICATION NUMBER: 60/095318	28	PRIOR FILING DATE: 1999-01-12
28	PRIOR FILING DATE: 1998-08-04	29	PRIOR APPLICATION NUMBER: 60/115733
29	PRIOR APPLICATION NUMBER: 60/095916	30	PRIOR FILING DATE: 1999-01-12
30	PRIOR FILING DATE: 1998-08-10	31	PRIOR APPLICATION NUMBER: 60/119549
31	PRIOR APPLICATION NUMBER: 60/096146	32	PRIOR FILING DATE: 1999-02-10
32	PRIOR FILING DATE: 1998-08-11	33	PRIOR APPLICATION NUMBER: 60/123618
33	PRIOR APPLICATION NUMBER: 60/096791	34	PRIOR FILING DATE: 1999-03-10
34	PRIOR FILING DATE: 1998-08-17	35	PRIOR APPLICATION NUMBER: 60/125259
35	PRIOR APPLICATION NUMBER: 60/097986	36	PRIOR FILING DATE: 1999-03-19
36	PRIOR FILING DATE: 1998-08-26	37	PRIOR APPLICATION NUMBER: 60/125775
37	PRIOR APPLICATION NUMBER: 60/098544	38	PRIOR FILING DATE: 1999-03-23
38	PRIOR FILING DATE: 1998-08-31	39	PRIOR APPLICATION NUMBER: 60/126773
39	PRIOR APPLICATION NUMBER: 60/099596	40	PRIOR FILING DATE: 1999-03-29
40	PRIOR FILING DATE: 1998-09-09	41	PRIOR APPLICATION NUMBER: 60/127887
41	PRIOR APPLICATION NUMBER: 60/099598	42	PRIOR FILING DATE: 1999-04-05
42	PRIOR FILING DATE: 1998-09-09	43	PRIOR APPLICATION NUMBER: 60/130232
43	PRIOR APPLICATION NUMBER: 60/099803	44	PRIOR FILING DATE: 1999-04-21
44	PRIOR FILING DATE: 1998-09-10	45	PRIOR APPLICATION NUMBER: 60/131022
45	PRIOR APPLICATION NUMBER: 60/099811	46	PRIOR FILING DATE: 1999-04-26
46	PRIOR FILING DATE: 1998-09-10	47	PRIOR APPLICATION NUMBER: 60/131270
47	PRIOR APPLICATION NUMBER: 60/099812	48	PRIOR FILING DATE: 1999-04-27
48	PRIOR FILING DATE: 1998-09-10	49	PRIOR APPLICATION NUMBER: 60/131291
49	PRIOR APPLICATION NUMBER: 60/099816	50	PRIOR FILING DATE: 1999-04-27
50	PRIOR FILING DATE: 1998-09-10	51	PRIOR APPLICATION NUMBER: 60/131445
51	PRIOR APPLICATION NUMBER: 60/100038	52	PRIOR FILING DATE: 1999-04-28
52	PRIOR FILING DATE: 1998-09-11	53	PRIOR APPLICATION NUMBER: 60/134287
53	PRIOR APPLICATION NUMBER: 60/100385	54	PRIOR FILING DATE: 1999-05-14
54	PRIOR FILING DATE: 1998-09-15	55	PRIOR APPLICATION NUMBER: 60/140650
55	PRIOR APPLICATION NUMBER: 60/100390	56	PRIOR FILING DATE: 1999-06-22
56	PRIOR FILING DATE: 1998-09-15	57	PRIOR APPLICATION NUMBER: 60/140723
57	PRIOR APPLICATION NUMBER: 60/100627	58	PRIOR FILING DATE: 1999-06-22
58	PRIOR FILING DATE: 1998-09-16	59	PRIOR APPLICATION NUMBER: 60/141037
59	PRIOR APPLICATION NUMBER: 60/100848	60	PRIOR FILING DATE: 1999-06-23
60	PRIOR FILING DATE: 1998-09-18	61	PRIOR APPLICATION NUMBER: 60/144758
61	PRIOR APPLICATION NUMBER: 60/100919	62	PRIOR FILING DATE: 1999-07-20
62	PRIOR FILING DATE: 1998-09-17	63	PRIOR APPLICATION NUMBER: 60/145698
63	PRIOR APPLICATION NUMBER: 60/101477	64	PRIOR FILING DATE: 1999-07-26
64	PRIOR FILING DATE: 1998-09-23	65	PRIOR APPLICATION NUMBER: 60/146222
65	PRIOR APPLICATION NUMBER: 60/101738	66	PRIOR FILING DATE: 1999-07-28
66	PRIOR FILING DATE: 1998-09-24	67	PRIOR APPLICATION NUMBER: 60/146963
67	PRIOR APPLICATION NUMBER: 60/101741	68	PRIOR FILING DATE: 1999-08-03
68	PRIOR FILING DATE: 1998-09-24	69	PRIOR APPLICATION NUMBER: 60/149320
69	PRIOR APPLICATION NUMBER: 60/101786		

; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKVTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPGKPISESHPILYFTNGHLY 60
DB 24 VEVKVTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPGKPISESHPILYFTNGHLY 83
QY 61 PTGSKSKRVSLLLQNPTVGVATLKLTDVHPSDTGYLCOVANPPDFYTNGLGLINLTVLV 120
DB 84 PTGSKSKRVSLLLQNPTVGVATLKLTDVHPSDTGYLCOVANPPDFYTNGLGLINLTVLV 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKEVYNWVRLGTPTPSPGSMVQDEVSGQLI 180
DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKEVYNWVRLGTPTPSPGSMVQDEVSGQLI 203
QY 181 LTNLSLTSSGTYRCVATNQMGASCELTLISVTEPSQGRVA 220
DB 204 LTNLSLTSSGTYRCVATNQMGASCELTLISVTEPSQGRVA 243

Search completed: August 4, 2005, 06:47:30
Job time : 60.8944 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 05:53:15 ; Search time 67.7067 Seconds
(without alignments)
1268.128 Million cell updates/sec

Title: US-10-607-565-83_COPY_24_245
Perfect score: 1164
Sequence: 1 VEVKVPTEPLSTPLGKTAE.....ASCELTSLVTEPSQGRVAEL 222

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_16Dec04:*

1: Geneseqp1980s:*

2: Geneseqp1990s:*

3: Geneseqp2000s:*

4: Geneseqp2001s:*

5: Geneseqp2002s:*

6: Geneseqp2003as:*

7: Geneseqp2003bs:*

8: Geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1164	100.0	245	3 AAB08940	Aab08940 Human sec
2	1164	100.0	246	3 AAB08926	Aab08926 Human sec
3	1155	99.2	326	8 ADF83097	Adf83097 Human cor
4	1155	99.2	327	3 AAY87251	Aay87251 Human sig
5	1155	99.2	327	3 AAY94857	Aay94857 Human pro
6	1155	99.2	327	4 AAY97585	Aay97585 Human sec
7	1155	99.2	327	5 AAB90354	Aab90354 Human pol
8	1155	99.2	327	5 AAU83709	Aau83709 Human PRO
9	1155	99.2	327	6 ABU80856	Abu80856 Human PRO
10	1155	99.2	327	6 ABO33822	Abo33822 Novel hum
11	1155	99.2	327	6 ABU82165	Abu82165 Novel hum
12	1155	99.2	327	6 ABJ72345	Abj72345 Human PRO
13	1155	99.2	327	6 ABJ72473	Abj72473 Human PRO
14	1155	99.2	327	6 ABO34368	Abo34368 Human sec
15	1155	99.2	327	7 ABJ72175	Abj72175 Human mem
16	1155	99.2	327	7 ADB83726	Adb83726 Novel hum
17	1155	99.2	327	7 ADB80832	Adb80832 Novel hum
18	1155	99.2	327	7 ADB73373	Adb73373 Novel hum
19	1155	99.2	327	7 ADB78455	Adb78455 Novel hum
20	1155	99.2	327	7 ADB85103	Adb85103 Human PRO
21	1155	99.2	327	7 ADB78209	Adb78209 Novel hum
22	1155	99.2	327	7 ADB87275	Adb87275 Human PRO
23	1155	99.2	327	7 ADB84857	Adb84857 Human PRO
24	1155	99.2	327	7 ADB83972	Adb83972 Novel hum
25	1155	99.2	327	7 ADB73127	Adb73127 Novel hum

ALIGNMENTS

RESULT 1

AAB08940

ID AAB08940 standard; protein; 245 AA.

XX AAB08940;

XX 30-AUG-2000 (first entry)

XX Human secreted protein sequence encoded by gene 13 SEQ ID NO:97.

XX Human; secreted protein; cytostatic; anti-proliferative; vulnary;
 KW immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
 KW hyperproliferative disorder; infectious disease; tissue regeneration;
 KW screening; food additive; preservative; wound healing;
 KW hyper-vascular disease; chromosome 11.

XX Homo sapiens.

XX WO200017222-A1.

XX 30-MAR-2000.

XX 22-SEP-1999; 99WO-US022012.

XX 23-SEP-1999; 98US-0101546P.

XX 02-OCT-1998; 98US-0102895P.

XX (HUMA-) HUMAN GENOME SCI INC.

PI Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;
 PI Komatsoulis G, Endress GA, Soppet DR;
 XX WPI; 2000-283538/24.

DR Human secreted proteins and coding sequences useful in diagnostic and
 PT therapeutic methods for disorders such as immune system or proliferative
 PT disorders, related to the proteins.

PS Disclosure; Page 40; 416pp; English.

CC The polynucleotide sequences given in AAA39052 to AAA39088 encode the
 CC human secreted proteins given in AAB08891 to AAB08984. The human secreted
 CC proteins can have activities based on the tissues and cells they are
 CC expressed in. Examples of the activities are: cytostatic; anti-
 CC proliferative; immunosuppressive; antibacterial; and vulnary. The
 CC secreted proteins and their related polynucleotide sequences are useful
 CC for diagnostic and therapeutic methods useful for diagnosing and treating
 CC disorders related to the secreted proteins. The proteins, and

CC	polynucleotide sequences may be useful for treating disorders of the
CC	immune system, hyperproliferative disorders, infectious disease,
CC	regeneration of tissues, for chemotaxis and for screening molecules that
CC	bind to the proteins. The proteins or polynucleotide sequences may be
CC	used as food additives or preservatives, to increase or decrease storage
CC	capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC	minerals, co-factors or other nutritional components. Agonists or
CC	antagonists of the proteins may be used to prevent scar tissue growth
CC	during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC	and AAB08890 are sequences used in the exemplification of the present
CC	invention
XX	
SQ	Sequence 245 AA;
Query Match 100.0%; Score 1164; DB 3; Length 245;	
Best Local Similarity 100.0%; Pred. No. 2e-81;	
Matches 222; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 VEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB	24 VEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
QY	61 PTGSKSKRVSLLONPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 120
DB	84 PTGSKSKRVSLLONPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 143
QY	121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLGTFPTTSPGSMVQDEVSGQLI 180
DB	144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLGTFPTTSPGSMVQDEVSGQLI 203
QY	181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVAEL 222
DB	204 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVAEL 245
RESULT 2	
ID	AAB08926
AC	AAB08926 standard; protein; 245 AA.
XX	
DT	30-AUG-2000 (first entry)
DE	Human secreted protein sequence encoded by gene 13 SEQ ID NO:83.
KW	Human; secreted protein; cytostatic; anti-proliferative; vulnerary;
KW	immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
KW	hyperproliferative disorder; infectious disease; tissue regeneration;
KW	screening; food additive; preservative; wound healing;
KW	hyper-vascular disease; chromosome 11.
OS	Homo sapiens.
XX	
PN	WO200017222-A1.
XX	
PD	30-MAR-2000.
XX	
PF	22-SEP-1999; 99WO-US022012.
XX	
PR	23-SEP-1998; 98US-0101546P.
PR	02-OCT-1998; 98US-0102895P.
XX	
PA	(HUMA-) HUMAN GENOME SCI INC.
XX	
PI	Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;
PI	Komatsoulis G, Endress GA, Soppet DR;
XX	
DR	WPI; 2000-283538/24.
DR	N-PSDB; AAA39087.
XX	
PT	Human secreted proteins and coding sequences useful in diagnostic and
PT	therapeutic methods for disorders such as immune system or proliferative
PT	disorders, related to the proteins.
XX	
PS	Claim 11; Page 376-377; 416pp; English.
XX	
CC	The polynucleotide sequences given in AAA39052 to AAA39088 encode the
CC	human secreted proteins given in AAB08891 to AAB08984. The human secreted
CC	proteins can have activities based on the tissues and cells they are
CC	expressed in. Examples of the activities are: cytostatic; anti-
CC	proliferative; immunosuppressive; antibacterial; and vulnerary. The
CC	secreted proteins and their related polynucleotide sequences are useful
CC	for diagnostic and therapeutic methods useful for diagnosing and treating
CC	disorders related to the secreted proteins. The proteins, and
CC	polynucleotide sequences may be useful for treating disorders of the
CC	immune system, hyperproliferative disorders, infectious disease,
CC	regeneration of tissues, for chemotaxis and for screening molecules that
CC	bind to the proteins. The proteins or polynucleotide sequences may be
CC	used as food additives or preservatives, to increase or decrease storage
CC	capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC	minerals, co-factors or other nutritional components. Agonists or
CC	antagonists of the proteins may be used to prevent scar tissue growth
CC	during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC	and AAB08890 are sequences used in the exemplification of the present
CC	invention
XX	
SQ	Sequence 246 AA;
Query Match 100.0%; Score 1164; DB 3; Length 246;	
Best Local Similarity 100.0%; Pred. No. 2e-81;	
Matches 222; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 VEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB	24 VEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
QY	61 PTGSKSKRVSLLONPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 120
DB	84 PTGSKSKRVSLLONPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 143
QY	121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLGTFPTTSPGSMVQDEVSGQLI 180
DB	144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLGTFPTTSPGSMVQDEVSGQLI 203
QY	181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVAEL 222
DB	204 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVAEL 245
RESULT 3	
ID	ADF83097
AC	ADF83097 standard; protein; 326 AA.
XX	
AC	ADF83097;
XX	
DT	26-FEB-2004 (first entry)
XX	
DE	Human corticol thymocyte receptor CTXL, overexpressed in cancer.
DE	
KW	Human; corticol thymocyte receptor; receptor; CTXL; cancer; cytostatic;
KW	vaccine; gene therapy.
OS	Homo sapiens.
XX	
XX	WO2003100000-A2.
XX	
XX	04-DEC-2003.
XX	
XX	22-MAY-2003; 2003WO-US016049.
XX	
XX	24-MAY-2002; 2002US-0382606P.
XX	25-JUL-2002; 2002US-0398099P.
XX	(TULA-) TULARIK INC.
XX	
PI	Li J, Mu D, Yang J;

XX WPI; 2004-035118/03.
DR N-PSDB; ADF03096.
DR GENBANK; XP_035095.
XX
PT Diagnosing a cancer in a mammal comprises determining RecQL5, CTXL,
PT USP13, MCL1, or Pellino 1 gene copy number in a biological sample from a
PT region of the mammal that is suspected to be precancerous or cancerous.
XX
XX Claim 54; SEQ ID NO 4; 174pp; English.
XX
XX The present sequence is the protein sequence of human cortical thymocyte
CC receptor (Xenopus laevis cts)-like (CTXL), previously known as a cortical
CC thymocyte marker in frogs, and a member of the immunoglobulin superfamily
CC having features of both antigen-specific receptors and adhesion
CC molecules. The invention is based on the finding of the overexpression of
CC CTXL and other genes (RecQL5, USP13, MCL1 and Pellino1) in certain
CC cancers, including breast cancer, colon cancer, lung cancer and ovarian
CC cancer, and the frequent amplification of these genes in cancer cells.
CC The genes, and their expression products, can be used diagnostically or
CC as targets for cancer therapy. They can also be used to identify and
CC design compounds useful in the diagnosis, prevention and therapy of
CC tumours and cancers, in vaccine development, and in methods for
CC determining the efficacy of a treatment regime. A claimed method for
CC inhibiting cancer or precancerous growth, especially in colon, ovarian or
CC breast tissue, uses an inhibitor that interacts with CTXL DNA or RNA. The
CC inhibitor is a small interfering RNA (siRNA), microRNA (miRNA), an
CC antisense RNA, and antisense DNA, a decoy molecule, a decoy DNA, a
CC ribozyme or small molecule.
XX
SQ Sequence 326 AA;
Query Match 99.2%; Score 1155; DB 8; Length 326;
Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPIFYNGHLY 60
Db 23 VEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPIFYNGHLY 82
QY 61 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSDTGYLQVNNPPDPYTNGLGLINLTVLV 120
Db 83 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSDTGYLQVNNPPDPYTNGLGLINLTVLV 142
QY 121 PPSNPLCSQSGTSGVSTALRCSSEGAPKPVYNNVRLGTPTPSGSMWQDEVSGQLI 180
Db 143 PPSNPLCSQSGTSGVSTALRCSSEGAPKPVYNNVRLGTPTPSGSMWQDEVSGQLI 202
QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
Db 203 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 242
RESULT 4
AAY87251
ID AAY87251 standard; protein; 327 AA.
AC AAY87251;
XX
XX 11-MAY-2000 (first entry)
XX
XX Human signal peptide containing protein HSP-28 SEQ ID NO:28.
XX
XX Human; signal peptide-containing protein; HSP; diagnosis; cancer;
KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW antimicrobial; neurotropic; neuroprotective; cardiovascular; hepatotropic;
KW antiasthmatic; gene therapy; cell proliferation; neurological disorder;
KW reproductive disorder; developmental disorder; arteriosclerosis;
KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
KW Parkinson's disease; Huntington's disease; ovulatory defect;
KW muscular dystrophy.
XX

OS Homo sapiens.
XX WO200000610-A2.
XX
XX 06-JAN-2000.
XX
XX 25-JUN-1999; 99WO-US014484.
XX
XX 26-JUN-1998; 98US-0090762P.
XX 31-JUL-1998; 98US-0094983P.
XX 01-OCT-1998; 98US-0102686P.
XX 11-DEC-1998; 98US-0112129P.
XX
XX (INCYTE) INCYTE PHARM INC.
XX
XX Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
PI Akerd Blom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
PI Bandman O;
XX
XX WPI; 2000-160673/14.
XX N-PSDB; AAZ98136.
XX
XX New human signal peptide-containing proteins useful in treatment,
PT prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
PT disease.
XX
XX Claim 1; Page 177-178; 327pp; English.
XX
XX AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the
CC human signal peptide-containing proteins HSP-1 to HSP-134. HSPs have
CC anticancer, anti-inflammatory, antimicrobial, neurotropic, hepatotropic,
CC neuroprotective, cardiovascular and antiasthmatic activities, and can be
CC used in gene therapy. HSPs can be used to treat or prevent disorders
CC associated with decreased activity or function of HSP. Antagonists of
CC HSP are used to treat or prevent disorders associated with increased
CC activity or function of HSP. Such diseases include cell proliferation
CC (including cancer), inflammation, cardiovascular, neurological,
CC reproductive or developmental disorders, (e.g. arteriosclerosis,
CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia, or
CC asthma, Crohn's disease, microbial or other infections, congestive or
CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSP
CC nucleic acids can be used for the recombinant production of HSP, for
CC detecting HSP in standard hybridisation and amplification assays (for
CC diagnosis and monitoring), in gene therapy, as antisense, triplex-forming
CC or ribozyme therapeutics, for detecting related sequences or genetic
CC variations, and for chromosomal mapping. HSP are also used to raise
CC specific antibodies (Ab) and to screen for agonists and antagonists
CC (potential therapeutic agents). Ab are used to diagnose, or monitor, HSP
CC -related diseases (in usual immunoassays), as therapeutic antagonists, in
CC competitive drug screens, and for purification of HSP from natural
CC sources
XX
SQ Sequence 327 AA;
Query Match 99.2%; Score 1155; DB 3; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPIFYNGHLY 60
Db 24 VEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPIFYNGHLY 83
QY 61 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSDTGYLQVNNPPDPYTNGLGLINLTVLV 120
Db 84 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSDTGYLQVNNPPDPYTNGLGLINLTVLV 143
QY 121 PPSNPLCSQSGTSGVSTALRCSSEGAPKPVYNNVRLGTPTPSGSMWQDEVSGQLI 180
Db 144 PPSNPLCSQSGTSGVSTALRCSSEGAPKPVYNNVRLGTPTPSGSMWQDEVSGQLI 203
QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220

Db 204 LTNLSTSSGTYRCVATNMGASCELTLVTEPSQGRVA 243

RESULT 5
AA94857
ID AAY94857 standard; protein; 327 AA.
XX
AC AAY94857;
XX
DT 12-JUN-2000 (first entry)
XX
DE Human protein clone HP10568.
XX
KW Human protein; hydrophobic domain; nutritional source; haematopoiesis;
KW cytokine production; cell proliferation; cell differentiation;
KW immune deficiency; infectious disease; autoimmune disorder; asthma;
KW multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis;
KW allergic reaction; osteoporosis; osteoarthritis; periodontal disease;
KW nervous system disorder; Alzheimer's disease; Parkinson's disease;
KW Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury;
KW systemic cytokine damage; tissue differentiation; contraceptive; stroke;
KW coagulation disorder; myocardial infarction; inflammatory condition;
KW septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour;
KW nephritis; therapy.
XX
OS Homo sapiens.
XX
PN WO200005367-A2.
XX
PD 03-FEB-2000.
XX
PF 22-JUL-1999; 99WO-JP003929.
XX
PR 24-JUL-1998; 98JP-00208820.
PR 07-AUG-1998; 98JP-00224105.
PR 25-AUG-1998; 98JP-00238116.
PR 09-SEP-1998; 98JP-00254736.
PR 29-SEP-1998; 98JP-00275505.
XX
XX (SAGA) SAGAMI CHEM RES CENT.
PA (PROT-) PROTEGENE INC.
XX
XX Kato S, Kimura T;
XX
XX WPI; 2000-182694/16.
DR
XX
PT Novel human proteins having hydrophobic domains useful for treating
PT osteoporosis, Alzheimer's disease, Parkinson's disease, asthma, multiple
PT sclerosis, rheumatoid arthritis, cancer, anemia, and stroke.
XX
PS Claim 1; Page 183-184; 351pp; English.
XX
CC This sequence represents a human protein of the invention, which has
CC hydrophobic domains. The DNA sequences can be used as a probe or as a
CC genetic marker. The protein can also be used as a marker, and to identify
CC potential genetic disorders. The DNA and protein can also be used as
CC nutritional sources or supplements. The protein exhibits cytokine, cell
CC proliferation, cell differentiation activities and induces production of
CC other cytokines in certain cell populations. The protein also exhibits
CC immune stimulating or immune suppressing activity. It can be used in the
CC treatment of various immune deficiencies and disorders, and to treat
CC infectious diseases caused by viral, bacterial, fungal or other
CC infections. The protein is also used for treating autoimmune disorders
CC such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid
CC arthritis. It is also useful in the treatment of allergic reactions and
CC conditions such as asthma, and in immune suppression after organ
CC transplantation. The protein is useful in regulation of haematopoiesis
CC and consequently in the treatment of myeloid or lymphoid cell
CC deficiencies. It is also used in compositions for tissue growth or
CC regeneration. The protein is also used in the treatment of osteoporosis
CC or osteoarthritis and in the treatment of periodontal disease and other
CC tooth repair processes. The protein is used in the treatment of nervous
CC system disorders such as Alzheimer's disease, Parkinson's disease, and

CC Huntington's disease. They are useful for protection or regeneration and
CC treatment of lung or liver fibrosis, reperfusion injury in various
CC tissues, and conditions resulting from systemic cytokine damage. They are
CC also used for promoting or inhibiting tissue differentiation. They are
CC also used as contraceptives since they exhibit activin or inhibin related
CC activities and as a fertility inducing therapeutic. They are used for
CC treating various coagulation disorders and in treatment and prevention of
CC conditions resulting from coagulation activities e.g. myocardial
CC infarction or stroke. They also acts as receptors, receptor ligands or
CC inhibitors or agonists of receptor/ligand interactions. They are used to
CC treat inflammatory conditions such as septic shock, sepsis, ischaemia
CC reperfusion injury, arthritis, and nephritis. They can be used to prevent
CC tumours
XX
SQ Sequence 327 AA;
Query Match 99.2%; Score 1155; DB 3; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
Db 24 VEVKPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
QY 61 PTGSKSRVSLLONPPTVGATLKLTDVHPSDTGYLCQVNNPPDPFYTNGLINLTVLV 120
Db 84 PTGSKSRVSLLONPPTVGATLKLTDVHPSDTGYLCQVNNPPDPFYTNGLINLTVLV 143
QY 121 PPSNPPLCSQSQTSGVGSSTALRCSSEGAPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180
Db 144 PPSNPPLCSQSQTSGVGSSTALRCSSEGAPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 203
QY 181 LTNLSTSSGTYRCVATNMGASCELTLVTEPSQGRVA 220
Db 204 LTNLSTSSGTYRCVATNMGASCELTLVTEPSQGRVA 243
RESULT 6
AA97585
ID AAY97585 standard; protein; 327 AA.
XX
AC AAY97585;
XX
DT 05-APR-2001 (first entry)
XX
DE Human secreted protein PRO7154.
XX
KW Secreted protein; human; PRO protein; neoplastic cell growth; tumour;
KW proliferation; leukaemia; lymphoid malignancy; inflammatory disorder;
KW angiogenic disorder; immunologic disorder; PRO7154.
XX
OS Homo sapiens.
XX
PN WO200075317-A2.
XX
PD 14-DEC-2000.
XX
PF 15-MAY-2000; 2000WO-US013358.
XX
PR 09-JUN-1999; 99US-0138385P.
PR 20-JUL-1999; 99US-0144790P.
PR 03-AUG-1999; 99US-0146843P.
PR 10-AUG-1999; 99US-0148188P.
PR 17-AUG-1999; 99US-0149320P.
PR 17-AUG-1999; 99US-0149327P.
PR 17-AUG-1999; 99US-0149396P.
PR 20-AUG-1999; 99US-0150114P.
PR 31-AUG-1999; 99US-0151700P.
PR 31-AUG-1999; 99US-0151734P.
XX
XX (GETH) GENENTECH INC.
XX
PI Botstein DA, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;

XX WPI; 2001-071075/08.
DR N-PSDB; AAA91019.
XX
XX Antibodies against PRO polypeptides, useful for diagnosing and treating
PT tumors are associated with gene amplification, neoplastic cell growth and
PT proliferation in mammals.
PT

XX Claim 61; Fig 12; 143pp; English.

XX This sequence is a human PRO protein of the invention. The PRO proteins
XX are secreted proteins. Antagonists or antibodies of PRO polypeptides are
XX useful for diagnosing and treating tumors are associated with gene
XX amplification, neoplastic cell growth and proliferation in mammals, and
XX those conditions characterised by overexpression and/or activation of the
XX amplified genes. Such conditions include benign or malignant tumours
XX (e.g. renal, liver, kidney, bladder, breast, gastric, ovarian,
XX colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic
XX carcinomas, sarcomas, glioblastomas and various head and neck tumours);
XX leukaemias and lymphoid malignancies; neuronal, glial, astrocytal,
XX hypothalamic, and other glandular, macrophageal, epithelial, stromal and
XX blastocoeleic disorders; and inflammatory, angiogenic and immunologic
XX disorders. These may further be used to qualitatively or quantitatively
XX detect the expression of proteins encoded by the amplified genes, and in
XX tumour diagnostics or prognostics. The PRO polypeptide or its antagonist
XX may be used for the preparation of a medicament in the treatment of a
XX condition, which is responsive to the PRO polypeptide, its antagonist or
XX anti-PRO antibody

XX Sequence 327 AA;

Query Match 99.2%; Score 1155; DB 4; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKVTPEPLSTPLGKTAELCTYSTSVGDSFALEWSFVQPKPISESHPIYFTNGHLY 60
DB 24 VEVKVTPEPLSTPLGKTAELCTYSTSVGDSFALEWSFVQPKPISESHPIYFTNGHLY 83

QY 61 PTGSKSRVSLQNPPTGVATLKLTDVHPSDTGYLCQVNNPPDYFTNGGLINLTIVL 120
DB 84 PTGSKSRVSLQNPPTGVATLKLTDVHPSDTGYLCQVNNPPDYFTNGGLINLTIVL 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSGQLI 180
DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSGQLI 203
QY 181 LTNLSLTSSGTYRCVATNMGASCELTLTSLVTEPSQGRVA 220
DB 204 LTNLSLTSSGTYRCVATNMGASCELTLTSLVTEPSQGRVA 243

RESULT 7
ABB90354
ID ABB90354 standard; protein; 327 AA.

XX ABB90354;

XX 24-MAY-2002 (first entry)

XX Human polypeptide SEQ ID NO 2730.

XX Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
XX anti-allergic; hepatotropic; antidiabetic; anti-inflammatory; antitumor;
XX vulnary; anticonvulsant; antibacterial; antifungal; antiparasitic;
XX cardiac; gene therapy; cancer; immune disorder; cardiovascular disorder;
XX neurological disease; infection; human; secreted protein.

XX Homo sapiens.

XX WO200190304-A2.

XX 29-NOV-2001.

XX 18-MAY-2001; 2001WO-US016450.
XX
XX 19-MAY-2000; 2000US-0205515P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Birse CE, Rosen CA;
XX
XX WPI; 2002-122018/16.
XX N-PSDB; ABL90763.

XX Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
XX prevention of neural, immune system, muscular, reproductive,
XX gastrointestinal, pulmonary, cardiovascular, renal and proliferative
XX disorders.

XX Claim 11; SEQ ID NO 2730; 2081pp + Sequence Listing; English.

XX The invention relates to novel genes (ABL89449-ABL90853) and proteins
XX (ABB89040-ABB90444) useful for preventing, treating or ameliorating
XX medical conditions e.g. by protein or gene therapy. The genes are
XX isolated from a range of human tissues disclosed in the specification.
XX The nucleic acids, proteins, antibodies and (ant)agonists are useful in
XX the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
XX ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
XX breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
XX disorders e.g. Addison's disease, allergies, autoimmune haemolytic
XX anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
XX multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
XX cardiovascular disorders such as myocardial ischaemias; (d) wound healing
XX ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
XX infectious diseases such as viral, bacterial, fungal and parasitic
XX infections. Note: The sequence data for this patent did not form part of
XX the printed specification, but was obtained in electronic format directly
XX from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 327 AA;

Query Match 99.2%; Score 1155; DB 5; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKVTPEPLSTPLGKTAELCTYSTSVGDSFALEWSFVQPKPISESHPIYFTNGHLY 60
DB 24 VEVKVTPEPLSTPLGKTAELCTYSTSVGDSFALEWSFVQPKPISESHPIYFTNGHLY 83

QY 61 PTGSKSRVSLQNPPTGVATLKLTDVHPSDTGYLCQVNNPPDYFTNGGLINLTIVL 120
DB 84 PTGSKSRVSLQNPPTGVATLKLTDVHPSDTGYLCQVNNPPDYFTNGGLINLTIVL 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSGQLI 180
DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSGQLI 203
QY 181 LTNLSLTSSGTYRCVATNMGASCELTLTSLVTEPSQGRVA 220
DB 204 LTNLSLTSSGTYRCVATNMGASCELTLTSLVTEPSQGRVA 243

RESULT 8

AAU83709

ID AAU83709 standard; protein; 327 AA.

XX AAU83709;

XX 08-MAY-2002 (first entry)

XX Human PRO protein, Seq ID No 236.

XX Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
XX breast cancer; prostate tumour; rectal tumour; liver tumour;
XX pericyte cell proliferation; chondrocyte cell proliferation;

KW tumour necrosis factor-alpha.
 XX Homo sapiens.
 OS WO200208288-A2.
 PN 31-JAN-2002.
 PD
 XX
 PF 29-JUN-2001; 2001WO-US021066.
 XX
 XX 20-JUL-2000; 2000US-0219556P.
 PR 25-JUL-2000; 2000US-0220585P.
 PR 25-JUL-2000; 2000US-0220605P.
 PR 25-JUL-2000; 2000US-0220607P.
 PR 25-JUL-2000; 2000US-0220624P.
 PR 25-JUL-2000; 2000US-0220638P.
 PR 25-JUL-2000; 2000US-0220664P.
 PR 25-JUL-2000; 2000US-0220666P.
 PR 26-JUL-2000; 2000US-0220893P.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 01-AUG-2000; 2000US-022425P.
 PR 22-AUG-2000; 2000US-0227133P.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 28-NOV-2000; 2000US-0253646P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001WO-US017092.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 DR WPI; 2002-172001/22.
 DR N-PSDB; ABK33653.
 XX
 PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful for treating a PRO related disorder and for diagnosing tumors such
 PT as lung cancer, colon cancer, breast tumor, prostate tumor, rectal tumor
 PT or liver tumor.
 XX
 PS Claim 11; Fig 236; 359pp; English.
 XX
 CC The invention relates to one hundred and twenty two nucleic acids
 CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
 CC encode human secreted proteins. The PRO nucleic acids, polypeptides,
 CC agonists and antagonists are useful for treating a PRO related disorder.
 CC The PRO polypeptides are useful for diagnosing tumours, especially lung
 CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. The PRO polypeptides are useful for stimulating the
 CC proliferation of, or gene expression, in pericyte cells, for stimulating
 CC the proliferation or differentiation of chondrocyte cells, for
 CC for stimulating or inhibiting the release of tumour necrosis factor-alpha from human blood,
 CC fibroblast cells. The PRO polypeptide may also be used as molecular
 CC weight markers and for tissue typing. The PRO nucleic acids have
 CC applications in molecular biology, including use as hybridisation probes,
 CC and in chromosome and gene mapping. AAU83592-AAU83713 represent human PRO
 CC protein sequences of the invention
 XX
 SQ Sequence 327 AA;
 Query Match 99.2%; Score 1155; DB 5; Length 327;
 Best Local Similarity 100.0%; Pred. No. 1.4e-80;
 Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
 DB 24 VEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
 QY 61 PTGSKSKRVSLQNPPTVGATLKLTDVHPDSTGTLYLCQVNNPPDPFYTNGLINLTVLV 120
 DB 84 PTGSKSKRVSLQNPPTVGATLKLTDVHPDSTGTLYLCQVNNPPDPFYTNGLINLTVLV 143
 QY 121 PPSNPLCSQSQTSTVGGSTALRCSSEGAPKPVVNWRLGTFPTPSPGSMVQDEVSGQLI 180
 DB 144 PPSNPLCSQSQTSTVGGSTALRCSSEGAPKPVVNWRLGTFPTPSPGSMVQDEVSGQLI 203
 QY 181 LTNLSLTSSGTYRCVATNQMGASCELTLSVTEPSQGRVA 220
 DB 204 LTNLSLTSSGTYRCVATNQMGASCELTLSVTEPSQGRVA 243
 RESULT 9
 ABU80856
 ID ABU80856 standard; protein; 327 AA.
 XX
 AC ABU80856;
 XX
 DT 23-JUN-2003 (first entry)
 XX
 DE Human PRO polypeptide #118.
 XX
 KW Human; PRO polypeptide; secreted and transmembrane protein;
 KW anti-PRO antibody; diagnostic assay; gene expression; tumour; cytostatic.
 XX
 OS Homo sapiens.
 XX
 XX US2003036635-A1.
 FN
 XX 20-FEB-2003.
 PD
 XX 28-AUG-2002; 2002US-00230163.
 PF
 XX 25-JUL-2000; 2000US-0220638P.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 DR WPI; 2003-342045/32.
 DR N-PSDB; ACA66958.
 XX
 PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful for the manufacture of a medicament for diagnosing or treating
 PT tumor.
 XX
 PS Claim 11; Fig 236; 314pp; English.
 XX
 CC The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides and polynucleotides are useful for preparing a medicament
 CC useful in the diagnosis and treatment of tumours. Anti-PRO antibodies are
 CC useful in diagnostic assays for PRO, by detecting its expression in
 CC specific cells, tissues or serum, and for affinity purification of PRO
 CC from recombinant cell culture or natural sources. ABU80739-ABU80860
 CC represent the human PRO polypeptides of the invention. Note: The sequence
 CC data for this patent was obtained in electronic format directly from the
 CC USPTO web site at seqdata.uspto.gov/psipdbEntry.html
 XX
 SQ Sequence 327 AA;
 Query Match 99.2%; Score 1155; DB 6; Length 327;

Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB 24 VEKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
QY 61 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYLQVNNPPDPFTYTNGLGLINLTVLV 120
DB 84 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYLQVNNPPDPFTYTNGLGLINLTVLV 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSGQLI 180
DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSGQLI 203
QY 181 LTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVA 220
DB 204 LTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVA 243

RESULT 10
ID ABO33822 standard; protein; 327 AA.
XX ABO33822;
DT 17-SEP-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO7154.
XX Human; secreted and transmembrane protein; PRO; cytostatic;
KW antarthritic; osteopathic; gene therapy; TNF-Agonist-Alpha;
KW chondrocyte stimulator; pericyte stimulator; fibroblast modulator;
KW pharmaceutical; diagnostic; biosensor; bioreactor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; bone disorder; cartilage disorder; sports injury;
arthritis; wound.
XX Homo sapiens.
OS US2003045687-A1.
FN US2003045687-A1.
PD 06-MAR-2003.
XX 12-AUG-2002; 2002US-00218631.
XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-512315/48.
DR N-PSDB; ACD68710.
XX New genes, and its encoded secreted and transmembrane polypeptides,
PT useful for stimulating tumor Necrosis Factor alpha, or chondrocyte or
PT pericyte proliferation, especially for treating lung tumors, arthritis or
PT wounds in a mammal.
XX Claim 11; Fig 236; 314pp; English.
XX The invention describes an isolated nucleic acid molecule comprising a
CC sequence with at least 80% identity to: (a) a nucleotide encoding any of
CC 122 PRO (secreted and transmembrane) polypeptides whose sequences are
CC fully defined in the specification; or (b) any of 122 nucleotide
CC sequences having e.g. 4834, 2504 or 1759 bp fully defined in the
CC specification; or the full length coding sequence of any these 122
CC nucleotide sequences. The PRO polypeptides or polynucleotides are useful
CC as pharmaceuticals, diagnostics, biosensors or bioreactors. These are

CC particularly useful for detecting tumours (e.g. lung tumour, colon
CC tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)
CC in a mammal, for stimulating the release of TNF-alpha from human blood,
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells, for stimulating proliferation of pericyte cells, or for modulating
CC normal human dermal fibroblast proliferation. The PRO nucleic acid or
CC polypeptide is also useful for treating tumours or various bone and/or
CC cartilage disorders (e.g. sports injuries or arthritis), or wounds. The
CC PRO polypeptides are useful in drug screening, particularly as targets
CC for therapeutic intervention in these diseases, and in the diagnostic
CC determination of the presence of these diseases. The PRO polypeptides are
CC also useful as molecular weight markers, or for chromosome
CC identification. The PRO genes are useful as hybridisation probes, or for
CC screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
CC also be used in gene therapy, particularly for replacing a defective
CC gene. This is the amino acid sequence of a novel human secreted and
CC transmembrane PRO polypeptide
XX Sequence 327 AA;

Query Match 99.2%; Score 1155; DB 6; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB 24 VEKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
QY 61 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYLQVNNPPDPFTYTNGLGLINLTVLV 120
DB 84 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYLQVNNPPDPFTYTNGLGLINLTVLV 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSGQLI 180
DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSGQLI 203
QY 181 LTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVA 220
DB 204 LTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVA 243

RESULT 11
ID ABO82165 standard; protein; 327 AA.
XX ABO82165;
DT 25-JUN-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO7154.
XX Human; secreted and transmembrane protein; PRO; cardiant; cytostatic;
KW antiangiogenic; hypotensive; vulnery; antiarteriosclerotic;
KW gene therapy; cardiovascular disorder; endothelial disorder;
KW angiocenic disorder; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; atherosclerosis; hypertension;
KW arterial restenosis; rheumatoid arthritis; angina; myocardial infarction;
KW thrombophlebitis; lymphangitis; tumour angiogenesis; breast carcinoma;
KW liver carcinoma; wound healing; chromosome mapping; gene mapping.
XX Homo sapiens.
OS US2003088063-A1.
FN US2003088063-A1.
PD 08-MAY-2003.
XX 12-AUG-2002; 2002US-00219003.
XX 25-JUL-2000; 2000US-0220664P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX

PA (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-393229/37.
 DR N-PSDB; ACA68614.
 XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
 PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
 PT infarction), endothelial or angiogenic disorders in a mammal.
 XX Claim 11; Fig 236; 314pp; English.
 XX The invention describes one hundred and eighty seven nucleic acids
 CC encoding novel human secreted and transmembrane (PRO) polypeptides. The
 CC PRO nucleic acids, polypeptides, agonists and antagonists are useful for
 CC treating or diagnosing a cardiovascular, endothelial or angiogenic
 CC disorder in a mammal, e.g. cardiac hypertrophy, trauma, cancer, age-
 CC related macular degeneration, atherosclerosis, hypertension, arterial
 CC restenosis, rheumatoid arthritis, angina, myocardial infarctions,
 CC thrombophlebitis, lymphangitis, tumour angiogenesis (such as breast
 CC carcinoma and liver carcinoma) and wound healing. The PRO nucleic acids
 CC have applications in molecular biology, including use as hybridisation
 CC probes, and in chromosome and gene mapping. This is the amino acid
 CC sequence of a novel human secreted and transmembrane PRO polypeptide
 XX Sequence 327 AA;
 SQ
 Query Match 99.2%; Score 1155; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 1.4e-80;
 Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 VEVKVTPEPLSTPLGKTAELTCTYSTVGDSPFALEWSFVQPKPISESHPILYFNGHLY 60
 DB 24 VEVKVTPEPLSTPLGKTAELTCTYSTVGDSPFALEWSFVQPKPISESHPILYFNGHLY 83
 QY 61 PTGSKSRVSLQNPPPTVGVAATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTLV 120
 DB 84 PTGSKSRVSLQNPPPTVGVAATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTLV 143
 QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTSPGSMVQDEVSGOLI 180
 DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTPTSPGSMVQDEVSGOLI 203
 QY 181 LTNLISLTSSGTYRCVATNMGSGASCELTLSVTEPSQGRVA 220
 DB 204 LTNLISLTSSGTYRCVATNMGSGASCELTLSVTEPSQGRVA 243
 RESULT 12
 ABJ72345
 ID ABJ72345 standard; protein; 327 AA.
 XX AC ABJ72345;
 XX 06-NOV-2003 (first entry)
 XX Human PRO7154 protein.
 XX PRO; proliferation; pericyte cell; TNF-alpha; blood; chondrocyte;
 KW differentiation; dermal fibroblast; tumour; gene therapy; cytostatic.
 XX Homo sapiens.
 XX US2003050448-A1.
 XX 13-MAR-2003.
 XX 28-AUG-2002; 2002US-00230414.
 XX 01-JUN-2001; 2001WO-US017800.
 XX 29-JUN-2001; 2001WO-US021066.

PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-521818/49.
 DR N-PSDB; ABT44343.
 XX New nucleic acid encoding for a PRO protein, useful for the manufacture
 PT of a medicament for diagnosing or treating tumors or for measuring or
 PT detecting expression of an associated gene.
 XX Claim 11; Fig 236; 315pp; English.
 XX The invention relates to a novel isolated nucleic acid encoding a fully
 CC defined PRO polypeptide. The molecules of the invention may be useful for
 CC stimulating proliferation or gene expression in pericyte cells or the
 CC release of TNF-alpha from human blood. Other possible uses include the
 CC stimulation or inhibition of chondrocyte proliferation or
 CC differentiation, the stimulation of human dermal fibroblast cell
 CC proliferation and the detection of the presence of a tumour within a
 CC mammal. Furthermore, the nucleic acid may be useful for the manufacture
 CC of a medicament for diagnosing or treating a tumour within a mammal or
 CC for measuring or detecting the expression of an associated gene, as well
 CC as during gene therapy. The current sequence is that of the human PRO
 CC protein of the invention
 XX Sequence 327 AA;
 SQ
 Query Match 99.2%; Score 1155; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 1.4e-80;
 Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 VEVKVTPEPLSTPLGKTAELTCTYSTVGDSPFALEWSFVQPKPISESHPILYFNGHLY 60
 DB 24 VEVKVTPEPLSTPLGKTAELTCTYSTVGDSPFALEWSFVQPKPISESHPILYFNGHLY 83
 QY 61 PTGSKSRVSLQNPPPTVGVAATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTLV 120
 DB 84 PTGSKSRVSLQNPPPTVGVAATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTLV 143
 QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTPTSPGSMVQDEVSGOLI 180
 DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTPTSPGSMVQDEVSGOLI 203
 QY 181 LTNLISLTSSGTYRCVATNMGSGASCELTLSVTEPSQGRVA 220
 DB 204 LTNLISLTSSGTYRCVATNMGSGASCELTLSVTEPSQGRVA 243
 RESULT 13
 ABJ72473
 ID ABJ72473 standard; protein; 327 AA.
 XX AC ABJ72473;
 XX 06-NOV-2003 (first entry)
 XX Human PRO7154 protein.
 XX PRO; blood; proliferation; pericyte cell; TNF alpha; chondrocyte;
 KW tumour necrosis factor; proliferation; differentiation; gene therapy;
 KW dermal fibroblast.
 XX Homo sapiens.
 XX US2003027988-A1.
 XX 06-FEB-2003.
 XX 26-AUG-2002; 2002US-00227884.

XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-503301/47.
DR N-PSDB; AB744626.
XX
PT New PRO protein encoding nucleic acid, useful for preparing PRO
PT polypeptides and anti-PRO antibodies for detecting the presence of a
PT tumor in a mammal.
XX
PS Claim 11; Fig 236; 324pp; English.
XX
CC The invention relates to a novel isolated PRO protein encoding nucleic
CC acid. The nucleic acid of the invention may be useful for preparing PRO
CC polypeptides and anti-PRO antibodies for detecting the presence of a
CC tumor in a mammal. Furthermore, the molecules of the invention may be
CC useful for stimulating proliferation or gene expression in pericyte
CC cells, the release of tumour necrosis factor (TNF)-alpha from human
CC blood, the proliferation or differentiation of chondrocyte cells and for
CC inhibiting the proliferation of normal human dermal fibroblast cells.
CC Finally, the molecules may be utilised during gene therapy. The current
CC sequence is that of the human PRO protein of the invention
XX
SQ Sequence 327 AA;
Query Match 99.2%; Score 1155; DB 6; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKPTPEPLSTPLGKTAELTCTYSTVGDSPFALEWSFVQPKPISEHPILYFTNGHLY 60
Db 24 VEVKPTPEPLSTPLGKTAELTCTYSTVGDSPFALEWSFVQPKPISEHPILYFTNGHLY 83
QY 61 PTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYLCQVNNPPDPFYTNGLGLINLTVLV 120
Db 84 PTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYLCQVNNPPDPFYTNGLGLINLTVLV 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYVWVRLGTPTSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYVWVRLGTPTSPGSMVQDEVSGQLI 203
QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLTSLVTEPSQGRVA 220
Db 204 LTNLSLTSSGTYRCVATNQMSASCELTLTSLVTEPSQGRVA 243
RESULT 14
ABO34368
ID ABO34368 standard; protein; 327 AA.
XX ABO34368;
XX
DT 19-SEP-2003 (first entry)
XX
DE Human secreted/transmembrane polypeptide PRO 7154.
XX
KW Human; chondrocyte stimulation; TNF-alpha stimulation; gene therapy;
KW human dermal fibroblast stimulation; tumour; tissue typing;
KW affinity purification.
XX
OS Homo sapiens.
XX
PN US2003044934-A1.
XX
PD 06-MAR-2003.
XX

PF 28-AUG-2002; 2002US-00230338.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-492274/46.
DR N-PSDB; ACD82293.
XX
PT New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX
PS Claim 19; Fig 236; 315pp; English.
XX
CC The invention relates to an isolated nucleic acid encoding a PRO
CC polypeptide. Nucleic acids that encode PRO can be used to generate either
CC transgenic animals or knock-out animals useful in developing and
CC screening of therapeutically useful reagents. The nucleic acids may also
CC be used in gene therapy for replacing defective gene, in chromosome
CC identification, as chromosome markers, or in generating probes to isolate
CC full length PRO cDNA. The PRO polypeptides are useful for chondrocyte
CC stimulation, TNF-alpha stimulation, human dermal fibroblasts stimulation
CC and for detecting the presence of tumour in a mammal. The PRO
CC polypeptides are useful as molecular markers for protein electrophoresis
CC and the isolated nucleic acids may be used for recombinantly expressing
CC those markers. The PRO polypeptides and nucleic acids may also be used in
CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
CC PRO and in affinity purification of PRO from recombinant cell culture or
CC natural sources. The present sequence represents the amino acid sequence
CC of a human secreted/transmembrane PRO polypeptide
XX
SQ Sequence 327 AA;
Query Match 99.2%; Score 1155; DB 6; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKPTPEPLSTPLGKTAELTCTYSTVGDSPFALEWSFVQPKPISEHPILYFTNGHLY 60
Db 24 VEVKPTPEPLSTPLGKTAELTCTYSTVGDSPFALEWSFVQPKPISEHPILYFTNGHLY 83
QY 61 PTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYLCQVNNPPDPFYTNGLGLINLTVLV 120
Db 84 PTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYLCQVNNPPDPFYTNGLGLINLTVLV 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYVWVRLGTPTSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYVWVRLGTPTSPGSMVQDEVSGQLI 203
QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLTSLVTEPSQGRVA 220
Db 204 LTNLSLTSSGTYRCVATNQMSASCELTLTSLVTEPSQGRVA 243
RESULT 15
ABJ72175
ID ABJ72175 standard; protein; 327 AA.
XX
AC ABJ72175;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human membrane bound receptor/protein PRO7154 amino acid sequence.
XX
KW Human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;

KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.

OS Homo sapiens.

XX US2003065147-A1.

XX 03-APR-2003.

XX 29-AUG-2002; 2002US-00232224.

XX 28-JUL-1999; 99US-0146222P.

XX 24-FEB-2000; 2000WO-US005004.

XX 02-MAR-2000; 2000WO-US005841.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021065.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2003-522018/49.

XX N-PSDB; ABT43999.

XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for the manufacture of a medicament for diagnosing or treating
PT tumor.

XX Claim 11; Fig 236; 315pp; English.

XX This invention relates to one hundred and twenty two novel nucleic acids
CC encoding human PRO membrane bound proteins or receptors. Extracellular
CC proteins play important roles in the formation, differentiation and
CC maintenance of multicellular organisms. The fate of many individual cells
CC (for example proliferation, migration or differentiation) is typically
CC governed by information received from other cells and the immediate
CC environment. The information is often transmitted by secreted
CC polypeptides (for example mitogenic factors, survival factors, cytotoxic
CC factors, differentiation factors, neuropeptides and hormones) which are
CC received and interpreted by diverse cell receptors or membrane bound
CC proteins. These membrane bound proteins and receptors may be of use as
CC pharmaceutical and diagnostic agents, such as in the blocking of receptor
CC -ligand interactions. The current invention provides the amino acid
CC sequences of novel human membrane bound receptors and proteins, along
CC with the cDNA sequences encoding them. The novel proteins of the
CC invention may have cytotatic activities through the stimulation of
CC chondrocytes. The nucleic acids of the invention may be useful for the
CC manufacture of a medicament for diagnosing or treating a tumour in a
CC mammal. In addition, they may be useful for measuring or detecting the
CC expression of a tumour associated gene. The present sequence is the amino
CC acid sequence of a human PRO protein of the invention

XX SQ Sequence 327 AA;

Query Match 99.2%; Score 1155; DB 7; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKVPTEPLSLGKTAELTCTYSTVSDSFALEWSFVQCKPISESHPILYFTNGHLY 60
DB 24 VEVKVPTEPLSLGKTAELTCTYSTVSDSFALEWSFVQCKPISESHPILYFTNGHLY 83
QY 61 PTGSKSKRVSLQNPPTVGATLKLTDVHPSTGTVLCQVNNPPDFYTNGLINLTVLV 120
DB 84 PTGSKSKRVSLQNPPTVGATLKLTDVHPSTGTVLCQVNNPPDFYTNGLINLTVLV 143
QY 121 PPSNPLCSQSGQTSGVGGTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVDVSGQLI 180
DB 144 PPSNPLCSQSGQTSGVGGTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVDVSGQLI 203
QY 181 LTNLSLSSGTYRCVATNQMGASCELTLVTEPSQGRVA 220

Db 204 LTNLSLSSGTYRCVATNQMGASCELTLVTEPSQGRVA 243

Search completed: August 4, 2005, 06:07:08
Job time : 68.7067 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 05:53:15 ; Search time 74.7214 Seconds
(without alignments)
1268.128 Million cell updates/sec

Title: US-10-607-565-83_COPY_1_245

Perfect score: 1286
Sequence: 1 MAELPGFPLCGALLGFLCLS.....ASCELTSLVTPSQGRVABL 245

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_16Dec04:*
1: Genesecp1980s:*
2: Genesecp1990s:*
3: Genesecp2000s:*
4: Genesecp2001s:*
5: Genesecp2002s:*
6: Genesecp2003as:*
7: Genesecp2003bs:*
8: Genesecp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	1286	100.0	245	3 AAB08940	Aab08940 Human sec
2	1286	100.0	246	3 AAB08926	Aab08926 Human sec
3	1277	99.3	327	3 AAY87251	Aay87251 Human sig
4	1277	99.3	327	3 AAY94857	Aay94857 Human pro
5	1277	99.3	327	4 AAY97585	Aay97585 Human sec
6	1277	99.3	327	5 ABB90354	Abb90354 Human pol
7	1277	99.3	327	5 AAU83709	Aau83709 Human PRO
8	1277	99.3	327	6 ABU80856	Abu80856 Human PRO
9	1277	99.3	327	6 ABO33822	Abos33822 Novel hum
10	1277	99.3	327	6 ABU82165	Abus2165 Novel hum
11	1277	99.3	327	6 ABU72345	Abj72345 Human PRO
12	1277	99.3	327	6 ABJ72473	Abj72473 Human PRO
13	1277	99.3	327	6 ABO34368	Abos34368 Human sec
14	1277	99.3	327	7 ABJ72175	Abj72175 Human mem
15	1277	99.3	327	7 ADB83726	Adb83726 Novel hum
16	1277	99.3	327	7 ADB80832	Adb80832 Novel hum
17	1277	99.3	327	7 ADB73373	Adb73373 Novel hum
18	1277	99.3	327	7 ADB78455	Adb78455 Novel hum
19	1277	99.3	327	7 ADB85103	Adb85103 Human PRO
20	1277	99.3	327	7 ADB78209	Adb78209 Novel hum
21	1277	99.3	327	7 ADB87275	Adb87275 Human PRO
22	1277	99.3	327	7 ADB84857	Adb84857 Human PRO
23	1277	99.3	327	7 ADB83972	Adb83972 Novel hum
24	1277	99.3	327	7 ADB73127	Adb73127 Novel hum
25	1277	99.3	327	7 ADC36965	Adc36965 Human PRO

ALIGNMENTS

RESULT 1

AAB08940
ID AAB08940 standard; protein; 245 AA.
XX AC AAB08940;
XX AC
DT 30-AUG-2000 (first entry)
XX
DE Human secreted protein sequence encoded by gene 13 SEQ ID NO:97.
XX
KW Human; secreted protein; cytostatic; anti-proliferative; vulnary;
KW immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
KW hyperproliferative disorder; infectious disease; tissue regeneration;
KW screening; food additive; preservative; wound healing;
KW hyper-vascular disease; chromosome 11.
XX
OS Homo sapiens.
XX
PN WO200017222-A1.
XX
PD 30-MAR-2000.
XX
PF 22-SEP-1999; 99WO-US022012.
XX
PR 23-SEP-1998; 98US-0101546P.
XX
PR 02-OCT-1998; 98US-0102895P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;
PI Komatsoulis G, Endress GA, Soppet DR;
XX
XX WPI; 2000-283538/24.
XX
DR Human secreted proteins and coding sequences useful in diagnostic and
XX therapeutic methods for disorders such as immune system or proliferative
XX disorders, related to the proteins.
XX
PS Disclosure; Page 40; 416pp; English.
XX
CC The polynucleotide sequences given in AAA39052 to AAA39088 encode the
XX human secreted proteins given in AAB08891 to AAB08984. The human secreted
XX proteins can have activities based on the tissues and cells they are
XX expressed in. Examples of the activities are: cytostatic; anti-
XX proliferative; immunosuppressive; antibacterial; and vulnary. The
XX secreted proteins and their related polynucleotide sequences are useful
XX for diagnostic and therapeutic methods useful for diagnosing and treating
XX disorders related to the secreted proteins. The proteins, and

Adc21955 Human PRO
Adc49986 Novel hum
Adc49185 Novel hum
Adc49702 Novel hum
Adc47563 Novel hum
Adc47308 Novel hum
Adc78183 Novel hum
Adc06418 Novel hum
Adc77937 Novel hum
Adc50900 Novel hum
Adc51146 Novel hum
Adc50627 Human PRO
Adc50381 Human PRO
Adc51392 Novel hum
Adc48939 Novel hum
Adc21110 Novel hum
Adc5954 Human PRO
Adc75183 Human PRO
Adc75929 Novel hum
Adc85161 Novel hum

CC polynucleotide sequences may be useful for treating disorders of the
CC immune system, hyperproliferative disorders, infectious disease,
CC regeneration of tissues, for chemotaxis and for screening molecules that
CC bind to the proteins. The proteins or polynucleotide sequences may be
CC used as food additives or preservatives, to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, co-factors or other nutritional components. Agonists or
CC antagonists of the proteins may be used to prevent scar tissue growth
CC during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC and AAB08890 are sequences used in the exemplification of the present
XX invention
SQ Sequence 245 AA;

Query Match 100.0%; Score 1286; DB 3; Length 245;
Best Local Similarity 100.0%; Pred. No. 6.1e-85;
Matches 245; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTABLTCTYSTVSGDSFALEWS 60
DB 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTABLTCTYSTVSGDSFALEWS 60
QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
DB 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLISVTEPSQG 240
DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLISVTEPSQG 240
QY 241 RVAEL 245
DB 241 RVAEL 245

RESULT 2
AAB08926
ID AAB08926 standard; protein; 246 AA.
XX AC AAB08926;
XX AC AAB08926;
DT 30-AUG-2000 (first entry)
DE Human secreted protein sequence encoded by gene 13 SEQ ID NO:83.
XX Human; secreted protein; cytostatic; anti-proliferative; vulnerary;
KW immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
KW hyperproliferative disorder; infectious disease; tissue regeneration;
KW screening; food additive; preservative; wound healing;
KW hyper-vascular disease; chromosome 11.
XX Homo sapiens.
OS
XX WO200017222-A1.
XX
XX 30-MAR-2000.
XX
XX 22-SEP-1999; 99WO-US022012.
XX
XX 23-SEP-1998; 98US-0101546P.
XX 02-OCT-1998; 98US-0102895P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;
PI Komatsoulis G, Endress GA, Soppet DR;
XX WPI; 2000-283538/24.
DR N-PSDB; AAA39087.

XX Human secreted proteins and coding sequences useful in diagnostic and
PT therapeutic methods for disorders such as immune system or proliferative
PT disorders, related to the proteins.
XX Claim 11; Page 376-377; 416pp; English.
XX The polynucleotide sequences given in AAA39052 to AAA39088 encode the
CC human secreted proteins given in AAB08891 to AAB08984. The human secreted
CC proteins can have activities based on the tissues and cells they are
CC expressed in. Examples of the activities are: cytostatic; anti-
CC proliferative; immunosuppressive; antibacterial; and vulnerary. The
CC secreted proteins and their related polynucleotide sequences are useful
CC for diagnostic and therapeutic methods useful for diagnosing and treating
CC disorders related to the secreted proteins. The proteins, and
CC polynucleotide sequences may be useful for treating disorders of the
CC immune system, hyperproliferative disorders, infectious disease,
CC regeneration of tissues, for chemotaxis and for screening molecules that
CC bind to the proteins. The proteins or polynucleotide sequences may be
CC used as food additives or preservatives, to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, co-factors or other nutritional components. Agonists or
CC antagonists of the proteins may be used to prevent scar tissue growth
CC during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC and AAB08890 are sequences used in the exemplification of the present
XX invention
SQ Sequence 246 AA;

Query Match 100.0%; Score 1286; DB 3; Length 246;
Best Local Similarity 100.0%; Pred. No. 6.1e-85;
Matches 245; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTABLTCTYSTVSGDSFALEWS 60
DB 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTABLTCTYSTVSGDSFALEWS 60
QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
DB 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLISVTEPSQG 240
DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLISVTEPSQG 240
QY 241 RVAEL 245
DB 241 RVAEL 245

RESULT 3
AAY87251
ID AAY87251 standard; protein; 327 AA.
XX AC AAY87251;
XX AC AAY87251;
DT 11-MAY-2000 (first entry)
XX
XX Human signal peptide containing protein HSP-28 SEQ ID NO:28.
DE
XX Human; signal peptide-containing protein; HSP; diagnosis; cancer;
KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW antimicrobial; neurotropic; neuroprotective; cardiovascular; hepatotropic;
KW antiaesthetic; gene therapy; cell proliferation; neurological disorder;
KW reproductive disorder; developmental disorder; arteriosclerosis;
KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
KW Parkinson's disease; Huntington's disease; ovulatory defect;
KW muscular dystrophy.

CC deficiencies. It is also used in compositions for tissue growth or
 CC regeneration. The protein is also used in the treatment of osteoporosis
 CC or osteoarthritis and in the treatment of periodontal disease and other
 CC tooth repair processes. The protein is used in the treatment of nervous
 CC system disorders such as Alzheimer's disease, Parkinson's disease, and
 CC Huntington's disease. They are useful for protection or regeneration and
 CC treatment of lung or liver fibrosis, reperfusion injury in various
 CC tissues, and conditions resulting from systemic cytokine damage. They are
 CC also used for promoting or inhibiting tissue differentiation. They are
 CC also used as contraceptives since they exhibit activin or inhibin related
 CC activities and as a fertility inducing therapeutic. They are used for
 CC treating various coagulation disorders and in treatment and prevention of
 CC conditions resulting from coagulation activities e.g. myocardial
 CC infarction or stroke. They also acts as receptors, receptor ligands or
 CC inhibitors or agonists of receptor/ligand interactions. They are used to
 CC treat inflammatory conditions such as septic shock, sepsis, ischaemia
 CC reperfusion injury, arthritis, and nephritis. They can be used to prevent
 CC tumours
 XX
 SQ Sequence 327 AA;

Query Match 99.3%; Score 1277; DB 3; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYTL 120
 DB 61 FVQPKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYTL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 QY 181 RLGTPTPSPGSMQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPSQG 240
 DB 181 RLGTPTPSPGSMQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPSQG 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 5
 AAY97585
 ID AAY97585 standard; protein; 327 AA.
 XX AAY97585;
 AC AAY97585;
 XX
 DT 05-APR-2001 (first entry)
 XX Human secreted protein PRO7154.
 DE
 XX
 XX Secreted protein; human; PRO protein; neoplastic cell growth; tumour;
 KW proliferation; leukaemia; lymphoid malignancy; inflammatory disorder;
 KW angiogenic disorder; immunologic disorder; PRO7154.
 XX
 OS Homo sapiens.
 XX
 PN WO200075317-A2.
 XX
 PD 14-DEC-2000.
 XX
 PF 15-MAY-2000; 2000WO-US013358.
 XX
 PR 09-JUN-1999; 99US-0138385P.
 PR 20-JUL-1999; 99US-0144790P.
 PR 03-AUG-1999; 99US-0146843P.
 PR 10-AUG-1999; 99US-0148188P.
 PR 17-AUG-1999; 99US-0149320P.

PR 17-AUG-1999; 99US-0149327P.
 PR 17-AUG-1999; 99US-0149396P.
 PR 20-AUG-1999; 99US-0150114P.
 PR 31-AUG-1999; 99US-0151700P.
 PR 31-AUG-1999; 99US-0151734P.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Botstein DA, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
 XX
 DR WPI; 2001-071075/08.
 DR N-PSDB; AAA91019.
 XX
 XX Antibodies against PRO polypeptides, useful for diagnosing and treating
 PT tumors are associated with gene amplification, neoplastic cell growth and
 PT proliferation in mammals.
 XX
 PS Claim 61; Fig 12; 143pp; English.
 XX
 CC This sequence is a human PRO protein of the invention. The PRO proteins
 CC are secreted proteins. Antagonists or antibodies of PRO polypeptides are
 CC useful for diagnosing and treating tumours are associated with gene
 CC amplification, neoplastic cell growth and proliferation in mammals, and
 CC those conditions characterised by overexpression and/or activation of the
 CC amplified genes. Such conditions include benign or malignant tumours
 CC (e.g. renal, liver, kidney, bladder, breast, gastric, ovarian,
 CC colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic
 CC carcinomas, sarcomas, glioblastomas and various head and neck tumours);
 CC leukaemias and lymphoid malignancies; neuronal, glial, astrocytal,
 CC hypothalamic, and other glandular, macrophageal, epithelial, stromal and
 CC blastocoeleic disorders; and inflammatory, angiogenic and immunologic
 CC disorders. These may further be used to qualitatively or quantitatively
 CC detect the expression of proteins encoded by the amplified genes, and in
 CC tumour diagnostics or prognostics. The PRO polypeptide or its antagonist
 CC may be used for the preparation of a medicament in the treatment of a
 CC condition, which is responsive to the PRO polypeptide, its antagonist or
 CC anti-PRO antibody
 XX
 SQ Sequence 327 AA;
 Query Match 99.3%; Score 1277; DB 4; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYTL 120
 DB 61 FVQPKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYTL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 QY 181 RLGTPTPSPGSMQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPSQG 240
 DB 181 RLGTPTPSPGSMQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPSQG 240
 QY 241 RVA 243
 DB 241 RVA 243
 RESULT 6
 ABB90354
 ID ABB90354 standard; protein; 327 AA.
 XX
 AC ABB90354;
 XX
 DT 24-MAY-2002 (first entry)
 XX

Human polypeptide SEQ ID NO 2730.

Cytostatic; immunosuppressive; neurotropic; neuroprotective; antiviral; antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer; vulnerary; anticonvulsant; antifungal; antiparasitic; cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder; neurological disease; infection; human; secreted protein.

Homo sapiens.

WO200190304-A2.

29-NOV-2001.

18-MAY-2001; 2001WO-US016450.

19-MAY-2000; 2000US-0205515P.

(HUMA-) HUMAN GENOME SCI INC.

Birse CE, Rosen CA;

WPI; 2002-122018/16.

N-PSDB; ABL90763.

Novel 1405 isolated polypeptides, useful for diagnosis, treatment and prevention of neural, immune system, muscular, reproductive, gastrointestinal, pulmonary, cardiovascular, renal and proliferative disorders.

Claim 11; SEQ ID NO 2730; 2081pp + Sequence Listing; English.

The invention relates to novel genes (ABL9449-ABL90853) and proteins (ABB9040-ABB90444) useful for preventing, treating or ameliorating medical conditions e.g. by protein or gene therapy. The genes are isolated from a range of human tissues disclosed in the specification. The nucleic acids, proteins, antibodies and (ant)agonists are useful in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and ovarian cancer and other cancers of the adrenal gland, bone, marrow, breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune disorders e.g. Addison's disease, allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c) cardiovascular disorders such as myocardial ischaemias; (d) wound healing; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f) infectious diseases such as viral, bacterial, fungal and parasitic infections. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at [ftp.wipo.int/pub/published_pct_sequences](http://wipo.int/pub/published_pct_sequences)

Sequence 327 AA;

Query Match 99.3%; Score 1277; DB 5; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGFLLCGALGFLCGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
DB 1 MAELPGFLLCGALGFLCGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISSHPILFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
DB 61 FVQPGKPISSHPILFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120

QY 121 CQVNNPDPFTYNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESGAPKPVYNNV 180
DB 121 CQVNNPDPFTYNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESGAPKPVYNNV 180

QY 181 RLCTEPTSPGSMVQDVESQQLITNLSTSSGTYRCVATNQMGASCELTLTSPFSQ 240
DB 181 RLCTEPTSPGSMVQDVESQQLITNLSTSSGTYRCVATNQMGASCELTLTSPFSQ 240

QY 241 RVA 243

Db 241 RVA 243

|||

RESULT 7

AAU83709

XX AAU83709 standard; protein; 327 AA.

XX AC AAU83709;

XX DT 08-MAY-2002 (first entry)

XX DE Human PRO protein, Seq ID No 236.

XX KW Human; secreted protein; PRO; tumour; lung cancer; colon cancer;

XX KW breast cancer; prostate tumour; rectal tumour; liver tumour;

XX KW pericyte cell proliferation; chondrocyte cell proliferation;

XX KW tumour necrosis factor-alpha.

XX OS Homo sapiens.

XX PN WO200208288-A2.

XX PD 31-JAN-2002.

XX PF 29-JUN-2001; 2001WO-US021066.

XX PR 20-JUL-2000; 2000US-0219556P.

XX PR 25-JUL-2000; 2000US-0220585P.

XX PR 25-JUL-2000; 2000US-0220605P.

XX PR 25-JUL-2000; 2000US-0220607P.

XX PR 25-JUL-2000; 2000US-0220624P.

XX PR 25-JUL-2000; 2000US-0220638P.

XX PR 25-JUL-2000; 2000US-0220664P.

XX PR 25-JUL-2000; 2000US-0220666P.

XX PR 26-JUL-2000; 2000US-0220893P.

XX PR 28-JUL-2000; 2000WO-US020710.

XX PR 01-AUG-2000; 2000US-0222425P.

XX PR 22-AUG-2000; 2000US-0227133P.

XX PR 23-AUG-2000; 2000WO-US023522.

XX PR 24-AUG-2000; 2000WO-US023328.

XX PR 10-NOV-2000; 2000WO-US030873.

XX PR 28-NOV-2000; 2000US-0253646P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 20-DEC-2000; 2000US-00747259.

XX PR 20-DEC-2000; 2000WO-US034956.

XX PR 28-FEB-2001; 2001WO-US006520.

XX PR 01-MAR-2001; 2001WO-US006566.

XX PR 22-MAR-2001; 2001US-00816744.

XX PR 10-MAY-2001; 2001US-00854208.

XX PR 10-MAY-2001; 2001US-00854280.

XX PR 25-MAY-2001; 2001WO-US017092.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX XX WPI; 2002-172001/22.

XX DR N-PSDB; ABK33653.

XX XX One hundred and twenty two nucleic acids encoding PRO polypeptides,

XX PT useful for treating a PRO related disorder and for diagnosing tumors such

XX PT as lung cancer, colon cancer, breast tumor, prostate tumor, rectal tumor

XX PT or liver tumor.

XX XX Claim 11; Fig 236; 359pp; English.

XX XX The invention relates to one hundred and twenty two nucleic acids

XX CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides

XX CC encode human secreted proteins. The PRO nucleic acids, polypeptides,

XX CC agonists and antagonists are useful for treating a PRO related disorder.

XX CC The PRO polypeptides are useful for diagnosing tumours, especially lung

CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. The PRO polypeptides are useful for stimulating the
 CC proliferation of, or gene expression, in pericyte cells, for stimulating
 CC the proliferation or differentiation of chondrocyte cells, for
 CC stimulating the release of tumour necrosis factor-alpha from human blood,
 CC for stimulating or inhibiting the proliferation of normal human dermal
 CC fibroblast cells. The PRO polypeptide may also be used as molecular
 CC weight markers and for tissue typing. The PRO nucleic acids have
 CC applications in molecular biology, including use as hybridisation probes,
 CC and in chromosome and gene mapping. AAU83592-AAU83713 represent human PRO
 CC protein sequences of the invention
 XX
 SQ Sequence 327 AA;

Query Match 99.3%; Score 1277; DB 5; Length 327;

Best Local Similarity 100.0%; Pred. No. 3.8e-84;

Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQLQNPTVGATIKLTDVHPSDTGYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQLQNPTVGATIKLTDVHPSDTGYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
 QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTVTEPSQG 240
 DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTVTEPSQG 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 8

ID ABU80856

XX ABU80856 standard; protein; 327 AA.

AC ABU80856;

XX

DT 23-JUN-2003 (first entry)

XX Human PRO polypeptide #118.

DE Human; PRO polypeptide; secreted and transmembrane protein;

XX anti-PRO antibody; diagnostic assay; gene expression; tumour; cytostatic.

XX Homo sapiens.

OS US2003036635-A1.

XX 20-FEB-2003.

XX 28-AUG-2002; 2002US-00230163.

XX 25-JUL-2000; 2000US-0220638P.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2003-342045/32.

XX N-PSDB; ACA6958.

XX

PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful for the manufacture of a medicament for diagnosing or treating
 PT tumor.

XX Claim 11; Fig 236; 314pp; English.

XX The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides and polynucleotides are useful for preparing a medicament
 CC useful in the diagnosis and treatment of tumours. Anti-PRO antibodies are
 CC useful in diagnostic assays for PRO, by detecting its expression in
 CC specific cells, tissues or serum, and for affinity purification of PRO
 CC from recombinant cell culture or natural sources. ABU80739-ABU80860
 CC represent the human PRO polypeptides of the invention. Note: The sequence
 CC data for this patent was obtained in electronic format directly from the
 CC USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html

SQ Sequence 327 AA;

Query Match 99.3%; Score 1277; DB 6; Length 327;

Best Local Similarity 100.0%; Pred. No. 3.8e-84;

Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQLQNPTVGATIKLTDVHPSDTGYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQLQNPTVGATIKLTDVHPSDTGYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
 QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTVTEPSQG 240
 DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTVTEPSQG 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 9

ABO33822

ID ABO33822 standard; protein; 327 AA.

XX ABO33822;

XX 17-SEP-2003 (first entry)

DT Novel human secreted and transmembrane protein PRO7154.

XX Human; secreted and transmembrane protein; PRO; cytostatic;

XX antiarthritic; osteopathic; gene therapy; TNF-agonist-alpha;

XX chondrocyte stimulator; pericyte stimulator; fibroblast modulator;

XX pharmaceutical; diagnostic; biosensor; bioreactor; tumour; lung tumour;

XX colon tumour; breast tumour; prostate tumour; rectal tumour;

XX liver tumour; bone disorder; cartilage disorder; sports injury;

XX arthritis; wound.

XX Homo sapiens.

XX US2003045687-A1.

XX 06-MAR-2003.

XX 12-AUG-2002; 2002US-00218631.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX

PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-512315/48.
 DR N-PSDB; ACD68710.
 XX New genes, and its encoded secreted and transmembrane polypeptides,
 PT useful for stimulating Tumor Necrosis Factor alpha, or chondrocyte or
 PT pericyte proliferation, especially for treating lung tumors, arthritis or
 PT wounds in a mammal.
 XX Claim 11; Fig 236; 314pp; English.
 PS The invention describes an isolated nucleic acid molecule comprising a
 CC sequence with at least 80% identity to: (a) a nucleotide encoding any of
 CC 122 PRO (secreted and transmembrane) polypeptides whose sequences are
 CC fully defined in the specification; or (b) any of 122 nucleotide
 CC sequences having e.g. 4834, 2504 or 1759 bp fully defined in the
 CC specification; or the full length coding sequence of any these 122
 CC nucleotide sequences. The PRO polypeptides or polynucleotides are useful
 CC as pharmaceuticals, diagnostics, biosensors or bioreactors. These are
 CC particularly useful for detecting tumors (e.g. lung tumour, colon
 CC tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)
 CC in a mammal, for stimulating the release of TNF-alpha from human blood,
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells, for stimulating proliferation of pericyte cells, or for modulating
 CC normal human dermal fibroblast proliferation. The PRO nucleic acid or
 CC polypeptide is also useful for treating tumors or various bone and/or
 CC cartilage disorders (e.g. sports injuries or arthritis), or wounds. The
 CC PRO polypeptides are useful in drug screening, particularly as targets
 CC for therapeutic intervention in these diseases, and in the diagnostic
 CC determination of the presence of these diseases. The PRO polypeptides are
 CC also useful as molecular weight markers, or for chromosome
 CC identification. The PRO genes are useful as hybridisation probes, or for
 CC screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
 CC also be used in gene therapy, particularly for replacing a defective
 CC gene. This is the amino acid sequence of a novel human secreted and
 CC transmembrane PRO polypeptide
 XX
 SQ Sequence 327 AA;
 Query Match 99.3%; Score 1277; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISSEHPILYFTNGHLVPTGSKSRVLLQNPPPTVGATLKLTDVHPSDTGYL 120
 DB 61 FVQPGKPISSEHPILYFTNGHLVPTGSKSRVLLQNPPPTVGATLKLTDVHPSDTGYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNW 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNW 180
 QY 181 RLCTFTTPPGSMVQDEVSQGLLTNLSTSSGTYRCVATNMGASCELTLTSTVPSQ 240
 DB 181 RLCTFTTPPGSMVQDEVSQGLLTNLSTSSGTYRCVATNMGASCELTLTSTVPSQ 240
 QY 241 RVA 243
 DB 241 RVA 243
 RESULT 10
 ABU82165
 ID ABU82165 standard; protein; 327 AA.

XX ABU82165;
 XX 25-JUN-2003 (first entry)
 XX Novel human secreted and transmembrane protein PRO7154.
 XX Human; secreted and transmembrane protein; PRO; cardiant; cytostatic;
 KW antiangiogenic; hypotensive; vulnery; antiarteriosclerotic;
 KW gene therapy; cardiovascular disorder; endothelial disorder;
 KW angiogenic disorder; cardiac hypertrophy; trauma; cancer;
 KW age-related macular degeneration; atherosclerosis; hypertension;
 KW arterial restenosis; rheumatoid arthritis; angina; myocardial infarction;
 KW thrombophlebitis; lymphangitis; tumour angiogenesis; breast carcinoma;
 KW liver carcinoma; wound healing; chromosome mapping; gene mapping.
 XX Homo sapiens.
 OS US2003088063-A1.
 XX 08-MAY-2003.
 XX 12-AUG-2002; 2002US-00219003.
 XX 25-JUL-2000; 2000US-0220664P.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-393229/37.
 DR N-PSDB; ACA68614.
 XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
 PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
 PT infarction), endothelial or angiogenic disorders in a mammal.
 XX Claim 11; Fig 236; 314pp; English.
 XX The invention describes one hundred and eighty seven nucleic acids
 CC encoding novel human secreted and transmembrane (PRO) polypeptides. The
 CC PRO nucleic acids, polypeptides, agonists and antagonists are useful for
 CC treating or diagnosing a cardiovascular, endothelial or angiogenic
 CC disorder in a mammal, e.g. cardiac hypertrophy, trauma, cancer, age-
 CC related macular degeneration, atherosclerosis, hypertension, arterial
 CC restenosis, rheumatoid arthritis, angina, myocardial infarctions,
 CC thrombophlebitis, lymphangitis, tumour angiogenesis (such as breast
 CC carcinoma and liver carcinoma) and wound healing. The PRO nucleic acids
 CC have applications in molecular biology, including use as hybridisation
 CC probes, and in chromosome and gene mapping. This is the amino acid
 CC sequence of a novel human secreted and transmembrane PRO polypeptide
 XX
 SQ Sequence 327 AA;
 Query Match 99.3%; Score 1277; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISSEHPILYFTNGHLVPTGSKSRVLLQNPPPTVGATLKLTDVHPSDTGYL 120
 DB 61 FVQPGKPISSEHPILYFTNGHLVPTGSKSRVLLQNPPPTVGATLKLTDVHPSDTGYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNW 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNW 180

```
QY 181 RLGTPTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLTSLVTEPSQG 240
    |||||
Db 181 RLGTPTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLTSLVTEPSQG 240
    |||||
QY 241 RVA 243
    |||
Db 241 RVA 243

RESULT 11
ABJ72345
ID ABJ72345 standard; protein; 327 AA.
XX
XX AC ABJ72345;
XX
XX DT 06-NOV-2003 (first entry)
XX
XX DE Human PRO7154 protein.
XX
XX PRO; proliferation; pericyte cell; TNF-alpha; blood; chondrocyte;
XX differentiation; dermal fibroblast; tumour; gene therapy; cytostatic.
XX
XX OS Homo sapiens.
XX
XX FN US2003050448-A1.
XX
XX PD 13-MAR-2003.
XX
XX PF 28-AUG-2002; 2002US-00230414.
XX
XX PR 01-JUN-2001; 2001WO-US017800.
XX
XX PR 29-JUN-2001; 2001WO-US021066.
XX
XX PR 09-APR-2002; 2002US-00119480.
XX
XX PA (GETH ) GENENTECH INC.
XX
XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX DR WPI: 2003-521818/49.
XX
XX DR N-PSDB; ABT44343.
XX
XX PT New nucleic acid encoding for a PRO protein, useful for the manufacture
XX of a medicament for diagnosing or treating tumors or for measuring or
XX detecting expression of an associated gene.
XX
XX PS Claim 11; Fig 236; 315pp; English.
XX
XX CC The invention relates to a novel isolated nucleic acid encoding a fully
XX defined PRO polypeptide. The molecules of the invention may be useful for
XX stimulating proliferation or gene expression in pericyte cells or the
XX release of TNF-alpha from human blood. Other possible uses include the
XX stimulation or inhibition of chondrocyte proliferation or
XX differentiation, the stimulation of human dermal fibroblast cell
XX proliferation and the detection of the presence of a tumour within a
XX mammal. Furthermore, the nucleic acid may be useful for the manufacture
XX of a medicament for diagnosing or treating a tumour within a mammal or
XX for measuring or detecting the expression of an associated gene, as well
XX as during gene therapy. The current sequence is that of the human PRO
XX protein of the invention
XX
XX SQ Sequence 327 AA;
    Query Match 99.3%; Score 1277; DB 6; Length 327;
    Best Local Similarity 100.0%; Pred. No. 3.8e-84;
    Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGFFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTABLTCTYSTSVGDSFALEWS 60
    |||||
Db 1 MAELPGFFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTABLTCTYSTSVGDSFALEWS 60
    |||||
QY 61 FVQPGKPISHPILYFTNGHLYPTGSKSRVSLQNPPVTGVATLKLTDVHPSDTGYL 120
    |||||
```

```
Db 61 FVQPGKPISHPILYFTNGHLYPTGSKSRVSLQNPPVTGVATLKLTDVHPSDTGYL 120
    |||||
QY 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSQTSGGSTALRCSSESGAPKPVYNNV 180
    |||||
Db 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSQTSGGSTALRCSSESGAPKPVYNNV 180
    |||||
QY 181 RLGTPTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLTSLVTEPSQG 240
    |||||
Db 181 RLGTPTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLTSLVTEPSQG 240
    |||||
QY 241 RVA 243
    |||
Db 241 RVA 243

RESULT 12
ABJ72473
ID ABJ72473 standard; protein; 327 AA.
XX
XX AC ABJ72473;
XX
XX DT 06-NOV-2003 (first entry)
XX
XX DE Human PRO7154 protein.
XX
XX PRO; blood; proliferation; pericyte cell; TNF alpha; chondrocyte;
XX tumour necrosis factor; proliferation; differentiation; gene therapy;
XX dermal fibroblast.
XX
XX OS Homo sapiens.
XX
XX PN US2003027988-A1.
XX
XX PD 06-FEB-2003.
XX
XX PF 26-AUG-2002; 2002US-00227884.
XX
XX PR 01-JUN-2001; 2001WO-US017800.
XX
XX PR 29-JUN-2001; 2001WO-US021066.
XX
XX PR 09-APR-2002; 2002US-00119480.
XX
XX PA (GETH ) GENENTECH INC.
XX
XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX DR WPI: 2003-503301/47.
XX
XX DR N-PSDB; ABT44626.
XX
XX PT New PRO protein encoding nucleic acid, useful for preparing PRO
XX polypeptides and anti-PRO antibodies for detecting the presence of a
XX tumor in a mammal.
XX
XX PS Claim 11; Fig 236; 324pp; English.
XX
XX CC The invention relates to a novel isolated PRO protein encoding nucleic
XX acid. The nucleic acid of the invention may be useful for preparing PRO
XX polypeptides and anti-PRO antibodies for detecting the presence of a
XX tumour in a mammal. Furthermore, the molecules of the invention may be
XX useful for stimulating proliferation or gene expression in pericyte
XX cells, the release of tumour necrosis factor (TNF)-alpha from human
XX blood, the proliferation or differentiation of chondrocyte cells and for
XX inhibiting the proliferation of normal human dermal fibroblast cells.
XX Finally, the molecules may be utilised during gene therapy. The current
XX sequence is that of the human PRO protein of the invention
XX
XX SQ Sequence 327 AA;
    Query Match 99.3%; Score 1277; DB 6; Length 327;
    Best Local Similarity 100.0%; Pred. No. 3.8e-84;
    Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1 MAELPGPFLCGALGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTCGYL 120
 DB 61 FVQPKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTCGYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESGAPKPVNWW 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESGAPKPVNWW 180
 QY 181 RLGTFTPPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQ 240
 DB 181 RLGTFTPPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQ 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 13
 ABO34368
 ID ABO34368 standard; protein; 327 AA.
 AC ABO34368;
 XX 19-SEP-2003 (first entry)
 DT Human secreted/transmembrane polypeptide PRO 7154.
 DE Human; chondrocyte stimulation; TNF-alpha stimulation; gene therapy;
 KW human dermal fibroblast stimulation; tumour; tissue typing;
 KW affinity purification.
 XX Homo sapiens.

XX US2003044934-A1.
 XX 06-MAR-2003.
 XX 28-AUG-2002; 2002US-00230338.
 XX 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-492274/46.
 DR N-PSDB; ACD82293.
 XX New transmembrane polypeptides and nucleic acids encoding the

PT polypeptides, useful in gene therapy, in chromosome identification, as
 PT chromosome markers, or in generating probes.
 XX Claim 19; Fig 236; 315pp; English.
 XX The invention relates to an isolated nucleic acid encoding a PRO
 CC polypeptide. Nucleic acids that encode PRO can be used to generate either
 CC transgenic animals or knock-out animals useful in developing and
 CC screening of therapeutically useful reagents. The nucleic acids may also
 CC be used in gene therapy for replacing defective gene, in chromosome
 CC identification, as chromosome markers, or in generating probes to isolate
 CC full length PRO cDNA. The PRO polypeptides are useful for chondrocyte
 CC stimulation, TNF-alpha stimulation, human dermal fibroblasts stimulation
 CC and for detecting the presence of tumour in a mammal. The PRO
 CC polypeptides are useful as molecular markers for protein electrophoresis
 CC and the isolated nucleic acids may be used for recombinantly expressing
 CC those markers. The PRO polypeptides and nucleic acids may also be used in

CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
 CC PRO and in affinity purification of PRO from recombinant cell culture or
 CC natural sources. The present sequence represents the amino acid sequence
 CC of a human secreted/transmembrane PRO polypeptide

XX SQ Sequence 327 AA;
 Query Match 99.3%; Score 1277; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTCGYL 120
 DB 61 FVQPKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTCGYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESGAPKPVNWW 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESGAPKPVNWW 180
 QY 181 RLGTFTPPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQ 240
 DB 181 RLGTFTPPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQ 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 14
 ABO72175
 ID ABO72175 standard; protein; 327 AA.
 AC ABO72175;
 XX 16-OCT-2003 (first entry)
 DT Human membrane bound receptor/protein PRO7154 amino acid sequence.
 XX Human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuropeptide; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.
 XX Homo sapiens.
 XX OS
 XX US2003065147-A1.
 XX 03-APR-2003.
 XX 29-AUG-2002; 2002US-00232224.
 XX 28-JUL-1999; 99US-0146222P.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-522018/49.
 DR N-PSDB; ABO743999.
 XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful for the manufacture of a medicament for diagnosing or treating

PT tumor.
XX Claim 11; Fig 236; 315pp; English.
XX
CC This invention relates to one hundred and twenty two novel nucleic acids
CC encoding human PRO membrane bound proteins or receptors. Extracellular
CC proteins play important roles in the formation, differentiation and
CC maintenance of multicellular organisms. The fate of many individual cells
CC (for example proliferation, migration or differentiation) is typically
CC governed by information received from other cells and the immediate
CC environment. The information is often transmitted by secreted
CC polypeptides (for example mitogenic factors, survival factors, cytotoxic
CC factors, differentiation factors, neurotrophins and hormones) which are
CC received and interpreted by diverse cell receptors or membrane bound
CC proteins. These membrane bound proteins and receptors may be of use as
CC pharmaceutical and diagnostic agents, such as in the blocking of receptor
CC -ligand interactions. The current invention provides the amino acid
CC sequences of novel human membrane bound receptors and proteins, along
CC with the cDNA sequences encoding them. The novel proteins of the
CC invention may have cytosolic activities through the stimulation of
CC chondrocytes. The nucleic acids of the invention may be useful for the
CC manufacture of a medicament for diagnosing or treating a tumour in a
CC mammal. In addition, they may be useful for measuring or detecting the
CC expression of a tumour associated gene. The present sequence is the amino
CC acid sequence of a human PRO protein of the invention
XX
SQ Sequence 327 AA;
Query Match 99.3%; Score 1277; DB 7; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
QY 61 FVQPGKPISEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDYTYNGLGLINLTIVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNVV 180
Db 121 CQVNNPPDYTYNGLGLINLTIVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNVV 180
QY 181 RLGTFTPPSGMVQDEVSGQLILTNLSITSSGTYRCVATNQMGASCELTLTVTEPSQG 240
Db 181 RLGTFTPPSGMVQDEVSGQLILTNLSITSSGTYRCVATNQMGASCELTLTVTEPSQG 240
QY 241 RVA 243
Db 241 RVA 243
RESULT 15
ADB83726
ID ADB83726 standard; protein; 327 AA.
AC ADB83726;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO7154.
XX
KW human; secreted and transmembrane protein; PRO; cytostatic; vulnery;
KW antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX

OS Homo sapiens.
XX US2003073814-A1.
XX PD 17-APR-2003.
XX
XX 12-AUG-2002; 2002US-00218849.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-644806/61.
XX N-PSDB; ADB83725.
XX
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
XX in gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX
XX Claim 11; Fig 236; 315pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF) -
CC alpha from human blood. PRO982, PRO357, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO1341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO381, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5722, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO1774, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This is the amino acid sequence of a human secreted and
CC transmembrane PRO polypeptide.
XX
SQ Sequence 327 AA;
Query Match 99.3%; Score 1277; DB 7; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
QY 61 FVQPGKPISEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120

[illegible]

Search completed: August 4, 2005, 06:07:07
Job time : 74.7214 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 06:13:42 ; Search time 66.3695 Seconds
(without alignments)
1447.018 Million cell updates/sec

Title: US-10-607-565-83

Perfect score: 1287

Sequence: 1 MAELPGFLLCGALLGLFCLLS.....SCELTSLVTEPSQGRVAELX 246

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1752860 seqs, 390397842 residues

Total number of hits satisfying chosen parameters: 1752860

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications_AA:*
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1286	99.9	245	9 US-09-820-893-98	Sequence 98, Appl
2	1286	99.9	245	15 US-10-607-565-83	Sequence 98, Appl
3	1286	99.9	246	9 US-09-820-893-83	Sequence 83, Appl
4	1286	99.9	246	15 US-10-607-565-83	Sequence 83, Appl
5	1277	99.2	327	14 US-10-227-884-236	Sequence 236, App
6	1277	99.2	327	14 US-10-230-163-236	Sequence 236, App
7	1277	99.2	327	14 US-10-230-338-236	Sequence 236, App
8	1277	99.2	327	14 US-10-218-631-236	Sequence 236, App
9	1277	99.2	327	14 US-10-230-414-236	Sequence 236, App
10	1277	99.2	327	14 US-10-232-224-236	Sequence 236, App
11	1277	99.2	327	14 US-10-216-159A-236	Sequence 236, App

12	1277	99.2	327	14	US-10-218-849-236	Sequence 236, App
13	1277	99.2	327	14	US-10-227-873-236	Sequence 236, App
14	1277	99.2	327	14	US-10-227-883-236	Sequence 236, App
15	1277	99.2	327	14	US-10-219-078-236	Sequence 236, App
16	1277	99.2	327	14	US-10-230-434-236	Sequence 236, App
17	1277	99.2	327	14	US-10-219-003-236	Sequence 236, App
18	1277	99.2	327	14	US-10-219-075-236	Sequence 236, App
19	1277	99.2	327	14	US-10-219-464-236	Sequence 236, App
20	1277	99.2	327	14	US-10-219-466-236	Sequence 236, App
21	1277	99.2	327	14	US-10-219-479-236	Sequence 236, App
22	1277	99.2	327	14	US-10-219-481-236	Sequence 236, App
23	1277	99.2	327	14	US-10-230-260-236	Sequence 236, App
24	1277	99.2	327	14	US-10-232-231-236	Sequence 236, App
25	1277	99.2	327	14	US-10-232-233-236	Sequence 236, App
26	1277	99.2	327	14	US-10-216-165-236	Sequence 236, App
27	1277	99.2	327	14	US-10-218-956-236	Sequence 236, App
28	1277	99.2	327	14	US-10-219-468-236	Sequence 236, App
29	1277	99.2	327	14	US-10-219-478-236	Sequence 236, App
30	1277	99.2	327	14	US-10-219-536-236	Sequence 236, App
31	1277	99.2	327	14	US-10-233-205-236	Sequence 236, App
32	1277	99.2	327	14	US-10-219-072-236	Sequence 236, App
33	1277	99.2	327	14	US-10-219-470-236	Sequence 236, App
34	1277	99.2	327	14	US-10-219-474-236	Sequence 236, App
35	1277	99.2	327	14	US-10-219-524-236	Sequence 236, App
36	1277	99.2	327	14	US-10-219-528-236	Sequence 236, App
37	1277	99.2	327	14	US-10-227-880-236	Sequence 236, App
38	1277	99.2	327	14	US-10-227-881-236	Sequence 236, App
39	1277	99.2	327	14	US-10-227-882-236	Sequence 236, App
40	1277	99.2	327	14	US-10-230-436-236	Sequence 236, App
41	1277	99.2	327	14	US-10-232-223-236	Sequence 236, App
42	1277	99.2	327	14	US-10-232-225-236	Sequence 236, App
43	1277	99.2	327	14	US-10-232-227-236	Sequence 236, App
44	1277	99.2	327	14	US-10-232-229-236	Sequence 236, App
45	1277	99.2	327	14	US-10-232-234-236	Sequence 236, App

ALIGNMENTS

RESULT 1
US-09-820-893-98
; Sequence 98, Application US/09820893
; Patent No. US20020076705A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: PZ033P1
; CURRENT APPLICATION NUMBER: US/09/820,893
; CURRENT FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 98
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-820-893-98

Query Match 99.9%; Score 1286; DB 9; Length 245;
Best Local Similarity 100.0%; Pred. No. 1.1e-96;
Matches 245; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MAELPGFLLCGALLGLFCLLSGLAVEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS	60
Db	1	MAELPGFLLCGALLGLFCLLSGLAVEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS	60
Qy	61	FVOPGKPISESHPIILYFTNGHLPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL	120
Db	61	FVOPGKPISESHPIILYFTNGHLPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL	120

Db 1 MAELPGFLCAGLFLCGLAVEVVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Qy 61 FVQPKKISRHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTCYTL 120
Db 61 FVQPKKISRHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTCYTL 120
Qy 121 CQVNNPDFYTNGLGLINLTLVPPSNPLCSQSQSTSVGGSTALRCSSSEGAPKPVYNNV 180
Db 121 CQVNNPDFYTNGLGLINLTLVPPSNPLCSQSQSTSVGGSTALRCSSSEGAPKPVYNNV 180
Qy 181 RLGTFTPPSGVQDVSQGLILTNLSSTSGTYRCVATNQMSASCELTLSVTPSQ 240
Db 181 RLGTFTPPSGVQDVSQGLILTNLSSTSGTYRCVATNQMSASCELTLSVTPSQ 240
Qy 241 RVAEL 245
Db 241 RVAEL 245

RESULT 5
US-10-227-884-236

; Sequence 236, Application US/10227884
; Publication No. US20030027988A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1G79
; CURRENT APPLICATION NUMBER: US/10/227,884
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15

; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464

```
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07

; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match          99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQCKPISESHPILYFTNGHLYPTGSKSKRVSLLLONPPTVGVATLKLTVDHPSDTGYL 120
Db 61 FVQCKPISESHPILYFTNGHLYPTGSKSKRVSLLLONPPTVGVATLKLTVDHPSDTGYL 120
QY 121 QVANNPPDYNTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESGAPKPYNVV 180
Db 121 QVANNPPDYNTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESGAPKPYNVV 180
QY 181 RLGTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSASCELTLSTVTEPSQG 240
Db 181 RLGTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSASCELTLSTVTEPSQG 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 6
US-10-230-163-236
; Sequence 236, Application US/10230163
; Publication No. US20030036635A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC96
; CURRENT APPLICATION NUMBER: US/10/230,163
; PRIOR FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
```

; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25

; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638

```
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match          99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MAELPGPFPCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
      |||||||
Db      1 MAELPGPFPCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
      |||||||

QY      61 FVQPGKPISESHPIFYFTNGHLYPTGSKSRVSLQNPPTVGVA TLKLDVHPSDTGTYL 120
      |||||||
Db      61 FVQPGKPISESHPIFYFTNGHLYPTGSKSRVSLQNPPTVGVA TLKLDVHPSDTGTYL 120
      |||||||

QY      121 CQVNNPPDYTYNGLGINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
      |||||||
Db      121 CQVNNPPDYTYNGLGINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
      |||||||

QY      181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGSASCELTLISVTEPSOG 240
      |||||||
Db      181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGSASCELTLISVTEPSOG 240
      |||||||

QY      241 RVA 243
      |||
Db      241 RVA 243

RESULT 7
US-10-230-338-236
; Sequence 236, Application US/10230338
; Publication No. US20030044934A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P35301C92
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: US/10/230,338
; PRIOR FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20

; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match          99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MAELPGPFPCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
      |||||||
Db      1 MAELPGPFPCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
      |||||||

QY      61 FVQPGKPISESHPIFYFTNGHLYPTGSKSRVSLQNPPTVGVA TLKLDVHPSDTGTYL 120
      |||||||
Db      61 FVQPGKPISESHPIFYFTNGHLYPTGSKSRVSLQNPPTVGVA TLKLDVHPSDTGTYL 120
      |||||||

QY      121 CQVNNPPDYTYNGLGINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
      |||||||
Db      121 CQVNNPPDYTYNGLGINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
      |||||||

QY      181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGSASCELTLISVTEPSOG 240
      |||||||
Db      181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGSASCELTLISVTEPSOG 240
      |||||||

QY      241 RVA 243
      |||
Db      241 RVA 243

RESULT 8
US-10-218-631-236
; Sequence 236, Application US/10218631
; Publication No. US20030045687A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P35301C14
; CURRENT FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: US/10/218,631
; PRIOR FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
```


; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-631-236

Query Match 99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGFLCGALLGFLCISGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGFLCGALLGFLCISGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISESHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISESHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDFYTNGLINLTIVLPPSNPLCSQSGQTSVGGSTALRCSSESSEGAKPVYNNW 180
Db 121 CQVNNPPDFYTNGLINLTIVLPPSNPLCSQSGQTSVGGSTALRCSSESSEGAKPVYNNW 180
QY 181 RLCTFTPPSGMVQDEVSGQLITNLSTSSGTYRCVATNQMSASCELTLSVTEPSQ 240
Db 181 RLCTFTPPSGMVQDEVSGQLITNLSTSSGTYRCVATNQMSASCELTLSVTEPSQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 9
US-10-230-414-236
; Sequence 236, Application US/10230414
; Publication No. US20030050448A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C98
; CURRENT APPLICATION NUMBER: US/10/230,414
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17

; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-414-236

Query Match 99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGFLCGALLGFLCISGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGFLCGALLGFLCISGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISESHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISESHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDFYTNGLINLTIVLPPSNPLCSQSGQTSVGGSTALRCSSESSEGAKPVYNNW 180
Db 121 CQVNNPPDFYTNGLINLTIVLPPSNPLCSQSGQTSVGGSTALRCSSESSEGAKPVYNNW 180
QY 181 RLCTFTPPSGMVQDEVSGQLITNLSTSSGTYRCVATNQMSASCELTLSVTEPSQ 240
Db 181 RLCTFTPPSGMVQDEVSGQLITNLSTSSGTYRCVATNQMSASCELTLSVTEPSQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 10
US-10-232-224-236
; Sequence 236, Application US/10232224
; Publication No. US20030065147A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C11
; CURRENT APPLICATION NUMBER: US/10/232,224
; CURRENT FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873

```
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-232-224-236

Query Match          99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
   |||||
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQLQNPPVTGVATLKLTDVHPSDTGYL 120
   |||||
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQLQNPPVTGVATLKLTDVHPSDTGYL 120

QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSGQTSVGGSTALRCSSEGAPKPVYNNW 180
   |||||
Db 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSGQTSVGGSTALRCSSEGAPKPVYNNW 180

QY 181 RLGTPTTPSPGSMQDEVSQGLILNLTLTSSGTRCVATNMQSGASCELTLTSVTEPSQG 240
   |||||
Db 181 RLGTPTTPSPGSMQDEVSQGLILNLTLTSSGTRCVATNMQSGASCELTLTSVTEPSQG 240

QY 241 RVA 243
   |||
Db 241 RVA 243
```

```
RESULT 11
US-10-216-159A-236
; Sequence 236, Application US/10216159A
; Publication No. US20030069397A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC6
; CURRENT APPLICATION NUMBER: US/10/216,159A
; CURRENT FILING DATE: 2002-08-09
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
```

```
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-216-159A-236

Query Match          99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
   |||||
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQLQNPPVTGVATLKLTDVHPSDTGYL 120
   |||||
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQLQNPPVTGVATLKLTDVHPSDTGYL 120

QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSGQTSVGGSTALRCSSEGAPKPVYNNW 180
   |||||
Db 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSGQTSVGGSTALRCSSEGAPKPVYNNW 180

QY 181 RLGTPTTPSPGSMQDEVSQGLILNLTLTSSGTRCVATNMQSGASCELTLTSVTEPSQG 240
   |||||
Db 181 RLGTPTTPSPGSMQDEVSQGLILNLTLTSSGTRCVATNMQSGASCELTLTSVTEPSQG 240

QY 241 RVA 243
   |||
Db 241 RVA 243
```

```
RESULT 12
US-10-218-849-236
; Sequence 236, Application US/10218849
; Publication No. US20030073814A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC11
; CURRENT APPLICATION NUMBER: US/10/218,849
; CURRENT FILING DATE: 2002-08-12
; PRIOR APPLICATION REMOVED - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-849-236

Query Match          99.2%; Score 1277; DB 14; Length 327;
```

Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MAELPGFLCAGLGLCLSLGLAVEVVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWS	60
Db	1	MAELPGFLCAGLGLCLSLGLAVEVVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWS	60
Qy	61	FVQPGKPISSHPILYFTNGHLIPTGSKSKRVSLIQNPPTVGVATLKLTDVHPSDTCTYL	120
Db	61	FVQPGKPISSHPILYFTNGHLIPTGSKSKRVSLIQNPPTVGVATLKLTDVHPSDTCTYL	120
Qy	121	QVNNPPDFTYNGLGLNLTVLVPSPNPLCSQSQSTVSGSGTALRCSSSGAPKPVYVNW	180
Db	121	QVNNPPDFTYNGLGLNLTVLVPSPNPLCSQSQSTVSGSGTALRCSSSGAPKPVYVNW	180
Qy	181	RLGTFPTPSGSMQDVSQGLIITNLISLTSSGTYRCVATNQMSGASCELTLSTVTPESQ	240
Db	181	RLGTFPTPSGSMQDVSQGLIITNLISLTSSGTYRCVATNQMSGASCELTLSTVTPESQ	240
Qy	241	RVA 243	
Db	241	RVA 243	

RESULT 13

US-10-227-873-236
; Sequence 236, Application US/10227873
; Publication No. US20030073816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: F3530P1C72
; CURRENT APPLICATION NUMBER: US/10/227,873
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06

; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178

; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09

; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLGSLGLAVEVKVPTPELSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db |||||
QY 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPYGVATLKLTDVHPSDTGYTL 120
Db |||||
QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPYNNV 180
Db |||||
QY 181 RLGTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLSTVTEPSOG 240
Db |||||
QY 241 RVA 243
Db 241 RVA 243

RESULT 14
US-10-227-883-236
; Sequence 236, Application US/10227883
; Publication No. US20030073817A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC78
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728

;	PRIOR FILING DATE:	1998-03-27	
;	PRIOR APPLICATION NUMBER:	60/081819	
;	PRIOR FILING DATE:	1998-04-15	
;	PRIOR APPLICATION NUMBER:	60/081955	
;	PRIOR FILING DATE:	1998-04-15	
;	PRIOR APPLICATION NUMBER:	60/082804	
;	PRIOR FILING DATE:	1998-04-22	
;	PRIOR APPLICATION NUMBER:	60/084441	
;	PRIOR FILING DATE:	1998-05-06	
;	PRIOR APPLICATION NUMBER:	60/085323	
;	PRIOR FILING DATE:	1998-05-13	
;	PRIOR APPLICATION NUMBER:	60/085579	
;	PRIOR FILING DATE:	1998-05-15	
;	PRIOR APPLICATION NUMBER:	60/086392	
;	PRIOR FILING DATE:	1998-05-22	
;	PRIOR APPLICATION NUMBER:	60/089532	
;	PRIOR FILING DATE:	1998-06-17	
;	PRIOR APPLICATION NUMBER:	60/089538	
;	PRIOR FILING DATE:	1998-06-17	
;	PRIOR APPLICATION NUMBER:	60/089905	
;	PRIOR FILING DATE:	1998-06-18	
;	PRIOR APPLICATION NUMBER:	60/090472	
;	PRIOR FILING DATE:	1998-06-24	
;	PRIOR APPLICATION NUMBER:	60/090557	
;	PRIOR FILING DATE:	1998-06-24	
;	PRIOR APPLICATION NUMBER:	60/090691	
;	PRIOR FILING DATE:	1998-06-25	
;	PRIOR APPLICATION NUMBER:	60/090695	
;	PRIOR FILING DATE:	1998-06-25	
;	PRIOR APPLICATION NUMBER:	60/091982	
;	PRIOR FILING DATE:	1998-07-07	
;	PRIOR APPLICATION NUMBER:	60/095302	
;	PRIOR FILING DATE:	1998-08-04	
;	PRIOR APPLICATION NUMBER:	60/095318	
;	PRIOR FILING DATE:	1998-08-04	
;	PRIOR APPLICATION NUMBER:	60/095916	
;	PRIOR FILING DATE:	1998-08-10	
;	PRIOR APPLICATION NUMBER:	60/096146	
;	PRIOR FILING DATE:	1998-08-11	
;	PRIOR APPLICATION NUMBER:	60/096791	
;	PRIOR FILING DATE:	1998-08-17	
;	PRIOR APPLICATION NUMBER:	60/097986	
;	PRIOR FILING DATE:	1998-08-26	
;	PRIOR APPLICATION NUMBER:	60/098544	
;	PRIOR FILING DATE:	1998-08-31	
;	PRIOR APPLICATION NUMBER:	60/099596	
;	PRIOR FILING DATE:	1998-09-09	
;	PRIOR APPLICATION NUMBER:	60/099598	
;	PRIOR FILING DATE:	1998-09-09	
;	PRIOR APPLICATION NUMBER:	60/099803	
;	PRIOR FILING DATE:	1998-09-10	
;	PRIOR APPLICATION NUMBER:	60/099811	
;	PRIOR FILING DATE:	1998-09-10	
;	PRIOR APPLICATION NUMBER:	60/099812	
;	PRIOR FILING DATE:	1998-09-10	
;	PRIOR APPLICATION NUMBER:	60/099816	
;	PRIOR FILING DATE:	1998-09-10	
;	PRIOR APPLICATION NUMBER:	60/100038	
;	PRIOR FILING DATE:	1998-09-11	
;	PRIOR APPLICATION NUMBER:	60/100385	
;	PRIOR FILING DATE:	1998-09-15	
;	PRIOR APPLICATION NUMBER:	60/100390	
;	PRIOR FILING DATE:	1998-09-15	
;	PRIOR APPLICATION NUMBER:	60/100627	
;	PRIOR FILING DATE:	1998-09-16	
;	PRIOR APPLICATION NUMBER:	60/100848	
;	PRIOR FILING DATE:	1998-09-18	
;	PRIOR APPLICATION NUMBER:	60/100919	
;	PRIOR FILING DATE:	1998-09-17	
;	PRIOR APPLICATION NUMBER:	60/101477	
;	PRIOR FILING DATE:	1998-09-23	
;	PRIOR APPLICATION NUMBER:	60/101738	
;	PRIOR FILING DATE:	1998-09-24	

1	PRIOR APPLICATION NUMBER: 60/101744
2	PRIOR FILING DATE: 1998-09-24
3	PRIOR APPLICATION NUMBER: 60/101786
4	PRIOR FILING DATE: 1998-09-25
5	PRIOR APPLICATION NUMBER: 60/101916
6	PRIOR FILING DATE: 1998-09-24
7	PRIOR APPLICATION NUMBER: 60/101922
8	PRIOR FILING DATE: 1998-09-24
9	PRIOR APPLICATION NUMBER: 60/106178
10	PRIOR FILING DATE: 1998-10-28
11	PRIOR APPLICATION NUMBER: 60/106248
12	PRIOR FILING DATE: 1998-10-29
13	PRIOR APPLICATION NUMBER: 60/106464
14	PRIOR FILING DATE: 1998-10-30
15	PRIOR APPLICATION NUMBER: 60/106905
16	PRIOR FILING DATE: 1998-11-03
17	PRIOR APPLICATION NUMBER: 60/108787
18	PRIOR FILING DATE: 1998-11-17
19	PRIOR APPLICATION NUMBER: 60/108800
20	PRIOR FILING DATE: 1998-11-17
21	PRIOR APPLICATION NUMBER: 60/108849
22	PRIOR FILING DATE: 1998-11-18
23	PRIOR APPLICATION NUMBER: 60/112422
24	PRIOR FILING DATE: 1998-12-15
25	PRIOR APPLICATION NUMBER: 60/113296
26	PRIOR FILING DATE: 1998-12-22
27	PRIOR APPLICATION NUMBER: 60/113605
28	PRIOR FILING DATE: 1998-12-23
29	PRIOR APPLICATION NUMBER: 60/113621
30	PRIOR FILING DATE: 1998-12-23
31	PRIOR APPLICATION NUMBER: 60/115558
32	PRIOR FILING DATE: 1999-01-12
33	PRIOR APPLICATION NUMBER: 60/115565
34	PRIOR FILING DATE: 1999-01-12
35	PRIOR APPLICATION NUMBER: 60/115733
36	PRIOR FILING DATE: 1999-01-12
37	PRIOR APPLICATION NUMBER: 60/119549
38	PRIOR FILING DATE: 1999-02-10
39	PRIOR APPLICATION NUMBER: 60/123618
40	PRIOR FILING DATE: 1999-03-10
41	PRIOR APPLICATION NUMBER: 60/125259
42	PRIOR FILING DATE: 1999-03-19
43	PRIOR APPLICATION NUMBER: 60/125775
44	PRIOR FILING DATE: 1999-03-23
45	PRIOR APPLICATION NUMBER: 60/126773
46	PRIOR FILING DATE: 1999-03-29
47	PRIOR APPLICATION NUMBER: 60/127887
48	PRIOR FILING DATE: 1999-04-05
49	PRIOR APPLICATION NUMBER: 60/130232
50	PRIOR FILING DATE: 1999-04-21
51	PRIOR APPLICATION NUMBER: 60/131022
52	PRIOR FILING DATE: 1999-04-26
53	PRIOR APPLICATION NUMBER: 60/131270
54	PRIOR FILING DATE: 1999-04-27
55	PRIOR APPLICATION NUMBER: 60/131291
56	PRIOR FILING DATE: 1999-04-27
57	PRIOR APPLICATION NUMBER: 60/131445
58	PRIOR FILING DATE: 1999-04-28
59	PRIOR APPLICATION NUMBER: 60/134287
60	PRIOR FILING DATE: 1999-05-14
61	PRIOR APPLICATION NUMBER: 60/140650
62	PRIOR FILING DATE: 1999-06-22
63	PRIOR APPLICATION NUMBER: 60/140723
64	PRIOR FILING DATE: 1999-06-22
65	PRIOR APPLICATION NUMBER: 60/141037
66	PRIOR FILING DATE: 1999-06-23
67	PRIOR APPLICATION NUMBER: 60/144758
68	PRIOR FILING DATE: 1999-07-20
69	PRIOR APPLICATION NUMBER: 60/145698
70	PRIOR FILING DATE: 1999-07-26
71	PRIOR APPLICATION NUMBER: 60/146222
72	PRIOR FILING DATE: 1999-07-28
73	PRIOR APPLICATION NUMBER: 60/146963

; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
Db 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
QY 181 RLGTFTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQG 240
Db 181 RLGTFTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQG 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 15
US-10-219-076-236
; Sequence 236, Application US/10219076
; Publication No. US20030078379A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530PIC62
; CURRENT APPLICATION NUMBER: US/10/219, 076
; CURRENT FILING DATE: 2002-08-14
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31

; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-219-076-236

Query Match 99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
Db 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
QY 181 RLGTFTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQG 240
Db 181 RLGTFTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQG 240
QY 241 RVA 243
Db 241 RVA 243

Search completed: August 4, 2005, 06:47:28
Job time : 67.3695 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 05:53:15 ; Search time 75.0264 Seconds
(without alignments)
1268.128 Million cell updates/sec

Title: US-10-607-565-83
Perfect score: 1287
Sequence: 1 MABLPGFLCGLLGLFLCLS.....SCELTSLVTFPSQGRVAELX 246

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A Geneseq_16Dec04:*
1: Geneseqp1980s:*
2: Geneseqp1990s:*
3: Geneseqp2000s:*
4: Geneseqp2001s:*
5: Geneseqp2002s:*
6: Geneseqp2003as:*
7: Geneseqp2003bs:*
8: Geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1286	99.9	245	3 AAB08940	Aab08940 Human sec
2	1286	99.9	246	3 AAB08926	Aab08926 Human sec
3	1277	99.2	327	3 AAY87251	Aay87251 Human sig
4	1277	99.2	327	3 AAY94857	Aay94857 Human pro
5	1277	99.2	327	4 AAY97585	Aay97585 Human sec
6	1277	99.2	327	5 ABB90354	Abb90354 Human pol
7	1277	99.2	327	5 AAU83709	Aau83709 Human PRO
8	1277	99.2	327	6 ABU80856	Abu80856 Human PRO
9	1277	99.2	327	6 ABO33822	Abo33822 Novel hum
10	1277	99.2	327	6 ABU82165	Abu82165 Novel hum
11	1277	99.2	327	6 ABJ72345	Abj72345 Human PRO
12	1277	99.2	327	6 ABJ72473	Abj72473 Human PRO
13	1277	99.2	327	6 ABO34368	Abo34368 Human sec
14	1277	99.2	327	7 ABJ72175	Abj72175 Human mem
15	1277	99.2	327	7 ADB83726	Adb83726 Novel hum
16	1277	99.2	327	7 ADB80832	Adb80832 Novel hum
17	1277	99.2	327	7 ADB73373	Adb73373 Novel hum
18	1277	99.2	327	7 ADB78455	Adb78455 Novel hum
19	1277	99.2	327	7 ADB85103	Adb85103 Human PRO
20	1277	99.2	327	7 ADB78209	Adb78209 Novel hum
21	1277	99.2	327	7 ADB87275	Adb87275 Human PRO
22	1277	99.2	327	7 ADB84857	Adb84857 Human PRO
23	1277	99.2	327	7 ADB83972	Adb83972 Novel hum
24	1277	99.2	327	7 ADB73127	Adb73127 Novel hum
25	1277	99.2	327	7 ADC36965	Adc36965 Human PRO

ALIGNMENTS

RESULT 1

AAB08940
ID AAB08940 standard; protein; 245 AA.

XX AC AAB08940;

XX AC (first entry)

DT 30-AUG-2000 (first entry)

DE Human secreted protein sequence encoded by gene 13 SEQ ID NO:97.

XX Human; secreted protein; cytostatic; anti-proliferative; vulnery;
KW immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
KW hyperproliferative disorder; infectious disease; tissue regeneration;
KW screening; food additive; preservative; wound healing;
KW hyper-vascular disease; chromosome 11.

XX Homo sapiens.

XX WO200017222-A1.

XX 30-MAR-2000.

XX 22-SEP-1999; 99WO-US022012.

XX 23-SEP-1998; 98US-0101546P.

XX 02-OCT-1998; 98US-0102895P.

XX (HUMA-) HUMAN GENOME SCI INC.

PI Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;

PI Komatsoulis G, Endress GA, Soppet DR;

XX WPI; 2000-283538/24.

XX Human secreted proteins and coding sequences useful in diagnostic and
PT therapeutic methods for disorders such as immune system or proliferative
PT disorders, related to the proteins.

PS Disclosure; Page 40; 416pp; English.

CC The polynucleotide sequences given in AAA39052 to AAA39088 encode the
CC human secreted proteins given in AAB08991 to AAB08984. The human secreted
CC proteins can have activities based on the tissues and cells they are
CC expressed in. Examples of the activities are: cytostatic; anti-
CC proliferative; immunosuppressive; antibacterial; and vulnery. The
CC secreted proteins and their related polynucleotide sequences are useful
CC for diagnostic and therapeutic methods useful for diagnosing and treating
CC disorders related to the secreted proteins. The proteins, and

CC polynucleotide sequences may be useful for treating disorders of the
CC immune system, hyperproliferative disorders, infectious disease,
CC regeneration of tissues, for chemotaxis and for screening molecules that
CC bind to the proteins. The proteins or polynucleotide sequences may be
CC used as food additives or preservatives, to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, co-factors or other nutritional components. Agonists or
CC antagonists of the proteins may be used to prevent scar tissue growth
CC during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC and AAB08890 are sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 245 AA;
Query Match. 99.9%; Score 1286; DB 3; Length 245;
Best Local Similarity 100.0%; Pred. No. 6.1e-85;
Matches 245; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
DB 1 MAELPGPFLLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPPTVGATLKLTDVHPSDGTGYL 120
DB 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPPTVGATLKLTDVHPSDGTGYL 120
QY 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
DB 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSA SCELTLT SVTPSQ 240
DB 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSA SCELTLT SVTPSQ 240
QY 241 RVAEL 245
DB 241 RVAEL 245
RESULT 2
AAB08926
ID AAB08926 standard; protein; 246 AA.
AC AAB08926;
XX
XX 30-AUG-2000 (first entry)
DE Human secreted protein sequence encoded by gene 13 SEQ ID NO:83.
XX Human; secreted protein; cytostatic; anti-proliferative; vulnery;
KW immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
KW hyperproliferative disorder; infectious disease; tissue regeneration;
KW screening; food additive; preservative; wound healing;
KW hyper-vascular disease; chromosome 11.
XX
OS Homo sapiens.
XX
XX WO200017222-A1.
XX
XX 30-MAR-2000.
XX
XX 22-SEP-1999; 99WO-US022012.
XX
XX 23-SEP-1998; 98US-0101546P.
PR 02-OCT-1998; 98US-0102895P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;
PI Komatsoulis G, Endress GA, Soppet DR;
XX WPI; 2000-283538/24.
XX
XX N-PSDB; AAA39087.

XX Human secreted proteins and coding sequences useful in diagnostic and
PT therapeutic methods for disorders such as immune system or proliferative
PT disorders, related to the proteins.
XX
PS Claim 11; Page 376-377; 416pp; English.
XX
CC The polynucleotide sequences given in AAA39052 to AAA39088 encode the
CC human secreted proteins given in AAB08891 to AAB08984. The human secreted
CC proteins can have activities based on the tissues and cells they are
CC expressed in. Examples of the activities are: cytostatic; anti-
CC proliferative; immunosuppressive; antibacterial; and vulnery. The
CC secreted proteins and their related polynucleotide sequences are useful
CC for diagnostic and therapeutic methods useful for diagnosing and treating
CC disorders related to the secreted proteins. The proteins, and
CC polynucleotide sequences may be useful for treating disorders of the
CC immune system, hyperproliferative disorders, infectious disease,
CC regeneration of tissues, for chemotaxis and for screening molecules that
CC bind to the proteins. The proteins or polynucleotide sequences may be
CC used as food additives or preservatives, to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, co-factors or other nutritional components. Agonists or
CC antagonists of the proteins may be used to prevent scar tissue growth
CC during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC and AAB08890 are sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 246 AA;
Query Match. 99.9%; Score 1286; DB 3; Length 246;
Best Local Similarity 100.0%; Pred. No. 6.1e-85;
Matches 245; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
DB 1 MAELPGPFLLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPPTVGATLKLTDVHPSDGTGYL 120
DB 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPPTVGATLKLTDVHPSDGTGYL 120
QY 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
DB 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSA SCELTLT SVTPSQ 240
DB 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSA SCELTLT SVTPSQ 240
QY 241 RVAEL 245
DB 241 RVAEL 245
RESULT 3
AAB08925
ID AAB08925 standard; protein; 327 AA.
AC AAB08925;
XX
XX 11-MAY-2000 (first entry)
XX
XX Human signal peptide containing protein HSPP-28 SEQ ID NO:28.
XX Human; signal peptide-containing protein; HSPP; diagnosis; cancer;
KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW antimicrobial; nootropic; neuroprotective; cardiovascular; hepatocytic;
KW antiasthmatic; gene therapy; cell proliferation; neurological disorder;
KW reproductive disorder; developmental disorder; arteriosclerosis;
KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
KW Parkinson's disease; Huntington's diseases; ovulatory defect;
KW muscular dystrophy.


```
XX OS Homo sapiens.
XX PN WO200000610-A2.
XX PD 06-JAN-2000.
XX PF 25-JUN-1999; 99WO-US014484.
XX PR 26-JUN-1998; 98US-0090762P.
XX PR 31-JUL-1998; 98US-0094983P.
XX PR 01-OCT-1998; 98US-0102686P.
XX PR 11-DEC-1998; 98US-0112129P.
XX PA (INCY-) INCYTE PHARM INC.
XX PI Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
XX PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
XX PI Bandman O;
XX DR WPI; 2000-160673/14.
XX DR N-PSDB; AAZ98136.
XX PT New human signal peptide-containing proteins useful in treatment,
XX PT prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
XX PT disease.
XX PS Claim 1; Page 177-178; 327pp; English.
XX XX
XX CC AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the
XX CC human signal peptide-containing proteins HSP-1 to HSP-134. HSPs have
XX CC anticancer, anti-inflammatory, antimicrobial, nontropic, hepatotropic,
XX CC neuroprotective, cardiovascular and antiasthmatic activities, and can be
XX CC used in gene therapy. HSPs can be used to treat or prevent disorders
XX CC associated with decreased activity or function of HSP. Antagonists of
XX CC HSP are used to treat or prevent disorders associated with increased
XX CC activity or function of HSP. Such diseases include cell proliferation
XX CC (including cancer), inflammation, cardiovascular, neurological,
XX CC reproductive or developmental disorders, (e.g. arteriosclerosis,
XX CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
XX CC asthma, Crohn's disease, microbial or other infections, congestive or
XX CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
XX CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSP
XX CC nucleic acids can be used for the recombinant production of HSP, for
XX CC detecting HSP in standard hybridisation and amplification assays (for
XX CC diagnosis and monitoring), in gene therapy, as antisense, triplex-forming
XX CC or ribozyme therapeutics, for detecting related sequences or genetic
XX CC variations, and for chromosomal mapping. HSP are also used to raise
XX CC specific antibodies (Ab) and to screen for agonists and antagonists
XX CC (potential therapeutic agents). Ab are used to diagnose, or monitor, HSP
XX CC -related diseases (in usual immunoassays), as therapeutic antagonists, in
XX CC competitive drug screens, and for purification of HSP from natural
XX CC sources
XX SQ Sequence 327 AA;

Query Match          99.2%; Score 1277; DB 3; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGFLCAGLGFCLSGLAIVEVKVPTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGFLCAGLGFCLSGLAIVEVKVPTPLGKTAELTCTYSTVSGDSFALEWS 60

QY 61 FVQGKPISESHPILYFTNGHLYPTGSKSRVSLQLQNPPTVGATLKLTDVHPSDCTYL 120
Db 61 FVQGKPISESHPILYFTNGHLYPTGSKSRVSLQLQNPPTVGATLKLTDVHPSDCTYL 120

QY 121 CQVNNPDDFTYNGLGLNLTVLPSPNPLCSQSGQTSVGGSTALRCSSSGAKPKPVYVNW 180
Db 121 CQVNNPDDFTYNGLGLNLTVLPSPNPLCSQSGQTSVGGSTALRCSSSGAKPKPVYVNW 180

QY 181 RLGTFTFPSPGSMVQDEVSGQLILTNLSSTSGTYRCVATNQMGASCELTLSTVPSQ 240
```

```
Db 181 RLGTFTFPSPGSMVQDEVSGQLILTNLSSTSGTYRCVATNQMGASCELTLSTVPSQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 4
AAY94857
ID AAY94857 standard; protein; 327 AA.
XX AC AAY94857;
XX DT 12-JUN-2000 (first entry)
XX DE Human protein clone HP10568.
XX KW Human protein; hydrophobic domain; nutritional source; haematopoiesis;
XX KW cytokine production; cell proliferation; cell differentiation;
XX KW immune deficiency; infectious disease; autoimmune disorder; asthma;
XX KW multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis;
XX KW allergic reaction; osteoporosis; osteoarthritis; periodontal disease;
XX KW nervous system disorder; Alzheimer's disease; Parkinson's disease;
XX KW Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury;
XX KW systemic cytokine damage; tissue differentiation; contraceptive; stroke;
XX KW coagulation disorder; myocardial infarction; inflammatory condition;
XX KW septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour;
XX KW nephritis; therapy.
XX OS Homo sapiens.
XX PN WO200005367-A2.
XX PD 03-FEB-2000.
XX PF 22-JUL-1999; 99WO-JF003929.
XX PR 24-JUL-1998; 98JP-00208820.
XX PR 07-AUG-1998; 98JP-00224105.
XX PR 25-AUG-1998; 98JP-00238116.
XX PR 09-SEP-1998; 98JP-00254736.
XX PR 29-SEP-1998; 98JP-00275505.
XX PA (SAGA) SAGAMI CHEM RES CENT.
XX PA (PROT-) PROTEGENE INC.
XX PI Kato S, Kimura T;
XX WPI; 2000-182694/16.
XX PT Novel human proteins having hydrophobic domains useful for treating
XX PT osteoporosis, Alzheimer's disease, Parkinson's disease, asthma, multiple
XX PT sclerosis, rheumatoid arthritis, cancer, anemia, and stroke.
XX PS Claim 1; Page 183-184; 351pp; English.
XX XX
XX CC This sequence represents a human protein of the invention, which has
XX CC hydrophobic domains. The DNA sequences can be used as a probe or as a
XX CC genetic marker. The protein can also be used as a marker, and to identify
XX CC potential genetic disorders. The DNA and protein can also be used as
XX CC nutritional sources or supplements. The protein exhibits cytokine, cell
XX CC proliferation, cell differentiation activities and induces production of
XX CC other cytokines in certain cell populations. The protein also exhibits
XX CC immune stimulating or immune suppressing activity. It can be used in the
XX CC treatment of various immune deficiencies and disorders, and to treat
XX CC infectious diseases caused by viral, bacterial, fungal or other
XX CC infections. The protein is also used for treating autoimmune disorders
XX CC such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid
XX CC arthritis. It is also useful in the treatment of allergic reactions and
XX CC conditions such as asthma, and in immune suppression after organ
XX CC transplantation. The protein is useful in regulation of haematopoiesis
XX CC and consequently in the treatment of myeloid or lymphoid cell
```


DE Human polypeptide SEQ ID NO 2730.
 XX Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
 KW anti-allergic; hepatotropic; antidiabetic; anti-inflammatory; antitumor;
 KW vulnary; anticonvulsant; antibacterial; antifungal; antiparasitic;
 KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
 KW neurological disease; infection; human; secreted protein.
 XX OS Homo sapiens.
 XX WO200190304-A2.
 XX 29-NOV-2001.
 XX 18-MAY-2001; 2001WO-US016450.
 XX 19-MAY-2000; 2000US-0205515P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX Birse CE, Rosen CA;
 XX WPI; 2002-122018/16.
 XX N-PSDB; ABL90763.
 XX Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
 PT prevention of neural, immune system, muscular, reproductive,
 PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative
 PT disorders.
 XX Claim 11; SEQ ID NO 2730; 2081pp + Sequence Listing; English.
 XX The invention relates to novel genes (ABL89449-ABL90853) and proteins
 CC (ABB89040-ABB90444) useful for preventing, treating or ameliorating
 CC medical conditions e.g. by protein or gene therapy. The genes are
 CC isolated from a range of human tissues disclosed in the specification.
 CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in
 CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
 CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
 CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
 CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
 CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
 CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
 CC cardiovascular disorders such as myocardial ischaemia; (d) wound healing
 CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
 CC infectious diseases such as viral, bacterial, fungal and parasitic
 CC infections. Note: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 327 AA;
 Query Match 99.2%; Score 1277; DB 5; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAELPGFLCALGFLCLSLAVEVVKVTEPLTGLKTAELTCTYSTVSGDSFALEWS 60
 DB 1 MAELPGFLCALGFLCLSLAVEVVKVTEPLTGLKTAELTCTYSTVSGDSFALEWS 60
 QY 61 FVQPGKPISESHPILYFTNGHLXPTGSKSRVSLQLQNPPTVGVATLKLTDVHPSDTGYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLXPTGSKSRVSLQLQNPPTVGVATLKLTDVHPSDTGYL 120
 QY 121 CQVNNPPDFYFTNGHLINLTVLPNPNPLCSQSQSTVSGGSTALRCSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYFTNGHLINLTVLPNPNPLCSQSQSTVSGGSTALRCSSEGAPKPVYNNV 180
 QY 181 RLGTFTPTSPGSMQVDSVSGOLILTNLSLTSSGTYRCVATNQMSACELTSLVTEPSQ 240
 DB 181 RLGTFTPTSPGSMQVDSVSGOLILTNLSLTSSGTYRCVATNQMSACELTSLVTEPSQ 240
 QY 241 RVA 243

Db 241 RVA 243

RESULT 7
 AAU83709
 ID AAU83709 standard; protein; 327 AA.

XX AC AAU83709;

XX 08-MAY-2002 (first entry)

XX Human PRO protein, Seq ID No 236.

XX Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
 KW breast cancer; prostate tumour; rectal tumour; liver tumour;
 KW pericyte cell proliferation; chondrocyte cell proliferation;
 KW tumour necrosis factor-alpha.

XX OS Homo sapiens.

XX WO200208288-A2.

XX 31-JAN-2002.

XX 29-JUN-2001; 2001WO-US021066.

XX 20-JUL-2000; 2000US-0219556P.

XX 25-JUL-2000; 2000US-0220585P.

XX 25-JUL-2000; 2000US-0220605P.

XX 25-JUL-2000; 2000US-0220624P.

XX 25-JUL-2000; 2000US-0220638P.

XX 25-JUL-2000; 2000US-0220664P.

XX 25-JUL-2000; 2000US-0220666P.

XX 26-JUL-2000; 2000US-0220893P.

XX 01-AUG-2000; 2000US-0222425P.

XX 22-AUG-2000; 2000US-0227113P.

XX 23-AUG-2000; 2000WO-US023522.

XX 24-AUG-2000; 2000WO-US023328.

XX 10-NOV-2000; 2000WO-US030873.

XX 28-NOV-2000; 2000US-0253646P.

XX 01-DEC-2000; 2000WO-US032678.

XX 20-DEC-2000; 2000US-00747259.

XX 20-DEC-2000; 2000WO-US034956.

XX 28-FEB-2001; 2001WO-US008520.

XX 01-MAR-2001; 2001WO-US006666.

XX 22-MAR-2001; 2001US-00816744.

XX 10-MAY-2001; 2001US-00854208.

XX 10-MAY-2001; 2001US-00854280.

XX 25-MAY-2001; 2001WO-US017092.

(GETH) GENENTECH INC.

Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski RJ;
 Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

WPI; 2002-172001/22.

N-PSDB; ABK33653.

One hundred and twenty two nucleic acids encoding PRO polypeptides,
 useful for treating a PRO related disorder and for diagnosing tumors such
 as lung cancer, colon cancer, breast tumor, prostate tumor, rectal tumor
 or liver tumor.

Claim 11; Fig 236; 359pp; English.

The invention relates to one hundred and twenty two nucleic acids
 encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
 encode human secreted proteins. The PRO nucleic acids, polypeptides,
 agonists and antagonists are useful for treating a PRO related disorder.
 The PRO polypeptides are useful for diagnosing tumors, especially lung

CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. The PRO polypeptides are useful for stimulating the
 CC proliferation of, or gene expression, in pericyte cells, for stimulating
 CC the proliferation or differentiation of chondrocyte cells, for
 CC stimulating the release of tumour necrosis factor-alpha from human blood,
 CC for stimulating or inhibiting the proliferation of normal human dermal
 CC fibroblast cells. The PRO polypeptide may also be used as molecular
 CC weight markers and for tissue typing. The PRO nucleic acids have
 CC applications in molecular biology, including use as hybridisation probes,
 CC and in chromosome and gene mapping. AAU83592-AAU83713 represent human PRO
 CC protein sequences of the invention
 XX
 SQ Sequence 327 AA;

Query Match 99.2%; Score 1277; DB 5; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAIVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAIVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
 DB 61 FVQPGKPISHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAKPKVYNW 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAKPKVYNW 180
 QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSAACELTSLVTPSPQ 240
 DB 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSAACELTSLVTPSPQ 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 8
 ABU80856
 ID ABU80856 standard; protein; 327 AA.
 XX
 AC ABU80856;
 XX
 DT 23-JUN-2003 (first entry)
 XX
 DE Human PRO polypeptide #118.
 XX
 KW Human; PRO polypeptide; secreted and transmembrane protein;
 KW anti-PRO antibody; diagnostic assay; gene expression; tumour; cytostatic.
 XX
 OS Homo sapiens.
 XX
 PN US2003036635-A1.
 XX
 PD 20-FEB-2003.
 XX
 PF 28-AUG-2002; 2002US-00230163.
 XX
 PR 25-JUL-2000; 2000US-0220638P.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 XX WPI; 2003-342045/32.
 DR
 DR N-PSDB; ACA66958.
 XX

PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful for the manufacture of a medicament for diagnosing or treating
 PT tumor.
 XX
 PS Claim 11; Fig 236; 314pp; English.
 XX
 CC The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides and polynucleotides are useful for preparing a medicament
 CC useful in the diagnosis and treatment of tumours. Anti-PRO antibodies are
 CC useful in diagnostic assays for PRO, by detecting its expression in
 CC specific cells, tissues or serum, and for affinity purification of PRO
 CC from recombinant cell culture or natural sources. ABU80739-ABU80860
 CC represent the human PRO polypeptides of the invention. Note: The sequence
 CC data for this patent was obtained in electronic format directly from the
 CC USPTO web site at seqdata.uspto.gov/psipgDIDEntry.html
 XX

SQ Sequence 327 AA;

Query Match 99.2%; Score 1277; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAIVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAIVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
 DB 61 FVQPGKPISHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAKPKVYNW 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAKPKVYNW 180
 QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSAACELTSLVTPSPQ 240
 DB 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSAACELTSLVTPSPQ 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 9
 ABO33822
 ID ABO33822 standard; protein; 327 AA.
 XX
 AC ABO33822;
 XX
 DT 17-SEP-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO7154.
 XX
 KW Human; secreted and transmembrane protein; PRO; cytostatic;
 KW antiarthritic; osteopathic; gene therapy; TNF-Agonist-Alpha;
 KW chondrocyte stimulator; pericyte stimulator; fibroblast modulator;
 KW pharmaceutical; diagnostic; biosensor; bioresactor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; bone disorder; cartilage disorder; sports injury;
 KW arthritis; wound.
 XX
 OS Homo sapiens.
 XX
 PN US2003045687-A1.
 XX
 PD 06-MAR-2003.
 XX
 PF 12-AUG-2002; 2002US-00218631.
 XX
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 XX

PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-512315/48.
XX N-PSDB; ACD68710.
XX New genes, and its encoded secreted and transmembrane polypeptides,
XX useful for stimulating Tumor Necrosis factor alpha, or chondrocyte or
XX pericyte proliferation, especially for treating lung tumors, arthritis or
XX wounds in a mammal.
XX Claim 11; Fig 236; 314pp; English.
XX The invention describes an isolated nucleic acid molecule comprising a
XX sequence with at least 80% identity to: (a) a nucleotide encoding any of
XX 122 PRO (secreted and transmembrane) polypeptides whose sequences are
XX fully defined in the specification; or (b) any of 122 nucleotide
XX sequences having e.g. 4834, 2504 or 1759 bp fully defined in the
XX specification; or the full length coding sequence of any these 122
XX nucleotide sequences. The PRO polypeptides or polynucleotides are useful
XX as pharmaceuticals, diagnostics, biosensors or bioreactors. These are
XX particularly useful for detecting tumours (e.g. lung tumour, colon
XX tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)
XX in a mammal, for stimulating the release of TNP-alpha from human blood,
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells, for stimulating proliferation of pericyte cells, or for modulating
XX normal human dermal fibroblast proliferation. The PRO nucleic acid or
XX polypeptide is also useful for treating tumours or various bone and/or
XX cartilage disorders (e.g. sports injuries or arthritis), or wounds. The
XX PRO polypeptides are useful in drug screening, particularly as targets
XX for therapeutic intervention in these diseases, and in the diagnostic
XX determination of the presence of these diseases. The PRO polypeptides are
XX also useful as molecular weight markers, or for chromosome
XX identification. The PRO genes are useful as hybridisation probes, or for
XX screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
XX also be used in gene therapy, particularly for replacing a defective
XX gene. This is the amino acid sequence of a novel human secreted and
XX transmembrane PRO polypeptide
XX
XX Sequence 327 AA;
Query Match 99.2%; Score 1277; DB 6; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Qy 61 FVOPGKPISESHPILYFTNGHLVPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVOPGKPISESHPILYFTNGHLVPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGYL 120
Qy 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESSEGAPKPVYVNW 180
Db 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESSEGAPKPVYVNW 180
Qy 181 RLGTFFPTPPSGMWQDVSQGLITNLSTSSGTYRCVATNQMSASCELTLSVTEPSQ 240
Db 181 RLGTFFPTPPSGMWQDVSQGLITNLSTSSGTYRCVATNQMSASCELTLSVTEPSQ 240
Qy 241 RVA 243
Db 241 RVA 243
RESULT 10
ABU82165
ID ABU82165 standard; protein; 327 AA.

XX AC ABU82165;
XX XX 25-JUN-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO7154.
XX XX Human; secreted and transmembrane protein; PRO; cardiant; cytostatic;
XX KW antiangiogenic; hypotensive; vulnenry; antiarteriosclerotic;
XX KW gene therapy; cardiovascular disorder; endothelial disorder;
XX KW angiogenic disorder; cardiac hypertrophy; trauma; cancer;
XX KW age-related macular degeneration; atherosclerosis; hypertension;
XX KW arterial restenosis; rheumatoid arthritis; angina; myocardial infarction;
XX KW thrombophlebitis; lymphangitis; tumour angiogenesis; breast carcinoma;
XX KW liver carcinoma; wound healing; chromosome mapping; gene mapping.
XX OS Homo sapiens.
XX XX US2003088063-A1.
XX XX 08-MAY-2003.
XX PF 12-AUG-2002; 2002US-00219003.
XX XX 25-JUL-2000; 2000US-0220664P.
XX PR 01-JUN-2001; 2001WO-US017800.
XX PR 29-JUN-2001; 2001WO-US021066.
XX PR 09-APR-2002; 2002US-00119480.
XX XX (GETH) GENENTECH INC.
XX PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX XX WPI; 2003-393229/37.
XX DR N-PSDB; ACA68614.
XX XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
XX useful in diagnosis and treatment of cardiovascular (e.g. myocardial
XX PT infarction), endothelial or angiogenic disorders in a mammal.
XX PS Claim 11; Fig 236; 314pp; English.
XX XX The invention describes one hundred and eighty seven nucleic acids
XX encoding novel human secreted and transmembrane (PRO) polypeptides. The
XX PRO nucleic acids, polypeptides, agonists and antagonists are useful for
XX treating or diagnosing a cardiovascular, endothelial or angiogenic
XX disorder in a mammal, e.g. cardiac hypertrophy, trauma, cancer, age-
XX related macular degeneration, atherosclerosis, hypertension, arterial
XX restenosis, rheumatoid arthritis, angina, myocardial infarctions,
XX thrombophlebitis, lymphangitis, tumour angiogenesis (such as breast
XX carcinoma and liver carcinoma) and wound healing. The PRO nucleic acids
XX have applications in molecular biology, including use as hybridisation
XX probes, and in chromosome and gene mapping. This is the amino acid
XX sequence of a novel human secreted and transmembrane PRO polypeptide
XX
XX Sequence 327 AA;
Query Match 99.2%; Score 1277; DB 6; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Qy 61 FVOPGKPISESHPILYFTNGHLVPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVOPGKPISESHPILYFTNGHLVPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGYL 120
Qy 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESSEGAPKPVYVNW 180
Db 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESSEGAPKPVYVNW 180

```
QY 181 RLGTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSGASCELTLVSVPESQ 240
    |||||
Db 181 RLGTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSGASCELTLVSVPESQ 240
    |||||
QY 241 RVA 243
    |||
Db 241 RVA 243
    |||

RESULT 11
ABJ72345
ID ABJ72345 standard; protein; 327 AA.
XX
XX AC ABJ72345;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human PRO7154 protein.
XX
XX PRO; proliferation; pericyte cell; TNF-alpha; blood; chondrocyte;
KW differentiation; dermal fibroblast; tumour; gene therapy; cytostatic.
XX
XX Homo sapiens.
XX
XX US2003050448-A1.
XX
XX 13-MAR-2003.
XX
XX 28-AUG-2002; 2002US-00230414.
XX
XX 01-JUN-2001; 2001WO-US017800.
PR
XX 29-JUN-2001; 2001WO-US021066.
PR
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX WPI; 2003-521818/49.
DR
XX N-PSDB; ABT44343.
XX
XX New nucleic acid encoding for a PRO protein, useful for the manufacture
PT of a medicament for diagnosing or treating tumors or for measuring or
PT detecting expression of an associated gene.
XX
XX Claim 11; Fig 236; 315pp; English.
XX
XX The invention relates to a novel isolated nucleic acid encoding a fully
CC defined PRO polypeptide. The molecules of the invention may be useful for
CC stimulating proliferation or gene expression in pericyte cells or the
CC release of TNF-alpha from human blood. Other possible uses include the
CC stimulation or inhibition of chondrocyte proliferation or
CC differentiation, the stimulation of human dermal fibroblast cell
CC proliferation and the detection of the presence of a tumour within a
CC mammal. Furthermore, the nucleic acid may be useful for the manufacture
CC of a medicament for diagnosing or treating a tumour within a mammal or
CC for measuring or detecting the expression of an associated gene, as well
CC as during gene therapy. The current sequence is that of the human PRO
CC protein of the invention
XX
XX Sequence 327 AA;
Query Match 99.2%; Score 1277; DB 6; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGFLCGALLGFLCSGLAVEVKVPTPEPLSTPLGKTAEPLCTYSTSVGDSFALEWS 60
    |||||
Db 1 MAELPGFLCGALLGFLCSGLAVEVKVPTPEPLSTPLGKTAEPLCTYSTSVGDSFALEWS 60
    |||||
QY 61 FVQPGKPISSEHPILFTNGHLFTGSKSKRVSLQNPPVTGVATLKLTDVHPSPDTGTYL 120
    |||||
```

```
Db 61 FVQPGKPISSEHPILFTNGHLFTGSKSKRVSLQNPPVTGVATLKLTDVHPSPDTGTYL 120
    |||||
QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPYNNV 180
    |||||
Db 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPYNNV 180
    |||||
QY 181 RLGTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSGASCELTLVSVPESQ 240
    |||||
Db 181 RLGTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSGASCELTLVSVPESQ 240
    |||||
QY 241 RVA 243
    |||
Db 241 RVA 243
    |||

RESULT 12
ABJ72473
ID ABJ72473 standard; protein; 327 AA.
XX
XX AC ABJ72473;
XX
DT 06-NOV-2003 (first entry)
XX
XX Human PRO7154 protein.
DE
XX
XX PRO; blood; proliferation; pericyte cell; TNF alpha; chondrocyte;
KW tumour necrosis factor; proliferation; differentiation; gene therapy;
KW dermal fibroblast.
XX
XX Homo sapiens.
XX
XX US2003027988-A1.
XX
XX 06-FEB-2003.
XX
XX 26-AUG-2002; 2002US-00227884.
XX
XX 01-JUN-2001; 2001WO-US017800.
PR
XX 29-JUN-2001; 2001WO-US021066.
PR
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX WPI; 2003-503301/47.
DR
XX N-PSDB; ABT44626.
XX
XX New PRO protein encoding nucleic acid, useful for preparing PRO
PT polypeptides and anti-PRO antibodies for detecting the presence of a
PT tumor in a mammal.
XX
XX Claim 11; Fig 236; 324pp; English.
XX
XX The invention relates to a novel isolated PRO protein encoding nucleic
CC acid. The nucleic acid of the invention may be useful for preparing PRO
CC polypeptides and anti-PRO antibodies for detecting the presence of a
CC tumour in a mammal. Furthermore, the molecules of the invention may be
CC useful for stimulating proliferation or gene expression in pericyte
CC cells, the release of tumour necrosis factor (TNF)-alpha from human
CC blood, the proliferation or differentiation of chondrocyte cells and for
CC inhibiting the proliferation of normal human dermal fibroblast cells.
CC Finally, the molecules may be utilised during gene therapy. The current
CC sequence is that of the human PRO protein of the invention
XX
XX Sequence 327 AA;
Query Match 99.2%; Score 1277; DB 6; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Qy 61 FVQPGKPISESHPILYFTNGHLYPTGSKSKRVSLIQNPPTVGVATLKLTDVHPSDGTGYL 120
Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKSKRVSLIQNPPTVGVATLKLTDVHPSDGTGYL 120
Qy 121 CQVNNPPDFYTNGLGLINLTVLPPSNPLCSQSQGTSVGGSTALRCSSEGAPKPVYNWV 180
Db 121 CQVNNPPDFYTNGLGLINLTVLPPSNPLCSQSQGTSVGGSTALRCSSEGAPKPVYNWV 180
Qy 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLSTVTPSQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLSTVTPSQG 240
Qy 241 RVA 243
Db 241 RVA 243

RESULT 13
ABO34368
ID ABO34368 standard; protein; 327 AA.
AC ABO34368;
XX
DT 19-SEP-2003 (first entry)
XX Human secreted/transmembrane polypeptide PRO 7154.
XX
XX Human; chondrocyte stimulation; TNF-alpha stimulation; gene therapy;
KW human dermal fibroblast stimulation; tumour; tissue typing;
KW affinity purification.
XX Homo sapiens.
XX
PN US2003044934-A1.
XX
PD 06-MAR-2003.
XX
PF 28-AUG-2002; 2002US-00230338.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-492274/46.
DR N-PSDB; ACD82293.
XX
XX New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX
PS Claim 19; Fig 236; 315pp; English.
XX

CC The invention relates to an isolated nucleic acid encoding a PRO
CC polypeptide. Nucleic acids that encode PRO can be used to generate either
CC transgenic animals or knock-out animals useful in developing and
CC screening of therapeutically useful reagents. The nucleic acids may also
CC be used in gene therapy for replacing defective gene, in chromosome
CC identification, as chromosome markers, or in generating probes to isolate
CC full length PRO cDNA. The PRO polypeptides are useful for chondrocyte
CC stimulation, TNF-alpha stimulation, human dermal fibroblasts stimulation
CC and for detecting the presence of tumour in a mammal. The PRO
CC polypeptides are useful as molecular markers for protein electrophoresis
CC and the isolated nucleic acids may be used for recombinantly expressing
CC those markers. The PRO polypeptides and nucleic acids may also be used in

CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
CC PRO and in affinity purification of PRO from recombinant cell culture or
CC natural sources. The present sequence represents the amino acid sequence
CC of a human secreted/transmembrane PRO polypeptide
XX
SQ Sequence 327 AA;
Query Match 99.2%; Score 1277; DB 6; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Qy 61 FVQPGKPISESHPILYFTNGHLYPTGSKSKRVSLIQNPPTVGVATLKLTDVHPSDGTGYL 120
Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKSKRVSLIQNPPTVGVATLKLTDVHPSDGTGYL 120
Qy 121 CQVNNPPDFYTNGLGLINLTVLPPSNPLCSQSQGTSVGGSTALRCSSEGAPKPVYNWV 180
Db 121 CQVNNPPDFYTNGLGLINLTVLPPSNPLCSQSQGTSVGGSTALRCSSEGAPKPVYNWV 180
Qy 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLSTVTPSQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLSTVTPSQG 240
Qy 241 RVA 243
Db 241 RVA 243

RESULT 14
ABJ72175
ID ABJ72175 standard; protein; 327 AA.
XX
AC ABJ72175;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human membrane bound receptor/protein PRO7154 amino acid sequence.
XX
KW Human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophic factor; hormone; cell receptor;
KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour.
XX
OS Homo sapiens.
XX
PN US2003065147-A1.
XX
PD 03-APR-2003.
XX
PF 29-AUG-2002; 2002US-00232224.
XX
PR 28-JUL-1999; 99US-0146222P.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 03-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI WPI; 2003-522018/49.
DR N-PSDB; ABT43999.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for the manufacture of a medicament for diagnosing or treating

PT tumor.
XX Claim 11; Fig 236; 315pp; English.
XX
XX This invention relates to one hundred and twenty two novel nucleic acids
CC encoding human PRO membrane bound proteins or receptors. Extracellular
CC proteins play important roles in the formation, differentiation and
CC maintenance of multicellular organisms. The fate of many individual cells
CC (for example proliferation, migration or differentiation) is typically
CC governed by information received from other cells and the immediate
CC environment. The information is often transmitted by secreted
CC polypeptides. (For example mitogenic factors, survival factors, cytotoxic
CC factors, differentiation factors, neuropeptides and hormones) which are
CC received and interpreted by diverse cell receptors or membrane bound
CC proteins. These membrane bound proteins and receptors may be of use as
CC pharmaceutical and diagnostic agents, such as in the blocking of receptor
CC -ligand interactions. The current invention provides the amino acid
CC sequences of novel human membrane bound receptors and proteins, along
CC with the cDNA sequences encoding them. The novel proteins of the
CC invention may have cytostatic activities through the stimulation of
CC chondrocytes. The nucleic acids of the invention may be useful for the
CC manufacture of a medicament for diagnosing or treating a tumour in a
CC mammal. In addition, they may be useful for measuring or detecting the
CC expression of a tumour associated gene. The present sequence is the amino
XX acid sequence of a human PRO protein of the invention
SQ Sequence 327 AA;
Query Match 99.2%; Score 1277; DB 7; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGFLLCGALLGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGFLLCGALLGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISESHPILYFTNGHLVPTGSKSRVSLQNPPTVGATVATKLTIDVHPSDTGYL 120
Db 61 FVQPGKPISESHPILYFTNGHLVPTGSKSRVSLQNPPTVGATVATKLTIDVHPSDTGYL 120
QY 121 CQVNNPDDFTYNGLGLINLTVPSPNPLCSQSGQTSVGGSTALRCSSEGAKPKVYNNV 180
Db 121 CQVNNPDDFTYNGLGLINLTVPSPNPLCSQSGQTSVGGSTALRCSSEGAKPKVYNNV 180
QY 181 RLCTFTPTSPGSMVQDEVSGQLITLNLSTSSGTYRCVATNQMSASCELITLSVTEPSQ 240
Db 181 RLCTFTPTSPGSMVQDEVSGQLITLNLSTSSGTYRCVATNQMSASCELITLSVTEPSQ 240
QY 241 RVA 243
Db 241 RVA 243
RESULT 15
ADB83726
ID ADB83726 standard; protein; 327 AA.
XX
AC ADB83726;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO7154.
XX human; secreted and transmembrane protein; PRO; cytostatic; vulnerary;
KW antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.

OS Homo sapiens.
XX US2003073814-A1.
XX
XX PD 17-APR-2003.
XX
XX PF 12-AUG-2002; 2002US-00218849.
XX
XX PR 01-JUN-2001; 2001WO-US017800.
XX
XX PR 29-JUN-2001; 2001WO-US021066.
XX
XX PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX PI Grimaldi JC, Guernsey AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX DR WPI; 2003-644806/61.
XX N-PSDB; ADB83725.
XX
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
XX in gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX
XX Claim 11; Fig 236; 315pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF) -
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO531, PRO1083, PRO840, PRO1080.
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
CC PRO1887, PRO1928, PRO1341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This is the amino acid sequence of a human secreted and
XX transmembrane PRO polypeptide.
XX
SQ Sequence 327 AA;
Query Match 99.2%; Score 1277; DB 7; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGFLLCGALLGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGFLLCGALLGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISESHPILYFTNGHLVPTGSKSRVSLQNPPTVGATVATKLTIDVHPSDTGYL 120

D _b	61	FVQCKKPISESHPLILYFTNGHLYPGSKSRVSLQLQNPPVTGVATLKLTDVHPSDGTGYL	120
Q _y	121	CQVNPNPDFYFNTGLGLINLTVLVPSPNPLCSQSQTSVGGSTALRCSSEGAPKFVNVW	180
D _b	121	CQVNPNPDFYFNTGLGLINLTVLVPSPNPLCSQSQTSVGGSTALRCSSEGAPKFVNVW	180
Q _y	181	RLGTFPTPSPGSMVDVSGQLIITNLISLTSSGTYRCVATNQMGASCELTLSTVEPSQG	240
D _b	181	RLGTFPTPSPGSMVDVSGQLIITNLISLTSSGTYRCVATNQMGASCELTLSTVEPSQG	240
Q _y	241	RVA 243 	
D _b	241	RVA 243 	

Search completed: August 4, 2005, 06:07:07
Job time : 76.0264 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 05:56:06 ; Search time 89.5513 Seconds
(without alignments)
1852.722 Million cell updates/sec

Title: US-10-607-565-60_COPY_4_327

Perfect score: 1685

Sequence: 1 LPGPFLCGLLGLCLSLA.....ERPSSASTVTTTKSLPMV 324

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt_03.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1677	99.5	327	2 Q96107	Q96107 homo sapien
2	1632	96.9	325	2 Q95791	Q95791 homo sapien
3	1462	86.8	284	2 Q9N442	Q9N442 homo sapien
4	1309	77.7	328	2 Q92109	Q92109 mus musculus
5	1305	77.4	304	2 Q9CV24	Q9CV24 mus musculus
6	988	58.6	248	2 Q9D074	Q9D074 mus musculus
7	408.5	24.2	387	2 Q86XK7	Q86XK7 homo sapien
8	408.5	24.2	412	2 Q6MZS4	Q6MZS4 homo sapien
9	399	23.7	259	2 Q722Q1	Q722Q1 homo sapien
10	392	23.3	430	2 Q8N4F1	Q8N4F1 homo sapien
11	389.5	23.1	407	2 Q8D234	Q8D234 mus musculus
12	359	21.3	432	2 Q6DD57	Q6DD57 xenopus lae
13	358.5	21.3	318	2 Q91664	Q91664 xenopus lae
14	355	21.1	335	2 Q9PWR4	Q9PWR4 gallus gall
15	352	20.9	335	2 Q9YGH1	Q9YGH1 gallus gall
16	347	20.6	335	2 Q9YGV5	Q9YGV5 gallus gall
17	343	20.4	372	2 Q90V50	Q90V50 brachydanio
18	338	20.1	323	2 Q8ND02	Q8ND02 homo sapien
19	334.5	19.9	319	2 Q9TU80	Q9TU80 canis famil
20	331.5	19.7	352	2 Q91W66	Q91W66 mus musculus
21	331.5	19.7	365	1 CXAR MOUSE	P97792 mus musculus
22	331.5	19.7	365	2 Q9DB78	Q9DB78 mus musculus
23	328.5	19.5	390	2 Q95K13	Q95K13 macaca fasc
24	324.5	19.3	394	2 Q925F2	Q925F2 mus musculus
25	322	19.1	365	2 Q8WMV3	Q8WMV3 bos taurus
26	319.5	19.0	300	2 Q9D9J0	Q9D9J0 mus musculus
27	319.5	19.0	319	2 Q9TU79	Q9TU79 sus scrofa
28	319.5	19.0	344	2 Q9R067	Q9R067 rattus norv
29	319.5	19.0	358	2 Q9R066	Q9R066 rattus norv
30	318.5	18.9	390	2 Q96AP7	Q96AP7 homo sapien
31	318.5	18.9	390	2 Q96T50	Q96T50 homo sapien

Q6ayd4 rattus norv
Q9da22 mus musculus
Q8n7t8 homo sapien
Q9ukv4 homo sapien
P78310 homo sapien
Q804r4 brachydanio
Q99795 homo sapien
Q9h6b4 homo sapien
Q8k190 rattus norv
Q8r373 mus musculus
Q9jka5 mus musculus
Q6nw88 brachydanio
Q920s5 mus musculus
Q640u3 xenopus tro

32 317 18.8 394 2 Q6AYD4
33 316.5 18.8 300 2 Q9DA22
34 316 18.8 406 2 Q8N7T8
35 312.5 18.5 344 2 Q9UKV4
36 312.5 18.5 365 1 CXAR_HUMAN
37 307 18.2 298 2 Q804R4
38 307 18.2 319 1 A33_HUMAN
39 306.5 18.2 373 2 Q9H6B4
40 302.5 18.0 372 2 Q8K1G0
41 300.5 17.8 373 2 Q8R373
42 300 17.8 319 1 A33_MOUSE
43 298 17.7 442 2 Q6NW88
44 296.5 17.6 373 2 Q920S5
45 294 17.4 332 2 Q640U3

ALIGNMENTS

RESULT 1

Q96107 PRELIMINARY; PRT; 327 AA.

AC Q96107; (TrEMBLrel. 19, Created)

DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)

DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)

DE V-set and immunoglobulin domain containing 2 (CTH Variant).

GN Name=VSI2; ORFNames=UNQ2770;

OS Homo sapiens (Human)

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE=Colon;

RX MEDLINE=22386257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
Diatchenko L., Narusina K., Farmer A.A., Rubin G.M., Hong L.,
Rapaport M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.B.,
Brownstein M.J., Uudin T.B., Toshiyuki S., Carninci P., Prange C.,
Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
Fahney J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
Kryzwicki M.I., Skalska U., Smalusz D.E., Schnerch A., Schein J.E.,
Jones S.J., Marra M.A.;
"Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

[2]

SEQUENCE FROM N.A.

RC TISSUE=Colon;

RA Director MGC Project;

RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.

[3]

SEQUENCE FROM N.A.

RA MEDLINE=2287296; PubMed=12975309; DOI=10.1101/gr.1293003;

RA Clark H.F., Gurney A.L., Abaya E., Baker K., Balgwin D., Brush J.,
Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
Eaton D., Foster J., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
Lewis L., Liao D., Mark M., Robbie E., Sanchez C., Schoenfeld J.,
Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
Vandlen R., Watanabe C., Wiand D., Woods K., Xie M.H., Yansura D.,
Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,
Godowski P.;

RT "The secreted protein discovery initiative (SPDI), a large-scale
 RT effort to identify novel human secreted and transmembrane proteins: a
 RT bioinformatics assessment.";
 RL Genome Res. 13:2265-2270(2003).
 DR ENBL; BC007313; AA070313.1; -.
 DR ENBL; AV358897; AA089256.1; -.
 DR HSP; O88792; I197.
 DR GO; GO:0004872; F:receptor activity; IEA.
 DR InterPro; IPR007110; Ig-like.
 DR Pfam; PF00047; Ig; 1.
 DR PROSITE; PS50835; IG LIKE; 2.
 SQ SEQUENCE 327 AA; 34348 MW; CF395AC7EF951AC1 CRC64;

Query Match 99.5%; Score 1677; DB 2; Length 327;
 Best Local Similarity 99.7%; Pred. No. 1.9e-109;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LPGPFLLGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
 DB 4 LPGPFLLGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
 QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYCQV 120
 DB 64 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYCQV 123
 QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNWVRLG 180
 DB 124 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNWVRLG 183
 QY 181 TPTTPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSTVTEPPQGRVA 240
 DB 184 TPTTPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSTVTEPPQGRVA 243
 QY 241 GALIGVLLGVLLLSVAACLVRFQKRGKKPKETYGGSDLREDAIAPGISEHTCMRADSS 300
 DB 244 GALIGVLLGVLLLSVAACLVRFQKRGKKPKETYGGSDLREDAIAPGISEHTCMRADSS 303
 QY 301 KGFLERPSSASTVTITTKSKLPMVV 324
 DB 304 KGFLERPSSASTVTITTKSKLPMVV 327

RESULT 2

O95791 PRELIMINARY; PRT; 325 AA.
 AC O95791;
 DT 01-MAY-1999 (TrEMBLrel. 10, Created)
 DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE CTH.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=99077161; PubMed=9862345;
 RX DOI=10.1002/(SICI)1521-4141(199812)28:12<4094::AID-IMMU4094>3.3.CO;2-U;
 RA Chretien I., Marcuz A., Courtet M., Katevuo K., Vainio O., Heath J.K.,
 RA White S.J., Du Pasquier L.;
 RT conserved thymocyte receptor, defines a molecular family
 RL Eur. J. Immunol. 28:4094-4104(1998).
 DR ENBL; AF061022; AAD17522.1; -.
 DR HSP; O88792; I197.
 DR GO; GO:0005887; C:integral to plasma membrane; TAS.
 DR GO; GO:0005624; C:membrane fraction; TAS.
 DR InterPro; IPR007110; Ig-like.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00408; IGC2; 1.
 DR PROSITE; PS50835; IG LIKE; 2.
 SQ SEQUENCE 325 AA; 34239 MW; B7B5B664CBCCFF4BB CRC64;

Query Match 96.9%; Score 1632; DB 2; Length 325;
 Best Local Similarity 97.8%; Pred. No. 2.7e-106;
 Matches 317; Conservative 2; Mismatches 3; Indels 2; Gaps 2;
 QY 1 LPGPFLLGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
 DB 4 LPGPFLLGALLGFLCLX-LAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDTFALEWSFVQ 62
 QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYCQV 120
 DB 63 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYCQV 122
 QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNWVRLG 180
 DB 123 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNWVRLG 182
 QY 181 TPTTPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSTVTEPPQGRVA 240
 DB 183 TPTTPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSTVTEPPQGRVT 242
 QY 241 GALIGVLLGVLLLSVAACLVRFQKRGKKPKETYGGSDLREDAIAPGISEHTCMRADSS 300
 DB 243 GALIGVLLGVLLLSVAACLVRFQKRGKKPKETYGGSDLREDAIAPGISEHTCMRADSS 302
 QY 301 KGFLERPSSASTVTITTKSKLPMVV 324
 DB 303 KGFLERP-SASTVTITTKSKLPMVV 325

RESULT 3

O9NX42 PRELIMINARY; PRT; 284 AA.
 AC O9NX42;
 DT 01-OCT-2000 (TrEMBLrel. 15, Created)
 DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Hypothetical protein FLJ20453.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Watanabe K., Kumagai A., Itakura S., Yamazaki M., Tashiro H., Ota T.,
 RA Suzuki Y., Obayashi M., Nishi T., Shibahara T., Tanaka T.,
 RA Nakamura Y., Isoigai T., Sugano S.;
 RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
 DR ENBL; AK000460; BA91179.1; -.
 DR HSP; O88792; I197.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003598; Ig_c2.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00408; IGC2; 1.
 DR PROSITE; PS50835; IG LIKE; 2.
 SQ SEQUENCE 284 AA; 29829 MW; 1F9E09C60856B9A9 CRC64;

Query Match 86.8%; Score 1462; DB 2; Length 284;
 Best Local Similarity 99.6%; Pred. No. 1.8e-94;
 Matches 280; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LPGPFLLGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
 DB 4 LPGPFLLGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
 QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYCQV 120
 DB 64 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYCQV 123
 QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNWVRLG 180
 DB 124 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNWVRLG 183

```

Qy 181 TPTSPGSMVQDEVSQGLILTNLSLTSSGTYRCVATNMQMSASCELTLSTVTEPPQGRVA 240
Db 184 TPTSPGSMVQDEVSQGLILTNLSLTSSGTYRCVATNMQMSASCELTLSTVTEPPQGRVA 243
Qy 241 GALIGVLLGVLLSVAACLVRFQKRGKPKETVGGSDLR 281
Db 244 GALIGVLLGVLLSVAACLVRFQKRGKPKETVGGSDLR 284

RESULT 4
Qy 092109 PRELIMINARY; PRT; 328 AA.
AC 092109;
DT 01-MAY-1999 (Tremblrel. 10, Created)
DT 01-MAY-1999 (Tremblrel. 10, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE CTM.
GN Name=2210413P10Rik;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=99077161; PubMed=9862345;
RX DOI=10.1002/(SICI)1521-4141(199812)28:12<4094::AID-IMMU4094>3.3.CO;2-U;
RA Chretien I., Marcuz A., Courtet M., Katevuo K., Vainio O., Heath J.K.,
RA White S.J., Du Pasquier L.;
RT "CTX, a Xenopus thymocyte receptor, defines a molecular family
RT conserved throughout vertebrates.";
RL Eur. J. Immunol. 28:4094-4104(1998).
DR HSSP; O88792; 1F97.
DR MGD; MGI:1928009; 2210413P10Rik.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
SQ SEQUENCE 328 AA; 34258 MW; 0DA4C7BF7E221255 CRC64;

Query Match 77.7%; Score 1309; DB 2; Length 328;
Best Local Similarity 79.0%; Pred. No. 1.1e-83;
Matches 256; Conservative 19; Mismatches 49; Indels 0; Gaps 0;

Qy 1 LPGPFLCAGLGLFCLSGLAVEVKVPTPEPLSTPIGKTAELTCTYSTVSGDSFALEWSFVQ 60
Db 5 LVGAFGLCGHLLGFVCLSGLAVEVTVPTPEPLSVPRGKTAELSCSYKTSVGNFALEWSFVQ 64
Qy 61 PGKPISESHPILYFTNGHLYPTGSKRVSLQNPPTVGATLKLTDVHPSDTGYTLCOV 120
Db 65 PGKPIASVPVLYFTNGHLYPTGSKADRALLLHDPPTGGATLKLTLDRSDTGYTLCNV 124
Qy 121 NNPDFFTYNGLGLNLTLVLPSPNPLCSQSGOTSVGGSTALRCSSSGAPKPVNNVRLG 180
Db 125 NNPDFFTYNGLGLNLTLVLPSPNPLCSQSGOTLVGSSAALGCRSSSGAPKPVNNVRLC 184
Qy 181 TPTSPGSMVQDEVSQGLILTNLSLTSSGTYRCVATNMQMSASCELTLSTVTEPPQGRVA 240
Db 185 SSPTPPGSMVQDEVSQGLILTNLSLTSSGTYRCVASHQMSASCELNLSTVSDSGRVA 244
Qy 241 GALIGVLLGVLLSVAACLVRFQKRGKPKETVGGSDLRDIAIRGISEHTCMRADSS 300
Db 245 GTLIGVLLGVLLSVAACLVRFQKRGKPKETVGGSDLRDIAIRGISEHTCMRADSS 304
Qy 301 KGLERPSSASTVTTTKSKLPMVV 324
Db 305 KELLEKSPCASAMTPTKSLSMVV 328

RESULT 5

```

```

Q9CVA4 PRELIMINARY; PRT; 304 AA.
ID 09CVA4;
AC 09CVA4;
DT 01-JUN-2001 (Tremblrel. 17, Created)
DT 01-JUN-2001 (Tremblrel. 17, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE Mus musculus adult male stomach cDNA, RIKEN full-length enriched
DE library, clone:2210413P10 product:CTM homolog (Fragment).
GN Name=2210413P10Rik;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; TISSUE=Stomach;
RX MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;
RA Carninci P., Hayashizaki Y.;
RA Carninci P.; Hayashizaki Y.;
RT "High-efficiency full-length cDNA cloning.";
RL Meth. Enzymol. 303:19-44(1999).
RN [2]
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; TISSUE=Stomach;
RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;
RA RIKEN FANTOM Consortium;
RA "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690(2001).
RN [3]
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; TISSUE=Stomach;
RX MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;
RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,
RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
RT "Normalization and subtraction of cap-trapper-selected cDNAs to
RT prepare full-length cDNA libraries for rapid discovery of new genes.";
RL Genome Res. 10:1617-1630(2000).
RN [5]
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; TISSUE=Stomach;
RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;
RA Shibata K., Itoh M., Aizawa K., Nagao K., Kitagawa T., Tashiro H., Itoh M.,
RA Konno H., Akiyama J., Nishi K., Kitagawa T., Tashiro H., Itoh M.,
RA Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,
RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,
RA Fujiwaka S., Inoue K., Togawa Y., Izawa M., Ohara E., Watanabe M.,
RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsura S., Kawai J.,
RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
RT "RIKEN integrated sequence analysis (RISA) system-384-format
RT sequencing Pipeline with 384 multicapillary sequencer.";
RL Genome Res. 10:1757-1771(2000).
RN [6]
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; TISSUE=Stomach;
RX ADACHI J., Aizawa K., Akahira S., Akimura T., Arai A., Aono H.,
RA Arakawa T., Bono H., Carninci P., Fukuda S., Fukunishi Y., Furuno M.,
RA Hanagaki T., Hara A., Hayatsu N., Hiramoto K., Hiraoka T., Horii F.,
RA Inotani K., Ishii Y., Itoh M., Izawa M., Kasukawa T., Kato H.,
RA Kawai J., Kojima Y., Konno H., Kouda M., Koya S., Kurihara C.,
RA Matsuyama T., Miyazaki A., Nishi K., Nomura K., Numazaki R., Ohno M.,
RA Okazaki Y., Okido T., Owa C., Saito H., Saito R., Sakai C., Sakai K.,
RA Sano H., Sasaki D., Shibata K., Shibata Y., Shinagawa A., Shiraki T.,
RA Sogabe Y., Suzuki H., Tagami M., Tanaka T., Takahashi F., Tanaka T.,
RA Tejima Y., Toya T., Yamamura T., Yasunishi A., Yoshida K., Yoshino M.,
RA Muramatsu M., Hayashizaki Y.;
RT Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.

```

```

DR EMBL; AK008920; BAB25968.1; -.
DR HSSP; 088792; 1F97.
DR MGD; MGI:1928009; 2210413P10Rik.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
FT NON TER 304
SQ SEQUENCE 304 AA; 31919 MW; 522BA38898AD7A9F CRC64;

Query Match 77.4%; Score 1305; DB 2; Length 304;
Best Local Similarity 83.3%; Pred. No. 1.9e-83;
Matches 250; Conservative 17; Mismatches 33; Indels 0; Gaps 0;

QY 1 LQPFPLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
Db 5 LVGAFLCGHLHGFVCLSGLAIVEVTPEPLSVPKGTARELSGYSKTSVGDNFALEWSFVQ 64
QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVLLQNPPPTGVATLKLTDVHPSDTGTYLCOV 120
Db 65 PGKPISASVPLVFTNGHLYPTGSKADRAILLHDPTGGTLATLKLTDLRPSDTGTLYCNV 124
QY 121 NNPPDPFTYNTGLGLINLTVLVPPSNPLCSQSGTSGVSTALRCSSEGAPKPYNNWRVLG 180
Db 125 NNPPDPFTYNTGLGLINLTVLVPPSHPLCSQSGTSGVGSAAALGCRSSEGAPKPYNNWERLG 184
QY 181 TPPTSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNMGASCELTLSTVTPPQGRVA 240
Db 185 SSTPTPPGSMVQDEVSGQLILTNLSLTSSGTVCVATNMGASCELTLSTVTPPQGRVA 244
QY 241 GALIGVLLGVLLSVAAFCLVRPQKRGKKPKETYGSGDLREDALAPGISEHTCMRADSS 300
Db 245 GTLIGVLLGVLLSVAAFCLIRPQKRGKKPKETYGSGDLREDATAPGVFEQASMRADHS 304

RESULT 6
Q9D0T4 PRELIMINARY; PRT; 248 AA.
AC Q9D0T4;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Mus musculus 18-day embryo whole body cDNA, RIKEN full-length enriched
DE library, clone:1190004B15 product:CTM homolog.
GN Name=2210413P10Rik;
OS Mus musculus (Mouse);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Theria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Whole body;
RX MEDLINE=9927253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;
RA Carninci P., Hayashizaki Y.;
RT "High-efficiency full-length cDNA cloning.";
RL Meth. Enzymol. 303:19-44(1999).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Whole body;
RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;
RA RIKEN FANTOM Consortium;
RT "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690(2001).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Whole body;
RA The FANTOM Consortium;
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60, 770 full-length cDNAs.";
RL Nature 420:563-573(2002).
RN [4]

SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Whole body;
RX MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;
RA Carninci P., Shibata Y., Hayatsu M., Sugahara Y., Shibata K., Itoh M.,
RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
RT "Normalization and subtraction of cap-trapper-selected cDNAs to
RT prepare full-length cDNA libraries for rapid discovery of new genes.";
RL Genome Res. 10:1617-1630(2000).
RN [5]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Whole body;
RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;
RA Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,
RA Konno H., Akiyama J., Nishi K., Kitsumi T., Tashiro H., Itoh M.,
RA Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,
RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,
RA Fujiwaka S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,
RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,
RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
RT "RIKEN integrated sequence analysis (RISA) system-384-format
RT sequencing pipeline with 384 multicapillary sequencer.";
RL Genome Res. 10:1757-1771(2000).
RN [6]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Whole body;
RA Adachi J., Aizawa K., Akahira S., Akimura T., Arai A., Aono H.,
RA Arakawa T., Bono H., Carninci P., Fukuda S., Fukunishi Y., Furuno M.,
RA Hanagaki T., Hara A., Hayatsu N., Hiramoto K., Hiraoka T., Hori F.,
RA Imotani K., Ishii Y., Itoh M., Izawa M., Kasukawa T., Kato H.,
RA Kawai J., Kojima Y., Komori H., Kouda M., Koya S., Kurihara C.,
RA Matsuura T., Miyazaki A., Nishi K., Nomura K., Numazaki R., Ohno M.,
RA Okazaki Y., Okido T., Owa C., Saito H., Saito R., Sakai C., Sakai K.,
RA Sano H., Sasaki D., Shibata K., Shibata Y., Shinagawa A., Shiraki T.,
RA Sogabe Y., Suzuki H., Tagami M., Tagawa A., Takahashi F., Tanaka T.,
RA Tejima Y., Toya T., Yamamura T., Yasunishi A., Yoshida K., Yoshino M.,
RA Muramatsu M., Hayashizaki Y.;
RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK004478; BAB23323.1; -.
DR HSSP; 088792; 1F97.
DR MGD; MGI:1928009; 2210413P10Rik.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003598; Ig_c2.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00408; IGC2; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
SQ SEQUENCE 248 AA; 26061 MW; 3146D8F85BD3BD81 CRC64;

Query Match 58.6%; Score 988; DB 2; Length 248;
Best Local Similarity 62.3%; Pred. No. 2.3e-61;
Matches 202; Conservative 14; Mismatches 28; Indels 80; Gaps 1;

QY 1 LQPFPLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
Db 5 LVGAFLCGHLHGFVCLSG-----GLATLKLTDLRPSDTGTLYCNV 44
QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVLLQNPPPTGVATLKLTDVHPSDTGTYLCOV 120
Db 23 -----GLATLKLTDLRPSDTGTLYCNV 44
QY 121 NNPPDPFTYNTGLGLINLTVLVPPSNPLCSQSGTSGVSTALRCSSEGAPKPYNNWRVLG 180
Db 45 NNPPDPFTYNTGLGLINLTVLVPPSHPLCSQSGTSGVGSAAALGCRSSEGAPKPYNNWERLG 104
QY 181 TPPTSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNMGASCELTLSTVTPPQGRVA 240
Db 105 SSTPTPPGSMVQDEVSGQLILTNLSLTSSGTVCVATNMGASCELTLSTVTPPQGRVA 164
QY 241 GALIGVLLGVLLSVAAFCLVRPQKRGKKPKETYGSGDLREDALAPGISEHTCMRADSS 300
Db 165 GTLIGVLLGVLLSVAAFCLIRPQKRGKKPKETYGSGDLREDATAPGVFEQASMRADHS 224
QY 301 KGFLEPPSSASVTVTTKSLPMVY 324

```



```
Db 207 IVPKKNP--NPTTGLVIGLNTFNFEQGYQCTAINRLGNSSCEIDLTSSHPVGIIGA 264
QY 243 LIGVLGVLSSVAAPCLVRFO-----KERGKK 270
Db 265 LIGSLVGAII-ISVVCFAKAKAKAKERNK 296

RESULT 9
Q8N4F1
ID Q8N4F1 PRELIMINARY; PRT; 259 AA.
AC Q722Q1
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE D3889N15.1 (Novel protein similar to X. laevis Cortical Thymocyte
DE Marker CTX) (Fragment).
GN Name=D3889N15.1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Scapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smallos D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RA Strausberg R.;
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC034411; AAH34411.1; -.
DR HSSP; P78310; IEAJ.
DR Genew; HGNC:16669; IGSF11.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003598; IG_c2.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00408; IGC2; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
SQ SEQUENCE 430 AA; 46245 MW; E53FC71BC10D049D CRC64;

Query Match 23.7%; Score 399; DB 2; Length 259;
Best Local Similarity 34.2%; Pred. No. 4e-20;
Matches 89; Conservative 54; Mismatches 97; Indels 20; Gaps 9;

QY 21 VEKVTPELSTPLGTAELTCTYSTSVG--DSFALEWSFVQKPISSHPI-LYPT-N 76
Db 5 VQVTIPDGFVNVVGSNVTLICITYTTTASREQLSIQWSFFHK-----KEMEPISYFSQ 60
QY 77 GHLYPTGSKSKVSLQNPPPTGVATLKLTDVHPSDTGTYLCVNNPPDPFTYNGLGILN 136
Db 61 GQAVAIQGFKDRITGNDP---GNASITISHMPADSGIYICDVNNPPDFLQNGQGLNV 117
QY 137 TVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRL-GTFPTSPGSMVQDEV 195
Db 118 SVLVKPSKPLCSVQGRPETGHTTISLCSALGTPSPVYVHKLGRDIVPVKENF--NPT 175
QY 196 SGQILTLNLSLTSSGYRCVATNMQSGASCELTLSTVTEPPQGRVAGALIGVLGLLSV 255
Db 176 TGILVIGLNTFNFEQGYQCTAINRLGNSSCEIDLTSSHPVGIIGALISLVGAII-I 234
QY 256 AAFCLVRFO-----KERGKK 270
Db 235 SVVCFARNKAKAKAKERNK 254

RESULT 10
Q8N4F1
ID Q8N4F1 PRELIMINARY; PRT; 430 AA.
AC Q8N4F1
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Brain and testis-specific immunoglobulin superfamily protein.
GN Name=IGSF11;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
```

```
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Scapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smallos D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RA Strausberg R.;
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC034411; AAH34411.1; -.
DR HSSP; P78310; IEAJ.
DR Genew; HGNC:16669; IGSF11.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003598; IG_c2.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00408; IGC2; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
SQ SEQUENCE 430 AA; 46245 MW; E53FC71BC10D049D CRC64;

Query Match 23.3%; Score 392; DB 2; Length 430;
Best Local Similarity 32.6%; Pred. No. 2.2e-19;
Matches 105; Conservative 57; Mismatches 132; Indels 28; Gaps 13;

QY 10 LLGFCLCS--GLAVEVKVPTPEP--LSTPLGKTAELTCTYSTSVG--DSFALEWSFVQKGP 64
Db 7 LLWNCFSRTGVAASLEVSSESGSQVARGQTAVLCTFTTSAALINLVIV-MVTPLSN 65
QY 65 ISESHPILYFTNGHLYPTGSK-SKRVSLQNPPPTGVATLKLTDVHPSDTGTYLCVNNP 123
Db 66 ANQPEQVILYQGGQMPDGPAPRFGHGRVGTGTMPATNV-SIFINNTQLSDTGTQCLVNNL 124
QY 124 PFYNTNGLGLNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFP 183
Db 125 PDIGGRNIGVTGLTVLVPPSAPHCPQGGSDIGSDVILLCSSSEGIPTPYLWEKLDN-T 183
QY 184 TSPSGSMVQDEVSGQILTLNLSLTSSGYRCVATNMQSGASCELTLSTVTEP-PQ--GRVA 240
Db 184 LKLPPTATQDQVQGTVTIRNISALSSGLYQCVASNAIGTSTCLLDLOVISPQPNIGLIA 243
QY 241 GALIG----VLLGVLLLSVAAPCLVRFOKRGKKPKETYGSGDLRDAIAPGISEHTCMR 296
Db 244 GA-IGTGAVIIIFCIALILGAFF---YMRSKNKEEEEEETPNEIREDDLPP-----K 291
QY 297 ADSSKGFLEPPSSASIVTTTKS 318
Db 292 CGSAKAFHTEISSDNDNLTSS 313

RESULT 11
Q9D2J4
ID Q9D2J4 PRELIMINARY; PRT; 407 AA.
```


AC Q9D2J4;
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
 DE Mus musculus adult male testis cDNA, RIKEN full-length enriched
 DE library, clone:493040524 product:similar to D889N15.1 (NOVEL PROTEIN
 DE SIMILAR TO X. LAEVIS CORTICAL THYMOCYTE MARKER CTX).
 GN Name=493040524Rik;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Testis;
 RX MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;
 RA Carninci P., Hayashizaki Y.;
 RT "High-efficiency full-length cDNA cloning.";
 RL Meth. Enzymol. 303:19-44(1999).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Testis;
 RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;
 RA RIKEN FANTOM Consortium;
 RT "Functional annotation of a full-length mouse cDNA collection.";
 RL Nature 409:685-690(2001).
 RN [3]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Testis;
 RA The FANTOM Consortium;
 RA the RIKEN Genome Exploration Research Group Phase I & II Team;
 RT "Analysis of the mouse transcriptome based on functional annotation of
 RT 60,770 full-length cDNAs.";
 RL Nature 420:563-573(2002).
 RN [4]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Testis;
 RX MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;
 RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,
 RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
 RT "Normalization and subtraction of cap-trapper-selected cDNAs to
 RT prepare full-length cDNA libraries for rapid discovery of new genes.";
 RL Genome Res. 10:1617-1630(2000).
 RN [5]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Testis;
 RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;
 RA Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,
 RA Konno H., Akiyama J., Nishi K., Kiteunai T., Tashiro H., Itoh M.,
 RA Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,
 RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,
 RA Fujiwaka S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,
 RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsura S., Kawai J.,
 RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
 RT "RIKEN integrated sequence analysis (RISA) system-384-format
 RT sequencing pipeline with 384 multicapillary sequencer.";
 RL Genome Res. 10:1757-1771(2000).
 RN [6]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Testis;
 RX Adachi J., Aizawa K., Akahira S., Akimura T., Arai A., Aono H.,
 RA Arakawa T., Bono H., Carninci P., Fukuda S., Fukunishi Y., Furuno M.,
 RA Hanagaki T., Hara A., Hayatsu N., Hiramoto K., Hiraoka T., Hori F.,
 RA Imotani K., Ishii Y., Itoh M., Izawa M., Kasukawa T., Kato H.,
 RA Kawai J., Kojima Y., Konno H., Kouda M., Koya S., Kurihara C.,
 RA Matsuyama T., Miyazaki A., Nishi K., Nomura K., Numazaki R., Ohno M.,
 RA Okazaki Y., Okido T., Owa C., Saito H., Saito R., Sakai C., Sakai K.,
 RA Sano H., Sasaki D., Shibata K., Shibata Y., Shinagawa A., Shiraki T.,
 RA Sogabe Y., Suzuki H., Tagami M., Tagawa A., Takahashi F., Tanaka T.,
 RA Tejima Y., Toya T., Yamamura T., Yasunishi A., Yoshida K., Yoshino M.,
 RA Muramatsu M., Hayashizaki Y.;
 RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.
 RN EMBL; AK019565; BAB31795.1; -

DR HSP; P06907; INEU.
 DR MGD; MGI:1926039; 493040524Rik.
 DR GO; GO:0016020; C-membrane; IEA.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003598; Ig_c2.
 DR InterPro; IPR000920; Myelin_p0.
 DR Pfam; PF00047; Ig; 1.
 DR PRINTS; PR00213; MYELINP0.
 DR SMART; SM00408; IGC2; 1.
 DR PROSITE; PS00835; IGLIKE; 2.
 DR SEQUENCE 407 AA; 44014 MW; B7094F818B868680 CRC64;
 SQ
 Query Match 23.1%; Score 389.5; DB 2; Length 407;
 Best Local Similarity 29.2%; Pred. No. 3e-19;
 Matches 97; Conservative 62; Mismatches 134; Indels 39; Gaps 11;
 QY 15 CLSGLA--VEVKVPTPLSTPLGKTAELTCTYTSVG--DSFALEWSFVQPKPISHP 70
 DB ||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||||
 15 CLAGQVSMVQVTIPDFVNVTVGSNVTLLCLYTTTEKSLKLSIQNSFFH-NKEMEERPI 73
 QY 71 ILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYLCVNNPPDFYTN 130
 DB ||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||||
 74 IYSEGGQASAIQPKDRIIGATNP---GNASTILHMQPADSGIYICDVNNPPHFVGN 130
 QY 131 LGHINLTVLVPPNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRL-GTPTTPSPGS 189
 DB ||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||||
 131 QGLLDVTLVKPSKPFCTIQRPAGHPISLCSLSAFGTSPLYYWNIEGNTIVPKES 190
 QY 190 MVQDEVSGQLILNLTLTSSGTRCVATNOMGASCELTLSVTPEPPQGRVAGALIGVL 249
 DB ||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||||
 191 F--NTATGVLVIGNLNFEQYYOCTAINSGLNSSCEIDLTSSHPVEGIIGALV 248
 QY 250 VLLLSVAAFCLVRF--QKERGKPKETYGSDI-----REDAI-APGISEHTCMR 296
 DB ||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||||
 249 AAVI-----ICVYFARKVKSKQKLNLSSTLEPMTKVVHPQOSEAISADGVQLEGLT 304
 QY 297 ADSSKGFLEPSSASTV-----TTTK 317
 DB ||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||:||||
 305 SSIIHAGHNTTEPTTAVLEPEYEPNPPLTTTQ 336
 RESULT 12
 Q6DDE7
 ID Q6DDE7 PRELIMINARY; PRT; 432 AA.
 AC Q6DDE7;
 DT 25-OCT-2004 (TrEMBLrel. 28, Created)
 DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
 DE LOC445876 protein (Fragment).
 OS Names=LOC445876;
 GN Xenopus laevis (African clawed frog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidea; Pipidae;
 OC Xenopodinae; Xenopus.
 OX NCBI_TaxID=8355;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Brain;
 RX MEDLINE=22341132; PubMed=12454917; DOI=10.1002/dvdy.10174;
 RA Klein S.L., Strausberg R.L., Wagner L., Pontius J., Clifton S.W.,
 RA Richardson P.;
 RT "Genetic and genomic tools for Xenopus research: The NIH Xenopus
 RL Dev. Dyn. 225:384-391(2002).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Brain;
 RX PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Uedlin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skala U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [3]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RA Klein S., Gerhard D.S.;
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC077626; AAH77626.1; -.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003598; Ig_c2.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 2.
DR SMART; SM00409; IGC2; 2.
DR SMART; SM00406; IGV; 1.
DR SMART; SM00405; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
FT NON_TER 1
SQ SEQUENCE 432 AA; 47215 MW; ACFE78FOA4ED30E6 CRC64;

Query Match 21.3%; Score 359; DB 2; Length 432;
Best Local Similarity 31.9%; Pred. No. 4.4e-17;
Matches 103; Conservative 53; Mismatches 127; Indels 40; Gaps 13;

QY 6 LCGALLGFLCLSLGLAVEKVPTEPLSTPL--GKTAELTCTYSTSVG--DSFPALEWS---FV 59
Db LCGTITG-----AVSKVIVNRPVQVRRGSGVLLPCSFRTAAALNRLNIITWVSPLL 96
QY 60 QPKPISEHPILYFTNGHLYPTGSK--SKRVSLQNPPTVGVATLKLTDVHPSDTGYLC 118
Db QPQLPLQ-----VISYEQGVESVSEYTGVRVAFPHPTT--DASILINQSRSDTGYHC 150
QY 119 QVNNPPDFYTNGLGLNLTLVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVNWNVR 178
Db TVINPDPGTFNGLGLTLVLPSPNPLCSQSGSTALRCSSEGAPKPVNWNVR 210
QY 179 LGFTFPSPGSMV----QDEVSGQLITNLTLSSGTYRCVATNMGASCELTLVSV--- 231
Db I-----PGEFVLITSQEGDLQSVTLNNVTPRASGFYRCTVSNQLGSGQTPELHIQVA 265
QY 232 TEPPOGEVAGALIGVLLGVLLSVAARCLVRFQKERCKPKETVGGSDIREDIAIGISE 291
Db VLTSTGVGVGVALINGVVLALFAIVLHLHQSGR-----TWQDQELR-DCKIQGRRE 319
QY 292 HTCWRDSSKGFLEPSSASTVT 314
Db 320 EPEM--EGAKNTVSPGKRSEVT 340

RESULT 13

Q91664
ID Q91664 PRELIMINARY; PRT; 318 AA.
AC Q91664;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE CTX.
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidae; Pipidae;

OC Xenopodinae; Xenopus.
OX NCBI_TaxID=8355;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ff; TISSUE=Thymus;
RX MEDLINE=96210130; PubMed=8625968;
RA Chretien I., Robert J., Marcuz A., Garcia-Sanz J.A., Courtet M.,
RA Du Pasquier L.;
RT "CTX, a novel molecule specifically expressed on the surface of
RT cortical thymocytes in Xenopus.";
RL Eur. J. Immunol. 26:780-791(1996).
DR EMBL; U43330; AAC59899.1; -.
DR HSSP; P78310; IKAC.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00409; IG; 2.
DR PROSITE; PS50835; IG_LIKE; 2.
SQ SEQUENCE 318 AA; 34429 MW; 6231D24B0B806C09 CRC64;

Query Match 21.3%; Score 358.5; DB 2; Length 318;
Best Local Similarity 33.2%; Pred. No. 3.4e-17;
Matches 102; Conservative 52; Mismatches 112; Indels 41; Gaps 13;

QY 5 FLCGALLGFLCLSLGLA--VEVKVPTPLSTPLGKTAELTCTV--STSVGDSFPALEWSFVQ 60
Db 3 FLFTTLG--LSUTALSHCVQVTIQPIINVTSGQATLYCTYILNNQNNLVIQNNIFQ 61
QY 61 PGKPISEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYLCQV 120
Db AKSQNQET--VFFYQNGQSLGSPSYKNRVTAAMSP--GNATITISNMQSQDTGYTCEV 116
QY 121 NNPPDFYTNGLGLNLTLVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVNWNVR-- 179
Db LNLPE--SSQGGKILLTLVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVNWNVR 174
QY 180 -GTFPTSPGSMVQDEVSGQLITNLTLSSGTYRCVATNMGASCELTLVTEPPQGR 238
Db NGLLKS--TSPQNNQK--GSLIGNLTDFEYGYRTCTANNLGNATCELNLH--TGEGGV 230
QY 239 VAGALIGVLL--GVLLLSVAARCLV--RFQK-----ERKKPKETV 275
Db IAAAVIGGLAAAIIFAVFLVVKRQKQKLPPTKEMKTGGNOYMAVSGEANEPPKENL 290
QY 276 GGSDLRE 282
Db 291 GASEPTE 297

RESULT 14

Q9PWR4
ID Q9PWR4 PRELIMINARY; PRT; 335 AA.
AC Q9PWR4;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE CT1 thymocyte antigen precursor.
GN Name=ChT1;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=H.B19; TISSUE=Thymus;
RA Katevuo K.H., Boyd R., Gobel T.T., Bean A., Dunon D., Imhof B.A.,
RA Vainio O.;
RL Submitted (JUN-1997) to the EMBL/GenBank/DBJ databases.
DR EMBL; Y14064; CAA74391.1; -.
DR HSSP; P78310; IKAC.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.

```
DR PROSITE; PS50835; IG_LIKE; 2.
KW Signal.
FT SIGNAL 1 21 Potential.
FT CHAIN 22 335 Cht1 thymocyte antigen.
SQ SEQUENCE 335 AA; 36509 MW; AA61595980798438 CRC64;

Query Match 21.1%; Score 355; DB 2; Length 335;
Best Local Similarity 32.1%; Pred. No. 6.4e-17;
Matches 86; Conservative 52; Mismatches 116; Indels 14; Gaps 6;

QY 13 FLCLSGLA-----VEVKVPTPEPLSTPLGKTAELTCTYSTS--VGDSFALEWSFVQPGKPI 65
DB 9 FPIATLAGHVGVVTVPEKTVNKGATLLCTYTSSQPLG-NFFIQWSFYSAKE-- 65

QY 66 SESHPILYFTNGHLIPTGSKSRVSLQLQNPTVGATLKLTDVHPSDTGTYLCOVNNPPD 125
DB 66 SOLHTIYYSEGQSYSGEKFDRITAATSP---GNASITISNMQPSDTGSGYTCVFSPQD 122

QY 126 FYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTP 185
DB 123 DAGQSKSVIVNVLVPSKPKFKIEGTPKGHLYLLCKCDQGLPHPTIRYWKVDE-NTL 181

QY 186 SPGSMVQDEVSGQLILNLSLTSSGTYRCVATNMGASCELTLTSLVTEPPQGRVAGALIG 245
DB 182 TPVTEYFNPDGTILYIGNLTTFETGHYRCIASNMGNSCTCELDLTSMHSDGNI VAGALIG 241

QY 246 VLLGVLLSVAAFCLVRFQKRGKKPK 273
DB 242 AILAAVILCAIVWLTKKAKKKSSNE 269

RESULT 15
QYGH1
ID QYGH1 PRELIMINARY; PRT; 335 AA.
AC QYGH1;
DT 01-MAY-1999 (TrEMBLrel. 10, Created)
DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Cht1 thymocyte antigen precursor.
GN Name=Cht1;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=RPRL line 0; TISSUE=Thymus;
RA Katevuo K.H., Boyd R., Gobel T.T., Bean A., Dunon D., Imhof B.A.,
RA Vainio O.;
DR EMBL; Y14063; CAA74390.1; --
DR HSSP; P78310; IKAC.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
KW Signal.
FT SIGNAL 1 21 Potential.
FT CHAIN 22 335 Cht1 thymocyte antigen.
SQ SEQUENCE 335 AA; 36553 MW; AA640C5CD02CB16D CRC64;

Query Match 20.9%; Score 352; DB 2; Length 335;
Best Local Similarity 32.1%; Pred. No. 1e-16;
Matches 86; Conservative 52; Mismatches 116; Indels 14; Gaps 6;

QY 13 FLCLSGLA-----VEVKVPTPEPLSTPLGKTAELTCTYSTS--VGDSFALEWSFVQPGKPI 65
DB 9 FPIATLAGHVGVVTVPEKTVNKGATLLCTYTSSQPLG-NFFIQWSFYSAKE-- 65

QY 66 SESHPILYFTNGHLIPTGSKSRVSLQLQNPTVGATLKLTDVHPSDTGTYLCOVNNPPD 125
DB 66 SOLHTIYYSEGQSYSGEKFDRITAATSP---GNASITISNMQPSDTGSGYTCVFSPQD 122

QY 126 FYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTP 185
DB 123 DAGQSKSVIVNVLVPSKPKFKIEGTPKGHLYLLCKCDQGLPHPTIRYWKVDE-NTL 181

QY 186 SPGSMVQDEVSGQLILNLSLTSSGTYRCVATNMGASCELTLTSLVTEPPQGRVAGALIG 245
DB 182 TPVTEYFNPDGTILYIGNLTTFETGHYRCIASNMGNSCTCELDLTSMHSDGNI VAGALIG 241

QY 246 VLLGVLLSVAAFCLVRFQKRGKKPK 273
DB 242 AILAAVILCAIVWLTKKAKKKSSNE 269

Search completed: August 4, 2005, 06:13:28
Job time : 90.5513 secs
```

This Page Blank (uspto)

disorders related to the secreted proteins. The proteins, and polynucleotide sequences may be useful for treating disorders of the immune system, hyperproliferative disorders, infectious disease, regeneration of tissues, for chemotaxis and for screening molecules that bind to the proteins. The proteins or polynucleotide sequences may be used as food additives or preservatives, to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, co-factors or other nutritional components. Agonists or antagonists of the proteins may be used to prevent scar tissue growth during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051 and AAB08890 are sequences used in the exemplification of the present invention

XX Sequence 327 AA;

Query Match 99.6%; Score 1692; DB 3; Length 327;
 Best Local Similarity 99.7%; Pred. No. 7.4e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTLYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTLYL 120

QY 121 CQVNNPPDFYTNGLGILNLTIVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
 DB 121 CQVNNPPDFYTNGLGILNLTIVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180

QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSVTBPPOG 240
 DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSVTBPPOG 240

QY 241 RVAGALIGVLLGVLLLSVAACFLVRQKRGKPKETYGSGDLREDAIAPGISEHTCMRA 300
 DB 241 RVAGALIGVLLGVLLLSVAACFLVRQKRGKPKETYGSGDLREDAIAPGISEHTCMRA 300

QY 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327
 DB 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327

RESULT 2

AA87251
 ID AAY87251 standard; protein; 327 AA.
 XX
 AC AAY87251;
 XX
 DT 11-MAY-2000 (first entry)
 XX
 DE Human signal peptide containing protein HSPP-28 SEQ ID NO:28.
 XX
 KW Human; signal peptide-containing protein; HSPP; diagnosis; cancer;
 KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
 KW antimicrobial; neuroprotection; cardiovascular; hepatotropic;
 KW antiasthmatic; gene therapy; cell proliferation; neurological disorder;
 KW reproductive disorder; developmental disorder; arteriosclerosis;
 KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
 KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
 KW muscular dystrophy.
 XX
 OS Homo sapiens.
 XX
 PN W020000610-A2.
 XX
 PD 06-JAN-2000.
 XX
 XX 25-JUN-1999; 99WO-US014484.
 XX
 XX 26-JUN-1998; 98US-0090762P.
 PR

PR 31-JUL-1998; 98US-0094983P.
 PR 01-OCT-1998; 98US-0102686P.
 PR 11-DEC-1998; 98US-0112129P.
 XX
 PA (INCY-) INCYTE PHARM INC.
 XX
 PI Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
 PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
 PI Bandman O;
 XX
 XX WPI; 2000-160673/14.
 DR N-PSDB; ANZ98136.
 XX
 PT New human signal peptide-containing proteins useful in treatment,
 PT prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
 PT disease.
 XX
 PS Claim 1; Page 177-178; 327pp; English.

CC AA298109 to AA298242 encode AAY87224 to AAY87357 which represent the
 CC human signal peptide-containing proteins HSPP-1 to HSPP-134. HSPPs have
 CC anticancer, anti-inflammatory, antimicrobial, nontoxic, hepatotropic,
 CC neuroprotective, cardiovascular and antiasthmatic activities, and can be
 CC used in gene therapy. HSPPs can be used to treat or prevent disorders
 CC associated with decreased activity or function of HSPP. Antagonists of
 CC HSPP are used to treat or prevent disorders associated with increased
 CC activity or function of HSPP. Such diseases include cell proliferation
 CC (including cancer), inflammation, cardiovascular, neurological,
 CC reproductive or developmental disorders, (e.g. arteriosclerosis,
 CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
 CC asthma, Crohn's disease, microbial or other infections, congestive or
 CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
 CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSPP
 CC nucleic acids can be used for the recombinant production of HSPP, for
 CC detecting HSPP in standard hybridisation and amplification assays (for
 CC diagnosis and monitoring), in gene therapy, as antisense, triplex-forming
 CC or ribozyme therapeutics, for detecting related sequences or genetic
 CC variations, and for chromosomal mapping. HSPP are also used to raise
 CC specific antibodies (Ab) and to screen for agonists and antagonists
 CC (potential therapeutic agents). Ab are used to diagnose, or monitor, HSPP
 CC -related diseases (in usual immunoassays), as therapeutic antagonists, in
 CC competitive drug screens, and for purification of HSPP from natural
 CC sources
 XX

XX Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 3; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTLYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTLYL 120

QY 121 CQVNNPPDFYTNGLGILNLTIVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
 DB 121 CQVNNPPDFYTNGLGILNLTIVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180

QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSVTBPPOG 240
 DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSVTBPPOG 240

QY 241 RVAGALIGVLLGVLLLSVAACFLVRQKRGKPKETYGSGDLREDAIAPGISEHTCMRA 300
 DB 241 RVAGALIGVLLGVLLLSVAACFLVRQKRGKPKETYGSGDLREDAIAPGISEHTCMRA 300

QY 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327
 DB 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327

RESULT 3

AA94857
ID AA94857 standard; protein; 327 AA.

XX
AC AA94857;

XX
DT 12-JUN-2000 (first entry)

XX
DE Human protein clone HP10568.

XX
KW Human protein; hydrophobic domain; nutritional source; haematopoiesis;
KW cytokine production; cell proliferation; cell differentiation;
KW immune deficiency; infectious disease; autoimmune disorder; asthma;
KW multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis;
KW allergic reaction; osteoporosis; osteoarthritis; periodontal disease;
KW nervous system disorder; Alzheimer's disease; Parkinson's disease;
KW Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury;
KW systemic cytokine damage; tissue differentiation; contraceptive; stroke;
KW coagulation disorder; myocardial infarction; inflammatory condition;
KW septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour;
KW nephritis; therapy.

XX
OS Homo sapiens.

XX
PN WO200005367-A2.

XX
PD 03-FEB-2000.

XX
PF 22-JUL-1999; 99WO-JP003929.

XX
PR 24-JUL-1998; 98JP-00208820.

XX
PR 07-AUG-1998; 98JP-00224105.

XX
PR 25-AUG-1998; 98JP-00238116.

XX
PR 03-SEP-1998; 98JP-00254736.

XX
PR 29-SEP-1998; 98JP-00275505.

XX
PA (SAGA) SAGAMI CHEM RES CENT.

XX
PI (PROT-) PROTEGENE INC.

XX
PI Kato S, Kimura T;

XX
PI WPI; 2000-182694/16.

XX
PT Novel human proteins having hydrophobic domains useful for treating

XX
PT osteoporosis, Alzheimer's disease, Parkinson's disease, asthma, multiple

XX
PT sclerosis, rheumatoid arthritis, cancer, anemia, and stroke.

XX
PS Claim 1; Page 183-184; 351pp; English.

XX
CC This sequence represents a human protein of the invention, which has
CC hydrophobic domains. The DNA sequences can be used as a probe or as a
CC genetic marker. The protein can also be used as a marker, and to identify
CC potential genetic disorders. The DNA and protein can also be used as
CC nutritional sources or supplements. The protein exhibits cytokine, cell
CC proliferation, cell differentiation activities and induces production of
CC other cytokines in certain cell populations. The protein also exhibits
CC immune stimulating or immune suppressing activity. It can be used in the
CC treatment of various immune deficiencies and disorders, and to treat
CC infectious diseases caused by viral, bacterial, fungal or other
CC infections. The protein is also used for treating autoimmune disorders
CC such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid
CC arthritis. It is also useful in the treatment of allergic reactions and
CC conditions such as asthma, and in immune suppression after organ
CC transplantation. The protein is useful in regulation of haematopoiesis
CC and consequently in the treatment of myeloid or lymphoid cell
CC deficiencies. It is also used in compositions for tissue growth or
CC regeneration. The protein is also used in the treatment of osteoporosis
CC or osteoarthritis and in the treatment of periodontal disease and other
CC tooth repair processes. The protein is used in the treatment of nervous
CC system disorders such as Alzheimer's disease, Parkinson's disease, and
CC Huntington's disease. They are useful for protection or regeneration and

CC treatment of lung or liver fibrosis, reperfusion injury in various
CC tissues, and conditions resulting from systemic cytokine damage. They are
CC also used for promoting or inhibiting tissue differentiation. They are
CC also used as contraceptives since they exhibit activin or inhibin related
CC activities and as a fertility inducing therapeutic. They are used for
CC treating various coagulation disorders and in treatment and prevention of
CC conditions resulting from coagulation activities e.g. myocardial
CC infarction or stroke. They also acts as receptors, receptor ligands or
CC inhibitors or agonists of receptor/ligand interactions. They are used to
CC treat inflammatory conditions such as septic shock, sepsis, ischaemia
CC reperfusion injury, arthritis, and nephritis. They can be used to prevent
CC tumours

XX
SQ Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 3; Length 327;
Best Local Similarity 99.7%; Pred. No. 8.8e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAEALTCTYSTVSGDSFALEWS 60
DB 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAEALTCTYSTVSGDSFALEWS 60
QY 61 FVQPGKPISSHPILYFTNGHLYPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGYL 120
DB 61 FVQPGKPISSHPILYFTNGHLYPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGLINLTIVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVNVW 180
DB 121 CQVNNPPDFYTNGLGLINLTIVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVNVW 180
QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASACELTSLVTEPQG 240
DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASACELTSLVTEPQG 240
QY 241 RVAGALIGVLLGVLLLSVAAAFCLVRFOKRGKPKETYGSGDLREDIAFGISEHTCMRA 300
DB 241 RVAGALIGVLLGVLLLSVAAAFCLVRFOKRGKPKETYGSGDLREDIAFGISEHTCMRA 300
QY 301 DSSKGFLERPSSASTVTTTKSLPMVW 327
DB 301 DSSKGFLERPSSASTVTTTKSLPMVW 327

RESULT 4

AA97585
ID AA97585 standard; protein; 327 AA.

XX
AC AA97585;

XX
DT 05-APR-2001 (first entry)

XX
DE Human secreted protein PRO7154.

XX
KW Secreted protein; human; PRO protein; neoplastic cell growth; tumour;
KW proliferation; leukaemia; lymphoid malignancy; inflammatory disorder;
KW angiogenic disorder; immunologic disorder; PRO7154.

XX
OS Homo sapiens.

XX
PN WO2000075317-A2.

XX
PD 14-DEC-2000.

XX
PF 15-MAY-2000; 2000WO-US013358.

XX
PR 09-JUN-1999; 99US-0138385P.

XX
PR 20-JUL-1999; 99US-0144790P.

XX
PR 03-AUG-1999; 99US-0146843P.

XX
PR 10-AUG-1999; 99US-0148188P.

XX
PR 17-AUG-1999; 99US-0149320P.

XX
PR 17-AUG-1999; 99US-0149327P.

XX
PR 17-AUG-1999; 99US-0149396P.

PR 20-AUG-1999; 99US-0150114P.
 PR 31-AUG-1999; 99US-0151700P.
 PR 31-AUG-1999; 99US-0151734P.
 XX
 PA (GETH) GENENTECH INC.
 PI Botstein DA, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
 XX WPI; 2001-071075/08.
 DR N-PSDB; AAA91019.
 XX
 XX Antibodies against PRO polypeptides, useful for diagnosing and treating
 PT tumors are associated with gene amplification, neoplastic cell growth and
 PT proliferation in mammals.
 XX
 XX Claim 61; Fig 12; 143pp; English.
 XX
 CC This sequence is a human PRO protein of the invention. The PRO proteins
 CC are secreted proteins. Antagonists or antibodies of PRO polypeptides are
 CC useful for diagnosing and treating tumors are associated with gene
 CC amplification, neoplastic cell growth and proliferation in mammals, and
 CC those conditions characterised by overexpression and/or activation of the
 CC amplified genes. Such conditions include benign or malignant tumours
 CC (e.g. renal, liver, kidney, bladder, breast, gastric, ovarian,
 CC colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic
 CC carcinomas, sarcomas, glioblastomas and various head and neck tumours);
 CC leukaemias and lymphoid malignancies; neuronal, glial, astrocytal,
 CC hypochalamic, and other glandular, macrophageal, epithelial, stromal and
 CC blastocoeleic disorders; and inflammatory, angiogenic and immunologic
 CC disorders. These may further be used to qualitatively or quantitatively
 CC detect the expression of proteins encoded by the amplified genes, and in
 CC tumour diagnostics or prognostics. The PRO polypeptide or its antagonist
 CC may be used for the preparation of a medicament in the treatment of a
 CC condition, which is responsive to the PRO polypeptide, its antagonist or
 CC anti-PRO antibody
 XX
 SQ Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 4; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 MAELPGPFCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVOPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTLYL 120
 DB 61 FVOPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTLYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLPVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLPVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 QY 181 RLGTFTPPSGMWQDEVSQGLILTNLSLTSSGTYRCVATNMGASCELTLTSVTEPPQG 240
 DB 181 RLGTFTPPSGMWQDEVSQGLILTNLSLTSSGTYRCVATNMGASCELTLTSVTEPPQG 240
 QY 241 RVAGALIGVLGVLILLSVAACFLVRFOKERGKKPKETYGGSDLRDAIAPGISEHTCMRA 300
 DB 241 RVAGALIGVLGVLILLSVAACFLVRFOKERGKKPKETYGGSDLRDAIAPGISEHTCMRA 300
 QY 301 DSSKGFLERPSSASTVTTTKSKLPMVV 327
 DB 301 DSSKGFLERPSSASTVTTTKSKLPMVV 327

RESULT 5
 ID ABB90354
 AC ABB90354 standard; protein; 327 AA.
 XX
 XX ABB90354;
 XX

DT 24-MAY-2002 (first entry)
 XX Human polypeptide SEQ ID NO 2730.
 XX
 KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
 KW antiatheric; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
 KW vulnary; anticonvulsant; antibacterial; antifungal; antiparasitic;
 KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
 KW neurological disease; infection; human; secreted protein.
 XX
 OS Homo sapiens.
 XX
 XX WO200190304-A2.
 XX
 XX 29-NOV-2001.
 XX
 XX 18-MAY-2001; 2001WO-US016450.
 XX
 XX 19-MAY-2000; 2000US-0205515P.
 XX
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Birse CE, Rosen CA;
 XX
 DR WPI; 2002-122018/16.
 DR N-PSDB; ABL90763.
 XX
 PT Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
 PT prevention of neural, immune system, muscular, reproductive,
 PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative
 PT disorders.
 XX
 PS Claim 11; SEQ ID NO 2730; 2081pp + Sequence Listing; English.
 XX
 CC The invention relates to novel genes (ABL9449-ABL90853) and proteins
 CC (ABB9040-ABB90444) useful for preventing, treating or ameliorating
 CC medical conditions e.g. by protein or gene therapy. The genes are
 CC isolated from a range of human tissues disclosed in the specification.
 CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in
 CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
 CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
 CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
 CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
 CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
 CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
 CC cardiovascular disorders such as myocardial ischaemia; (d) wound healing
 CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
 CC infectious diseases such as viral, bacterial, fungal and parasitic
 CC infections. Note: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 5; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 MAELPGPFCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVOPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTLYL 120
 DB 61 FVOPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTLYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLPVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLPVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 QY 181 RLGTFTPPSGMWQDEVSQGLILTNLSLTSSGTYRCVATNMGASCELTLTSVTEPPQG 240
 DB 181 RLGTFTPPSGMWQDEVSQGLILTNLSLTSSGTYRCVATNMGASCELTLTSVTEPPQG 240

QY 241 RVAGALIGVLLGVLLLSVAACFLVRFQKRGKKPKETGGSDLRDAIAPGISEHTCMRA 300
DB 241 RVAGALIGVLLGVLLLSVAACFLVRFQKRGKKPKETGGSDLRDAIAPGISEHTCMRA 300
QY 301 DSSKGFLERPSSASTVTTTKSLPMVV 327
DB 301 DSSKGFLERPSSASTVTTTKSLPMVV 327

RESULT 6
AAU83709
ID AAU83709 standard; protein; 327 AA.

AC AAU83709;

XX 08-MAY-2002 (first entry)

XX Human PRO protein, Seq ID No 236.

XX Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
KW breast cancer; prostate tumour; rectal tumour; liver tumour;
KW pericyte cell proliferation; chondrocyte cell proliferation;
KW tumour necrosis factor-alpha.

OS Homo sapiens.

XX WO200208288-A2.

XX 31-JAN-2002.

XX 29-JUN-2001; 2001WO-US021066.

XX 20-JUL-2000; 2000US-0219556P.

XX 25-JUL-2000; 2000US-0220585P.

XX 25-JUL-2000; 2000US-0220605P.

XX 25-JUL-2000; 2000US-0220607P.

XX 25-JUL-2000; 2000US-0220624P.

XX 25-JUL-2000; 2000US-0220638P.

XX 25-JUL-2000; 2000US-0220664P.

XX 25-JUL-2000; 2000US-0220666P.

XX 26-JUL-2000; 2000US-0220893P.

XX 28-JUL-2000; 2000WO-US020710.

XX 01-AUG-2000; 2000US-022425P.

XX 22-AUG-2000; 2000US-0227133P.

XX 23-AUG-2000; 2000WO-US023522.

XX 24-AUG-2000; 2000WO-US023328.

XX 10-NOV-2000; 2000WO-US030873.

XX 28-NOV-2000; 2000US-0253646P.

XX 01-DEC-2000; 2000WO-US032678.

XX 20-DEC-2000; 2000US-00747259.

XX 20-DEC-2000; 2000WO-US034956.

XX 28-FEB-2001; 2001WO-US006520.

XX 01-MAR-2001; 2001WO-US006666.

XX 22-MAR-2001; 2001US-00816744.

XX 10-MAY-2001; 2001US-00854208.

XX The invention relates to one hundred and twenty two nucleic acids
CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
CC encode human secreted proteins. The PRO nucleic acids, polypeptides,
CC agonists and antagonists are useful for treating a PRO related disorder.
CC The PRO polypeptides are useful for diagnosing tumours, especially lung
CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. The PRO polypeptides are useful for stimulating the
CC proliferation of, or gene expression, in pericyte cells, for stimulating
CC the proliferation or differentiation of chondrocyte cells, for
CC stimulating the release of tumour necrosis factor-alpha from human blood,
CC for stimulating or inhibiting the proliferation of normal human dermal
CC fibroblast cells. The PRO polypeptide may also be used as molecular
CC weight markers and for tissue typing. The PRO nucleic acids have
CC applications in molecular biology, including use as hybridisation probes,
CC and in chromosome and gene mapping. AAU83592-AAU83713 represent human PRO
CC protein sequences of the invention
XX
SQ Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 5; Length 327;
Best Local Similarity 99.7%; Pred. No. 8.8e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGFPCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVGDSFALEWS 60
DB 1 MAELPGFPCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVGDSFALEWS 60
QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPTVGVAATLKLTDVHPSDGTYL 120
DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPTVGVAATLKLTDVHPSDGTYL 120
QY 121 CQVNNPDPFYTGGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSGSGAPKPVNVW 180
DB 121 CQVNNPDPFYTGGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSGSGAPKPVNVW 180
QY 181 RLGTFTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSVTEPPQG 240
DB 181 RLGTFTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSVTEPSQG 240
QY 241 RVAGALIGVLLGVLLLSVAACFLVRFQKRGKKPKETGGSDLRDAIAPGISEHTCMRA 300
DB 241 RVAGALIGVLLGVLLLSVAACFLVRFQKRGKKPKETGGSDLRDAIAPGISEHTCMRA 300
QY 301 DSSKGFLERPSSASTVTTTKSLPMVV 327
DB 301 DSSKGFLERPSSASTVTTTKSLPMVV 327

RESULT 7

ABU80856
ID ABU80856 standard; protein; 327 AA.
XX
AC ABU80856;
XX
DT 23-JUN-2003 (first entry)
XX
XX Human PRO polypeptide #118.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW anti-PRO antibody; diagnostic assay; gene expression; tumour; cytostatic.
XX Homo sapiens.
XX
XX US2003036635-A1.
XX
XX 20-FEB-2003.
XX
XX 28-AUG-2002; 2002US-00230163.
XX
XX 25-JUL-2000; 2000US-0220638P.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.

(GETH) GENENTECH INC.

BAKER KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

WPI; 2002-172001/22.

DR N-PSDB; ABK33653.

XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for treating a PRO related disorder and for diagnosing tumors such
PT as lung cancer, colon cancer, breast tumor, prostate tumor, rectal tumor
PT or liver tumor.

XX Claim 11; Fig 236; 359pp; English.

PS

PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-342045/32.
DR N-PSDB; ACA66958.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for the manufacture of a medicament for diagnosing or treating
PT tumor.
XX
XX Claim 11; Fig 236; 314pp; English.
XX
XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides and polynucleotides are useful for preparing a medicament
CC useful in the diagnosis and treatment of tumours. Anti-PRO antibodies are
CC useful in diagnostic assays for PRO, by detecting its expression in
CC specific cells, tissues or serum, and for affinity purification of PRO
CC from recombinant cell culture or natural sources. ABU80739-ABU80860
CC represent the human PRO polypeptides of the invention. Note: The sequence
CC data for this patent was obtained in electronic format directly from the
CC USPTO web site at seqdata.uspto.gov/psipeDIDEntry.html
XX
XX Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 8.8e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAEITCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAEITCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDYFTNGLGLINLTVPSPNPLCSQSGQTSVSGSTALRCSSEGAPKPYNNV 180
Db 121 CQVNNPPDYFTNGLGLINLTVPSPNPLCSQSGQTSVSGSTALRCSSEGAPKPYNNV 180
QY 181 RLGTFTTSPSGMVQDEVSGQLLTNLSTSSGTYRCVATNQMSASCELTLSVTEPPQG 240
Db 181 RLGTFTTSPSGMVQDEVSGQLLTNLSTSSGTYRCVATNQMSASCELTLSVTEPPQG 240
QY 241 RVAGALIGVLLGVLSSVAACFLVRQKRGKKPKETYGGSDLRDADAIAPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLSSVAACFLVRQKRGKKPKETYGGSDLRDADAIAPGISEHTCMRA 300
QY 301 DSKGFLERPSSASTVTTTKSLPMVV 327
Db 301 DSKGFLERPSSASTVTTTKSLPMVV 327

RESULT 8
ABO33822
ID ABO33822 standard; protein; 327 AA.
XX
XX ABO33822;
DT 17-SEP-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO7154.
DE Human; secreted and transmembrane protein; PRO; cytostatic;
KW antithetic; osteopathic; gene therapy; TNF-Agonist-Alpha;
KW chondrocyte stimulator; pericyte stimulator; fibroblast modulator;
KW pharmaceutical; diagnostic; biosensor; bioreactor; tumour; lung tumour;

KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; bone disorder; cartilage disorder; sports injury;
XX arthritis; wound.
XX Homo sapiens.
XX US2003045687-A1.
XX 06-MAR-2003.
XX
XX 12-AUG-2002; 2002US-00218631.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-512315/48.
XX N-PSDB; ACD68710.
XX
XX New genes, and its encoded secreted and transmembrane polypeptides,
PT useful for stimulating Tumor Necrosis Factor alpha, or chondrocyte or
PT pericyte proliferation, especially for treating lung tumors, arthritis or
PT wounds in a mammal.
XX
XX Claim 11; Fig 236; 314pp; English.

The invention describes an isolated nucleic acid molecule comprising a
sequence with at least 80% identity to: (a) a nucleotide encoding any of
122 PRO (secreted and transmembrane) polypeptides whose sequences are
fully defined in the specification; or (b) any of 122 nucleotide
sequences having e.g. 4834, 2504 or 1759 bp fully defined in the
specification; or the full length coding sequence of any these 122
nucleotide sequences. The PRO polypeptides or polynucleotides are useful
as pharmaceuticals, diagnostics, biosensors or bioreactors. These are
particularly useful for detecting tumours (e.g. lung tumour, colon
tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)
in a mammal, for stimulating the release of TNF-alpha from human blood,
for stimulating the proliferation or differentiation of chondrocyte
cells, for stimulating proliferation of pericyte cells, or for modulating
normal human dermal fibroblast proliferation. The PRO nucleic acid or
polypeptide is also useful for treating tumours or various bone and/or
cartilage disorders (e.g. sports injuries or arthritis), or wounds. The
PRO polypeptides are useful in drug screening, particularly as targets
for therapeutic intervention in these diseases, and in the diagnostic
determination of the presence of these diseases. The PRO polypeptides are
also useful as molecular weight markers, or for chromosome
identification. The PRO genes are useful as hybridisation probes, or for
screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
also be used in gene therapy, particularly for replacing a defective
gene. This is the amino acid sequence of a novel human secreted and
transmembrane PRO polypeptide

Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 8.8e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAEITCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAEITCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDYFTNGLGLINLTVPSPNPLCSQSGQTSVSGSTALRCSSEGAPKPYNNV 180
XX
XX Sequence 327 AA;

Db 121 CQVNNPPDYFTNGGLINLTVLPPSNPLCSQSQTSGVSTALRCSSEGAPEPVNVW 180
Qy 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTSLVTEPPQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTSLVTEPPQG 240
Qy 241 RVAGALIGVLLGVLLSVAAPCLVRFQKRGKKPKETVGGSDLRDAIAPGISHTCMRA 300
Db 241 RVAGALIGVLLGVLLSVAAPCLVRFQKRGKKPKETVGGSDLRDAIAPGISHTCMRA 300
Qy 301 DSSKGFLERPSSASTVTTTKSKLPMVV 327
Db 301 DSSKGFLERPSSASTVTTTKSKLPMVV 327
RESULT 9
ABU82165
ID ABU82165 standard; protein; 327 AA.
XX AC ABU82165;
XX DT 25-JUN-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO7154.
XX KW Human; secreted and transmembrane protein; PRO; cardiant; cytostatic;
KW antiangiogenic; hypotensive; vulnery; antiarteriosclerotic;
KW gene therapy; cardiovascular disorder; endothelial disorder;
KW angiogenic disorder; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; atherosclerosis; hypertension;
KW arterial restenosis; rheumatoid arthritis; angina; myocardial infarction;
KW thrombophlebitis; lymphangitis; tumour angiogenesis; breast carcinoma;
KW liver carcinoma; wound healing; chromosome mapping; gene mapping.
XX OS Homo sapiens.
XX PN US2003088063-A1.
XX PD 08-MAY-2003.
XX PF 12-AUG-2002; 2002US-00219003.
XX PR 25-JUL-2000; 2000US-0220664P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX DR WPI; 2003-393229/37.
DR N-PSDB; ACA68614.
XX PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.
XX PS Claim 11; Fig 236; 314pp; English.
XX CC The invention describes one hundred and eighty seven nucleic acids
CC encoding novel human secreted and transmembrane (PRO) polypeptides. The
CC PRO nucleic acids, polypeptides, agonists and antagonists are useful for
CC treating or diagnosing a cardiovascular, endothelial or angiogenic
CC disorder in a mammal, e.g. cardiac hypertrophy, trauma, cancer, age-
CC related macular degeneration, atherosclerosis, hypertension, arterial
CC restenosis, rheumatoid arthritis, angina, myocardial infarctions,
CC thrombophlebitis, lymphangitis, tumour angiogenesis (such as breast
CC carcinoma and liver carcinoma) and wound healing. The PRO nucleic acids
CC have applications in molecular biology, including use as hybridisation
CC probes, and in chromosome and gene mapping. This is the amino acid
CC sequence of a novel human secreted and transmembrane PRO polypeptide

XX SQ Sequence 327 AA;
Query Match 99.5%; Score 1691; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 8.8e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 MAELPGPFLCGALIGFLCLSGLAVEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGPFLCGALIGFLCLSGLAVEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Qy 61 FVQPGKPISSHPILYFTNGHLVPTGSKSRVSLLONPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISSHPILYFTNGHLVPTGSKSRVSLLONPPTVGATLKLTDVHPSDTGYL 120
Qy 121 CQVNNPPDYFTNGGLINLTVLPPSNPLCSQSQTSGVSTALRCSSEGAPEPVNVW 180
Db 121 CQVNNPPDYFTNGGLINLTVLPPSNPLCSQSQTSGVSTALRCSSEGAPEPVNVW 180
Qy 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTSLVTEPPQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTSLVTEPPQG 240
Qy 241 RVAGALIGVLLGVLLSVAAPCLVRFQKRGKKPKETVGGSDLRDAIAPGISHTCMRA 300
Db 241 RVAGALIGVLLGVLLSVAAPCLVRFQKRGKKPKETVGGSDLRDAIAPGISHTCMRA 300
Qy 301 DSSKGFLERPSSASTVTTTKSKLPMVV 327
Db 301 DSSKGFLERPSSASTVTTTKSKLPMVV 327
RESULT 10
ABJ72345
ID ABJ72345 standard; protein; 327 AA.
XX AC ABJ72345;
XX DT 06-NOV-2003 (first entry)
XX DE Human PRO7154 protein.
XX KW PRO; proliferation; pericyte cell; TNF-alpha; blood; chondrocyte;
KW differentiation; dermal fibroblast; tumour; gene therapy; cytostatic.
XX OS Homo sapiens.
XX PN US2003050448-A1.
XX PD 13-MAR-2003.
XX PF 28-AUG-2002; 2002US-00230414.
XX PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX DR WPI; 2003-521818/49.
DR N-PSDB; ABT44343.
XX PT New nucleic acid encoding for a PRO protein, useful for the manufacture
PT of a medicament for diagnosing or treating tumors or for measuring or
PT detecting expression of an associated gene.
XX PS Claim 11; Fig 236; 315pp; English.
XX CC The invention relates to a novel isolated nucleic acid encoding a fully
CC defined PRO polypeptide. The molecules of the invention may be useful for

CC stimulating proliferation or gene expression in pericyte cells or the
 CC release of TNF-alpha from human blood. Other possible uses include the
 CC stimulation or inhibition of chondrocyte proliferation or
 CC differentiation, the stimulation of human dermal fibroblast cell
 CC proliferation and the detection of the presence of a tumour within a
 CC mammal. Furthermore, the nucleic acid may be useful for the manufacture
 CC of a medicament for diagnosing or treating a tumour within a mammal or
 CC for measuring or detecting the expression of an associated gene, as well
 CC as during gene therapy. The current sequence is that of the human PRO
 CC protein of the invention
 XX
 SQ Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 6; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
 DB 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
 QY 121 CQVNNPPDFYNTGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
 DB 121 CQVNNPPDFYNTGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
 QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLSTVTEPPOG 240
 DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLSTVTEPPOG 240
 QY 241 RVAGALIGVLLGVLVLSVAACFLVRQKRGKPKETYGGSDLRDAIAPGISEHTCMRA 300
 DB 241 RVAGALIGVLLGVLVLSVAACFLVRQKRGKPKETYGGSDLRDAIAPGISEHTCMRA 300
 QY 301 DSSKGFLERPSSASTVTTTTSKLPMMV 327
 DB 301 DSSKGFLERPSSASTVTTTTSKLPMMV 327

RESULT 11
 ABJ72473
 ID ABJ72473 standard; protein; 327 AA.

XX AC ABJ72473;
 XX DT 06-NOV-2003 (first entry)
 XX DE Human PRO7154 protein.
 XX KW PRO; blood; proliferation; pericyte cell; TNF alpha; chondrocyte;
 XX KW tumour necrosis factor; proliferation; differentiation; gene therapy;
 XX KW dermal fibroblast.

XX OS Homo sapiens.
 XX PN US2003027988-A1.
 XX PD 06-FEB-2003.
 XX XX 26-AUG-2002; 2002US-00227884.
 XX PR 01-JUN-2001; 2001WO-US017800.
 XX PR 29-JUN-2001; 2001WO-US021066.
 XX PR 03-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.
 XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

DR WPI; 2003-503301/47.
 DR N-PSDB; ABT44626.
 XX
 PT New PRO protein encoding nucleic acid, useful for preparing PRO
 PT polypeptides and anti-PRO antibodies for detecting the presence of a
 PT tumor in a mammal.
 XX
 PS Claim 11; Fig 236; 324pp; English.
 XX
 CC The invention relates to a novel isolated PRO protein encoding nucleic
 CC acid. The nucleic acid of the invention may be useful for preparing PRO
 CC polypeptides and anti-PRO antibodies for detecting the presence of a
 CC tumour in a mammal. Furthermore, the molecules of the invention may be
 CC useful for stimulating proliferation or gene expression in pericyte
 CC cells, the release of tumour necrosis factor (TNF)-alpha from human
 CC blood, the proliferation or differentiation of chondrocyte cells and for
 CC inhibiting the proliferation of normal human dermal fibroblast cells.
 CC Finally, the molecules may be utilised during gene therapy. The current
 CC sequence is that of the human PRO protein of the invention
 XX
 SQ Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 6; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
 DB 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
 QY 121 CQVNNPPDFYNTGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
 DB 121 CQVNNPPDFYNTGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
 QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLSTVTEPPOG 240
 DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLSTVTEPPOG 240
 QY 241 RVAGALIGVLLGVLVLSVAACFLVRQKRGKPKETYGGSDLRDAIAPGISEHTCMRA 300
 DB 241 RVAGALIGVLLGVLVLSVAACFLVRQKRGKPKETYGGSDLRDAIAPGISEHTCMRA 300
 QY 301 DSSKGFLERPSSASTVTTTTSKLPMMV 327
 DB 301 DSSKGFLERPSSASTVTTTTSKLPMMV 327

RESULT 12
 ABO34368
 ID ABO34368 standard; protein; 327 AA.
 XX
 AC ABO34368;
 XX
 DT 19-SEP-2003 (first entry)
 XX
 DE Human secreted/transmembrane polypeptide PRO 7154.
 XX
 KW Human; chondrocyte stimulation; TNF-alpha stimulation; gene therapy;
 KW human dermal fibroblast stimulation; tumour; tissue typing;
 KW affinity purification.

XX OS Homo sapiens.
 XX PN US2003044934-A1.
 XX PD 06-MAR-2003.
 XX XX 28-AUG-2002; 2002US-00230338.

PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-492274/46.
 DR N-PSDB; ACD82293.
 XX
 XX New transmembrane polypeptides and nucleic acids encoding the
 PT polypeptides, useful in gene therapy, in chromosome identification, as
 PT chromosome markers, or in generating probes.
 XX
 XX Claim 19; Fig 236; 315pp; English.
 XX
 CC The invention relates to an isolated nucleic acid encoding a PRO
 CC polypeptide. Nucleic acids that encode PRO can be used to generate either
 CC transgenic animals or knock-out animals useful in developing and
 CC screening of therapeutically useful reagents. The nucleic acids may also
 CC be used in gene therapy for replacing defective gene, in chromosome
 CC identification, as chromosome markers, or in generating probes to isolate
 CC full length PRO cDNA. The PRO polypeptides are useful for chondrocyte
 CC stimulation, TNF-alpha stimulation, human dermal fibroblasts stimulation
 CC and for detecting the presence of tumour in an mammal. The PRO
 CC polypeptides are useful as molecular markers for protein electrophoresis
 CC and the isolated nucleic acids may be used for recombinantly expressing
 CC those markers. The PRO polypeptides and nucleic acids may also be used in
 CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
 CC PRO and in affinity purification of PRO from recombinant cell culture or
 CC natural sources. The present sequence represents the amino acid sequence
 CC of a human secreted/transmembrane PRO polypeptide
 XX
 SQ Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 6; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 MAELPGFLCGALLGFLCGLAVEVVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGFLCGALLGFLCGLAVEVVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAKPVTNVV 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAKPVTNVV 180
 QY 181 RLGTFTPPSGMVQDEVSQGLILTNLSLTSSGTYRCVATNQMSASCELTLSTVTPPQG 240
 DB 181 RLGTFTPPSGMVQDEVSQGLILTNLSLTSSGTYRCVATNQMSASCELTLSTVTPPQG 240
 QY 241 RVAGALIGVLLGVLLSVAFCVLRQKRGKPKETYGSGDLREDIAIACISEHTCMRA 300
 DB 241 RVAGALIGVLLGVLLSVAFCVLRQKRGKPKETYGSGDLREDIAIACISEHTCMRA 300
 QY 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327
 DB 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327

RESULT 13
 ID ABJ72175 standard; protein; 327 AA.
 XX
 AC ABJ72175;
 XX
 DT 16-OCT-2003 (first entry)

XX Human membrane bound receptor/protein PRO7154 amino acid sequence.
 DE
 XX Human; PRO; membrane bound protein; membrane bound receptor;
 XX cell proliferation; cell migration; cell differentiation;
 XX mitogenic factor; survival factor; cytotoxic factor;
 XX differentiation factor; neuroepithelial; hormone; cell receptor;
 XX receptor-ligand interaction; cytoskeletal; chondrocyte; tumour.
 OS Homo sapiens.
 XX
 XX US2003065147-A1.
 XX 03-APR-2003.
 XX 29-AUG-2002; 2002US-00232224.
 XX 28-JUL-1999; 99US-0146222P.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 03-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-522018/49.
 DR N-PSDB; ABT43999.
 XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful for the manufacture of a medicament for diagnosing or treating
 PT tumor.
 XX
 PS Claim 11; Fig 236; 315pp; English.
 XX
 CC This invention relates to one hundred and twenty two novel nucleic acids
 CC encoding human PRO membrane bound proteins or receptors. Extracellular
 CC proteins play important roles in the formation, differentiation and
 CC maintenance of multicellular organisms. The fate of many individual cells
 CC (for example proliferation, migration or differentiation) is typically
 CC governed by information received from other cells and the immediate
 CC environment. The information is often transmitted by secreted
 CC polypeptides (for example mitogenic factors, survival factors, cytotoxic
 CC factors, differentiation factors, neuroepithelial and hormones) which are
 CC received and interpreted by diverse cell receptors or membrane bound
 CC proteins. These membrane bound proteins and receptors may be of use as
 CC pharmaceutical and diagnostic agents, such as in the blocking of receptor
 CC ligand interactions. The current invention provides the amino acid
 CC sequences of novel human membrane bound receptors and proteins, along
 CC with the cDNA sequences encoding them. The novel proteins of the
 CC invention may have cytostatic activities through the stimulation of
 CC chondrocytes. The nucleic acids of the invention may be useful for the
 CC manufacture of a medicament for diagnosing or treating a tumour in a
 CC mammal. In addition, they may be useful for measuring or detecting the
 CC expression of a tumour associated gene. The present sequence is the amino
 CC acid sequence of a human PRO protein of the invention
 XX
 SQ Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 7; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 MAELPGFLCGALLGFLCGLAVEVVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGFLCGALLGFLCGLAVEVVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYL 120

QY 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVNV 180
Db 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVNV 180
QY 181 RLGTFTPTSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNMGSAACELTILSVTEPPQG 240
Db 181 RLGTFTPTSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNMGSAACELTILSVTEPPSQG 240
QY 241 RVAGALIGVLLGVLNLSVAAFCLVRFQKRGKKPKETYGGSDLREDIAIAPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLNLSVAAFCLVRFQKRGKKPKETYGGSDLREDIAIAPGISEHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTKSKLPVWV 327
Db 301 DSSKGFLEPSSASTVTTTKSKLPVWV 327
RESULT 14
ADB83726
ID ADB83726 standard; protein; 327 AA.
XX
AC ADB83726;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO7154.
XX
KW human; secreted and transmembrane protein; PRO; cytostatic; vulnerary;
KW antiarthritic; pericyte cell proliferation; chondrocyte cell proliferation;
KW pericyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2003073814-A1.
XX
PD 17-APR-2003.
XX
PF 12-AUG-2002; 2002US-00218849.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-644806/61.
DR N-PSDB; ADB83725.
XX
PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
XX Claim 11; Fig 236; 315pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF) -
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC

CC PRO1478, PRO1134, PRO825, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1386, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO3431, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This is the amino acid sequence of a human secreted and
CC transmembrane PRO polypeptide.
XX
SQ Sequence 327 AA;
Query Match 99.5%; Score 1691; DB 7; Length 327;
Best Local Similarity 99.7%; Pred. No. 8.8e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSGLAIVEKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAIVEKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
QY 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVLSLQNPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVLSLQNPPTVGATLKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVNV 180
Db 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVNV 180
QY 181 RLGTFTPTSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNMGSAACELTILSVTEPPQG 240
Db 181 RLGTFTPTSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNMGSAACELTILSVTEPPSQG 240
QY 241 RVAGALIGVLLGVLNLSVAAFCLVRFQKRGKKPKETYGGSDLREDIAIAPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLNLSVAAFCLVRFQKRGKKPKETYGGSDLREDIAIAPGISEHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTKSKLPVWV 327
Db 301 DSSKGFLEPSSASTVTTTKSKLPVWV 327
RESULT 15
ADB80832
ID ADB80832 standard; protein; 327 AA.
XX
AC ADB80832;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO7154.
XX
KW Human; secreted and transmembrane protein; PRO; cytostatic; vulnerary;
KW antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW

KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
XX US2003088068-A1.
XX
XX 08-MAY-2003.
XX
XX 13-AUG-2002; 2002US-00219481.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX
XX 29-JUN-2001; 2001WO-US021066.
XX
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU,
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WT;
XX
XX WPI: 2003-657982/62.
XX
XX N-PSDB: ADB80831.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
XX useful in gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX
XX Claim 11; Fig 236; 305pp; English.
XX

The invention describes an isolated PRO (secreted and transmembrane)
polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
useful for stimulating the proliferation of or gene expression in
pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
for stimulating the proliferation or differentiation of chondrocyte
cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
are useful for stimulating the release of tumour necrosis factor (TNF)-
alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
PRO1025, PRO1181, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
stimulating the proliferation of normal human dermal fibroblasts cells.
PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
inhibiting the proliferation of normal human dermal fibroblast cells. PRO
polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
are useful for detecting the presence of tumour in a mammal which
involves comparing the level of expression of the above PRO polypeptides
in a test sample of cells taken from the mammal, and a control sample of
normal cells of the same cell type, where a higher level of expression of
the PRO polypeptides in the test sample as compared to the control sample
is indicative of the presence of tumour in the mammal. The tumour is lung
tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
liver tumour. (I) is useful as molecular weight markers, for tissue
typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
useful for chromosome and gene mapping or gene therapy. (II) is useful
for generating transgenic animals or knock-out animals which are useful
screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
is useful for treating bone and/or cartilage disorders (e.g., arthritis,
sport injuries). This is the amino acid sequence of a human secreted and
transmembrane PRO polypeptide.

XX Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 7; Length 327;
Best Local Similarity 99.7%; Pred. No. 8.8e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MAELPGFLCGALIGFLCGLAVVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db |||||
Qy 1 MAELPGFLCGALIGFLCGLAVVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db |||||
Qy 61 FVQPKDISESHPILYFTNGHLYPTGSKSRVSLLOHPPTVGVAATLKLTDVHPDGTGYL 120
Db |||||
Qy 61 FVQPKDISESHPILYFTNGHLYPTGSKSRVSLLOHPPTVGVAATLKLTDVHPDGTGYL 120
Db |||||
Qy 121 CQVNNPDPFTYNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
Db |||||
Qy 121 CQVNNPDPFTYNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
Db |||||
Qy 181 RLGTFFTPSPGSMVQDEVSGQLITNLSTSSGTTCYRCVATNQMGASCELTLSTVTEPPQG 240
Db |||||
Qy 181 RLGTFFTPSPGSMVQDEVSGQLITNLSTSSGTTCYRCVATNQMGASCELTLSTVTEPSQG 240
Db |||||
Qy 241 RVAGALIGVLLGVLLLSVAAFCVRFQKRGKPKPKETYGGSDLRDADAIAFGISEHTCMRA 300
Db |||||
Qy 241 RVAGALIGVLLGVLLLSVAAFCVRFQKRGKPKPKETYGGSDLRDADAIAFGISEHTCMRA 300
Db |||||
Qy 301 DSSKGFLERPSSASTVTTTKSKLPMVV 327
Db |||||
Qy 301 DSSKGFLERPSSASTVTTTKSKLPMVV 327
Db |||||

Search completed: August 4, 2005, 06:07:05
Job time : 103.73 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.
OM protein - protein search, using sw model
Run on: August 4, 2005, 06:13:42 ; Search time 87.4135 Seconds
(without alignments)
1447.018 Million cell updates/sec

Title: US-10-607-565-60_COPY_4_327
Perfect score: 1685
Sequence: 1 LFGPFICGALLGFLCISGLA.....ERPSSASTVTTTKSKLPMV 324

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1752860 seqs, 390397842 residues
Total number of hits satisfying chosen parameters: 1752860

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA:
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1685	100.0	327	9	US-09-820-893-60
2	1685	100.0	327	15	US-10-607-565-60
3	1677	99.5	327	14	US-10-227-884-236
4	1677	99.5	327	14	US-10-230-163-236
5	1677	99.5	327	14	US-10-230-338-236
6	1677	99.5	327	14	US-10-218-631-236
7	1677	99.5	327	14	US-10-230-414-236
8	1677	99.5	327	14	US-10-232-224-236
9	1677	99.5	327	14	US-10-216-159A-236
10	1677	99.5	327	14	US-10-218-849-236
11	1677	99.5	327	14	US-10-227-873-236

12	1677	99.5	327	14	US-10-227-883-236	Sequence 236, App
13	1677	99.5	327	14	US-10-219-076-236	Sequence 236, App
14	1677	99.5	327	14	US-10-230-434-236	Sequence 236, App
15	1677	99.5	327	14	US-10-219-003-236	Sequence 236, App
16	1677	99.5	327	14	US-10-219-075-236	Sequence 236, App
17	1677	99.5	327	14	US-10-219-464-236	Sequence 236, App
18	1677	99.5	327	14	US-10-219-466-236	Sequence 236, App
19	1677	99.5	327	14	US-10-219-479-236	Sequence 236, App
20	1677	99.5	327	14	US-10-219-481-236	Sequence 236, App
21	1677	99.5	327	14	US-10-230-260-236	Sequence 236, App
22	1677	99.5	327	14	US-10-232-231-236	Sequence 236, App
23	1677	99.5	327	14	US-10-232-233-236	Sequence 236, App
24	1677	99.5	327	14	US-10-216-165-236	Sequence 236, App
25	1677	99.5	327	14	US-10-218-956-236	Sequence 236, App
26	1677	99.5	327	14	US-10-219-468-236	Sequence 236, App
27	1677	99.5	327	14	US-10-219-478-236	Sequence 236, App
28	1677	99.5	327	14	US-10-219-536-236	Sequence 236, App
29	1677	99.5	327	14	US-10-233-205-236	Sequence 236, App
30	1677	99.5	327	14	US-10-219-072-236	Sequence 236, App
31	1677	99.5	327	14	US-10-219-474-236	Sequence 236, App
32	1677	99.5	327	14	US-10-219-474-236	Sequence 236, App
33	1677	99.5	327	14	US-10-219-524-236	Sequence 236, App
34	1677	99.5	327	14	US-10-219-528-236	Sequence 236, App
35	1677	99.5	327	14	US-10-227-881-236	Sequence 236, App
36	1677	99.5	327	14	US-10-227-882-236	Sequence 236, App
37	1677	99.5	327	14	US-10-230-436-236	Sequence 236, App
38	1677	99.5	327	14	US-10-232-223-236	Sequence 236, App
39	1677	99.5	327	14	US-10-232-225-236	Sequence 236, App
40	1677	99.5	327	14	US-10-232-229-236	Sequence 236, App
41	1677	99.5	327	14	US-10-232-234-236	Sequence 236, App
42	1677	99.5	327	14	US-10-219-060-236	Sequence 236, App
43	1677	99.5	327	14	US-10-216-160-236	Sequence 236, App
44	1677	99.5	327	14		
45	1677	99.5	327	14		

ALIGNMENTS

RESULT 1
US-09-820-893-60
; Sequence 60, Application US/09820893
; Patent No. US20020076705A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033PI
; CURRENT APPLICATION NUMBER: US/09/820,893
; CURRENT FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 60
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-820-893-60

Query Match	100.0%;	Score	1685;	DB	9;	Length	327;
Best Local Similarity	100.0%;	Pred. NO.	7.8e-120;				
Matches	324;	Conservative	0;	Mismatches	0;	Indels	0;
						Gaps	0;
Qy	1	LPGPFICGALLGFLCISGLAVEVKVPTPEPLSTPLGKTABLTCTYTSVGDSPALEWSFVQ	60				
Db	4	LPGPFICGALLGFLCISGLAVEVKVPTPEPLSTPLGKTABLTCTYTSVGDSPALEWSFVQ	63				
Qy	61	PGKPTSEHPILFYFTNGHLYPTGSKSKRVSLQNPPVTGVATILKLTDPHSDTGTTCYLCQV	120				
Db	64	PGKPTSEHPILFYFTNGHLYPTGSKSKRVSLQNPPVTGVATILKLTDPHSDTGTTCYLCQV	123				

QY 121 NNPPDFYTNGLGINLITVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVWVRIG 180
Db |||||
QY 124 NNPPDFYTNGLGINLITVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVWVRIG 183
Db |||||
QY 181 TPTPTSPGMVDEVSQQLILNLNLSITSSGTYRCVATNMQSASCELTLSVTEPPQGRVA 240
Db |||||
QY 184 TPTPTSPGMVDEVSQQLILNLNLSITSSGTYRCVATNMQSASCELTLSVTEPPQGRVA 243
Db |||||
QY 241 GALIGVLLGVLLLSVAACFLVRPQERGGKPKETYGGSDLRDAIAPGISEHTCMRADSS 300
Db |||||
QY 244 GALIGVLLGVLLLSVAACFLVRPQERGGKPKETYGGSDLRDAIAPGISEHTCMRADSS 303
Db |||||
QY 301 KGFLERPSSASTVTTTKSLPMVW 324
Db |||||
QY 304 KGFLERPSSASTVTTTKSLPMVW 327
Db |||||

RESULT 2

US-10-607-565-60
; Sequence 60, Application US/10607565
; Publication No. US20040048294A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033P1
; CURRENT APPLICATION NUMBER: US/10/607,565
; PRIOR FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: US/09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/101,546
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 60
; TYPE: PRT
; LENGTH: 327
; ORGANISM: Homo sapiens
US-10-607-565-60

Query Match 100.0%; Score 1685; DB 15; Length 327;
Best Local Similarity 100.0%; Pred. No. 7.8e-120;
Matches 324; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 LPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
Db |||||
QY 4 LPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
Db |||||
QY 61 PKGPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPVTGVATLKLTDVHPSDTGTVLCOV 120
Db |||||
QY 64 PKGPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPVTGVATLKLTDVHPSDTGTVLCOV 123
Db |||||
QY 121 NNPPDFYTNGLGINLITVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVWVRIG 180
Db |||||
QY 124 NNPPDFYTNGLGINLITVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVWVRIG 183
Db |||||
QY 181 TPTPTSPGMVDEVSQQLILNLNLSITSSGTYRCVATNMQSASCELTLSVTEPPQGRVA 240
Db |||||
QY 184 TPTPTSPGMVDEVSQQLILNLNLSITSSGTYRCVATNMQSASCELTLSVTEPPQGRVA 243
Db |||||
QY 241 GALIGVLLGVLLLSVAACFLVRPQERGGKPKETYGGSDLRDAIAPGISEHTCMRADSS 300
Db |||||
QY 244 GALIGVLLGVLLLSVAACFLVRPQERGGKPKETYGGSDLRDAIAPGISEHTCMRADSS 303
Db |||||
QY 301 KGFLERPSSASTVTTTKSLPMVW 324
Db |||||
QY 304 KGFLERPSSASTVTTTKSLPMVW 327
Db |||||

RESULT 3

US-10-227-884-236
; Sequence 236, Application US/10227884

Publication No. US20030027988A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PLC79
; CURRENT APPLICATION NUMBER: US/10/227,884
; PRIOR FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916

QY 241 GALIGVLLGVLLLSVAACFLVRFQKRGKKPKKTYGGSDLRDADATAPGISEHTCMRADSS 300
Db |||||
244 GALIGVLLGVLLLSVAACFLVRFQKRGKKPKKTYGGSDLRDADATAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTTSKLPWV 324
Db ||||| 304 KGFLERPSSASTVTTTTSKLPWV 327

RESULT 4

US-10-230-163-236
; Sequence 236, Application US/10230163
; Publication No. US20030036635A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PJC96
; CURRENT APPLICATION NUMBER: US/10/230,163
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422

PRIOR FILING DATE: 1998-12-15
PRIOR APPLICATION NUMBER: 60/113296
PRIOR FILING DATE: 1998-12-22
PRIOR APPLICATION NUMBER: 60/113605
PRIOR FILING DATE: 1998-12-23
PRIOR APPLICATION NUMBER: 60/113621
PRIOR FILING DATE: 1998-12-23
PRIOR APPLICATION NUMBER: 60/115558
PRIOR FILING DATE: 1999-01-12
PRIOR APPLICATION NUMBER: 60/115565
PRIOR FILING DATE: 1999-01-12
PRIOR APPLICATION NUMBER: 60/115733
PRIOR FILING DATE: 1999-01-12
PRIOR APPLICATION NUMBER: 60/119549
PRIOR FILING DATE: 1999-02-10
PRIOR APPLICATION NUMBER: 60/123618
PRIOR FILING DATE: 1999-03-10
PRIOR APPLICATION NUMBER: 60/125259
PRIOR FILING DATE: 1999-03-19
PRIOR APPLICATION NUMBER: 60/125775
PRIOR FILING DATE: 1999-03-23
PRIOR APPLICATION NUMBER: 60/126773
PRIOR FILING DATE: 1999-03-29
PRIOR APPLICATION NUMBER: 60/127887
PRIOR FILING DATE: 1999-04-05
PRIOR APPLICATION NUMBER: 60/130232
PRIOR FILING DATE: 1999-04-21
PRIOR APPLICATION NUMBER: 60/131022
PRIOR FILING DATE: 1999-04-26
PRIOR APPLICATION NUMBER: 60/131270
PRIOR FILING DATE: 1999-04-27
PRIOR APPLICATION NUMBER: 60/131291
PRIOR FILING DATE: 1999-04-27
PRIOR APPLICATION NUMBER: 60/131445
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 60/134287
PRIOR FILING DATE: 1999-05-14
PRIOR APPLICATION NUMBER: 60/140650
PRIOR FILING DATE: 1999-06-22
PRIOR APPLICATION NUMBER: 60/140723
PRIOR FILING DATE: 1999-06-22
PRIOR APPLICATION NUMBER: 60/141037
PRIOR FILING DATE: 1999-06-23
PRIOR APPLICATION NUMBER: 60/144758
PRIOR FILING DATE: 1999-07-20
PRIOR APPLICATION NUMBER: 60/145698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: 60/146222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: 60/146963
PRIOR FILING DATE: 1999-08-03
PRIOR APPLICATION NUMBER: 60/149320
PRIOR FILING DATE: 1999-08-17
PRIOR APPLICATION NUMBER: 60/149638
PRIOR FILING DATE: 1999-08-17
PRIOR APPLICATION NUMBER: 60/151733
PRIOR FILING DATE: 1999-08-31
PRIOR APPLICATION NUMBER: 60/164418
PRIOR FILING DATE: 1999-11-09
PRIOR APPLICATION NUMBER: 60/166361
PRIOR FILING DATE: 1999-11-16
PRIOR APPLICATION NUMBER: 60/169445
PRIOR FILING DATE: 1999-12-07
PRIOR APPLICATION NUMBER: 60/169495
PRIOR FILING DATE: 1999-12-07
PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1 LRGPFLLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
|||||

Db 4 LRGPFLLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63
Qy 61 PGKPISESHPILYFTNGHLYPTGSKSRVSLLONPPTVGATLKLTDVHPSDTGTLYCQV 120
Db 64 PGKPISESHPILYFTNGHLYPTGSKSRVSLLONPPTVGATLKLTDVHPSDTGTLYCQV 123
Qy 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGSSTALRCSSEGAPKPVYNNWVRLG 180
Db 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGSSTALRCSSEGAPKPVYNNWVRLG 183
Qy 181 TPPTSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNQMGSAACELTILSVTPPPQGRVA 240
Db 184 TPPTSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNQMGSAACELTILSVTPPPQGRVA 243
Qy 241 GALIGVLLGVLLSVAACLVRFQKRGKKPKETVCGSLRDIAIAPGISEHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAACLVRFQKRGKKPKETVCGSLRDIAIAPGISEHTCMRADSS 303
Qy 301 KGFLERPSSASTVTTTKSKLPWV 324
Db 304 KGFLERPSSASTVTTTKSKLPWV 327

RESULT 5

US-10-230-338-236
; Sequence 236, Application US/10230338
; Publication No. US2003004934A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530PIC92
; CURRENT APPLICATION NUMBER: US/10/230,338
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-338-236

Query Match 99.5%; Score 1677; DB 14; Length 327;

Best Local Similarity 99.7%; Pred. No. 3.2e-119; Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LPGPFLCAGLLGFLCGLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
Db 4 LPGPFLCAGLLGFLCGLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63

QY 61 PKPISSEHPILYFTNGHLIPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYLCOV 120
Db 64 PKPISSEHPILYFTNGHLIPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYLCOV 123

QY 121 NNPPDFYNTGLGLNLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 180
Db 124 NNPPDFYNTGLGLNLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 183

QY 181 TPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPPQGRVA 240
Db 184 TPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPPQGRVA 243

QY 241 GALIGVLLGVLLSVAAFCVRFQKRGKKPKETTYGGSDLRDAIAPGISEHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAAFCVRFQKRGKKPKETTYGGSDLRDAIAPGISEHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTTSKLPWV 324
Db 304 KGFLERPSSASTVTTTTSKLPWV 327

RESULT 6

US-10-218-631-236
; Sequence 236, Application US/10218631
; Publication No. US20030045687A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C14
; CURRENT APPLICATION NUMBER: US/10/218,631
; PRIOR FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327

; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-631-236

Query Match 99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LPGPFLCAGLLGFLCGLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
Db 4 LPGPFLCAGLLGFLCGLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63

QY 61 PKPISSEHPILYFTNGHLIPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYLCOV 120
Db 64 PKPISSEHPILYFTNGHLIPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYLCOV 123

QY 121 NNPPDFYNTGLGLNLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 180
Db 124 NNPPDFYNTGLGLNLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 183

QY 181 TPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPPQGRVA 240
Db 184 TPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPPQGRVA 243

QY 241 GALIGVLLGVLLSVAAFCVRFQKRGKKPKETTYGGSDLRDAIAPGISEHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAAFCVRFQKRGKKPKETTYGGSDLRDAIAPGISEHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTTSKLPWV 324
Db 304 KGFLERPSSASTVTTTTSKLPWV 327

RESULT 7

US-10-230-414-236
; Sequence 236, Application US/10230414
; Publication No. US20030050448A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C98
; CURRENT APPLICATION NUMBER: US/10/230,414
; PRIOR FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728

```

; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR PUBLICATION NUMBER: 60/079656
; PRIOR APPLICATION NUMBER: 60/033269
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining prior application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 245

```

```

; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-232-224-236

Query Match          99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0

QY      1  LPGPFLCGALLGFLCISGLAVEVKVPTEPLSTPLGKTAEILTCTYSTSVGDSFALEWSFVQ 60
        |||
Db       4  LPGPFLCGALLGFLCISGLAVEVKVPTEPLSTPLGKTAEILTCTYSTSVGDSFALEWSFVQ 63

QY      61  PGKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGVAATLKLTDVHPSDGTGYLCQV 120
        |||
Db       64  PGKPISSEHPILYFTNGHLPTGSKSRVSLQNPPTVGVAATLKLTDVHPSDGTGYLCQV 123

QY      121  NNPPDFYFTNGGLGILNLTVPNPPLCSQSQGTSVGGSTALRCSSESSEGAPKPVYNNVRLG 180
        |||
Db       124  NNPPDFYFTNGGLGILNLTVPNPPLCSQSQGTSVGGSTALRCSSESSEGAPKPVYNNVRLG 183

QY      181  TFTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSGASCELTLSVTEPPQGRVA 240
        |||
Db       184  TFTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSGASCELTLSVTEPPQGRVA 243

QY      241  GALLIGVLLGLLSVAACFLVRFOKRGKKPKETGYGSGDLREDIAIAPGISHTCMRADSS 300

```

RESULT 9

US-10-216-159A-236

Sequence 236, Application US/10216159A

Publication No. US20030069397A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.

APPLICANT: Desnoyers, Luc

APPLICANT: Gerritsen, Mary

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Grimaldi, J. Christopher

APPLICANT: Gurney, Austin L.

APPLICANT: Smith, Victoria

APPLICANT: Stephan, Jean-Philippe F.

APPLICANT: Watanabe, Colin L.

APPLICANT: Wood, William I.

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

TITLE OF INVENTION: ACIDS ENCODING THE SAME

FILE REFERENCE: P3530PIC6

CURRENT APPLICATION NUMBER: US/10/216,159A

CURRENT FILING DATE: 2002-08-09

PRIOR APPLICATION NUMBER: 10/119,480

PRIOR FILING DATE: 2002-04-09

PRIOR APPLICATION NUMBER: 60/059113

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/062287

PRIOR FILING DATE: 1997-10-17

PRIOR APPLICATION NUMBER: 60/063549

PRIOR FILING DATE: 1997-10-28

PRIOR APPLICATION NUMBER: 60/064103


```
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-216-159A-236

Query Match          99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LGGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
Db 4 LGGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63

QY 61 PKGPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPPTVGVAATLKLTVDHPSDTGYLCOV 120
Db 64 PKGPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPPTVGVAATLKLTVDHPSDTGYLCOV 123

QY 121 NNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRIG 180
Db 124 NNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRIG 183

QY 181 TPTTSPGSMVQDEVSGQILTNLSLTSSGTVCVATNMGASCELTLSTVTEPPQGRVA 240
Db 184 TPTTSPGSMVQDEVSGQILTNLSLTSSGTVCVATNMGASCELTLSTVTEPPQGRVA 243

QY 241 GALIGVLLGVLLSVAAFCLVRFQKRGKKPKETYGGSGLRDAIAPGISHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAAFCLVRFQKRGKKPKETYGGSGLRDAIAPGISHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTKSKLPMV 324
Db 304 KGFLERPSSASTVTTTKSKLPMV 327

RESULT 10
US-10-218-849-236
; Sequence 236, Application US/10218849
; Publication No. US20030073814A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC11
; CURRENT APPLICATION NUMBER: US/10/218,849
; PRIOR FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 60/079728
; Remaining Prior Application data removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-216-159A-236

Query Match          99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LGGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
Db 4 LGGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63

QY 61 PKGPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPPTVGVAATLKLTVDHPSDTGYLCOV 120
Db 64 PKGPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPPTVGVAATLKLTVDHPSDTGYLCOV 123

QY 121 NNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRIG 180
Db 124 NNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRIG 183

QY 181 TPTTSPGSMVQDEVSGQILTNLSLTSSGTVCVATNMGASCELTLSTVTEPPQGRVA 240
Db 184 TPTTSPGSMVQDEVSGQILTNLSLTSSGTVCVATNMGASCELTLSTVTEPPQGRVA 243

QY 241 GALIGVLLGVLLSVAAFCLVRFQKRGKKPKETYGGSGLRDAIAPGISHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAAFCLVRFQKRGKKPKETYGGSGLRDAIAPGISHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTKSKLPMV 324
Db 304 KGFLERPSSASTVTTTKSKLPMV 327

RESULT 10
US-10-218-849-236
; Sequence 236, Application US/10218849
; Publication No. US20030073814A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC11
; CURRENT APPLICATION NUMBER: US/10/218,849
; PRIOR FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 60/079728
; Remaining Prior Application data removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-849-236

Query Match          99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LGGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
Db 4 LGGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63

QY 61 PKGPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPPTVGVAATLKLTVDHPSDTGYLCOV 120
Db 64 PKGPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPPTVGVAATLKLTVDHPSDTGYLCOV 123

QY 121 NNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRIG 180
Db 124 NNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRIG 183

QY 181 TPTTSPGSMVQDEVSGQILTNLSLTSSGTVCVATNMGASCELTLSTVTEPPQGRVA 240
Db 184 TPTTSPGSMVQDEVSGQILTNLSLTSSGTVCVATNMGASCELTLSTVTEPPQGRVA 243

QY 241 GALIGVLLGVLLSVAAFCLVRFQKRGKKPKETYGGSGLRDAIAPGISHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAAFCLVRFQKRGKKPKETYGGSGLRDAIAPGISHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTKSKLPMV 324
Db 304 KGFLERPSSASTVTTTKSKLPMV 327

RESULT 11
US-10-227-873-236
; Sequence 236, Application US/10227873
; Publication No. US20030073816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC72
; CURRENT APPLICATION NUMBER: US/10/227,873
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
```



```
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
```

```
Query Match          99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred.No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LRGFLCGALLGFLCISGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
    |||||
Db 4 LRGFLCGALLGFLCISGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
    |||||

QY 61 PKPTSESHPILYFTNGHLYPTGSKSKRVSLQLQNPPTVGVATLKLTDVHPSTGTGYLCQV 120
    |||||
Db 64 PKPTSESHPILYFTNGHLYPTGSKSKRVSLQLQNPPTVGVATLKLTDVHPSTGTGYLCQV 123
    |||||

QY 121 NNPPDPYTNGLGILNLTVLVPPSNPLCSOGGTSVGGSTALRCSSEGAPKPVYNWVRIG 180
    |||||
Db 124 NNPPDPYTNGLGILNLTVLVPPSNPLCSOGGTSVGGSTALRCSSEGAPKPVYNWVRIG 183
    |||||

QY 181 TPTTSPGSMVDVSGQLILNLSLTSSGTYRCVATNQMGSASCELTLTSVTEPPQGRVA 240
    |||||
Db 184 TPTTSPGSMVDVSGQLILNLSLTSSGTYRCVATNQMGSASCELTLTSVTEPPQGRVA 243
    |||||

QY 241 GALIGVLLGVLLSVAAPCLVRFQERKKPKETTYGGSDLRDADAIPGISEHTCMRADSS 300
    |||||
Db 244 GALIGVLLGVLLSVAAPCLVRFQERKKPKETTYGGSDLRDADAIPGISEHTCMRADSS 303
    |||||

QY 301 KGFLERPSSASTVTTTKSKLPMWV 324
    |||||
Db 304 KGFLERPSSASTVTTTKSKLPMWV 327
    |||||

RESULT 12
US-10-227-883-236
; Sequence 236, Application US/10227883
; Publication No. US20030073817A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530PIC78
; CURRENT APPLICATION NUMBER: US/10/227,883
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
```

;
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14

;
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LPGPFLLGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
DB 4 LPGPFLLGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
QY 61 PGKPISESHPILYFTNGHLYPTGSKRVSLLONPPTVGATLKLTDVHPSDTGTLYLCQV 120
DB 64 PGKPISESHPILYFTNGHLYPTGSKRVSLLONPPTVGATLKLTDVHPSDTGTLYLCQV 123
QY 121 NNPPDFYTNGLGLINLTIVLPPSNPLCSQSGQTSVGSSTALRCSSEGAPKPVYNNWVRLG 180
DB 124 NNPPDFYTNGLGLINLTIVLPPSNPLCSQSGQTSVGSSTALRCSSEGAPKPVYNNWVRLG 183
QY 181 TPTSPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASASCELTLTSTVTPPGQGRVA 240
DB 184 TPTSPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASASCELTLTSTVTPPGQGRVA 243
QY 241 GALIGVLLGVLLSVAAFCLVRFQKRGKKPKETYGSDLRDAIAPGISEHTCMRADSS 300
DB 244 GALIGVLLGVLLSVAAFCLVRFQKRGKKPKETYGSDLRDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTKSKLPWV 324
DB 304 KGFLERPSSASTVTTTKSKLPWV 327

RESULT 13
US-10-219-076-236
; Sequence 236, Application US/10219076
; Publication No. US20030078379A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.

```
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C62
; CURRENT APPLICATION NUMBER: US/10/219,076
; CURRENT FILING DATE: 2002-08-14
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986

; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe P.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C82
; CURRENT APPLICATION NUMBER: US/10/230,434
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986

Query Match          99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LFGPFLCGALLGFLCGLGLAVEVKVPTPLSTPLGKTAELTCTYSTVGDSFALEWSFVQ 60
Db 4 LFGPFLCGALLGFLCGLGLAVEVKVPTPLSTPLGKTAELTCTYSTVGDSFALEWSFVQ 63
QY 61 PKGPISHPILYFTNGHLVPTGSKSKRVSLQNPPTVGATLKLTDVHPSTGTGYLCQV 120
Db 64 PKGPISHPILYFTNGHLVPTGSKSKRVSLQNPPTVGATLKLTDVHPSTGTGYLCQV 123
QY 121 NNPPDPYTNGLGINLTVLPSPNPLCSOGQTSVGGSTALRCSSSEGAPKPVNWRVLG 180
Db 124 NNPPDPYTNGLGINLTVLPSPNPLCSOGQTSVGGSTALRCSSSEGAPKPVNWRVLG 183
QY 181 TPTTSPGSMQDEVSQQLILNLSLTSSGTGYRCVATNQMSASCELTLSTVTEPPQGRVA 240
Db 184 TPTTSPGSMQDEVSQQLILNLSLTSSGTGYRCVATNQMSASCELTLSTVTEPPQGRVA 243
QY 241 GALIGVLLGVLLSVAAPCLVRFQERKKPKETVGGSDLRDAIAPGISEHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAAPCLVRFQERKKPKETVGGSDLRDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTKSLPMVV 324
Db 304 KGFLERPSSASTVTTTKSLPMVV 327

RESULT 14
US-10-230-434-236
; Sequence 236, Application US/10230434
; Publication No. US20030078380A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
```

1 PRIOR FILING DATE: 1998-08-26
2 PRIOR APPLICATION NUMBER: 60/098544
3 PRIOR FILING DATE: 1998-08-31
4 PRIOR APPLICATION NUMBER: 60/099596
5 PRIOR FILING DATE: 1998-09-09
6 PRIOR APPLICATION NUMBER: 60/099598
7 PRIOR FILING DATE: 1998-09-09
8 PRIOR APPLICATION NUMBER: 60/099803
9 PRIOR FILING DATE: 1998-09-10
10 PRIOR APPLICATION NUMBER: 60/099811
11 PRIOR FILING DATE: 1998-09-10
12 PRIOR APPLICATION NUMBER: 60/099812
13 PRIOR FILING DATE: 1998-09-10
14 PRIOR APPLICATION NUMBER: 60/099816
15 PRIOR FILING DATE: 1998-09-10
16 PRIOR APPLICATION NUMBER: 60/100038
17 PRIOR FILING DATE: 1998-09-11
18 PRIOR APPLICATION NUMBER: 60/100385
19 PRIOR FILING DATE: 1998-09-15
20 PRIOR APPLICATION NUMBER: 60/100390
21 PRIOR FILING DATE: 1998-09-15
22 PRIOR APPLICATION NUMBER: 60/100627
23 PRIOR FILING DATE: 1998-09-16
24 PRIOR APPLICATION NUMBER: 60/100848
25 PRIOR FILING DATE: 1998-09-18
26 PRIOR APPLICATION NUMBER: 60/100919
27 PRIOR FILING DATE: 1998-09-17
28 PRIOR APPLICATION NUMBER: 60/101477
29 PRIOR FILING DATE: 1998-09-23
30 PRIOR APPLICATION NUMBER: 60/101738
31 PRIOR FILING DATE: 1998-09-24
32 PRIOR APPLICATION NUMBER: 60/101741
33 PRIOR FILING DATE: 1998-09-24
34 PRIOR APPLICATION NUMBER: 60/101786
35 PRIOR FILING DATE: 1998-09-25
36 PRIOR APPLICATION NUMBER: 60/101916
37 PRIOR FILING DATE: 1998-09-24
38 PRIOR APPLICATION NUMBER: 60/101922
39 PRIOR FILING DATE: 1998-09-24
40 PRIOR APPLICATION NUMBER: 60/106178
41 PRIOR FILING DATE: 1998-10-28
42 PRIOR APPLICATION NUMBER: 60/106248
43 PRIOR FILING DATE: 1998-10-29
44 PRIOR APPLICATION NUMBER: 60/106464
45 PRIOR FILING DATE: 1998-10-30
46 PRIOR APPLICATION NUMBER: 60/106905
47 PRIOR FILING DATE: 1998-11-03
48 PRIOR APPLICATION NUMBER: 60/108787
49 PRIOR FILING DATE: 1998-11-17
50 PRIOR APPLICATION NUMBER: 60/108801
51 PRIOR FILING DATE: 1998-11-17
52 PRIOR APPLICATION NUMBER: 60/108849
53 PRIOR FILING DATE: 1998-11-18
54 PRIOR APPLICATION NUMBER: 60/112422
55 PRIOR FILING DATE: 1998-12-15
56 PRIOR APPLICATION NUMBER: 60/113296
57 PRIOR FILING DATE: 1998-12-22
58 PRIOR APPLICATION NUMBER: 60/113605
59 PRIOR FILING DATE: 1998-12-23
60 PRIOR APPLICATION NUMBER: 60/113621
61 PRIOR FILING DATE: 1998-12-23
62 PRIOR APPLICATION NUMBER: 60/115558
63 PRIOR FILING DATE: 1999-01-12
64 PRIOR APPLICATION NUMBER: 60/115565
65 PRIOR FILING DATE: 1999-01-12
66 PRIOR APPLICATION NUMBER: 60/115733
67 PRIOR FILING DATE: 1999-01-12
68 PRIOR APPLICATION NUMBER: 60/119549
69 PRIOR FILING DATE: 1999-02-10
70 PRIOR APPLICATION NUMBER: 60/123618
71 PRIOR FILING DATE: 1999-03-10
72 PRIOR APPLICATION NUMBER: 60/125259
73 PRIOR FILING DATE: 1999-03-19

1 PRIOR APPLICATION NUMBER: 60/125775
2 PRIOR FILING DATE: 1999-03-23
3 PRIOR APPLICATION NUMBER: 60/126773
4 PRIOR FILING DATE: 1999-03-29
5 PRIOR APPLICATION NUMBER: 60/127887
6 PRIOR FILING DATE: 1999-04-05
7 PRIOR APPLICATION NUMBER: 60/130232
8 PRIOR FILING DATE: 1999-04-21
9 PRIOR APPLICATION NUMBER: 60/131022
10 PRIOR FILING DATE: 1999-04-26
11 PRIOR APPLICATION NUMBER: 60/131270
12 PRIOR FILING DATE: 1999-04-27
13 PRIOR APPLICATION NUMBER: 60/131291
14 PRIOR FILING DATE: 1999-04-27
15 PRIOR APPLICATION NUMBER: 60/131445
16 PRIOR FILING DATE: 1999-04-28
17 PRIOR APPLICATION NUMBER: 60/134287
18 PRIOR FILING DATE: 1999-05-14
19 PRIOR APPLICATION NUMBER: 60/140650
20 PRIOR FILING DATE: 1999-06-22
21 PRIOR APPLICATION NUMBER: 60/140723
22 PRIOR FILING DATE: 1999-06-22
23 PRIOR APPLICATION NUMBER: 60/141037
24 PRIOR FILING DATE: 1999-06-23
25 PRIOR APPLICATION NUMBER: 60/144758
26 PRIOR FILING DATE: 1999-07-20
27 PRIOR APPLICATION NUMBER: 60/145698
28 PRIOR FILING DATE: 1999-07-26
29 PRIOR APPLICATION NUMBER: 60/146222
30 PRIOR FILING DATE: 1999-07-28
31 PRIOR APPLICATION NUMBER: 60/149663
32 PRIOR FILING DATE: 1999-08-03
33 PRIOR APPLICATION NUMBER: 60/149320
34 PRIOR FILING DATE: 1999-08-17
35 PRIOR APPLICATION NUMBER: 60/149638
36 PRIOR FILING DATE: 1999-08-17
37 PRIOR APPLICATION NUMBER: 60/151733
38 PRIOR FILING DATE: 1999-08-31
39 PRIOR APPLICATION NUMBER: 60/164418
40 PRIOR FILING DATE: 1999-11-09
41 PRIOR APPLICATION NUMBER: 60/166361
42 PRIOR FILING DATE: 1999-11-16
43 PRIOR APPLICATION NUMBER: 60/169445
44 PRIOR FILING DATE: 1999-12-07
45 PRIOR APPLICATION NUMBER: 60/169495
46 PRIOR FILING DATE: 1999-12-07
47 PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.5%; Score 1677; DB 14; Length 327;

Best Local Similarity 99.7%; Pred. No. 3.2e-119;

Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60

DB 4 LPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63

QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATIKLTDVHPSDGTLYLCOV 120

DB 64 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATIKLTDVHPSDGTLYLCOV 123

QY 121 NNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 180

DB 124 NNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 183

QY 181 TPPTSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNQMGASCSCLTILSVTEPPQGRVA 240

DB 184 TPPTSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNQMGASCSCLTILSVTEPPQGRVA 243

QY 241 GALIGVLLGVLLSVAAFCVRFQKPKETYGSGDLREDAIAPGISEHTCMRADSS 300

DB 244 GALIGVLLGVLLSVAAFCVRFQKPKETYGSGDLREDAIAPGISEHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTTSKSLPMWV 324

```
Db          304 KGFLERPSSASTVTTTKSKLPWV 327
|||||
RESULT 15
US-10-219-003-236
; Sequence 236, Application US/10219003
; Publication No. US2003008063A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C12
; CURRENT APPLICATION NUMBER: US/10/219,003
; PRIOR FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
```

;
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 LPPFPFCGALLGFLCSGLAVEVKVPTPLSTPLGKTAEITCTYSTSVGDSFALEWSFVQ 60
DB 4 LPPFPFCGALLGFLCSGLAVEVKVPTPLSTPLGKTAEITCTYSTSVGDSFALEWSFVQ 63
QY 61 PGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGTLYLCOV 120
DB 64 PGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGTLYLCOV 123

QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSOGQTSVGGSTALRCSSEGAPKPVYNWVRLG 180
DB 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSOGQTSVGGSTALRCSSEGAPKPVYNWVRLG 183
QY 181 TPTTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSA SCELTLTSVTEPPQGRVA 240
DB 184 TPTTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSA SCELTLTSVTEPPQGRVA 243
QY 241 GALIGVLLGVLLLSVAAFCFLVRFOKRGKKPKETYGSGDLREDAIAPGISEHTCMRADSS 300
DB 244 GALIGVLLGVLLLSVAAFCFLVRFOKRGKKPKETYGSGDLREDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTTSKSLPMVV 324
DB 304 KGFLERPSSASTVTTTTSKSLPMVV 327

Search completed: August 4, 2005, 06:47:27
Job time : 88.4135 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 06:13:42 ; Search time 88.2229 Seconds
(without alignments)
1447.018 Million cell updates/sec

Title: US-10-607-565-60

Perfect score: 1699

Sequence: 1 MAELPGFLLCGALLGFLCLS.....ERPSSASTVTTTKSLPMV 327

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1752860 seqs, 390397842 residues

Total number of hits satisfying chosen parameters: 1752860

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1699	100.0	327	9	US-09-820-893-60
2	1699	100.0	327	15	US-10-607-565-60
3	1691	99.5	327	14	US-10-227-883-236
4	1691	99.5	327	14	US-10-230-163-236
5	1691	99.5	327	14	US-10-230-338-236
6	1691	99.5	327	14	US-10-218-631-236
7	1691	99.5	327	14	US-10-230-414-236
8	1691	99.5	327	14	US-10-232-224-236
9	1691	99.5	327	14	US-10-216-159A-236
10	1691	99.5	327	14	US-10-218-849-236
11	1691	99.5	327	14	US-10-227-873-236

12	1691	99.5	327	14	US-10-227-883-236	Sequence 236, App
13	1691	99.5	327	14	US-10-219-076-236	Sequence 236, App
14	1691	99.5	327	14	US-10-230-434-236	Sequence 236, App
15	1691	99.5	327	14	US-10-219-003-236	Sequence 236, App
16	1691	99.5	327	14	US-10-219-075-236	Sequence 236, App
17	1691	99.5	327	14	US-10-219-464-236	Sequence 236, App
18	1691	99.5	327	14	US-10-219-466-236	Sequence 236, App
19	1691	99.5	327	14	US-10-219-479-236	Sequence 236, App
20	1691	99.5	327	14	US-10-219-481-236	Sequence 236, App
21	1691	99.5	327	14	US-10-230-260-236	Sequence 236, App
22	1691	99.5	327	14	US-10-232-231-236	Sequence 236, App
23	1691	99.5	327	14	US-10-232-233-236	Sequence 236, App
24	1691	99.5	327	14	US-10-216-165-236	Sequence 236, App
25	1691	99.5	327	14	US-10-218-956-236	Sequence 236, App
26	1691	99.5	327	14	US-10-219-468-236	Sequence 236, App
27	1691	99.5	327	14	US-10-219-478-236	Sequence 236, App
28	1691	99.5	327	14	US-10-219-536-236	Sequence 236, App
29	1691	99.5	327	14	US-10-233-205-236	Sequence 236, App
30	1691	99.5	327	14	US-10-219-072-236	Sequence 236, App
31	1691	99.5	327	14	US-10-219-470-236	Sequence 236, App
32	1691	99.5	327	14	US-10-219-474-236	Sequence 236, App
33	1691	99.5	327	14	US-10-219-524-236	Sequence 236, App
34	1691	99.5	327	14	US-10-219-528-236	Sequence 236, App
35	1691	99.5	327	14	US-10-227-881-236	Sequence 236, App
36	1691	99.5	327	14	US-10-227-882-236	Sequence 236, App
37	1691	99.5	327	14	US-10-230-436-236	Sequence 236, App
38	1691	99.5	327	14	US-10-227-882-236	Sequence 236, App
39	1691	99.5	327	14	US-10-232-223-236	Sequence 236, App
40	1691	99.5	327	14	US-10-232-225-236	Sequence 236, App
41	1691	99.5	327	14	US-10-232-227-236	Sequence 236, App
42	1691	99.5	327	14	US-10-232-229-236	Sequence 236, App
43	1691	99.5	327	14	US-10-232-234-236	Sequence 236, App
44	1691	99.5	327	14	US-10-219-060-236	Sequence 236, App
45	1691	99.5	327	14	US-10-216-160-236	Sequence 236, App

ALIGNMENTS

RESULT 1
US-09-820-893-60
; Sequence 60, Application US/09820893
; Patent No. US20020076705A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033PI
; CURRENT APPLICATION NUMBER: US/09/820,893
; CURRENT FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 60
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-820-893-60

Query Match 100.0%; Score 1699; DB 9; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.3e-121;
Matches 327; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MAELPGFLLCGALLGFLCLSGLAVEVKVPEPLSTPLGKTAELTCTYSTVGDSFALEWS 60
Db 1 MAELPGFLLCGALLGFLCLSGLAVEVKVPEPLSTPLGKTAELTCTYSTVGDSFALEWS 60
Qy 61 FVOPGKPISESHPIIFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVOPGKPISESHPIIFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120

Qy	121	CQVNNPDPFYTNGLGLINLTVLVPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV	180
Db	121	CQVNNPDPFYTNGLGLINLTVLVPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV	180
Qy	181	RLGTFPTPPSPGSMQVDEVSQGLILNLNLSITSSGTYRCVATNQMGASCELTLISVTEPPQG	240
Db	181	RLGTFPTPPSPGSMQVDEVSQGLILNLNLSITSSGTYRCVATNQMGASCELTLISVTEPPQG	240
Qy	241	RVAGALIGVLGLVLLLSVAAFCFLVRFOKRGKKPKETYGGSLREDALAPGISEHTCMRA	300
Db	241	RVAGALIGVLGLVLLLSVAAFCFLVRFOKRGKKPKETYGGSLREDALAPGISEHTCMRA	300
Qy	301	DSSKGFLERPSSASTVTTTTSKGLPMWV	327
Db	301	DSSKGFLERPSSASTVTTTTSKGLPMWV	327

RESULT 2
US-10-607-565-60
; Sequence 60, Application US/10607565
; Publication No. US20040048294A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human secreted proteins

```

; Publication No. US20030027988A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William L.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C79
; CURRENT APPLICATION NUMBER: US/10/227,884
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916

```

; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/098596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/098598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/098811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/098812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/098816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12

; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.5%; Score 1691; DB 14; Length 327;

Best Local Similarity 99.7%; Pred. No. 3.4e-120;

Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MAELPGFPCGALLGFLCLSGLAIVEKVPTPEPLSTPLGKTABLTCTYSTSVGDSFALEWS 60

Db 1 MAELPGFPCGALLGFLCLSGLAIVEKVPTPEPLSTPLGKTABLTCTYSTSVGDSFALEWS 60

Qy 61 FVOPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPVTGVATLKLTVHPSDTCTYL 120

Db 61 FVOPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPVTGVATLKLTVHPSDTCTYL 120

Qy 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAKPVVNW 180

Db 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAKPVVNW 180

Qy 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSVTEPPQG 240

Db 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSVTEPPSQG 240


```
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-631-236

Query Match          99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTABLTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTABLTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGTYL 120

QY 121 CQVNNPPDPFYTNGLGILNLTVLVPPSNPLCSOGQTSVGGSTALRCSSEGAPKPYNNV 180
Db 121 CQVNNPPDPFYTNGLGILNLTVLVPPSNPLCSOGQTSVGGSTALRCSSEGAPKPYNNV 180

QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNOMGSASCELTLSVTEPPQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNOMGSASCELTLSVTEPPQG 240

QY 241 RVAGALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300

QY 301 DSSKGFLERPSSASTVTTTTSKLPWV 327
Db 301 DSSKGFLERPSSASTVTTTTSKLPWV 327
```

```
RESULT 6
US-10-218-631-236
; Sequence 236, Application US/10218631
; Publication No. US20030045687A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C14
; CURRENT APPLICATION NUMBER: US/10/218,631
; CURRENT FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
```

```
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-631-236

Query Match          99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTABLTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTABLTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGTYL 120

QY 121 CQVNNPPDPFYTNGLGILNLTVLVPPSNPLCSOGQTSVGGSTALRCSSEGAPKPYNNV 180
Db 121 CQVNNPPDPFYTNGLGILNLTVLVPPSNPLCSOGQTSVGGSTALRCSSEGAPKPYNNV 180

QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNOMGSASCELTLSVTEPPQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNOMGSASCELTLSVTEPPQG 240

QY 241 RVAGALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300

QY 301 DSSKGFLERPSSASTVTTTTSKLPWV 327
Db 301 DSSKGFLERPSSASTVTTTTSKLPWV 327

RESULT 7
US-10-230-414-236
; Sequence 236, Application US/10230414
; Publication No. US20030050448A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C98
; CURRENT APPLICATION NUMBER: US/10/230,414
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
```

; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-414-236

Query Match 99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGFPLCGALLGFLCGLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
DB 1 MAELPGFPLCGALLGFLCGLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVOPGKPISESHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
DB 61 FVOPGKPISESHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGILNLTVPSPNPLCSQSGQTSVGGSTALRCSSSSGAPKPVNVW 180
DB 121 CQVNNPPDFYTNGLGILNLTVPSPNPLCSQSGQTSVGGSTALRCSSSSGAPKPVNVW 180
QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGSASCELTLSTVTEPPOG 240
DB 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGSASCELTLSTVTEPPOG 240
QY 241 RVAGALIGVLLGVLLLSVAFAFCLVRQKRGKPKETYGGSDDLREDAIAPGISEHTCMRA 300
DB 241 RVAGALIGVLLGVLLLSVAFAFCLVRQKRGKPKETYGGSDDLREDAIAPGISEHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTTSKLPVMV 327
DB 301 DSSKGFLEPSSASTVTTTTSKLPVMV 327

RESULT 8

US-10-232-224-236
; Sequence 236, Application US/10232224
; Publication No. US20030065147A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C111
; CURRENT APPLICATION NUMBER: US/10/232,224
; CURRENT FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-232-224-236

Query Match 99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGFPLCGALLGFLCGLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
DB 1 MAELPGFPLCGALLGFLCGLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVOPGKPISESHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
DB 61 FVOPGKPISESHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGILNLTVPSPNPLCSQSGQTSVGGSTALRCSSSSGAPKPVNVW 180
DB 121 CQVNNPPDFYTNGLGILNLTVPSPNPLCSQSGQTSVGGSTALRCSSSSGAPKPVNVW 180
QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGSASCELTLSTVTEPPOG 240
DB 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGSASCELTLSTVTEPPOG 240
QY 241 RVAGALIGVLLGVLLLSVAFAFCLVRQKRGKPKETYGGSDDLREDAIAPGISEHTCMRA 300
DB 241 RVAGALIGVLLGVLLLSVAFAFCLVRQKRGKPKETYGGSDDLREDAIAPGISEHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTTSKLPVMV 327
DB 301 DSSKGFLEPSSASTVTTTTSKLPVMV 327

RESULT 9

US-10-216-159A-236
; Sequence 236, Application US/10216159A
; Publication No. US20030069397A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530PIC6
; CURRENT APPLICATION NUMBER: US/10/216,159A
; CURRENT FILING DATE: 2002-08-09
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103


```
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-216-159A-236

Query Match          99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPLSTPLGKTABLTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPLSTPLGKTABLTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDFYTNGLGLINLTIVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
Db 121 CQVNNPPDFYTNGLGLINLTIVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPPQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPPQG 240
QY 241 RVAGALIGVLLGVLLSVAAFLVRFQKRGKKPKETYGSGDLREDIAIAPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLLSVAAFLVRFQKRGKKPKETYGSGDLREDIAIAPGISEHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327
Db 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327

RESULT 10
US-10-218-849-236
; Sequence 236, Application US/10218849
; Publication No. US20030073814A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: F3530PIC11
; CURRENT APPLICATION NUMBER: US/10/218,849
; PRIOR FILING DATE: 2002-08-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
```

```
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-849-236

Query Match          99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPLSTPLGKTABLTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPLSTPLGKTABLTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDFYTNGLGLINLTIVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
Db 121 CQVNNPPDFYTNGLGLINLTIVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPPQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPPQG 240
QY 241 RVAGALIGVLLGVLLSVAAFLVRFQKRGKKPKETYGSGDLREDIAIAPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLLSVAAFLVRFQKRGKKPKETYGSGDLREDIAIAPGISEHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327
Db 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327

RESULT 11
US-10-227-873-236
; Sequence 236, Application US/10227873
; Publication No. US20030073816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC72
; CURRENT APPLICATION NUMBER: US/10/227,873
; PRIOR FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
```


;
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
;
;
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
;

```
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match          99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGFPCGALLGFLCGLSLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
   |||||
Db 1 MAELPGFPCGALLGFLCGLSLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKRVSLLQNPPVTGVATLKLTDVHPSDTGTYL 120
   |||||
Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKRVSLLQNPPVTGVATLKLTDVHPSDTGTYL 120

QY 121 CQVNNPPDYFTNGLGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
   |||||
Db 121 CQVNNPPDYFTNGLGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180

QY 181 RLCTFTPPSGMVQDEVSGQLITLNLSTSTYRCVATNOMGSASCELTLTSLVTPPOG 240
   |||||
Db 181 RLCTFTPPSGMVQDEVSGQLITLNLSTSTYRCVATNOMGSASCELTLTSLVTPPOG 240

QY 241 RVAGALIGVLLGLVLLSVAACFLVRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300
   |||||
Db 241 RVAGALIGVLLGLVLLSVAACFLVRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300

QY 301 DSKGFLERPSSASTVTTTKSLPMV 327
   |||||
Db 301 DSKGFLERPSSASTVTTTKSLPMV 327

RESULT 12
US-10-227-883-236
; Sequence 236, Application US/10227883
; Publication No. US20030073817A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C78
; CURRENT APPLICATION NUMBER: US/10/227,883
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
```

```
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14

; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match          99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGFLCGALLGFLCLSLGLAVEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
   |||||
Db 1 MAELPGFLCGALLGFLCLSLGLAVEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
   |||||
QY 61 FVOPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPTVGVATLKLTDVHPSDTGTYL 120
   |||||
Db 61 FVOPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPTVGVATLKLTDVHPSDTGTYL 120
   |||||
QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSESGAPKPVYNNV 180
   |||||
Db 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSESGAPKPVYNNV 180
   |||||
QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTILSVTEPPQG 240
   |||||
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTILSVTEPPSQG 240
   |||||
QY 241 RVAGALIGVLLGVLLLSVAAFCVLRFQKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300
   |||||
Db 241 RVAGALIGVLLGVLLLSVAAFCVLRFQKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300
   |||||
QY 301 DSSKGFLEPSSASTVTTTKSKLPMV 327
   |||||
Db 301 DSSKGFLEPSSASTVTTTKSKLPMV 327

RESULT 13
US-10-219-076-236
; Sequence 236, Application US/10219076
; Publication No. US20030078379A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
```

```
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC62
; CURRENT FILING DATE: 2002-08-14
; PRIOR APPLICATION NUMBER: US/10/219,076
; PRIOR FILING DATE: 2002-08-14
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986

Query Match          99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFICGALLGFLCISGLAVEKVPTEPLSTPLGTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFICGALLGFLCISGLAVEKVPTEPLSTPLGTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGLINLTLYVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
Db 121 CQVNNPPDFYTNGLGLINLTLYVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
QY 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSAELTSLVTPPQG 240
Db 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSAELTSLVTPSQG 240
QY 241 RVAGALIGVLLGVLISVAACFLVRFOKERGKKPKETYGGSGLREDIAIPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLISVAACFLVRFOKERGKKPKETYGGSGLREDIAIPGISEHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327
Db 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327

RESULT 14
US-10-230-434-236
; Sequence 236, Application US/10230434
; Publication No. US20030078380A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Deenoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
```

```
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC82
; CURRENT APPLICATION NUMBER: US/10/230,434
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
```



```
Db          301 DSSKGLERPSSASTVTTTKSLPMVV 327
RESULT 15
US-10-219-003-236
; Sequence 236, Application US/10219003
; Publication No. US2003088063A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C12
; CURRENT APPLICATION NUMBER: US/10/219,003
; CURRENT FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
```

1	PRIOR FILING DATE: 1998-12-23	
2	PRIOR APPLICATION NUMBER: 60/115558	
3	PRIOR FILING DATE: 1999-01-12	
4	PRIOR APPLICATION NUMBER: 60/115565	
5	PRIOR FILING DATE: 1999-01-12	
6	PRIOR APPLICATION NUMBER: 60/115733	
7	PRIOR FILING DATE: 1999-01-12	
8	PRIOR APPLICATION NUMBER: 60/119549	
9	PRIOR FILING DATE: 1999-02-10	
10	PRIOR APPLICATION NUMBER: 60/123618	
11	PRIOR FILING DATE: 1999-03-10	
12	PRIOR APPLICATION NUMBER: 60/125259	
13	PRIOR FILING DATE: 1999-03-19	
14	PRIOR APPLICATION NUMBER: 60/125775	
15	PRIOR FILING DATE: 1999-03-23	
16	PRIOR APPLICATION NUMBER: 60/126773	
17	PRIOR FILING DATE: 1999-03-29	
18	PRIOR APPLICATION NUMBER: 60/127887	
19	PRIOR FILING DATE: 1999-04-05	
20	PRIOR APPLICATION NUMBER: 60/130232	
21	PRIOR FILING DATE: 1999-04-21	
22	PRIOR APPLICATION NUMBER: 60/131022	
23	PRIOR FILING DATE: 1999-04-26	
24	PRIOR APPLICATION NUMBER: 60/131270	
25	PRIOR FILING DATE: 1999-04-27	
26	PRIOR APPLICATION NUMBER: 60/131291	
27	PRIOR FILING DATE: 1999-04-27	
28	PRIOR APPLICATION NUMBER: 60/131445	
29	PRIOR FILING DATE: 1999-04-28	
30	PRIOR APPLICATION NUMBER: 60/134287	
31	PRIOR FILING DATE: 1999-05-14	
32	PRIOR APPLICATION NUMBER: 60/140650	
33	PRIOR FILING DATE: 1999-06-22	
34	PRIOR APPLICATION NUMBER: 60/140723	
35	PRIOR FILING DATE: 1999-06-22	
36	PRIOR APPLICATION NUMBER: 60/141037	
37	PRIOR FILING DATE: 1999-06-23	
38	PRIOR APPLICATION NUMBER: 60/144758	
39	PRIOR FILING DATE: 1999-07-20	
40	PRIOR APPLICATION NUMBER: 60/145698	
41	PRIOR FILING DATE: 1999-07-26	
42	PRIOR APPLICATION NUMBER: 60/146222	
43	PRIOR FILING DATE: 1999-07-28	
44	PRIOR APPLICATION NUMBER: 60/146963	
45	PRIOR FILING DATE: 1999-08-03	
46	PRIOR APPLICATION NUMBER: 60/149320	
47	PRIOR FILING DATE: 1999-08-17	
48	PRIOR APPLICATION NUMBER: 60/149638	
49	PRIOR FILING DATE: 1999-08-17	
50	PRIOR APPLICATION NUMBER: 60/151733	
51	PRIOR FILING DATE: 1999-08-31	
52	PRIOR APPLICATION NUMBER: 60/164418	
53	PRIOR FILING DATE: 1999-11-09	
54	PRIOR APPLICATION NUMBER: 60/166361	
55	PRIOR FILING DATE: 1999-11-16	
56	PRIOR APPLICATION NUMBER: 60/169445	
57	PRIOR FILING DATE: 1999-12-07	
58	PRIOR APPLICATION NUMBER: 60/169495	
59	PRIOR FILING DATE: 1999-12-07	
60	PRIOR APPLICATION NUMBER: 60/169835	

Query Match	99.5%	Score 1691;	DB 14;	Length 327;
Best Local Similarity	99.7%;	Pred. 0.3,4e-120;		
Matches 326;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0
Qy	1	MAELPGPFLCGALLGFLCISGLAIEVVKVPTEPLSTPLGKTABLTCTCYTSGVDSFALEWS	60	
Db	1	MAELPGPFLCGALLGFLCISGLAIEVVKVPTEPLSTPLGKTABLTCTCYTSGVDSFALEWS	60	
Qy	61	FVQPKPTSESHPILYFTNGHLYTGSKSRVSLQNPPVTGVATILKLDTHVPSDTGYL	120	
Db	61	FVQPKPTSESHPILYFTNGHLYTGSKSRVSLQNPPVTGVATILKLDTHVPSDTGYL	120	

Qy	121	QVNNPDDFYNTGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV	180
Db	121	QVNNPDDFYNTGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV	180
Qy	181	RLGTFPTSPSGMWQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTILSVTEPPQG	240
Db	181	RLGTFPTSPSGMWQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTILSVTEPPQG	240
Qy	241	RVAGALIGVLLGVLLLSVAAPCLVRFQKRGKKPKETYGGSDLRDRTAPGISEHTCMRA	300
Db	241	RVAGALIGVLLGVLLLSVAAPCLVRFQKRGKKPKETYGGSDLRDRTAPGISEHTCMRA	300
Qy	301	DSSKGFLERPSSASTVTVTTSKLPVV	327
Db	301	DSSKGFLERPSSASTVTVTTSKLPVV	327

Search completed: August 4, 2005, 06:47:26
Job time : 90.2229 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 05:53:15 ; Search time 98.8153 Seconds
(without alignments)
1268.128 Million cell updates/sec

Title: US-10-607-565-60_COPY_4_327
Perfect score: 1685
Sequence: 1 LPQFFICGALLGLCLSLGLA.....ERPSSASTVTTTKSKLPMV 324

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 segs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_16Dec04:.*
1: Geneseqp1980s:.*
2: Geneseqp1990s:.*
3: Geneseqp2000s:.*
4: Geneseqp2001s:.*
5: Geneseqp2002s:.*
6: Geneseqp2003as:.*
7: Geneseqp2003bs:.*
8: Geneseqp2004s:.*

pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1678	99.6	327	3	AAB08903 Human sec
2	1677	99.5	327	3	AAY87251 Human sig
3	1677	99.5	327	3	AAY94857 Human pro
4	1677	99.5	327	4	AAY97585 Human sec
5	1677	99.5	327	5	ABB90354 Human pol
6	1677	99.5	327	5	AAB83709 Human pro
7	1677	99.5	327	6	ABU80856 Human PRO
8	1677	99.5	327	6	ABO33822 Novel hum
9	1677	99.5	327	6	ABU82165 Novel hum
10	1677	99.5	327	6	ABJ72345 Human PRO
11	1677	99.5	327	6	ABJ72473 Human PRO
12	1677	99.5	327	6	ABO34368 Human sec
13	1677	99.5	327	7	ABJ72175 Human mem
14	1677	99.5	327	7	ADB83726 Novel hum
15	1677	99.5	327	7	ADB80832 Novel hum
16	1677	99.5	327	7	ADB73373 Novel hum
17	1677	99.5	327	7	ADB78455 Novel hum
18	1677	99.5	327	7	ADB85103 Human PRO
19	1677	99.5	327	7	ADB78209 Novel hum
20	1677	99.5	327	7	ADB87275 Human PRO
21	1677	99.5	327	7	ADB84857 Human PRO
22	1677	99.5	327	7	ADB831972 Novel hum
23	1677	99.5	327	7	ADB73127 Novel hum
24	1677	99.5	327	7	ADC36965 Human PRO
25	1677	99.5	327	7	ADC21955 Human PRO

ALIGNMENTS

RESULT 1

AAB08903

ID AAB08903 standard; protein; 327 AA.

XX AC AAB08903;

XX DT 30-AUG-2000 (first entry)

XX DE Human secreted protein sequence encoded by gene 13 SEQ ID NO:60.

XX KW Human; secreted protein; cytostatic; anti-proliferative; vulnary;
KW immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
KW hyperproliferative disorder; infectious disease; tissue regeneration;
KW screening; food additive; preservative; wound healing;
KW hyper-vascular disease; chromosome 11.

XX OS Homo sapiens.

XX PN WO200017222-A1.

XX PD 30-MAR-2000.

XX PF 22-SEP-1999; 99WO-US022012.

XX PR 23-SEP-1998; 98US-0101546P.

XX PR 02-OCT-1998; 98US-0102895P.

XX PA (HUMA-) HUMAN GENOME SCI INC.

PI Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;

PI Komatsoulis G, Endress GA, Soppet DR;

DR WPI; 2000-283538/24.

DR N-PSDB; AAA39064.

PT Human secreted proteins and coding sequences useful in diagnostic and

PT therapeutic methods for disorders such as immune system or proliferative

PT disorders, related to the proteins.

XX Claim 1; Page 359-360; 416pp; English.

PS The polynucleotide sequences given in AAA39052 to AAA39088 encode the
CC human secreted proteins given in AAB08891 to AAB08984. The human secreted
CC proteins can have activities based on the tissues and cells they are
CC expressed in. Examples of the activities are: cytostatic; anti-
CC proliferative; immunosuppressive; antibacterial; and vulnary. The
CC secreted proteins and their related polynucleotide sequences are useful
CC for diagnostic and therapeutic methods useful for diagnosing and treating

CC disorders related to the secreted proteins. The proteins, and
CC polynucleotide sequences may be useful for treating disorders of the
CC immune system, hyperproliferative disorders, infectious disease,
CC regeneration of tissues, for chemotaxis and for screening molecules that
CC bind to the proteins. The proteins or polynucleotide sequences may be
CC used as food additives or preservatives, to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, co-factors or other nutritional components. Agonists or
CC antagonists of the proteins may be used to prevent scar tissue growth
CC during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC and AA088890 are sequences used in the exemplification of the present
CC invention

XX SQ Sequence 327 AA;

Query Match 99.6%; Score 1678; DB 3; Length 327;
Best Local Similarity 99.7%; Pred. No. 5.7e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 LFGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
DB 4 LFGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
QY 61 PKKPISSEHPILYFTNGHLYPTGSKSKRVSLIQNPPTVGATLKLTDVHPSDTGYLCQV 120
DB 64 PKKPISSEHPILYFTNGHLYPTGSKSKRVSLIQNPPTVGATLKLTDVHPSDTGYLCQV 123
QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGTSGVSTALRCSSEGAPKPYNNVRLG 180
DB 124 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGTSGVSTALRCSSEGAPKPYNNVRLG 183
QY 181 TPTPTSPGSMVQDEVSGQILNLTLNLSLTSSGTYRCVATNQMGASCELTLTSTVTEPPQGRVA 240
DB 184 TPTPTSPGSMVQDEVSGQILNLTLNLSLTSSGTYRCVATNQMGASCELTLTSTVTEPPQGRVA 243
QY 241 GALIGVLLGVLLSVAAFCFLVRFQKRGKKPKETGYGSDLRDAIAPGISEHTCMRADSS 300
DB 244 GALIGVLLGVLLSVAAFCFLVRFQKRGKKPKETGYGSDLRDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTTSKLPWV 324
DB 304 KGFLERPSSASTVTTTTSKLPWV 327

RESULT 2

AA087251

ID AAY87251 standard; protein; 327 AA.

XX AC AAY87251;

XX 11-MAY-2000 (first entry)

XX Human signal peptide containing protein HSP-28 SEQ ID NO:28.

XX Human; signal peptide-containing protein; HSP; diagnosis; cancer;
KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW antimicrobial; neuroprotective; cardiovascular; hepatotropic;
KW antistatic; gene therapy; cell proliferation; neurological disorder;
KW reproductive disorder; developmental disorder; arteriosclerosis;
KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
KW muscular dystrophy.

OS Homo sapiens.

XX W020000610-A2.

XX 06-JAN-2000.

XX 25-JUN-1999; 99WO-US014484.

XX 26-JUN-1998; 98US-0090762P.

XX

PR

PR 31-JUL-1998; 98US-0094983P.
PR 01-OCT-1998; 98US-0102686P.
PR 11-DEC-1998; 98US-0112129P.
XX (INCY-) INCYTE PHARM INC.
XX Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
PI Bandman O;
XX WPI: 2000-160673/14.
DR N-PSDB; AA298136.
XX New human signal peptide-containing proteins useful in treatment,
PT prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
PT disease.
XX Claim 1; Page 177-178; 327pp; English.

XX AA298109 to AA298242 encode AAY87224 to AAY87357 which represent the
CC human signal peptide-containing proteins HSP-1 to HSP-134. HSPs have
CC anticancer, anti-inflammatory, antimicrobial, nootropic, hepatotropic,
CC neuroprotective, cardiovascular and antiasthmatic activities, and can be
CC used in gene therapy. HSPs can be used to treat or prevent disorders
CC associated with decreased activity or function of HSP. Antagonists of
CC HSP are used to treat or prevent disorders associated with increased
CC activity or function of HSP. Such diseases include cell proliferation
CC (including cancer), inflammation, cardiovascular, neurological,
CC reproductive or developmental disorders, (e.g. arteriosclerosis,
CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
CC asthma, Crohn's disease, microbial or other infections, congestive or
CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSP
CC nucleic acids can be used for the recombinant production of HSP, for
CC detecting HSP in standard hybridisation and amplification assays (for
CC diagnosis and monitoring), in gene therapy, as antisense, triplex-forming
CC or ribozyme therapeutics, for detecting related sequences or genetic
CC variations, and for chromosomal mapping. HSP are also used to raise
CC specific antibodies (Ab) and to screen for agonists and antagonists
CC (potential therapeutic agents). Ab are used to diagnose, or monitor, HSP
CC -related diseases (in usual immunoassays), as therapeutic antagonists, in
CC competitive drug screens, and for purification of HSP from natural
CC sources

XX SQ Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 3; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 LFGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
DB 4 LFGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
QY 61 PKKPISSEHPILYFTNGHLYPTGSKSKRVSLIQNPPTVGATLKLTDVHPSDTGYLCQV 120
DB 64 PKKPISSEHPILYFTNGHLYPTGSKSKRVSLIQNPPTVGATLKLTDVHPSDTGYLCQV 123
QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGTSGVSTALRCSSEGAPKPYNNVRLG 180
DB 124 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGTSGVSTALRCSSEGAPKPYNNVRLG 183
QY 181 TPTPTSPGSMVQDEVSGQILNLTLNLSLTSSGTYRCVATNQMGASCELTLTSTVTEPPQGRVA 240
DB 184 TPTPTSPGSMVQDEVSGQILNLTLNLSLTSSGTYRCVATNQMGASCELTLTSTVTEPPQGRVA 243
QY 241 GALIGVLLGVLLSVAAFCFLVRFQKRGKKPKETGYGSDLRDAIAPGISEHTCMRADSS 300
DB 244 GALIGVLLGVLLSVAAFCFLVRFQKRGKKPKETGYGSDLRDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTTSKLPWV 324
DB 304 KGFLERPSSASTVTTTTSKLPWV 327

RESULT 3

AA94857
 ID AAY94857 standard; protein; 327 AA.
 AC AAY94857;
 XX
 DT 12-JUN-2000 (first entry)
 XX
 DE Human protein clone HP10568.
 XX
 KW Human protein; hydrophobic domain; nutritional source; haematopoiesis;
 KW cytokine production; cell proliferation; cell differentiation;
 KW immune deficiency; infectious disease; autoimmune disorder; asthma;
 KW multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis;
 KW allergic reaction; osteoporosis; osteoarthritis; periodontal disease;
 KW nervous system disorder; Alzheimer's disease; Parkinson's disease;
 KW Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury;
 KW systemic cytokine damage; tissue differentiation; contraceptive; stroke;
 KW coagulation disorder; myocardial infarction; inflammatory condition;
 KW septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour;
 KW nephritis; therapy.
 XX
 OS Homo sapiens.
 XX
 PN WO200005367-A2.
 XX
 PD 03-FEB-2000.
 XX
 PF 22-JUL-1999; 99WO-JP003929.
 XX
 PR 24-JUL-1998; 98JP-00208820.
 PR 07-AUG-1998; 98JP-00224105.
 PR 25-AUG-1998; 98JP-00238116.
 PR 09-SEP-1998; 98JP-00254736.
 PR 29-SEP-1998; 98JP-00275505.
 XX
 (SAGA) SAGAMI CHEM RES CENT.
 (PROT-) PROTEGENE INC.
 PA
 PA Kato S, Kimura T;
 PI
 XX
 WPI; 2000-182694/16.
 XX
 XX Novel human proteins having hydrophobic domains useful for treating
 PT osteoporosis, Alzheimer's disease, Parkinson's disease, asthma, multiple
 PT sclerosis, rheumatoid arthritis, cancer, anemia, and stroke.
 XX
 PS Claim 1; Page 183-184; 351pp; English.
 XX
 CC This sequence represents a human protein of the invention, which has
 CC hydrophobic domains. The DNA sequences can be used as a probe or as a
 CC genetic marker. The protein can also be used as a marker, and to identify
 CC potential genetic disorders. The DNA and protein can also be used as
 CC nutritional sources or supplements. The protein exhibits cytokine, cell
 CC proliferation, cell differentiation activities and induces production of
 CC other cytokines in certain cell populations. The protein also exhibits
 CC immune stimulating or immune suppressing activity. It can be used in the
 CC treatment of various immune deficiencies and disorders, and to treat
 CC infectious diseases caused by viral, bacterial, fungal or other
 CC infections. The protein is also used for treating autoimmune disorders
 CC such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid
 CC arthritis. It is also useful in the treatment of allergic reactions and
 CC conditions such as asthma, and in immune suppression after organ
 CC transplantation. The protein is useful in regulation of haematopoiesis
 CC and consequently in the treatment of myeloid or lymphoid cell
 CC deficiencies. It is also used in compositions for tissue growth or
 CC regeneration. The protein is also used in the treatment of osteoporosis
 CC or osteoarthritis and in the treatment of periodontal disease and other
 CC tooth repair processes. The protein is used in the treatment of nervous
 CC system disorders such as Alzheimer's disease, Parkinson's disease, and
 CC Huntington's disease. They are useful for protection or regeneration and

CC treatment of lung or liver fibrosis, reperfusion injury in various
 CC tissues, and conditions resulting from systemic cytokine damage. They are
 CC also used for promoting or inhibiting tissue differentiation. They are
 CC also used as contraceptives since they exhibit activin or inhibin related
 CC activities and as a fertility inducing therapeutic. They are used for
 CC treating various coagulation disorders and in treatment and prevention of
 CC conditions resulting from coagulation activities e.g. myocardial
 CC infarction or stroke. They also acts as receptors, receptor ligands or
 CC inhibitors or agonists of receptor/ligand interactions. They are used to
 CC treat inflammatory conditions such as septic shock, sepsis, ischaemia
 CC reperfusion injury, arthritis, and nephritis. They can be used to prevent
 CC tumours
 XX

SQ Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 3; Length 327;

Best Local Similarity 99.7%; Pred. No. 6.8e-113;

Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LPGPFLLCGALLGFLCLSGLAWEVKVTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60

Db 4 LPGPFLLCGALLGFLCLSGLAWEVKVTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63

QY 61 PGKPISESHPILYFTNGHLYPTGSKRVSLQNPPVTGVATLKLTDVHPSDTGTLYLCQV 120

Db 64 PGKPISESHPILYFTNGHLYPTGSKRVSLQNPPVTGVATLKLTDVHPSDTGTLYLCQV 123

QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVSGSTALRCSSEGAPKPYNNWRLG 180

Db 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVSGSTALRCSSEGAPKPYNNWRLG 183

QY 181 TFPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSCASCELTLSVTPEPPQGRVA 240

Db 184 TFPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSCASCELTLSVTPEPPQGRVA 243

QY 241 GALIGVLLGVLLSVAAFCFLVRPQKRGKKPKETYGGSDLRDALIAPGISEHTCMRADSS 300

Db 244 GALIGVLLGVLLSVAAFCFLVRPQKRGKKPKETYGGSDLRDALIAPGISEHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTKSKLPMVV 324

Db 304 KGFLERPSSASTVTTTKSKLPMVV 327

RESULT 4

AA97585

ID AAY97585 standard; protein; 327 AA.

XX

AC AAY97585;

XX

DT 05-APR-2001 (first entry)

XX

DE Human secreted protein PRO7154.

XX

KW Secreted protein; human; PRO protein; neoplastic cell growth; tumour;
 KW proliferation; leukaemia; lymphoid malignancy; inflammatory disorder;
 KW angiogenic disorder; immunologic disorder; PRO7154.

XX

OS Homo sapiens.

XX

PN WO200075317-A2.

XX

PD 14-DEC-2000.

XX

PF 15-MAY-2000; 2000WO-US013358.

XX

PR 09-JUN-1999; 99US-0138385P.

XX

PR 20-JUL-1999; 99US-0144790P.

XX

PR 03-AUG-1999; 99US-0146843P.

XX

PR 10-AUG-1999; 99US-0148188P.

XX

PR 17-AUG-1999; 99US-0149320P.

XX

PR 17-AUG-1999; 99US-0149327P.

XX

PR 17-AUG-1999; 99US-0149396P.

PR 20-AUG-1999; 99US-0150114P.
 PR 31-AUG-1999; 99US-0151700P.
 PR 31-AUG-1999; 99US-0151734P.
 XX
 XX (GETH) GENENTECH INC.
 PA
 PA Botstein DA, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
 PI WPI; 2001-071075/08.
 DR N-PSDB; AAA91019.
 XX
 XX Antibodies against PRO polypeptides, useful for diagnosing and treating
 PT tumors are associated with gene amplification, neoplastic cell growth and
 PT proliferation in mammals.
 XX
 XX Claim 61; Fig 12; 143pp; English.
 PS
 PS This sequence is a human PRO protein of the invention. The PRO proteins
 CC are secreted proteins. Antagonists or antibodies of PRO polypeptides are
 CC useful for diagnosing and treating tumors are associated with gene
 CC amplification, neoplastic cell growth and proliferation in mammals, and
 CC those conditions characterised by overexpression and/or activation of the
 CC amplified genes. Such conditions include benign or malignant tumours
 CC (e.g. renal, liver, kidney, bladder, breast, gastric, ovarian,
 CC colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic
 CC carcinomas, sarcomas, glioblastomas and various head and neck tumours);
 CC leukaemias and lymphoid malignancies; neuronal, glial, astrocytal,
 CC hypothalamic, and other glandular, macrophageal, epithelial, stromal and
 CC blastocoele disorders; and inflammatory, angiogenic and immunologic
 CC disorders. These may further be used to qualitatively or quantitatively
 CC detect the expression of proteins encoded by the amplified genes, and in
 CC tumour diagnostics or prognostics. The PRO polypeptide or its antagonist
 CC may be used for the preparation of a medicament in the treatment of a
 CC condition, which is responsive to the PRO polypeptide, its antagonist or
 CC anti-PRO antibody
 XX
 XX Sequence 327 AA;
 SQ
 Query Match 99.5%; Score 1677; DB 4; Length 327;
 Best Local Similarity 99.7%; Pred. No. 6.8e-113;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LPGPFLCGALLGFLCLSGLAWEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
 DB 4 LPGPFLCGALLGFLCLSGLAWEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
 QY 61 PGKPISEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATILKLTVDHPSDTGYLCQV 120
 DB 64 PGKPISEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATILKLTVDHPSDTGYLCQV 123
 QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 180
 DB 124 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 183
 QY 181 TPTTSPGSMQDEVSQGLILTNLSLTSSGTVCATNQMGASCELTLSTVTEPQGRVA 240
 DB 184 TPTTSPGSMQDEVSQGLILTNLSLTSSGTVCATNQMGASCELTLSTVTEPQGRVA 243
 QY 241 GALIGVLLGVLLLSVAACFLVRFQERGGKPKETVGGSDLRDADAIPGISHTCMRADSS 300
 DB 244 GALIGVLLGVLLLSVAACFLVRFQERGGKPKETVGGSDLRDADAIPGISHTCMRADSS 303
 QY 301 KGFLERPSSASTVTTTKSKLPMVV 324
 DB 304 KGFLERPSSASTVTTTKSKLPMVV 327
 RESULT 5
 ID ABB90354 standard; protein; 327 AA.
 XX
 AC ABB90354;
 XX

DT 24-MAY-2002 (first entry)
 XX Human polypeptide SEQ ID NO 2730.
 DE
 XX Cytostatic; immunosuppressive; nontropic; neuroprotective; antiviral;
 KW anti-allergic; hepatotropic; antidiabetic; anti-inflammatory; anti-ulcer;
 KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
 KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
 KW neurological disease; infection; human; secreted protein.
 XX
 OS Homo sapiens.
 XX
 XX WO200190304-A2.
 PN
 XX 29-NOV-2001.
 PD
 XX 18-MAY-2001; 2001WO-US016450.
 PF
 XX 19-MAY-2000; 2000US-020551SP.
 PR
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA
 XX Birse CE, Rosen CA;
 PI
 XX WPI; 2002-122018/16.
 DR N-PSDB; ABL90763.
 XX
 XX Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
 PT prevention of neural, immune system, muscular, reproductive,
 PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative
 PT disorders.
 XX
 XX Claim 11; SEQ ID NO 2730; 2081pp + Sequence Listing; English.
 PS
 PS The invention relates to novel genes (ABL9449-ABL90853) and proteins
 CC (ABB89040-ABB90444) useful for preventing, treating or ameliorating
 CC medical conditions e.g. by protein or gene therapy. The genes are
 CC isolated from a range of human tissues disclosed in the specification.
 CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in
 CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
 CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
 CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
 CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
 CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
 CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
 CC cardiovascular disorders such as myocardial ischaemias; (d) wound healing
 CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
 CC infectious diseases such as viral, bacterial, fungal and parasitic
 CC infections. Note: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 327 AA;
 SQ
 Query Match 99.5%; Score 1677; DB 5; Length 327;
 Best Local Similarity 99.7%; Pred. No. 6.8e-113;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LPGPFLCGALLGFLCLSGLAWEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
 DB 4 LPGPFLCGALLGFLCLSGLAWEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
 QY 61 PGKPISEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATILKLTVDHPSDTGYLCQV 120
 DB 64 PGKPISEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATILKLTVDHPSDTGYLCQV 123
 QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 180
 DB 124 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 183
 QY 181 TPTTSPGSMQDEVSQGLILTNLSLTSSGTVCATNQMGASCELTLSTVTEPQGRVA 240
 DB 184 TPTTSPGSMQDEVSQGLILTNLSLTSSGTVCATNQMGASCELTLSTVTEPQGRVA 243

QY 241 GALIGVLLGVLISVAACFLVRFOKRGKKPKETGGSDLRDAIAPGISEHTCMRADSS 300
DB 244 GALIGVLLGVLISVAACFLVRFOKRGKKPKETGGSDLRDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTKSKLPMVV 324
DB 304 KGFLERPSSASTVTTTKSKLPMVV 327
RESULT 6
AAU83709
ID AAU83709 standard; protein; 327 AA.
AC AAU83709;
DT 08-MAY-2002 (first entry)
DE Human PRO protein, Seq ID No 236.
XX
KW Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
KW breast cancer; prostate tumour; rectal tumour; liver tumour;
KW pricyte cell proliferation; chondrocyte cell proliferation;
KW tumour necrosis factor-alpha.
OS Homo sapiens.
XX
XX WO200208288-A2.
XX
XX 31-JAN-2002.
XX
XX 29-JUN-2001; 2001WO-US021066.
XX
XX 20-JUL-2000; 2000US-0219556P.
XX 25-JUL-2000; 2000US-0220385P.
XX 25-JUL-2000; 2000US-0220605P.
XX 25-JUL-2000; 2000US-0220607P.
XX 25-JUL-2000; 2000US-0220624P.
XX 25-JUL-2000; 2000US-0220638P.
XX 25-JUL-2000; 2000US-0220664P.
XX 25-JUL-2000; 2000US-0220666P.
XX 26-JUL-2000; 2000US-0220893P.
XX 28-JUL-2000; 2000WO-US020710.
XX 01-AUG-2000; 2000US-0222425P.
XX 22-AUG-2000; 2000US-0227133P.
XX 23-AUG-2000; 2000WO-US023522.
XX 24-AUG-2000; 2000WO-US023328.
XX 10-NOV-2000; 2000WO-US030873.
XX 28-NOV-2000; 2000US-0253646P.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001WO-US006520.
XX 01-MAR-2001; 2001WO-US006666.
XX 22-MAR-2001; 2001US-00816744.
XX 10-MAY-2001; 2001US-00854208.
XX 10-MAY-2001; 2001US-00854280.
XX 25-MAY-2001; 2001WO-US017092.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX WPI; 2002-172001/22.
XX N-PSDB; ABK33653.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for treating a PRO related disorder and for diagnosing tumors such
PT as lung cancer, colon cancer, breast tumor, prostate tumor, rectal tumor
PT or liver tumor.
XX
XX Claim 11; Fig 236; 359pp; English.
PS

XX The invention relates to one hundred and twenty two nucleic acids
CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
CC encode human secreted proteins. The PRO nucleic acids, polypeptides,
CC agonists and antagonists are useful for treating a PRO related disorder.
CC The PRO polypeptides are useful for diagnosing tumours, especially lung
CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. The PRO polypeptides are useful for stimulating the
CC proliferation of, or gene expression, in pericyte cells, for stimulating
CC the proliferation or differentiation of chondrocyte cells, for
CC stimulating the release of tumour necrosis factor-alpha from human blood,
CC for stimulating or inhibiting the proliferation of normal human dermal
CC fibroblast cells. The PRO polypeptide may also be used as molecular
CC weight markers and for tissue typing. The PRO nucleic acids have
CC applications in molecular biology, including use as hybridisation probes,
CC and in chromosome and gene mapping. AAU83592-AAU83713 represent human PRO
CC protein sequences of the invention
XX
SQ Sequence 327 AA;
Query Match 99.5%; Score 1677; DB 5; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 LPGAFLCGALLGFLCISGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
DB 4 LPGAFLCGALLGFLCISGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
QY 61 PGKPISEHPILYFTNGHLIYPTGSKSRVLLQNPPTVGATVATLKTLDVHPSDGTGYLCQV 120
DB 64 PGKPISEHPILYFTNGHLIYPTGSKSRVLLQNPPTVGATVATLKTLDVHPSDGTGYLCQV 123
QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSOSGQTSVGSSTALRCSSEGAPKPVNNWVRLG 180
DB 124 NNPPDFYTNGLGILNLTVLVPPSNPLCSOSGQTSVGSSTALRCSSEGAPKPVNNWVRLG 183
QY 181 TFPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSA SCELTL SVTTPPQGRVA 240
DB 184 TFPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSA SCELTL SVTTPPQGRVA 243
QY 241 GALIGVLLGVLISVAACFLVRFOKRGKKPKETGGSDLRDAIAPGISEHTCMRADSS 300
DB 244 GALIGVLLGVLISVAACFLVRFOKRGKKPKETGGSDLRDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTKSKLPMVV 324
DB 304 KGFLERPSSASTVTTTKSKLPMVV 327
RESULT 7
ABU80856
ID ABU80856 standard; protein; 327 AA.
AC ABU80856;
XX
XX 23-JUN-2003 (first entry)
XX
XX Human PRO polypeptide #118.
XX
XX Human; PRO polypeptide; secreted and transmembrane protein;
KW anti-PRO antibody; diagnostic assay; gene expression; tumour; cytostatic.
XX
XX Homo sapiens.
XX
XX US2003036635-A1.
XX
XX 20-FEB-2003.
XX
XX 28-AUG-2002; 2002US-00230163.
XX
XX 25-JUL-2000; 2000US-0220638P.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.

PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-342045/32.
DR N-PSDB; ACA66958.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for the manufacture of a medicament for diagnosing or treating
PT tumor.
XX
XX Claim 11; Fig 236; 314pp; English.
PS
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides and polynucleotides are useful for preparing a medicament
CC useful in the diagnosis and treatment of tumours. Anti-PRO antibodies are
CC useful in diagnostic assays for PRO, by detecting its expression in
CC specific cells, tissues or serum, and for affinity purification of PRO
CC from recombinant cell culture or natural sources. ABU80739-ABU80860
CC represent the human PRO polypeptides of the invention. Note: The sequence
CC data for this patent was obtained in electronic format directly from the
CC USPTO web site at seqdata.uspto.gov/paipsdIDentry.html
XX
SQ Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LFGPFLCGALLGFLCLSGLAIVEVKVPTPLSLPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
Db 4 LFGPFLCGALLGFLCLSGLAIVEVKVPTPLSLPLGKTAELTCTYSTSVGDSFALEWSFVQ 63

QY 61 PKGPISSEHPILYFTNGHLIYPTGSKSKRVSLQLQNPPPTGVATLKLTDVHPSDTGTYLCOV 120
Db 64 PKGPISSEHPILYFTNGHLIYPTGSKSKRVSLQLQNPPPTGVATLKLTDVHPSDTGTYLCOV 123

QY 121 NNPPDPFTYNGGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNVRLG 180
Db 124 NNPPDPFTYNGGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNVRLG 183

QY 181 TPTPTSPGSMQDEVSGQILTNLSLTSSSTYRCVATNMGASCBELTSLVTEPPQGRVA 240
Db 184 TPTPTSPGSMQDEVSGQILTNLSLTSSSTYRCVATNMGASCBELTSLVTEPPQGRVA 243

QY 241 GALIGVLLGVLILLSVAAPCLVRFQERKKPKETYGGSDLRDAIAPGISHTCMRADSS 300
Db 244 GALIGVLLGVLILLSVAAPCLVRFQERKKPKETYGGSDLRDAIAPGISHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTKSLPMVV 324
Db 304 KGFLERPSSASTVTTTKSLPMVV 327

RESULT 8
ABO33822
ID ABO33822 standard; protein; 327 AA.
XX
AC ABO33822;
XX
DT 17-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO154.
XX
KW Human; secreted and transmembrane protein; PRO; Cytostatic;
KW antarthritic; osteopathic; gene therapy; TNF-Agonist-Alpha;
KW chondrocyte stimulator; pericyte stimulator; fibroblast modulator;
KW pharmaceutical; diagnostic; biosensor; bioreactor; tumour; lung tumour;

KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; bone disorder; cartilage disorder; sports injury;
XX arthritis; wound.
XX Homo sapiens.
XX OS
XX US2003045687-A1.
XX PN
XX 06-MAR-2003.
XX PD
XX
XX 12-AUG-2002; 2002US-00218631.
XX PF
XX 01-JUN-2001; 2001WO-US017800.
XX PR
XX 29-JUN-2001; 2001WO-US021086.
XX PR
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX PA
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX WPI; 2003-512315/48.
XX DR
XX N-PSDB; ACD68710.
XX
XX New genes, and its encoded secreted and transmembrane polypeptides,
PT useful for stimulating Tumor Necrosis Factor alpha, or chondrocyte or
PT pericyte proliferation, especially for treating lung tumors, arthritis or
PT wounds in a mammal.
XX
XX Claim 11; Fig 236; 314pp; English.
XX
CC The invention describes an isolated nucleic acid molecule comprising a
CC sequence with at least 80% identity to: (a) a nucleotide encoding any of
CC 122 PRO (secreted and transmembrane) polypeptides whose sequences are
CC fully defined in the specification; or (b) any of 122 nucleotide
CC sequences having e.g. 4834, 2504 or 1759 bp fully defined in the
CC specification; or the full length coding sequence of any these 122
CC nucleotide sequences. The PRO polypeptides or polynucleotides are useful
CC as pharmaceuticals, diagnostics, biosensors or bioreactors. These are
CC particularly useful for detecting tumours (e.g. lung tumour, colon
CC tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)
CC in a mammal, for stimulating the release of TNF-alpha from human blood,
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells, for stimulating proliferation of pericyte cells, or for modulating
CC normal human dermal fibroblast proliferation. The PRO nucleic acid or
CC polypeptide is also useful for treating tumours or various bone and/or
CC cartilage disorders (e.g. sports injuries or arthritis), or wounds. The
CC PRO polypeptides are useful in drug screening, particularly as targets
CC for therapeutic intervention in these diseases, and in the diagnostic
CC determination of the presence of these diseases. The PRO polypeptides are
CC also useful as molecular weight markers, or for chromosome
CC identification. The PRO genes are useful as hybridisation probes, or for
CC screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
CC also be used in gene therapy, particularly for replacing a defective
CC gene. This is the amino acid sequence of a novel human secreted and
CC transmembrane PRO polypeptide
XX
SQ Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LFGPFLCGALLGFLCLSGLAIVEVKVPTPLSLPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
Db 4 LFGPFLCGALLGFLCLSGLAIVEVKVPTPLSLPLGKTAELTCTYSTSVGDSFALEWSFVQ 63

QY 61 PKGPISSEHPILYFTNGHLIYPTGSKSKRVSLQLQNPPPTGVATLKLTDVHPSDTGTYLCOV 120
Db 64 PKGPISSEHPILYFTNGHLIYPTGSKSKRVSLQLQNPPPTGVATLKLTDVHPSDTGTYLCOV 123

QY 121 NNPPDPFTYNGGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNVRLG 180
XX

Db 124 NNPPDFYTNGLGLINLTVLPVPPSNPLCSQSGQTSVGGSTALRCSSESGAPKPVYNWVRLG 183
QY 181 TFTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTSLSVTPPPQGRVA 240
Db 184 TFTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTSLSVTPPPQGRVA 243
QY 241 GALIGVLLGVLVLSVAAFCLVRQKRGKPKKTYGGSDLRDAIAPGISEHTCMRADSS 300
Db 244 GALIGVLLGVLVLSVAAFCLVRQKRGKPKKTYGGSDLRDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTTSKLPWV 324
Db 304 KGFLERPSSASTVTTTTSKLPWV 327
RESULT 9
ABU82165
ID ABU82165 standard; protein; 327 AA.
XX AC ABU82165;
XX DT 25-JUN-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO7154.
XX KW Human; secreted and transmembrane protein; PRO; cardiac; cytostatic;
KW antidiabetic; hypotensive; vulnery; antiarteriosclerotic;
KW gene therapy; cardiovascular disorder; endothelial disorder;
KW angiogenic disorder; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; atherosclerosis; hypertension;
KW arterial restenosis; rheumatoid arthritis; angina; myocardial infarction;
KW thrombophlebitis; lymphangitis; tumour angiogenesis; breast carcinoma;
KW liver carcinoma; wound healing; chromosome mapping; gene mapping.
XX OS Homo sapiens.
XX PN US2003088063-A1.
XX PD 08-MAY-2003.
XX PF 12-AUG-2002; 2002US-00219003.
XX PR 25-JUL-2000; 2000US-0220664P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-393229/37.
DR N-PSDB; ACA68614.
XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.
XX Claim 11; Fig 236; 314pp; English.
XX The invention describes one hundred and eighty seven nucleic acids
CC encoding novel human secreted and transmembrane (PRO) polypeptides. The
CC PRO nucleic acids, polypeptides, agonists and antagonists are useful for
CC treating or diagnosing a cardiovascular, endothelial or angiogenic
CC disorder in a mammal, e.g. cardiac hypertrophy, trauma, cancer, age-
CC related macular degeneration, atherosclerosis, hypertension, arterial
CC restenosis, rheumatoid arthritis, angina, myocardial infarctions,
CC thrombophlebitis, lymphangitis, tumour angiogenesis (such as breast
CC carcinoma and liver carcinoma) and wound healing. The PRO nucleic acids
CC have applications in molecular biology, including use as hybridisation
CC probes, and in chromosome and gene mapping. This is the amino acid
CC sequence of a novel human secreted and transmembrane PRO polypeptide

XX SQ Sequence 327 AA;
Query Match 99.5%; Score 1677; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113; Indels 0; Gaps 0;
Matches 323; Conservative 0; Mismatches 1;
QY 1 LPQPFLLCGALLGFLCLSLGLAVEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWFSVQ 60
Db 4 LPQPFLLCGALLGFLCLSLGLAVEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWFSVQ 63
QY 61 PGKPISESHPILYFTNGHLYPTGSKSRVSLLONPPTVGATVATLKLTDVHPSDTGTLYCQV 120
Db 64 PGKPISESHPILYFTNGHLYPTGSKSRVSLLONPPTVGATVATLKLTDVHPSDTGTLYCQV 123
QY 121 NNPPDFYTNGLGLINLTVLPVPPSNPLCSQSGQTSVGGSTALRCSSESGAPKPVYNWVRLG 180
Db 124 NNPPDFYTNGLGLINLTVLPVPPSNPLCSQSGQTSVGGSTALRCSSESGAPKPVYNWVRLG 183
QY 181 TFTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTSLSVTPPPQGRVA 240
Db 184 TFTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTSLSVTPPPQGRVA 243
QY 241 GALIGVLLGVLVLSVAAFCLVRQKRGKPKKTYGGSDLRDAIAPGISEHTCMRADSS 300
Db 244 GALIGVLLGVLVLSVAAFCLVRQKRGKPKKTYGGSDLRDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTTSKLPWV 324
Db 304 KGFLERPSSASTVTTTTSKLPWV 327
RESULT 10
ABJ72345
ID ABJ72345 standard; protein; 327 AA.
XX AC ABJ72345;
XX DT 06-NOV-2003 (first entry)
XX DE Human PRO7154 protein.
XX KW PRO; proliferation; pericyte cell; TNF-alpha; blood; chondrocyte;
KW differentiation; dermal fibroblast; tumour; gene therapy; cytostatic.
XX OS Homo sapiens.
XX PN US2003050448-A1.
XX PD 13-MAR-2003.
XX PF 28-AUG-2002; 2002US-00230414.
XX PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-521818/49.
DR N-PSDB; ABT44343.
XX New nucleic acid encoding for a PRO protein, useful for the manufacture
PT of a medicament for diagnosing or treating tumors or for measuring or
PT detecting expression of an associated gene.
XX Claim 11; Fig 236; 315pp; English.
XX The invention relates to a novel isolated nucleic acid encoding a fully
CC defined PRO polypeptide. The molecules of the invention may be useful for

CC stimulating proliferation or gene expression in pericyte cells or the
 CC release of TNF-alpha from human blood. Other possible uses include the
 CC stimulation or inhibition of chondrocyte proliferation or
 CC differentiation, the stimulation of human dermal fibroblast cell
 CC proliferation and the detection of the presence of a tumour within a
 CC mammal. Furthermore, the nucleic acid may be useful for the manufacture
 CC of a medicament for diagnosing or treating a tumour within a mammal or
 CC for measuring or detecting the expression of an associated gene, as well
 CC as during gene therapy. The current sequence is that of the human PRO
 CC protein of the invention
 XX
 XX
 SQ Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 6; Length 327;
 Best Local Similarity 99.7%; Pred. No. 6.8e-113;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LPPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
 Db 4 LPPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63
 QY 61 PGKPISESHPILYFTNGHLIYPTGSKSKRVSLNQNPPTVGVAATLKLTVDHPSDTGYLCQV 120
 Db 64 PGKPISESHPILYFTNGHLIYPTGSKSKRVSLNQNPPTVGVAATLKLTVDHPSDTGYLCQV 123
 QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNWRLG 180
 Db 124 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNWRLG 183
 QY 181 TPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQMSASCELTLSTVTEPQGRVA 240
 Db 184 TPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQMSASCELTLSTVTEPQGRVA 243
 QY 241 GALIGVLLGVLLSVAAFLVRFQKRGKKPKETYGSGDLREDATAPIGISEHTCMRADSS 300
 Db 244 GALIGVLLGVLLSVAAFLVRFQKRGKKPKETYGSGDLREDATAPIGISEHTCMRADSS 303
 QY 301 KGFLERPSSASTVTTTTSKLPVV 324
 Db 304 KGFLERPSSASTVTTTTSKLPVV 327

RESULT 11
 ABJ72473
 ID ABJ72473 standard; protein; 327 AA.
 XX
 AC ABJ72473;
 XX
 XX 06-NOV-2003 (first entry)
 XX
 DE Human PRO7154 protein.
 XX
 XX PRO; blood; proliferation; pericyte cell; TNF alpha; chondrocyte;
 KW tumour necrosis factor; proliferation; differentiation; gene therapy;
 KW dermal fibroblast.
 XX
 OS Homo sapiens.
 XX
 XX US2003027988-A1.
 XX
 XX 06-FEB-2003.
 XX
 XX 26-AUG-2002; 2002US-00227884.
 XX
 XX 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX

DR WPI; 2003-503301/47.
 DR N-PSDB; ABT44626.
 XX
 PT New PRO protein encoding nucleic acid, useful for preparing PRO
 PT polypeptides and anti-PRO antibodies for detecting the presence of a
 PT tumour in a mammal.
 XX
 XX Claim 11; Fig 236; 324pp; English.
 XX
 CC The invention relates to a novel isolated PRO protein encoding nucleic
 CC acid. The nucleic acid of the invention may be useful for preparing PRO
 CC polypeptides and anti-PRO antibodies for detecting the presence of a
 CC tumour in a mammal. Furthermore, the molecules of the invention may be
 CC useful for stimulating proliferation or gene expression in pericyte
 CC cells, the release of tumour necrosis factor (TNF)-alpha from human
 CC blood, the proliferation or differentiation of chondrocyte cells and for
 CC inhibiting the proliferation of normal human dermal fibroblast cells.
 CC Finally, the molecules may be utilised during gene therapy. The current
 CC sequence is that of the human PRO protein of the invention
 XX
 XX Sequence 327 AA;
 SQ
 Query Match 99.5%; Score 1677; DB 6; Length 327;
 Best Local Similarity 99.7%; Pred. No. 6.8e-113;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LPPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
 Db 4 LPPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63
 QY 61 PGKPISESHPILYFTNGHLIYPTGSKSKRVSLNQNPPTVGVAATLKLTVDHPSDTGYLCQV 120
 Db 64 PGKPISESHPILYFTNGHLIYPTGSKSKRVSLNQNPPTVGVAATLKLTVDHPSDTGYLCQV 123
 QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNWRLG 180
 Db 124 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNWRLG 183
 QY 181 TPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQMSASCELTLSTVTEPQGRVA 240
 Db 184 TPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQMSASCELTLSTVTEPQGRVA 243
 QY 241 GALIGVLLGVLLSVAAFLVRFQKRGKKPKETYGSGDLREDATAPIGISEHTCMRADSS 300
 Db 244 GALIGVLLGVLLSVAAFLVRFQKRGKKPKETYGSGDLREDATAPIGISEHTCMRADSS 303
 QY 301 KGFLERPSSASTVTTTTSKLPVV 324
 Db 304 KGFLERPSSASTVTTTTSKLPVV 327
 RESULT 12
 ABO34368
 ID ABO34368 standard; protein; 327 AA.
 XX
 AC ABO34368;
 XX
 XX 19-SEP-2003 (first entry)
 XX
 XX Human secreted/transmembrane polypeptide PRO 7154.
 XX
 KW Human; chondrocyte stimulation; TNF-alpha stimulation; gene therapy;
 KW human dermal fibroblast stimulation; tumour; tissue typing;
 KW affinity purification.
 XX
 OS Homo sapiens.
 XX
 XX US2003044934-A1.
 PN
 XX 06-MAR-2003.
 XX
 XX 28-AUG-2002; 2002US-00230338.
 XX


```
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH ) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX WPI; 2003-492274/46.
XX N-PSDB; ACD82293.
XX
XX New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX
XX Claim 19; Fig 236; 315pp; English.
XX
XX The invention relates to an isolated nucleic acid encoding a PRO
CC polypeptide. Nucleic acids that encode PRO can be used to generate either
CC transgenic animals or knock-out animals useful in developing and
CC screening of therapeutically useful reagents. The nucleic acids may also
CC be used in gene therapy for replacing defective gene, in chromosome
CC identification, as chromosome markers, or in generating probes to isolate
CC full length PRO cDNA. The PRO polypeptides are useful for chondrocyte
CC stimulation, TNF-alpha stimulation, human dermal fibroblasts stimulation
CC and for detecting the presence of tumour in an mammal. The PRO
CC polypeptides are useful as molecular markers for protein electrophoresis
CC and the isolated nucleic acids may be used for recombinantly expressing
CC those markers. The PRO polypeptides and nucleic acids may also be used in
CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
CC PRO and in affinity purification of PRO from recombinant cell culture or
CC natural sources. The present sequence represents the amino acid sequence
CC of a human secreted/transmembrane PRO polypeptide
XX
XX Sequence 327 AA;
SQ
Query Match 99.5%; Score 1677; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 LPGPFLCGALLGFLCGLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
DB 4 LPGPFLCGALLGFLCGLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
QY 61 PGKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPPTVGATLKLTDVHPSDTGTLYCQV 120
DB 64 PGKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPPTVGATLKLTDVHPSDTGTLYCQV 123
QY 121 NNPPDFYTNGLGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNVRLG 180
DB 124 NNPPDFYTNGLGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNVRLG 183
QY 181 TPTSPSGMVQDEVSGQILNLNLTSSGTRCVATNQMGASCBTLTSLVTEPPQGRVA 240
DB 184 TPTSPSGMVQDEVSGQILNLNLTSSGTRCVATNQMGASCBTLTSLVTEPPQGRVA 243
QY 241 GALIGVLLGVLLSLVAACLVRFQKRGKKPKETVCGSDLRDAIAPGISEHTCMRADSS 300
DB 244 GALIGVLLGVLLSLVAACLVRFQKRGKKPKETVCGSDLRDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTKSKLPMV 324
DB 304 KGFLERPSSASTVTTTKSKLPMV 327
RESULT 13
ID ABJ72175
XX ABJ72175 standard; protein; 327 AA.
XX AC ABJ72175;
XX
XX 16-OCT-2003 (first entry)
```

```
XX
XX Human membrane bound receptor/protein PRO7154 amino acid sequence.
DE
XX Human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
XX Homo sapiens.
OS
XX
XX US2003065147-A1.
XX
XX 03-APR-2003.
XX
XX 29-AUG-2002; 2002US-00232224.
XX
XX 28-JUL-1999; 99US-0146222P.
XX 24-FEB-2000; 2000WO-US005004.
XX 02-MAR-2000; 2000WO-US005841.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH ) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX WPI; 2003-522018/49.
XX N-PSDB; ABT43999.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for the manufacture of a medicament for diagnosing or treating
PT tumor.
XX
XX Claim 11; Fig 236; 315pp; English.
XX
XX This invention relates to one hundred and twenty two novel nucleic acids
CC encoding human PRO membrane bound proteins or receptors. Extracellular
CC proteins play important roles in the formation, differentiation and
CC maintenance of multicellular organisms. The fate of many individual cells
CC (for example proliferation, migration or differentiation) is typically
CC governed by information received from other cells and the immediate
CC environment. The information is often transmitted by secreted
CC polypeptides (for example mitogenic factors, survival factors, cytotoxic
CC factors, differentiation factors, neuropeptides and hormones) which are
CC received and interpreted by diverse cell receptors or membrane bound
CC proteins. These membrane bound proteins and receptors may be of use as
CC pharmaceutical and diagnostic agents, such as in the blocking of receptor
CC -ligand interactions. The current invention provides the amino acid
CC sequences of novel human membrane bound receptors and proteins, along
CC with the cDNA sequences encoding them. The novel proteins of the
CC invention may have cytostatic activities through the stimulation of
CC chondrocytes. The nucleic acids of the invention may be useful for the
CC manufacture of a medicament for diagnosing or treating a tumour in a
CC mammal. In addition, they may be useful for measuring or detecting the
CC expression of a tumour associated gene. The present sequence is the amino
CC acid sequence of a human PRO protein of the invention
XX
XX Sequence 327 AA;
```

```
Query Match 99.5%; Score 1677; DB 7; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 LPGPFLCGALLGFLCGLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
DB 4 LPGPFLCGALLGFLCGLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
QY 61 PGKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPPTVGATLKLTDVHPSDTGTLYCQV 120
DB 64 PGKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPPTVGATLKLTDVHPSDTGTLYCQV 123
```

QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNVVRUG 180
 DB 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNVVRUG 183
 QY 181 TPTSPGSMWQDEVSGQILNLNLSTSSGTVRCVATNMGASCELTLSTVTEPQGRVA 240
 DB 184 TPTSPGSMWQDEVSGQILNLNLSTSSGTVRCVATNMGASCELTLSTVTEPQGRVA 243
 QY 241 GALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETVGGSDLRDADAIPGISEHTCMRADSS 300
 DB 244 GALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETVGGSDLRDADAIPGISEHTCMRADSS 303
 QY 301 KGFLERPSSASTVTTTKSKLPMWV 324
 DB 304 KGFLERPSSASTVTTTKSKLPMWV 327

RESULT 14
 ADB83726
 ID ADB83726 standard; protein; 327 AA.
 XX
 AC ADB83726;
 XX
 XT 04-DEC-2003 (first entry)
 XX
 DE
 XX
 XX Novel human secreted and transmembrane protein PRO7154.
 KW human; secreted and transmembrane protein; PRO; cytostatic; vulnerary;
 KW antiarthritic; pericyte cell proliferation; chondrocyte cell proliferation;
 KW pericyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 XX US2003073814-A1.
 XX
 PD 17-APR-2003.
 XX
 XX 12-AUG-2002; 2002US-00218849.
 XX
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Desnoyers L, Gerritson ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 DR WPI; 2003-644806/61.
 DR N-PSDB; ADB83725.
 XX
 PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 PT in gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX
 XX Claim 11; Fig 236; 315pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF) -
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,

CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1338, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO3940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptide
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (III) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This is the amino acid sequence of a human secreted and
 CC transmembrane PRO polypeptide.
 XX
 SQ Sequence 327 AA;
 Query Match 99.5%; Score 1677; DB 7; Length 327;
 Best Local Similarity 99.7%; Pred. No. 6.8e-113;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LPGPFLCAGLLGFLCLSGLAIVEVKVTEPLSTPLGKTAELTCTYSTVSGDSPALESFVQ 60
 DB 4 LPGPFLCAGLLGFLCLSGLAIVEVKVTEPLSTPLGKTAELTCTYSTVSGDSPALESFVQ 63
 QY 61 PGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGTYLQV 120
 DB 64 PGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGTYLQV 123
 QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNVVRUG 180
 DB 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNVVRUG 183
 QY 181 TPTSPGSMWQDEVSGQILNLNLSTSSGTVRCVATNMGASCELTLSTVTEPQGRVA 240
 DB 184 TPTSPGSMWQDEVSGQILNLNLSTSSGTVRCVATNMGASCELTLSTVTEPQGRVA 243
 QY 241 GALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETVGGSDLRDADAIPGISEHTCMRADSS 300
 DB 244 GALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETVGGSDLRDADAIPGISEHTCMRADSS 303
 QY 301 KGFLERPSSASTVTTTKSKLPMWV 324
 DB 304 KGFLERPSSASTVTTTKSKLPMWV 327

RESULT 15
 ADB80832
 ID ADB80832 standard; protein; 327 AA.
 XX
 AC ADB80832;
 XX
 XT 04-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO7154.
 XX
 KW Human; secreted and transmembrane protein; PRO; cytostatic; vulnerary;
 KW antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation,

KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX Homo sapiens.
XX US2003088068-A1.
XX 08-MAY-2003.
XX 13-AUG-2002; 2002US-00219481.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI: 2003-657982/62.
XX N-PSDB; ADB80831.
XX
PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
PS Claim 11; Fig 236; 305pp; English.
XX

CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1486, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This is the amino acid sequence of a human secreted and
CC transmembrane PRO polypeptide.

XX Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 7; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY	1	LPGPFLCGALLGFLCLSGLA	VEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ	60
DB	4	LPGPFLCGALLGFLCLSGLA	VEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ	63
QY	61	PGKPISESHPILYFTNGHLYPTGSKSRV	LSLLQNPPTVGVAATLKLTDVHPSDGTGYLCQV	120
DB	64	PGKPISESHPILYFTNGHLYPTGSKSRV	LSLLQNPPTVGVAATLKLTDVHPSDGTGYLCQV	123
QY	121	NNPPDFVTYNGGLINLTVLVPPSNPLCS	QSGQTSVGGSTALRCSSSEGAPKPVYNWVRLG	180
DB	124	NNPPDFVTYNGGLINLTVLVPPSNPLCS	QSGQTSVGGSTALRCSSSEGAPKPVYNWVRLG	183
QY	181	TFPTPSFGSMVQDEVSGQILITNLSTSG	TYRCVATNQMGSA	240
DB	184	TFPTPSFGSMVQDEVSGQILITNLSTSG	TYRCVATNQMGSA	243
QY	241	GALIGVLLGVLLLSVA	AFCLVRFQKRGKKPKETYGGSDLR	300
DB	244	GALIGVLLGVLLLSVA	AFCLVRFQKRGKKPKETYGGSDLR	303
QY	301	KGFLERPSSASTVTTT	TKSKLPWVV	324
DB	304	KGFLERPSSASTVTTT	TKSKLPWVV	327

Search completed: August 4, 2005, 06:07:06
Job time : 99.8153 secs

This Page Blank (uspto)